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Introduction
One of the main causes of morbidity and mortality in the modern world is cancer [1]. Accord-
ing to World Health Organization (WHO) reports the worldwide mortality rate due to malig-
nant neoplasms is 12.5%, but in the Western world this is about 30% in the 45-75 year age 
group. In The Netherlands the prevalence of different types of cancer varies between sexes; 
amongst men prostate cancer (21%) and amongst women breast cancer (33%) are the most 
frequently diagnosed types, expressed as percentage of all registered tumour patients. Lung 
(16% men, 8% women) and colorectal carcinomas (13%) are major cancers as well (The Neth-
erlands Cancer Registry). In this respect the incidence of cancers from neuroendocrine origin, 
the main tumour type discussed in this thesis, is very low; less than 0.1% [2]. Because of slow 
progression of the disease the prevalence is much higher, however.
Many different clinical tools are available to detect tumours. Several imaging modalities can 
be employed to visualize tumours and their metastases, including radiography using X-rays, 
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear 
imaging. The latter includes gamma (γ)-radiation, both planar- and single-photon emission 
computed tomography- (SPECT) imaging and positron (β+) emission tomography (PET). For 
therapy surgery is the first option, followed by (adjuvant) chemotherapy, external beam radia-
tion therapy (EBRT), radionuclide therapy, or combinations thereof. The ideal situation during 
therapy would be that only, or at least primarily, tumour cells are removed, damaged or killed, 
while harmful side effects on normal cells and tissues are reduced to a minimum. Any undesir-
able effects may be unavoidable though. 
Over the last decades progress has been achieved concerning specific targeting of tumour 
cells. This concept is based on the presence of biomarkers expressed only, mainly or in high 
density on malignant cells in comparison to healthy cells. Targeting agents with specific lig-
and-binding properties to these biomarkers, can be applied as tumour targeting tools for 
diagnostic or therapeutic use. Diagnostic imaging is feasible when γ- or β+-emitting radio-
nuclides or other imaging tags are labelled to tumour-specific antibodies or peptides. These 
antibodies and peptides can have a therapeutic effect as such, but when conjugated with a 
therapeutic alpha (α)- or beta (β—)-emitting radionuclide or other cytotoxic compound DNA 
damage can be induced to destroy tumour cells expressing the biomarkers, while sparing 
healthy tissues.
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1. Tools for targeted tumour therapy: focus on monoclonal 
antibodies and peptides
1.1 Monoclonal antibodies
The technique developed by Köhler and Milstein in 1975 to prepare monoclonal antibodies 
(mAb) with predefined specificity offered the possibility to produce a huge variety of specific 
antibodies [3]. Antibody-secreting B-lymphocytes were isolated from animal spleen cells in 
cell culture and immortalized by fusion with a cancer cell line; forming so-called hybridomas. 
Originating from one hybridoma cell, continuous production and secretion of many mAb in 
large amounts became available. MAbs specifically identify one epitope, such as receptors 
or structural components of the cell membrane. The CD (Cluster of Differentiation) series of 
antibodies targeting white blood cells are numbered up to 350 recently [4]. These antibodies 
are being used as diagnostic markers in many diseases where immune functions need to be 
monitored, such as in HIV infection, but also to characterize different subtypes of leukaemia. 
Also applications of mAbs in e.g. characterization of malignant tissues and for pregnancy tests 
were developed.
Therapeutic use of mAbs is employed to treat diseases such as rheumatoid arthritis, multiple 
sclerosis, psoriasis, and a variety of cancers, including non-Hodgkin’s lymphoma, colorectal 
cancer, head and neck cancer and breast cancer [5]. More than 20 products have been ap-
proved by the Food and Drug Administration (FDA) and over 200 mAbs are currently in clinical 
trials [6]. The therapeutic efficacy of mAbs, especially in solid tumours, appeared to be limited 
though, therefore radionuclides or toxic drugs were conjugated to several mAbs to enhance 
their therapeutic results [7]. Treatment of non-Hodgin lymphoma patients with ibritumom-
ab tiuxitan (Zevalin®) and tositumomab (Bexxar®), both anti CD20 mAbs radiolabelled with 
Figure 1, adapted from Majidi et al. [5]. Graphical representation of intact immunoglobulin G (IgG) antibody and 
antibody fragments. ABD: antigen-binding domain; Fab: antibody fragment; Fv: variable fragment; ScFv: single chain 
variable fragment; VH: Variable domains of heavy chain; VL: Variable domains of light chain; CH1-3: constant regions 
of heavy chain; CL: constant region of light chain. 
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90Y/111In and 131I respectively, results in good response rates, higher than those with unlabelled 
mAbs [4, 5]. This result reflects one of the major successes of radionuclide therapy for tumour 
therapy. 
Antibodies are large (~150 kDa) globular plasma proteins consisting of two identical heavy 
chains and light chains connected by disulfide bonds, as shown in Figure 1. Drawbacks of the 
large size of mAbs are instability and relatively long circulation times and poor tissue penetra-
tion. When radiolabelled mAbs are administered this may result in a high radiation dose to 
the bone marrow, causing decreased normal blood cell counts and increased incidence of 
myelodysplastic syndrome (MDS) or even leukaemia [8]. 
Therefore research into application of smaller F(ab) or F(ab)
2
 fragments of mAbs (~50 kDa or 
~100 kDa) and preparation of minibodies (110 kDa) or diabodies (55 kDa) with more favour-
able pharmacokinetic properties is ongoing. Engineered synthetic small and stable Ab frag-
ments such as single chain antibodies (ScFv) prepared by phage display technique (~25 kDa), 
nanobodies (15 kDa) derived from heavy chains of camelids, and so-called Affibody molecules 
(~7 kDa) are therefore promising new targeting tools [5, 9-13]. Generally, reduced size of anti-
body fragments facilitates blood clearance resulting in higher tumour-to-background ratios.
Radiolabelled nanobodies and Affibody molecules specifically targeting breast tumour cells, 
present examples of recent progress and opens new perspectives for clinical applications of 
antibody-based tumour diagnosis and therapy [14, 15]. 
1.2 Peptides
Since the late 1980’s peptides, synthesized to mimic natural ligands of receptors, are being de-
veloped as tools for specific tumour cell targeting. Different kinds of receptors e.g. hormone-, 
growth factor- or folate receptors, are often overexpressed on tumour cells, enabling discrimi-
nation between malignant and normal tissues [16-20]. The number of amino acid residues 
needed to synthesize these biologically active peptides varies between four to more than fifty, 
with a molecular size ranging between 0.5 to 6 kDa. The much smaller size of tumour-specific 
peptide analogues compared to that of antibodies reveals several advantages: rapid tissue 
penetration combined with a rapid clearance; no antigenicity; easy synthesis and simple to be 
modified chemically [20]. Moreover, peptides can be easily conjugated with chelates to enable 
radiolabelling with metallic radionuclides. 
Tumours originating from functioning neuroendocrine cells often show overexpression of re-
ceptors for peptide hormones such as somatostatin, glucagon like peptide (GLP-1) or gastrin. 
The group of neuroendocrine tumours (NETs) is quite heterogeneous. The classifi cation accord-
ing to WHO and European Neuroendocrine Tumour Society (ENETS) guidelines are based on a 
combination of clinical and pathological features specifi c for the organ the tumours originate 
from and on production/secretion of hormones [21-23]. Functioning endocrine tumours are 
named according to respective hormones that are produced, such as insulinomas, gastrinomas 
or carcinoids when serotonin is secreted. Five subtypes of the somatostatin receptors are known 
of which subtype 2 (sst2) is predominantly expressed in NETs, although subtype 3 and 5 overex-
pression has been described in several cases as well, e.g. in paraganglioma [20, 24, 25].
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The incidence of NETs is very low (~2/100.000 per year) [2]. Moreover, these tumours often 
remain undetected for a long period, because generally they grow relatively slowly. Upon 
diagnosis many patients present with metastasized disease [26], which limits the possibili-
ties to cure these patients using surgery or EBRT, whereas chemotherapy offers only limited 
beneficial effects [27]. This urged development of new tools to improve both diagnostics and 
therapy for NETs. Somatostatin, gastrin and other peptide analogues seemed to offer promis-
ing perspectives in this respect when tagged with radionuclides either for diagnostic imaging 
or radionuclide therapy [20, 28]. 
The small cyclic peptide hormone somatostatin shows inhibitory effects on secretion of vari-
ous hormones. Two native somatostatin structures occur; a 14 and a 28 amino acid sequence, 
that are rapidly degraded upon injection, however. Octreotide, consisting of 8 amino acids 
(~1 kDa) in a cyclic structure, is a still biologically active and stable somatostatin analogue. 
Insertion of two D-residues instead of the natural occurring L-amino acids provided improved 
stability. Several octreotide derivatives, e.g. Sandostatin-LAR (long-acting release), are being 
applied intramuscularly to successfully reduce hormone-based clinical symptoms such as 
flushing and diarrhoea, thereby improving quality of life of patients suffering from hormone 
producing NETs. Sandostatin-LAR treatment resulted in less than 10% of the patients in objec-
tive tumour regression though [29]. 
Over the years many variants of the eight amino acid sequence of octreotide have been de-
veloped (some examples shown in Table 1). In Tyr3-octreotide the phenylalanine (Phe) residue 
at position 3 has been replaced by tyrosine (Tyr). When in addition the threoninol group at the 
C-terminus (position 8) has been exchanged by threonine Tyr3-octreotate is obtained, show-
ing higher affinity for sst2 than octreotide [30]. By insertion of 1-Nal at position 3 instead of Tyr, 
the somatostatin analogues Nal3-octreotide (NOC) or Nal3-octreotate (NATE) were obtained 
[31, 32]. The characteristics regarding receptor specificity and affinity vary among the various 
somatostatin analogues [30]. 
Next to a variety of somatostatin analogues, other radiopeptide analogues of ligands specifi-
cally binding to hormone receptors have been generated targeting several human tumours, as 
reviewed by Reubi et al. [20]. Examples comprise gastrin releasing peptide (GRP) or bombesin 
analogues that can be applied in patients with breast or prostate carcinoma as GRP-receptors 
are often over-expressed on these tumour cells [33, 34]. Neurotensin analogues may target 
Table 1: Several 8 amino acid somatostatin analogues. The SS-bridge between the two cysteine (Cys) residues at 
position 2 and 7 forms the ring of the cyclic peptide. 
Position: 1 2 3 4 5 6 7 8
Octreotide D-Phe Cys Phe D-Trp Lys Thr Cys Thr(ol)
Tyr3-octreotide D-Phe Cys Tyr D-Trp Lys Thr Cys Thr(ol)
Tyr3-octreotate D-Phe Cys Tyr D-Trp Lys Thr Cys Thr
NOC D-Phe Cys 1-NaI D-Trp Lys Thr Cys Thr(ol)
NATE D-Phe Cys 1-NaI D-Trp Lys Thr Cys Thr
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e.g. exocrine pancreatic tumours [20, 35]. GLP-1 analogues, such as exendin-3 and 4, were 
developed to target GLP-1 receptors being over-expressed in nearly all cases of insulinoma, 
in a high incidence in gastrinomas, and in 30% of cases of carcinoids [36-39]. Cholecystokinin 
(CCK) or gastrin analogues have been developed to specifically target CCK2-receptors over-
expressed in most insulinomas, but also in the majority of medullary thyroid cancers (MTC), 
stromal ovarian cancers, astrocytomas, and small cell lung carcinomas (SCLC) [40-42]. Several 
stable radiolabelled GRP, neurotensin, GLP-1 and CCK peptide analogues have been devel-
oped recently, primarily for diagnostic use. Examples are shown in Table 2. The molecular sizes, 
net charges and renal uptake and retention of these peptide analogues vary largely.
2. Radiolabelling of peptide analogues
123I-iodination of the Tyr residue in octreotide was the first route applied to create radiolabelled 
somatostatin analogues for diagnostic purposes [17, 45]. Rapid degradation of these iodinated 
ligands and therefore fast washout of radioactivity from targeted cells, plus the hepatobiliary 
excretion of the radiopeptide demonstrated that this compound was a suboptimal imaging 
agent, however [46]. Therefore 111In-labelling was performed using octreotide chelated with 
diethylenetriaminepentaacetic acid (DTPA, Figure 2) at the N-terminus. 111In-DTPA-octreotide 
showed improved cellular retention in comparison with the radioiodinated peptide, because 
of internalization of the receptor-ligand complex and retention of the radionuclide in lyso-
somes [47]. Furthermore the fast renal excretion of 111In-DTPA-octreotide facilitated clear 
visualization of liver metastases during scintigraphy [48]. Promising preclinical studies with 
111In-DTPA-octreotide in rats were readily followed by the first diagnostic imaging of patients 
suffering from tumours of neuroendocrine origin.
To enable stable conjugation of therapeutic radionuclides to peptide analogues the cyclic 
chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA, Figure 2) was being 
linked to peptides. DTPA is especially suited for 111In-labelling; 90Y, 177Lu, 68Ga, and 111In all can be 
stably complexed by DOTA. In the latter case a heating procedure (>900C) is needed to chelate 
the trivalent metal ions into the DOTA ‘cage’.
Table 2: Overview of peptide ligands, other than somatostatin, the tumours targeted and examples of developed 
peptide analogues.
Peptide ligands Peptide receptor expressing tumours (a.o.) Analogues
Bombesin, GRP Breast, prostate Demobesin, AMBA [33, 34, 43]
Neurotensin Exocrine pancreas MP2530 [35]
GLP-1 Insulinoma, gastrinoma exendin 3, 4 [37, 38]
CCK2/gastrin Neuroendocrine, MTC, SCLC MG0-11, CCK8 [41, 42, 44] 
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Dependent on the physical radiation characteristics of the respective radionuclides used (list-
ed in Table 3), radiolabelled peptide analogues are suited either for diagnostic (γ or β+ radia-
tion) or for therapeutic purposes (Auger/conversion electrons or β—-radiation). 
Octreoscan®, 111In-DTPA-octreotide, is being used as the gold standard in diagnostic γ-camera 
imaging to monitor the disease in patients with NET since the introduction in the early nine-
ties of the previous century [48, 49]. An example of Octreoscan scintigraphy is shown in Figure 
3. Also PET imaging using 68Ga- or 18F-labelled somatostatin analogues is being performed 
to localise tumours and/or metastases with a higher sensitivity than using SPECT. PET has a 
higher resolution and enables accurate quantification of the tumour uptake, an indication of 
the magnitude of tumour somatostatin receptor expression [50-55]. 
Figure 2: Molecular structure of the chelators DTPA (diethylenetriaminepentaacetic acid) and DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid).
Table 3: Characteristics of various radionuclides.
Radionuclide Radiation γ energy (keV)
Max. particle energy 
(keV) Max. range Half-life 
111In
γ-radiation, 
Augers/CE 
171 and 245
3 and 19 (Augers) 
114 and 218 (CE)
10 μm (Augers)
0.5 mm (CE)
2.8 d
90Y β—-radiation 2281 12 mm 2.7 d
177Lu
γ-radiation, 
β—-radiation
113 and 208 430 2 mm 6.7 d
 68Ga β+-radiation 1920 9 mm 68 min
18F β+-radiation 635 2 mm 110 min
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Peptide receptor radionuclide therapy (PRRT) was 
first accomplished with 111In-DTPA-octreotide. It 
was hypothesized that 111In could be effective in 
radionuclide therapy because 111In emits Auger- 
and conversion electrons next to γ-radiation. In-
deed, beneficial effects were observed in patients 
with metastasized disease that were treated with 
high activity doses of 111In-DTPA-octreotide [56]. 
Stable disease, minor or partial tumour remis-
sion was found in 50% of 40 evaluable patients. 
Radiolabelling with the therapeutic β—-radiation 
emitting radionuclides 90Y and 177Lu of either Tyr3-
octreotide or Tyr3-octreotate, accelerated the 
application of PRRT in many centres. More pro-
nounced therapeutic effects were achieved than 
after 111In PRRT as recently reviewed [57-61]. Al-
though inter-study comparison is difficult because 
of variations among treatment protocols concern-
ing patient selection, inclusion criteria and defini-
tions of responses, it can be stated that significant 
survival benefit and improvement of quality of 
life is achieved after PRRT with 90Y-DOTA,Tyr3-oc-
treotide or 177Lu-DOTA,Tyr3-octreotate in patient 
groups not eligible for other treatment options 
[62]. Although complete remission was achieved 
in a minority of the patients, minor and partial re-
missions, i.e. 25-50% or >50% reduction of tumour 
size according tot SWOG criteria, has been described in 10-40% of the cases. Progression of 
disease was still encountered in approximately 20% of patients, while the remainder of the 
patients achieved stable disease.
Two clinical trials in a few patients to perform therapy with gastrin- and bombesin-analogues 
have been performed recently as well. 90Y-labelled minigastrin was administered to MTC pa-
tients, and 177Lu-AMBA to patients with prostate cancer [44, 63]. 
Spleen Liver
Kidney  Kidney
 Bladder
Figure 3: Visualization of physiological uptake 
of 111In-DTPA-octreotide during Octreoscan 
scintigraphy in spleen, liver, kidneys and bladder 
(posterior view). 
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3. Renal uptake and retention of radiopeptides
The kidneys are very important organs to maintain homeostasis regarding salt balance and 
blood pressure. Moreover, the blood is filtered in the kidneys about twenty five times a day 
and waste molecules are collected in excess water to be excreted into the urine. 
A:
B:
Figure 4: Schematic overview 
of the kidney (A) and nephrons 
(B), the functional units of the 
kidney. Abbreviations: AA/EA: 
aff erent and eff erent arteriole, G: 
glomerulus, PT/DT: proximal and 
distal tubule, LH: Lis of Henle, CD: 
collecting duct, RV: renal vein. (A): 
Adapted from www.nlm.nih.gov 
images, (B) Illustration made by 
Stuart Koelewijn.
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Each kidney contains one to two million nephrons, the functional filtering units that are main-
ly located in the outer part of the kidney; the cortex. Two nephrons are depicted schematically 
in Figure 4B. Blood enters the glomeruli via an afferent arteriole (AA) of the renal artery. In the 
capillary network in the glomeruli (G) waste and useful molecules are filtered from the blood 
and transported into the proximal tubules (PT). Waste molecules are excreted into the urine 
via the loop of Henle (LH), the distal tubules (DT) and the collecting duct (CD) leading to the 
renal pelvis and the bladder. In the first, convoluted, part of the PT useful molecules like small 
proteins (<60 kDa) and peptides are reabsorbed to prevent loss of valuable substances. 
The chelators DTPA and DOTA are charged molecules in neutral milieu, facilitating fast excre-
tion of radiolabelled DTPA/DOTA chelated peptides via the kidneys into the urine. This is an 
advantage for optimal visualization of liver metastases because of the low abdominal back-
ground compared to clearance via the liver/intestines as found for iodinated peptides [17]. 
However, due to partial renal reabsorption and retention of administered DTPA/DOTA che-
lated radiopeptides, the kidneys are the activity dose limiting organs during PRRT with thera-
peutic β—-radiation emitting radionuclides [64]. Depending, among others, on the number 
of charged amino acid residues the renal uptake and retention of several different tumour 
targeting peptide analogues appeared to be highly variable [37, 65-67].
As for the mechanism of renal uptake of radiopeptides, it appeared that megalin, a receptor lo-
cated at the apical side in the S1 and S2 part of the proximal tubules in the renal cortex, plays a 
very important role. Megalin functions, in 
close interaction with cubilin and amnion-
less, as an endocytic receptor to reabsorb 
glomerular filtered substances, primarily 
small proteins and peptides including al-
bumin, transferrin, vitamin-carrier proteins 
as well as peptide hormones and drugs 
[68, 69]. It is a very large protein of about 
600 kDa, primarily consisting of a large 
extracellular domain, a transmembrane 
segment and a small cytoplasmic domain 
[70]. In the extracellular part three types 
of repeats characteristic for members of 
the low-density lipoprotein (LDL)-recep-
tor family are expressed, resulting in four 
ligand-binding clusters, as illustrated in 
Figure 5. Each of the four clusters contains 
both acidic and basic amino acid residues 
that may facilitate high-affinity, charge-de-
pendent receptor-ligand interactions [71]. 
Radiolabelled octreotide or octreotate 
analogues are positively charged peptides 
because they contain a Lys residue. There-
Figure 5: Schematic overview of the structure of 
amnionless, cubilin and megalin, adapted from [72]. The 
numbers 1-4 indicate the four diff erent ligand-binding 
clusters of megalin.
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fore it has been hypothesized that reabsorption of somatostatin analogues involves recogni-
tion of at least one of the four ligand-binding clusters of megalin that is negatively charged 
[73, 74]. An important role for megalin can be postulated as well concerning the high renal 
uptake and retention of gastrin and GLP-1 peptide analogues [64].
The retained renal radioactivity after intravenous administration of radiopeptides is primarily 
localised in the cortex, because of partial reabsorption in the proximal tubules. This inhomo-
geneous distribution of radioactivity is demonstrated in ex vivo autoradiograms of kidneys, but 
can also be visualized in SPECT images.
4. Nephrotoxicity after PRRT
Due to partial renal uptake and retention of therapeutically radiolabelled somatostatin pep-
tide analogues, the kidneys appeared to be the organs at risk after PRRT. In 1999 the first com-
munication on late renal damage after 90Y-DOTA,Tyr3-octreotide PRRT was published [75]. It is 
known that kidneys may malfunction several months after they have been exposed to high 
activity doses [76]. Therefore, a safe radiation dose was accepted as threshold tolerated by kid-
neys on the basis of experience from external beam radiation therapy (EBRT). After EBRT the 
risk of development of nephropathy within 5 years after a cumulative renal absorbed dose of 
23 Gy is 5%, increasing to 50% after a 28 Gy dose [77]. Although in PRRT the nature of the de-
livered radiation dose differs from that in EBRT, a threshold of 23-27 Gy has first been adapted 
for PRRT studies as well. Recently a 37-45 Gy limit of biologically equivalent dose (BED) kidney 
radiation dose was accepted as safe limit, taking into account a.o. characteristics of the ap-
plied radionuclide, dose fractionation, kidney mass and the non-uniform localization of renal 
radioactivity [78, 79]
Insights in the long-term process leading to radiation nephrotoxicity caused by PRRT has been 
reviewed recently [64]. Irradiation of the kidneys may lead to fibrosis, a process that takes 
several months. Irradiation may, dependent on the dose, induce a chronic state of oxidative 
stress by the generation of reactive oxygen species (ROS) [80]. These ROS a.o. inactivate mi-
tochondrial enzymes and damage DNA which may lead to cell apoptosis [81]. In the kidneys 
a decreased glomerular filtration rate (GFR) and loss of protein in the urine is found, bringing 
about progressive kidney damage [82]. From several studies related to radiation-induced ne-
phropathy it was clear that the renin-angiotensin-aldosterone system (RAAS) plays a crucial 
role [83-85]. It appeared that angiotensin II is an important mediator in the progression of 
renal disease. It primarily up-regulates the levels of several cytokines, e.g. interleukin-8 (IL-8), 
promoting monocyte/macrophage and neutrophil migration, and transforming growth fac-
tor (TGF)-β, stimulating the proliferation of fibroblasts [82, 86]. Finally, glomerulosclerosis and 
tubulointerstitial fibrosis ultimately lead to loss of renal function. 
In rat 177Lu-DOTA,Tyr3-octreotate PRRT studies long-term nephrotoxicity has been described 
[87], with features also encountered in early case reports on renal insufficiency in patients 
after 90Y-DOTA,Tyr3-octreotide PRRT [75]. Beyond 70-80 days after a renal absorbed dose of 
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60 Gy excretion of protein in the urine of the rats was detected. Urinary protein content was 
increasing over time because of disturbed reabsorption of filtered peptides and proteins in 
the proximal tubules. Rats lost body weight at this stage, indicating health problems. After 
euthanasia histological examination of kidney sections demonstrated aberrations both in tu-
bules and glomeruli in the renal cortex where radioactivity had been retained. Grading of the 
histological renal damage was performed according to the following scheme.
5. Reduction of renal uptake of radiopeptides
The risk of nephrotoxicity urged for reduction of the absorbed kidney radiation dose to en-
able application of PRRT at high activity doses. Reduction of the uptake of the radiopeptide 
in the kidney will enlarge the therapeutic window; that is enabling increase of the cumulative 
tumour radiation dose without harmful effects on the kidney [75, 88].
Co-infusion with lysine and arginine (Lys/Arg) during PRRT partially prevents the renal reab-
sorption of radiopeptides resulting in less renal retention of radioactivity [88]. This method of 
kidney protection found its way to general clinical application during somatostatin analogue-
based PRRT, resulting in approximately 40% reduction of renal radioactivity [57, 60, 89, 90].
Recently, co-infusion of the plasma expander Gelofusine was described to achieve a similar 
reduction of renal retention of 111In-DTPA-octreotide [91]. A transient proteinuria is induced 
upon Gelofusine infusion, probably by disturbance of the effective megalin-mediated reab-
sorption processes in the kidney [92, 93]. Both in rats and in humans 40% less renal radioactiv-
ity was encountered after Gelofusine infusion [94, 95]. 
Moreover, as a new approach to obtain decreased levels of renal radioactivity, co-injection 
of fragments of the megalin ligand albumin also effectively reduced renal uptake of various 
radiopeptides [96, 97]. 
Grade 1 Inflammatory infiltrate in glomeruli, little dilatation of tubules
Grade 2 Grade 1 + more tubular dilatation, basal membrane thickening, few protein cylinders in 
tubules
Grade 3 Shrinkage of few glomeruli, flat tubule epithelium, strong tubule dilatation and basal 
membrane thickening, more protein cylinders
Grade 4 Increased shrinkage of glomeruli, strongly dilated tubules with massive protein 
cylinders and signs of fibrosis
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6. Mitigation of nephrotoxicity after PRRT
Besides reduction of the initial uptake and retention of radiolabelled peptides in the kidneys, 
interference in the process leading to kidney failure on the long-term, renal fibrosis, is another 
approach to accomplish less kidney damage after PRRT. This may be achieved following two 
pathways:
1: Application of anti-oxidants to inhibit the harmful effects of ROS
2: Inhibition of angiotensin II effects
Therefore, non-tumour-bearing and tumour-bearing rats received iv or ip amifostine or tau-
rine, L158.809 or captopril in their drinking water starting 10 days prior PRRT with 370 or 460 
MBq 177Lu-DOTA,Tyr3-octreotate. During the follow-up of more than 140 days after PRRT body 
weight, levels of urinary protein, serum urea and creatinine and renal 99mTc-DMSA uptake levels 
were determined, supplemented with kidney histology after euthanasia, as described below.
6.1: Amifostine and taurine; antioxidants 
The radical scavenger amifostine was developed to protect people from radiation effects 
during a nuclear war. Nowadays amifostine is FDA-approved for application as cytoprotector 
during radiotherapy [98, 99] and chemotherapy [100, 101] to protect healthy tissues such as 
kidneys, salivary glands and progenitor cells in bone marrow [102]. The pro-drug amifostine 
is converted into the active compound WR-1065 after dephosphorylation by the enzyme al-
kaline phosphatase (AP) which is 100 times more active in various healthy tissues than in 
tumours [103]. After EBRT in preclinical rat studies amifostine treatment resulted in kidney-
protective effects without interference in tumoural therapeutic effects [104, 105], confirmed 
by protection from long-term toxicity by amifostine after irradiation by 177Lu-DOTA,Tyr3-oc-
treotate PRRT in rats [106]. 
Taurine, 2-aminoethanesulphonic acid (C
2
H
7
NSO
3
), is a small molecule acting as an anti-ox-
idant. Addition of taurine to drinking water of rats reduced nephrotoxicity after treatment 
with cisplatin or cyclosporine A, both producing free oxygen radicals [107, 108]. These results 
encouraged to examine taurine as kidney protector during PRRT. 
6.2. L158.809 and Captopril; inhibitors of angiotensin II
As previously mentioned, angiotensin II plays a crucial role in the cascade of events leading to 
renal insufficiency. Therefore two ways to inhibit the harmful effects of angiotensin II leading 
to fibrosis were explored in PRRT. 
First, the application of an an giotensin II receptor blocker (ARB) to inhibit the effects of an-
giotensin II from any source directly at the receptor level was tested, because a clinical case 
report supported successful treatment using the ARB losartan in radiation nephropathy [109]. 
Furthermore, preliminary studies in which the ARB L158.809 was added to the drinking water 
of rats after 177Lu-DOTA,Tyr3-octreotate PRRT suggested renal protection [110]. 
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Second, an angiotensin converting enzyme inhibitor (ACEI) blocking the ACE dependent con-
version of angiotensin I into angiotensin II was examined for its kidney protective effects dur-
ing PRRT [111]. In a clinical trial in 55 subjects administration of the ACEI captopril after total 
body irradiation prior to haematopoietic stem cell transplantation suggested protection from 
chronic renal failure [112]. Captopril also showed favourable kidney protective results in rat 
studies after EBRT [113]. 
7. Autoradiography and small animal SPECT
In preclinical biodistribution studies with radiopeptides to quantify the uptake in various or-
gans of (tumour-bearing) mice or rats, generally the level of radioactivity in dissected organs 
is determined using a γ-counter. The localization of the radioactivity within the organs or 
tumours is not known, however.
The techniques of autoradiography and molecular imaging both provide information on the 
localization of radiolabelled agents within animals and/or tissues.
7.1 Autoradiography
To obtain ex vivo autoradiograms, visual images of accumulated radioactivity, 10 μm cryosec-
tions are cut from freshly frozen radioactive organs or tumours. Radioactivity can originate 
from several radionuclides with different characteristics, such as 111In, 177Lu, 99mTc or 68Ga. Ra-
dioactive tissue sections are exposed to sensitive phosphor imaging screens with high resolu-
tion. After the read out, detected radioactivity is depicted as black regions within the tissue 
section. Moreover the level of retained radioactivity can be adequately quantified. Using this 
technique the non-uniform distribution of radioactivity after administration of radiolabelled 
peptides within kidneys has been demonstrated, both in animals and humans [114, 115].
7.2 Small animal SPECT
Recent technical improvements of sensitivity and resolution of γ-cameras dedicated for small 
animal SPECT offer new opportunities in preclinical research in rodents [116, 117]. The resolu-
tion of SPECT is in the sub-millimeter range, allowing 3D visualization of retained radioactiv-
ity within targeted tissues after administration of radiolabelled agents. Furthermore, accurate 
absolute quantification of accumulated radioactivity in tissues such as tumours and kidneys 
is feasible [118]. Advantages of small animal molecular imaging include non-invasive in vivo 
functional imaging and following radiotracers over time within one animal. This may result in 
reduction of animal numbers needed to test new radiotracers. Moreover, monitoring of late 
side effects, development of disease or therapeutic effects after intervention, will be new fea-
tures in preclinical research. 
In Figure 6A the inhomogeneous distribution of radioactivity within kidneys and xenografted 
tumours of human origin in immunodeficient mice is visualized using multi-pinhole collimat-
ed SPECT/CT. This non-uniform pattern is confirmed by ex vivo autoradiography, as shown 
in Figures 6B and 6C [119]. With regard to rat PRRT experiments, reduction of renal retention 
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of radiolabelled octreotate using lysine and/or Gelofusine was nicely visualized and quanti-
fied [120], also showing that most radioactivity is retained in the renal cortex.Several clinically 
used radiopharmaceuticals are available to image kidney anatomy and renal function in small 
animals as well. The uptake of 99mTc-labelled dimercaptosuccinic acid (99mTc-DMSA) is directly 
related to tubular function [121]. Several hours after injection radioactivity is accumulated in 
the renal cortex because of peritubular extraction of 99mTc-DMSA from the blood and tubu-
lar reabsorption after glomerular filtration. Next to this static imaging the dynamic excretion 
processes in the kidney can be visualized and quantified using radiolabelled DTPA or 99mTc-
labelled mercaptoacetyltriglycine (MAG3). Clearance of 111In-DTPA can be used to monitor glo-
merular filtration and 99mTc-MAG3 is primarily rapidly extracted from the blood by cells lining 
the proximal tubules [121, 122]. Both agents are rapidly excreted via the renal pelvis into the 
urine. The extent of their renal uptake and excretion rate reflects the condition of the kidneys.
Tumour
Kidney
Bladder
Figure 6: (A) SPECT/CT of a mouse 
bearing two sst2-expressing H69 
tumours in the shoulder region 24 
h after injection of 111In-DOTA,Tyr3-
octreotate. Autoradiograms of the 
H69 tumour at the right (B) and a 
kidney (C).
C
BA
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Outline of the thesis
The main aims of the studies presented in this thesis are:
• To gain insight into the mechanisms of renal uptake and retention of various tumour 
targeting radiopeptides that are applied in PRS and PRRT
• To investigate ways to reduce the renal uptake and retention of tumour targeting radio-
peptides without affecting tumour uptake
• To monitor renal function after PRRT using dedicated small animal SPECT
A general introduction of this thesis is given in Chapter 1.1. It consists of a short overview of 
the development of PRRT over the last decades, characteristics of various tumour targeting 
peptide analogues and their renal uptake, and a preface on a putative mechanism of renal 
retention of radiopeptides. Furthermore, various agents that were studied to reduce renal 
uptake and toxicity are introduced. In Chapter 1.2 an overview of the status of kidney protec-
tion strategies during PRRT with radiolabelled somatostatin analogues is reported. Both clini-
cal and preclinical data are summarized, with emphasis on co-infusion of the cationic amino 
acids lysine and arginine enabling a reduction of 40% of radiolabelled somatostatin peptide 
analogues. Suggestions for future options to reduce renal toxicity after PRRT are described.
Chapter 2 consists of four manuscripts regarding the mechanisms of renal uptake and re-
tention of several tumour-targeting radiolabelled peptides. In Chapter 2.1 the renal uptake 
of five different peptide analogues in rats and mice of both sexes is described. After renal 
reabsorption radiopeptides appear to be retained mainly in the proximal tubules, located in 
the renal cortex, as is demonstrated in Chapter 2.2. Administration of sodium maleate and 
colchicine, agents that inhibit endocytic processes, appeared to reduce the renal retention 
of radiopeptides. Therefore a role of the multi-ligand scavenger receptor megalin in the renal 
reabsorption of radiopeptides was suggested. From our studies using kidney-specific megalin 
deficient mice, described in Chapters 2.3 and 2.4, indeed it appeared that megalin plays an 
important role in this respect for all radiopeptides tested despite differences concerning spe-
cificity, size and charge. This conclusion was important for development of new strategies to 
interfere in the renal reabsorption process of radiopeptides. 
Chapter 3 deals with two agents examined for reduction of renal radioactivity after admin-
istration of radiolabelled octreotate in somatostatin receptor-expressing CA20948 tumour-
bearing rats. The gelatine-based plasma expander Gelofusine was one of these. Infusion of 
Gelofusine leads to temporary proteinuria and previous experiments demonstrated a reduc-
tion of 40 to 60% of the renal retention of radioactivity when co-administered with radiola-
belled octreotate. For translation to clinical use, we investigated the dose-response effect of 
Gelofusine as described in Chapter 3.1. As second agent the anti-oxidant and cytoprotector 
amifostine was co-administered during PRRT because of its described long-term kidney-pro-
tective effects after EBRT and earlier PRRT studies. As described in Chapter 3.2 we examined 
the effect of amifostine co-administration regarding potential interference in anti-tumour ef-
fects after PRRT, the reduction of the initial renal uptake of radiopeptides in tumour-bearing 
rats and of co-incubation in in vitro binding assays using a megalin-expressing cell line.
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The development of dedicated small animal SPECT cameras opened new possibilities in pre-
clinical research on the application of radiopeptides labelled with γ-emitters. This is because 
high resolution enables detailed visualization of targeted tissues as well as accurate quanti-
fication of retained radioactivity. In Chapter 4 the application of non-invasive animal SPECT 
imaging to monitor the renal function of rats after 177Lu-DOTA,Tyr3-octreotate PRRT is de-
scribed. Three radiopharmaceuticals were administered to visualize and quantify glomerular 
filtration (111In-DTPA), tubular reabsorption (99mTc-DMSA) and tubular excretion (99mTc-MAG3). 
In Chapter 4.1 it is described that the uptake of 99mTc-DMSA could be accurately correlated 
with kidney function status. The localization and quantification of retained 99mTc-DMSA was 
investigated using in vivo SPECT imaging and ex vivo autoradiography in kidney sections, as is 
also shown in Chapter 4.2. In this chapter dynamic imaging to monitor the renal clearance 
of 111In-DTPA and 99mTc-MAG3 was performed besides static 99mTc-DMSA scintigraphy beyond 
100 days after PRRT, with or without lysine kidney protection. In Chapter 4.3 we report that 
nephrotoxicity was encountered in mice beyond 100 days after absorbed renal 111In-radiation 
doses of more than 40 Gy. 
A summary including indications for future directions of research into safe application of PRRT 
is given in Chapter 5. 
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Abstract
This review focuses on the present status of kidney protection during peptide receptor radio-
nuclide therapy (PRRT) using radiolabelled somatostatin analogues. This treatment modality 
for somatostatin receptor-positive tumours is limited by renal reabsorption and retention of 
radiolabelled peptides resulting in dose-limiting high kidney radiation doses. Radiation ne-
phropathy has been described in several patients. Studies on the mechanism and localiza-
tion demonstrate that renal uptake of radiolabelled somatostatin analogues largely depends 
on the megalin/cubulin system in the proximal tubule cells. Thus methods are needed that 
interfere with this reabsorption pathway to achieve kidney protection. Such methods include 
co-administration of basic amino acids, the bovine gelatine-containing solution Gelofusine 
or albumin fragments. Amino acids are already commonly used in the clinical setting during 
PRRT. Other compounds that interfere with renal reabsorption capacity (maleic acid and col-
chicine) are not suitable for clinical use because of potential toxicity. The safe limit for the renal 
radiation dose during PRRT is not exactly known. Dosimetry studies applying the principle of 
the biological equivalent dose (correcting for the effect of dose fractionation) suggest that a 
BED of about 37 Gy is the threshold for development of kidney toxicity. This threshold is lower 
when risk factors for development of renal damage exist: age over 60 years, hypertension, dia-
betes mellitus and previous chemotherapy. A still experimental pathway for kidney protection 
is mitigation of radiation effects, possibly achievable by co-treatment with amifostine (Ethyol), 
a radiation protector, or with blockers of the renin-angiotensin-aldosterone system. Future 
perspectives on improving kidney protection during PRRT include combinations of agents to 
reduce renal retention of radiolabelled peptides, eventually together with mitigating medi-
cines. Moreover, new somatostatin analogues with lower renal retention may be developed. 
Furthermore, knowledge on kidney protection from radiolabelled somatostatin analogues 
may be expanded to other peptides.
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Introduction
Peptide receptor radionuclide therapy (PRRT) is a relatively new treatment modality for soma-
tostatin-receptor positive tumours, such as neuroendocrine tumours that hardly respond to 
chemotherapy. These tumours often show a high expression of somatostatin receptors [1-3] 
compared to normal tissues. The basis for the use of radiolabelled somatostatin analogues 
in the treatment of somatostatin receptor-positive tumours is binding of the radiolabelled 
compound to the receptor and subsequent internalization of the receptor-ligand complex 
[4-6]. Receptor-mediated internalization of 111In-DTPA-octreotide results in degradation to me-
tabolites in the lysosomes [7]. These metabolites are retained in the lysosomes of tumour cells 
positive for somatostatin receptor subtype 2 (sst2), causing prolonged local irradiation. 
The first radiolabelled somatostatin analogue used for PRRT in patients with somatostatin 
receptor-positive tumours was 111In-DTPA-octreotide [8]. 111In emits Auger electrons, internal 
conversion electrons and γ-radiation. Treatment of patients with metastasized neuroendo-
crine tumours with high-dose 111In-DTPA-octreotide was encouraging, although objective re-
sponses were uncommon [9-11]. 
In order to improve the therapeutic efficacy, β particle-emitting radionuclides were coupled 
to somatostatin analogues. The chelator DTPA cannot be stably labelled with 90Y (maximum β 
energy 2.3 MeV, half-life 64 hours). Therefore DOTA,Tyr3-octreotide was introduced as targeting 
peptide which also has an improved affinity for sst
2
 as compared to DTPA-octreotide (Table 1). 
Several groups have reported beneficial effects of 90Y-DOTA,Tyr3-octreotide in patients suffer-
ing from somatostatin receptor-positive tumours [12-16] both in terms of objective response 
and quality of life. Complete and partial remissions in most studies with 90Y-DOTA,Tyr3-octreo-
tide have been in the range of 10-30%, higher than those obtained with 111In-DTPA-octreotide 
[17].
A few years ago, the radiolabelled somatostatin analogue 177Lu-DOTA,Tyr3-octreotate was intro-
duced. It differs from DOTA,Tyr3-octreotide in that the C-terminal threoninol is replaced with 
threonine. Compared to DOTA,Tyr3-octreotide, DOTA,Tyr3-octreotate has a ninefold higher af-
sst1 sst2 sst3 sst4 sst5
SS28 5.2 2.7 7.7 5.6 4.0
Octreotide >10000 2.0 187 >1000 22
DTPA-octreotide >10000 12 3790 >1000 299
111In-DTPA-octreotide >10000 22 182 >1000 237
DOTA,Tyr3-octreotide >10000 14 880 >1000 393
90Y-DOTA,Tyr3-octreotide >10000 11 389 >10000 114
DOTA,Tyr3-octreotate >10000 1.5 >1000 453 547
Table 1: IC50 values (nanomoles) of somatostatin analogues for somatostatin receptor subtypes (sst) (adapted from 
reference [3]). 
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finity for sst2 [3] (Table 1). In phase 1 and 2 studies using 177Lu-DOTA,Tyr3-octreotate, partial 
and complete remissions were found in up to 30% of patients. Additionally, treatment resulted 
in a significant improvement of quality of life [18]. 
Overall, treatment with radiolabelled somatostatin analogues is a promising new tool in the 
management of patients with otherwise untreatable, metastasized neuroendocrine tumours. 
Tumour regression results are encouraging and compare favourably with those of the lim-
ited number of alternative treatment approaches [17]. However, soon after the start of clinical 
studies, concern was raised about absorbed radiation dose to the kidneys and the bone mar-
row. Because renal function impairment has been reported [14, 19-21], several studies have 
been started to reduce the risk of nephrotoxicity during PRRT. 
The aim of this review is to summarize the current status on kidney protection in PRRT with 
radiolabelled somatostatin analogues.
Renal radiation is dose-limiting in PRRT 
The radiolabelled somatostatin analogues that are being used in PRRT are predominantly 
cleared by the kidneys. The small peptides are filtered by the glomeruli and most of the activ-
ity is excreted via the urine. However, about 2% of the total dose is reabsorbed by the proximal 
tubular cells. After transport to the lysosomes, the (metabolized) radioligand is retained there 
[7], resulting in prolonged kidney irradiation. 
In most clinical PRRT studies with 90Y-DOTA,Tyr3-octreotide it was found that the kidney ab-
sorbed radiation dose is the major dose-limiting factor and in several articles renal toxicity 
after PRRT was found. In a dose-escalating study [19, 20], 1 out of 30 patients had grade 2 renal 
toxicity. This 58 years old patient, who had suffered from hypertension for 6 years, received 
3.3 GBq 90Y-DOTA,Tyr3-octreotide in three cycles, and the reported estimated kidney absorbed 
radiation dose was 12 Gy. One year later his serum creatinine had returned to normal, but 
his 99mTc-DTPA scintigraphy remained abnormal, indicating reduced glomerular filtration rate. 
In an intra-patient dose-escalating study [14], renal toxicity was seen in 4 out of 29 treated 
patients after administration of cumulative activities of 7611-8924 MBq/m2 90Y-DOTA,Tyr3-oc-
treotide. None of these four patients received co-infusion of amino acids. Two of them needed 
haemodialysis treatment. Serum creatinine levels started to rise 2-4 months after the last treat-
ment cycle in these patients. As the 25 patients who had no renal toxicity received cumulative 
activities up to 7400 MBq/m2 (some with amino acids for kidney protection) the authors sug-
gested this cumulative activity to be the threshold dose of 90Y-DOTA,Tyr3-octreotide for renal 
toxicity.
However, Cybulla et al. [21] reported a case history of a 78 years old patient who was treated 
with 5659 MBq/m2 90Y-DOTA,Tyr3-octreotide. She developed progressive deterioration of renal 
function within 15 months after cessation of PRRT and developed end-stage renal disease. 
This patient had been treated with ten chemotherapy cycles in the years preceding PRRT. Stof-
fel et al. [22] reported a patient who was treated with six cycles of 90Y-DOTA,Tyr3-octreotide for 
metastasized medullary thyroid carcinoma. She developed renal failure 10 months after the 
last treatment cycle, eventually in needed haemodialysis. 
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Based on these studies, it is generally acknowledged that the kidney is a major dose-limiting 
organ in PRRT with radiolabelled somatostatin analogues. 
Radiation nephropathy after PRRT
Several authors have reported the clinical and histological fi ndings in radiation nephropathy 
caused by PRRT. Moll et al. [23] described the clinical course of fi ve patients that had been 
included in the study of Otte et al. using 90Y-DOTA,Tyr3-octreotide [14]. In these fi ve patients 
the onset of renal failure ranged from 0.5-6 months after treatment with 7600-8900 MBq/m2. 
All patients had normal blood pressure and serum creatinine levels before treatment; and one 
had received chemotherapy treatment previously. At onset of renal failure all had hyperten-
sion, proteinuria and microscopic haematuria. In one patient fragmentocytes were found. In 
three patients kidney biopsy showed the picture of thrombotic microangiopathy. Capillary 
loop collapse, focal segmental thrombi of fi brin and other proteins in capillaries, mesangiolysis 
and double contouring of the basement membrane were seen. Arterioles and small arteries 
showed transmural hyalin deposits and were partially or completely occluded by fi brin and 
protein thrombi. Tubular atrophy and interstitial fi brosis were prominent in all cases. Deposition 
of fi brin, IgM and IgA was observed in both the lumen and the wall of arterioles and arteries.
The patient described by Stoffel et al. [22] had no change in kidney function until she was ad-
mitted for progressive weakness, anaemia and arterial hypertension ten months after her last 
PRRT treatment. She had mild glomerular and tubular proteinuria, as well as a low creatinine 
clearance (CLR) of 14 ml/min. Kidney biopsy showed segmental mesangiolysis in 6/15 glom-
eruli with disruption and vacuolar expansion of the mesangium. No pathognomic deposits 
were present. There was marked tubular atrophy and compensatory interstitial fibrosis, as well 
as minimal arterial damage. No intra-arterial thrombosis or necrosis were observed. Unfortu-
nately, Stoffel et al. did not include administered activity or dosimetry data. Barone et al. [24] 
reported two patients who suffered from hypertension, proteinuria, oedema and anaemia 
after 90Y-DOTA,Tyr3-octreotide treatment. At biopsy, radiation-induced microangiopathy was 
proven in one of these patients. The conventional calculated kidney absorbed doses were 27.5 
and 27.1 Gy, whereas the biological equivalent doses (BEDs) were 54.1 and 56.1 Gy.
In our institution kidney biopsies in four patients have shown no histological damage after 
treatment with 90Y-DOTA,Tyr3-octreotide (kidney absorbed doses of 29.3 and 32.3 Gy) and 111In-
DTPA-octreotide (absorbed doses of 35 and 49 Gy) (unpublished data). The intervals between 
first treatment and biopsy ranged between 12 and 17 months. 
Animal data on targeted radionuclide therapy-related renal toxicity are scarce. Lewis et al. 
[25] found no functional or histological damage up to 38 days after administration of 847-903 
MBq 177Lu-DOTA,Tyr3-octreotate (corresponding to a kidney absorbed dose of 107-114 Gy). We 
found that severe renal toxicity became apparent later than 100 days after injection of 555 
MBq 177Lu-DOTA,Tyr3-octreotate in rats, which resulted in renal absorbed doses of about 70 Gy 
[26]. Although some damage was seen in the glomeruli as evidenced by glomerulus shrink-
age, in this model the main site of renal damage was the tubules. Basal membrane thicken-
ing and dilatation of flat tubule epithelium with massive protein cylinders in the lumen were 
noticed. Signs of peripheral fibrosis were present as well.
Chapter 1.240
In PRRT the site of histological damage is, amongst other factors, dependent on the particle 
range of the radionuclide used. In the case of 90Y, radiation damage is mostly in the glomeruli, 
as evidenced by the picture of thrombotic microangiopathy, and tubuli. For radionuclides 
with shorter ranges, such as the β emitter 177Lu or the α emitter in the study of Jaggi et al. [27], 
the damage is predominantly in the tubules with no or less damage in the glomeruli. This is in 
agreement with microdosimetric studies [28].
Prevention of radiation nephropathy and enlargement of the 
therapeutic window in PRRT
The following issues are important in the prevention of radiation nephropathy and in allowing 
the administration of higher doses in PRRT within safe kidney radiation limits:
• Knowing the uptake mechanism to develop renal uptake inhibitors.
• Knowing and not exceeding the maximum safe renal radiation dose and the use of dose 
fractionation.
• Reduction of kidney uptake of radiolabelled peptides by uptake inhibitors.
• Mitigation of radiation effects.
• Development of new peptides with a higher affinity for the receptor or lower renal uptake.
Mechanism and localisation of uptake
The proximal tubule is the site where filtered low molecular weight proteins, peptides 
and electrolytes are reabsorbed [29, 30] to prevent loss of valuable substrates for metabo-
lism. Radiolabelled peptides are small and therefore filtered by the glomeruli and partly 
reabsorbed in the proximal tubules. This is supported by ex vivo autoradiography stud-
ies that have shown that part of the injected 111In-DTPA-octreotide is located in the cor-
tex of the kidney (Figure 1). Micro-autoradiography of kidneys after administration of 
177Lu-DOTA,Tyr3-octreotate in rats demonstrated that radioactivity was retained in the proximal 
tubules [31]. In the human kidney the distribution of radioactivity was also inhomogeneously 
distributed [32]. Three patients that underwent nephrectomy because of renal cancer were 
injected with 111In-DTPA-octreotide prior to the surgery. Ex vivo autoradiography of healthy 
kidney tissue showed that the radioactivity was localized predominantly in the cortex in a 
striped pattern, with the highest radioactivity in the inner cortical zone [32].
The megalin/cubilin system plays a significant role in 
the reabsorption of many low molecular weight pro-
teins and peptides via receptor-mediated endocyto-
sis. Barone et al. showed in studies with wild opossum 
kidney cells that uptake of 111In-DTPA-octreotide was 
inhibited by different megalin ligands [33]. In kidney-
specific megalin-deficient mice it was shown that the 
uptake of 111In-DTPA-octreotide was only 15-30 % of 
uptake in normal mice [34]. These studies indicate 
that megalin plays an essential role in renal uptake of 
radiolabelled somatostatin analogues.
Figure 1. Ex vivo autoradiogram of a rat 
kidney 24 h after injection of 111In-DTPA-
octreotide showing the radioactivity 
distribution.
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Although most data point to proximal tubular reabsorption as the main site of uptake, other 
factors like sst2-mediated or peritubular uptake may play a role as well. Glomeruli, tubule cells 
and vasa recta in the human kidney express sst2 [35, 36]. In a study of 10 patients the kidney 
uptake of 111In-DTPA-octreotide was reduced by 18% due to treatment with high doses of 
unlabelled octreotide as compared to no octreotide treatment [37].
Stahl et al. reported a 20% reduction of renal uptake of 111In-DOTA,Tyr3-octreotide by proben-
ecid, which is a blocker of various organic anion transporters [38], suggesting that also peritu-
bular uptake of somatostatin analogues can occur. We were not able to confirm this finding in 
rats (unpublished data) however.
Maximum safe renal radiation dose: dosimetry and effects of dose fractionation
In the recent decade, several data have been reported that can help to estimate the maximum 
radiation dose that can be safely delivered to the kidney in PRRT. 
In fractionated external beam radiation therapy, the risk to develop radiation nephropathy 
within 5 years after renal absorbed doses of 23 Gy is 5%, rising to 50% after renal absorbed 
doses of 28 Gy [39]. However, it should be kept in mind that a radiation dose delivered during 
radionuclide therapy differs in many respects from a dose delivered by external beam irradia-
tion. In radionuclide therapy: (a) the dose rate is lower, (b) the penetration range of the radia-
tion is shorter and (c) the radionuclide has a specific intra-organ distribution, while in external 
beam radiation therapy the radiation is delivered homogeneously to the organ that is in the 
field of irradiation [40-42] .
So, in PRRT dosimetry is needed for establishment of the maximum safe dose to the kidneys 
and for patient-tailored therapy planning. Several authors reported large interindividual up-
take and radiation doses [43-46] stressing the need for such an approach. For optimal do-
simetry time-consuming methods are required, that include pharmacokinetic, biodistribution 
and washout studies, preferably with the same peptide and radionuclide used for therapy [43]. 
This is feasible with radionuclides that have both β—- and γ-emissions like 111In and 177Lu, but 
not with the pure β—-emitter 90Y. 
To determine absorbed doses of 90Y-DOTA,Tyr3-octreotide, strategies using 111In-DTPA-octreo-
tide [44], 86Y-DOTA,Tyr3-octreotide [24, 47] and 111In-DOTA,Tyr-octreotide [45, 48-50] have been 
reported. It seems reasonable to consider 86Y-DOTA,Tyr3-octreotide the most reliable because 
86Y is chemically identical to 90Y. However, the use of the positron-emitter 86Y is limited by its 
poor availability, the positron abundance of 33% and the relatively short half-life of about 14 
hours. 111In is more convenient in use, but minor changes in the peptide and differences in 
radionuclide can significantly influence sst2-mediated uptake and therefore the reliability of 
dosimetry data [3]. As the major part of kidney uptake is not sst2-mediated, this might not play 
a dominant role for the kidney. So, both 86Y-labelled and 111In-labelled DOTA,Tyr3-octreotide 
can probably reliably predict the renal absorbed radiation dose during treatment with 90Y-
DOTA,Tyr3-octreotide. For the use of 111In-DTPA-octreotide, comparison studies have shown 
that dosimetry values obtained using 86Y-DOTA,Tyr3-octreotide can be either underestimated 
[51] or overestimated [44].
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Another method to estimate absorbed doses is the use of 68Ga-labelled analogues. The level 
of somatostatin receptor expression of primary and/or metastasized tumours may be quanti-
fied (expressed in SUV) using 68Ga PET imaging, as described for 68Ga-DOTA,Tyr3-octreotide 
[52, 53] and 68Ga-DOTA-NOC (68Ga-DOTA,1-Nal3-octreotide) [46, 54, 55]. It has been shown that, 
especially combined with CT scanning, this imaging modality has a very high specificity and 
sensitivity [53]. 68Ga PET/CT imaging is safe, reproducible and relatively cheap and is therefore 
attractive to select and monitor patients during PRRT. The normal physiologic distribution of 
68Ga-DOTA-NOC shows a SUV
max
 of approximately 1 as background level for muscle, up to 125 
for tumour whereas the mean kidney uptake has a SUV
max
 of 12.6, although with a range of 
4-22 [56]. This means that optimization of PRRT for each individual might be realizable using 
68Ga PET/CT scintigraphy [57], although dosimetry is hampered by the short half life of 68Ga. 
Again, it must be considered when the radiopeptide used for imaging is different from that 
used for PRRT, the reliability of dosimetry might be adversely affected. Dosimetry performed in 
PRRT is therefore only valuable, when its outcome correlates with radiation effects and when 
it predicts toxicity. Ultimately, factors that may influence the response of the kidney to a radia-
tion dose are: the nature of the peptide, the type of radionuclide used in combination with its 
intrarenal distribution, fractionation and the existence of risk factors for renal damage. These 
aspects are discussed in the following sections.
Choice of peptide
The choice of peptide might slightly influence the kidney absorbed dose. Forrer et al. [50] 
found a (not statistically significant) higher tumour-to-kidney for 111In-DOTA,Tyr3-octreotide 
as compared to 111In-DOTA,Tyr3-octreotate. Data from our institution show that tumour-to-
kidney ratio was significantly higher for 177Lu-DOTA,Tyr3-octreotate than for 177Lu-DOTA,Tyr3-
octreotide [58].
Choice of the radionuclide and its intrarenal distribution
In a study of 21 patients with renal absorbed doses up to 45 Gy following treatment with 
111In-DTPA-octreotide, no renal toxicity was seen during a follow-up of 3 years [9]. 111In emits 
two γ-rays and in addition Auger electrons with a tissue penetration of 0.02 - 10 μm and 
conversion electrons with a penetration of 200-500 μm. Using a microdosimetry model, Koni-
jnenberg et al. [59] found that 111In- and 177Lu-labelled somatostatin analogues are likely to 
have higher renal toxicity thresholds than 90Y, whose emitted electrons have a path length of 
12 mm. Consequently, the inhomogeneous, mostly cortical, intrarenal distribution of radio-
labelled somatostatin analogues is only of importance for 177Lu- and 111In-labelled peptides. 
In studies with 177Lu-DOTA,Tyr3-octreotate in our institution, the maximum kidney absorbed 
dose was limited to 23 Gy. In over 500 patients treated so far only 2 patients have had a reduc-
tion in renal function, both probably unrelated to the therapy. One patient had a CRL of 41 
ml/min at baseline and renal function further deteriorated during therapy. The other patient 
had heart failure due to increasing tricuspid insufficiency [60]. In another study, we evaluated 
the loss of renal function in 28 patients treated with 90Y-DOTA,Tyr3-octreotide and 37 patients 
treated with 177Lu-DOTA,Tyr3-octreotate over a period of at least 18 months after the last ther-
apy cycle [61]. All patients received amino acid solutions and the total kidney absorbed radia-
tion dose, was limited to 27 Gy. In the 90Y-DOTA,Tyr3-octreotide group nine patients had a CRL 
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loss per year of more than 15% versus two patients in the 177Lu-DOTA,Tyr3-octreotate group. 
The mean yearly decline in CRL was not significantly different between the two groups (7.3% 
per year in the 90Y-DOTA,Tyr3-octreotide group versus 3,8% per year in the 177Lu-DOTA,Tyr3-
octreotate group) but the cumulative renal absorbed doses was significantly higher in the 
90Y-DOTA,Tyr3-octreotide group ( 26.9 versus 19.7 Gy). 
Bodei et al. [62] analysed the renal function loss in 23 patients treated with 90Y-DOTA,Tyr3-
octreotide and in 5 patients treated with 177Lu-DOTA,Tyr3-octreotate. In nine patients kidney 
toxicity occurred (according to NCI criteria), all from the 90Y-DOTA,Tyr3-octreotide group. How-
ever, all five patients in the 177Lu-DOTA,Tyr3]-octreotate had some CRL function loss at 1-year 
follow-up.
In general, it seems safe to treat with 177Lu-labelled peptides. In this respect the study of For-
rer et al. [63] is of particular relevance. These authors administered one cycle of 7400 MBq 
177Lu-DOTA,Tyr3-octreotide to 27 patients who had been treated with 90Y-DOTA,Tyr3-octreotide. 
Serum creatinine did not rise in the course of this treatment, offering new, safe treatment op-
tions.
Effects of fractionation
Experimental studies show that the kidney has an extensive capacity for repair of sublethal 
radiation damage. The size per fraction markedly influenced the total dose tolerated [64, 65]. 
So, there is reason to take advantage of the effects of fractionation in the current dosimetry 
protocols.
Barone et al. [24] reported dosimetric data of 18 patients treated with 90Y-DOTA,Tyr3-octreotide 
and correlated these data with changes in CRL loss. The injected activities were individual-
ized so that the renal absorbed dose did not exceed 27 Gy. Despite this limit, several patients 
developed renal toxicity as notified by significant CRL loss, proteinuria, hypertension, oedema 
and anaemia. The CRL loss did not correlate with the renal absorbed dose, even after correc-
tion for actual kidney volume using CT. In contrast, the BED (corrected for CT-assessed actual 
kidney volume) that was estimated according to the linear quadratic (LQ) model correlated 
well with the yearly loss of CRL. The LQ model allows evaluation of the effects of fractionation 
on biological effects of radiation. The effects are a linear and quadratic function of the dose 
per fraction and a function of the fraction number [66]. The study of Barone et al. [24] indicates 
that a calculated BED between 27 and 42 Gy correlates with CRL loss rates of up to 10% per 
year, whereas a BED higher than 45 Gy would result in a yearly CRL loss of 26-56%. 
For comparison, when the available data of Otte et al. [14] are put in the LQ model (assum-
ing that the absorbed dose was 3.2 mGy/MBq [45], and the T1/2
EFF
 was 31 as calculated from 
Barone et al. [24]) the BEDs uncorrected for actual kidney volume ranged from 56 to 64 Gy. The 
patient reported by Cybulla et al. [21], who had had chemotherapy in the past, would have 
had a BED of 39 Gy. These numbers underline the proposed safe BED by Valkema et al. [61] and 
Barone et al. [24] of about 37 Gy. A recent study of Bodei et al. [62] suggests a similar maximum 
BED of 40 Gy in patients without risk factors.
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Effects of previous toxic insults on radiation effects
The clinical observation of kidney damage after PRRT in patients with hypertension ([19, 20], 
or after chemotherapy [21] indicates that other medical factors influence the radiation effects 
to the kidney. In the study of Valkema et al., five risk factors were identified for more rapid kid-
ney function loss: cumulative renal absorbed doses more than 25 Gy, diabetes, hypertension, 
age>60 years and renal radiation dose >14 Gy per cycle [61]. This was confirmed in the study 
of Barone et al., who found that hypertension, diabetes mellitus or previous chemotherapy 
negatively influenced the response of kidney to radiation [24]. Bodei et al. [62] recently recom-
mended a BED of 28 Gy as the maximum safe BED in patients with risk factor such as diabetes 
and hypertension.
Classical dosimetry is performed with standard reference kidney volumes, based on planar 
scintigraphy and is not corrected for fractionation. Therefore, new methods that include the 
actual kidney size and that take into account the intrarenal activity distribution and the effects 
of fractionation may be better tools for clinical practise in PRRT. Additional studies need to be 
performed to evaluate the value of such methods.  
Reduction of uptake of radiolabelled somatostatin analogues
Methods to reduce the uptake of radiolabelled somatostatin analogues are shown schemati-
cally in Figure 2.
Radiolabelled 
somatostatin 
analogue
Blood
Lumen
Megalin receptor
Gelofusine
Amino acids
1
2
3
lysosomes
Figure 2: Schematic drawing of two methods to reduce the uptake of radiolabelled somatostatin analogues in a 
proximal tubule cell (adapted from Behr et al. [67]). Infused molecules of Gelofusine or positively charged amino 
acids are freely fi ltered and enter the tubular fl uid (step 1). This results in megalin-mediated reabsorption of these two 
compounds, preventing reabsorption of freely fi ltered radiolabelled somatostatin analogues (step 2). Consequently, a 
lower amount of radiolabelled metabolites is retained in the lysosomes. Colchicine inhibits the return of the megalin-
receptor to the cell surface (step 3).
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Mogensen and Solling [68] found that proximal tubular reabsorption of low molecular weight 
proteins and peptides can be reduced by positively charged basic amino acids. This finding 
led many to investigate whether these amino acids might reduce renal reabsorption of radio-
labelled somatostatin analogues. Hammond et al. [69] were the first to publish a semiquan-
titative study  in humans showing that the renal uptake of [111In-DPTA0]octreotide could be 
reduced by a commercially available mixture of amino acids. A total of 35.2 g arginine and 9.8 
g lysine was infused in each of these 16 patients. Behr et al. [70] showed that the renal uptake 
of radiolabelled monoclonal antibody fragments could be significantly reduced by about 80% 
in mice. De Jong et al. [71] showed that co-injection of 400 mg/kg lysine reduced rat kidney 
uptake of [111In-DPTA0]octreotide by about 40%. Arginine reduced the kidney uptake by 18% 
[71]. Also, D-lysine co-injection lowered kidney uptake of [111In-DPTA0]octreotide [72]. Based 
on these (pre)clinical data various amino acid infusion schedules have been tested in patients.
We [73] tested five different amino acid solutions in patients injected with 111In-DTPA-octreo-
tide. Infusion of a commercially available amino acid solution (1500 ml, containing 10.3 g 
lysine and 16 g arginine) reduced the kidney uptake by 21%. Infusion of 25, 50 and 75 g of 
lysine resulted in reductions of 17%, 15% and 44%, respectively. A combination of 25 g of 
lysine and 25 g arginine (combination named Lys/Arg) resulted in a reduction of 33%. Figure 
3 shows the results of abdominal scintigraphy in an example patient in this study. Two signs 
of toxicity were noted in this study. Due to high osmolarity, patients often suffer from nau-
sea and vomiting. In this study the frequency of nausea and vomiting was the highest (50% 
of patients) during infusion of the commercially available amino acid solution. Vomiting and 
nausea were less frequent when the other solutions tested were infused. The second toxic-
ity concern was hyperkalaemia. This might be caused by an extracellularly directed shift of 
potassium secondary to an increased production of ketonic bodies in an acidic environment, 
as lysine is a ketogenic amino acid [74-78]. In our study, infusion of 75 g lysine resulted in 
Figure 3. Abdominal scintigraphy in the same patient after administration of 220 MBq 111In-DTPA-octreotide. Images 
were obtained without (A) and with (B) co-infusion of Lys/Arg. Renal radioactivity was 52% of control when Lys/Arg 
was infused. From reference [73].
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elevated potassium concentrations in three patients (6.3, 6.7 and 6.8 mmol/l) out of eight. The 
highest potassium concentration among the nine patients infused with 25 g lysine plus 25 
g arginine was 6.0 mmol/l [73]. Other metabolic changes caused by infusion of amino acids 
were mild hypophosphataemia (with both lysine solutions and mixed amino acids solutions) 
and elevated urea levels (with mixed amino acid solutions) [79].
Jamar et al. [47] also compared various amino acid solutions as well. They showed that a mixed 
amino acid solution (1,800 ml, containing 240 g mixed amino acids including 10.3 g lysine and 
16 g arginine) reduced the renal uptake of 86Y-DOTA,Tyr3-octreotide by 21 % with concurrent 
reductions in estimated kidney radiation doses when applied to 90Y-DOTA,Tyr3-octreotide ther-
apy. Prolongation of the infusion further enhanced the reduction. The maximum allowed dose 
of 90Y-DOTA,Tyr3-octreotide that would result in a 23 Gy kidney absorbed dose was calculated. 
The maximum allowed dose was 46% and 62% higher for mixed amino acids and the combi-
nation of 25 g lysine and 25 g arginine, respectively. Chinol et al. [80] reported the absence of 
renal toxicity after cumulative injected activities of 7.4-11 GBq 90Y-DOTA,Tyr3-octreotide. The 
administered activity could safely be enlarged to 12-18 GBq with co-infusion of amino acids in 
a new cohort of patients, suggesting that co-infusion of amino acids allows dose-escalation. 
Only reversible grade 1 renal toxicity was seen in two patients. 
Taken together it can be concluded that co-administration of amino acid solutions can indeed 
be used to administer higher doses of radiolabelled somatostatin analogues without risk of 
nephrotoxicity. The side effects are moderate and mostly easy to handle. In our institution, we 
have not encountered any serious problems with the routine infusion of Lys/Arg administra-
tions in hundreds of patients. Some studies in rats have shown renal damage after high-dose 
lysine administration [81-83], whereas others show beneficial effects of amino acid solutions 
in acute tubular necrosis in patients [84]. The long-term toxicity of amino acid solutions re-
mains to be determined in humans, but no cases of nephrotoxicity induced by lysine or argi-
nine have been reported.
As already discussed, the renal uptake of radiolabelled somatostatin analogues is at least part-
ly associated with the megalin/cubilin system. Triggered by this finding, Van Eerd et al. [85] 
tested the potential of the plasma expander Gelofusine in mice and rats to reduce kidney 
uptake of radiolabelled somatostatin analogues (Figure 4). Gelofusine consists of succinylated 
bovine gelatine molecules and is used in clinical emergencies as a plasma expander. Infusion 
of Gelofusine has been reported to result in enhanced excretion of megalin ligands [86, 87]. 
Van Eerd et al. found that co-injection of Gelofusine reduced kidney uptake of 111In-DTPA-
octreotide by about 45 %, comparable to the reductions found following co-injection of lysine 
[85]. This preclinical study was followed by a study in five healthy subjects, which showed 
comparable results [88]. Recently, we [89] and Gotthardt et al. [90] showed that the combina-
tion of Gelofusine and lysine can even further reduce the renal uptake of radiolabelled soma-
tostatin analogues in rats as an additive effect. 
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There have been some safety concerns because of a relatively high incidence of allergic reac-
tions, however [91, 92]. Patients infused with Gelofusine during PRRT in Bad Berka showed 
promising results concerning the reduction of renal retention of either 90Y- or 177Lu-labelled 
somatostatin analogues [93]. A randomized study to compare renal uptake of 177Lu-DOTA,Tyr3-
octreotate in patients either receiving Lys/Arg alone or a combination of amino acids and 
Gelofusine, is planned to be performed in our institution. In a preclinical study tumour up-
take was unaffected when the combination of Gelofusine plus lysine was administered to sst
2 
receptor-expressing tumour-bearing rats [94].
The anti-gout drug colchicine is known to inhibit microtubule function in cells, especially 
those in proximal tubule cells. Microtubules are essential in the intracellular trafficking of 
all kinds of organelles, including endocytosed receptor-ligand complexes. After injection of 
colchicine, it has been shown that intracellular distribution of megalin is greatly changed: it 
moves from the brush membrane to other cellular compartments [95]. In line with this, we 
[96] have shown that administration of colchicine significantly lowers the kidney uptake of 
111In-DTPA-octreotide in rats. The combination of colchicine with lysine results in an additive 
reduction of renal uptake [96]. The use of colchicine in the clinical setting is hindered by the 
small therapeutic index of the compound. 
Sodium maleate, has been shown to reduce renal uptake of radiolabelled somatostatin ana-
logues in rats. The sodium maleate was administered either as a co-injection or several hours 
prior to administration of radiolabelled peptide and reduced renal uptake to 15-30% of the 
uptake in controls [31, 71]. Maleate impairs megalin-mediated endocytosis by reducing en-
ergy metabolism in the cells. Maleate administration did not affect localization of 111In-DTPA-
octreotide in ex vivo autoradiography. Also megalin expression was unchanged in immuno-
histochemistry studies [31]. Although an effective tool to lower renal uptake or radiolabelled 
peptides, this drug is not an option for clinical use because serious toxic effects have been 
described  [71, 97, 98]. 
Recently, a new method to reduce the renal retention of several radiolabelled peptides, 
including somatostatin analogues, has been introduced: co-administration of albumin frag-
Figure 4. Ex vivo autoradiography of kidney sections 24 h after injection of 40 MBq 111In-DOTA,Tyr3-octreotate with 
co-injection of saline (A) or 80 mg/kg Gelofusine (B).
A B
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ments with a molecular weight between 3 and 50 kDa, in both in vitro and in vivo studies 
[99, 100]. Albumin (molecular weight 67 kDa), which is a megalin ligand, is only marginally 
reabsorbed in the renal tubular cells, whereas the smaller fragments are reabsorbed to a high 
extent. Therefore this method probably also interferes with the megalin-mediated reabsorp-
tion pathway, as the albumin fragments may inhibit renal absorption of radiopeptides in a 
competitive way which can be different from the mechanism of interference when basic ami-
no acids are co-administered. Combination of these two methods to reduce renal retention 
would give more insight into this issue. 
Mitigating the effects of radiation 
Another renoprotective strategy is to reverse or interfere with the cascade of events after 
radiation. As radiation causes a chronic state of oxidative stress with continuous production 
of reactive oxygen species, the radioprotective drug amifostine (Ethyol, WR-2721) has success-
fully been used in the protection of healthy tissues in the case of radiation therapy of throat 
tumours [101] and during chemotherapy with cisplatinum [102]. After injection, this drug is 
activated by alkaline phosphatases and subsequently taken up by healthy cells. The kidney 
concentrations of the active metabolite WR-1065 are about 100 times higher than tumour 
concentrations [102], which forms the basis for selective protection of healthy tissue. We have 
recently shown that amifostine can ameliorate functional renal damage in rat kidneys [103]. 
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the development of radi-
ation damage to the kidney. There are several reports of Cohen et al. indicating that treatment 
with angiotensine converting enzyme (ACE) inhibitors or angiotensin II-receptor blockers 
(ARB’s) prevents  the development of radiation damage, and in bone marrow transplantation 
experiments in rats after total body irradiation could even successfully correct established 
radiation nephropathy [104-108]. A randomized controlled study in patients on the protec-
tive effect of the ACE inhibitor captopril on nephropathy after bone marrow transplantation 
showed increased survival in the experimental group compared to the placebo controls [109]. 
Jaggi et al. [110] tested the effects of RAAS block in a mouse model of nephropathy induced 
by internal radiation using radioimmunotherapy with an antibody labelled with an α-emitter. 
They showed, however, that treatment with captopril enhanced renal functional and histo-
logical damage. This might point to species differences in renal radiation sensitivity, or to a 
compensatory mechanism of increased angiotensine II production by a non-ACE-dependent 
pathway which is not activated in the external radiation-induced nephropathy [111]. But treat-
ment with the aldosterone receptor antagonist spironolactone and, to a lesser extent, treat-
ment with an angiotensine II receptor blocker was able to prevent the development of histo-
pathological and functional changes caused by α emitter internal radiation. Preliminary data 
from our institution show that addition of an ARB to lysine (in order to interfere with the RAAS 
system) ameliorates 177Lu-DOTA,Tyr3-octreotate-induced nephropathy in rats [112].
Development of new peptides with a higher affi nity for the somatostatin 
receptor or with lower renal uptake
Enlarging the therapeutic window in PRRT can be achieved either by increasing the tumour 
uptake or by reducing the renal uptake, as has recently been reviewed [113]. Development of 
new somatostatin analogues with better targeting properties in PRRT is a possible approach 
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to increasing the therapeutic tumour dose. New, stable somatostatin analogues with a higher 
affinity for somatostatin receptors compared to the commonly used somatostatin analogues 
might improve the therapeutic effect [114]. A nice example is DOTA-NOC ([DOTA0,1-Nal3]oc-
treotide), which has a high affinity for sst2, 3 and 5, and in preclinical models has shown 
increased tumour uptake together with lower renal uptake compared to other somatostatin 
analogues [115]. This resulted in a more than twofold increase in tumour to kidney ratio. How-
ever, a recent study in 95 patients, revealed that uptake by normal organs, but not the kidney, 
and radiation doses were higher with 177Lu-DOTA-NOC than with 177Lu-DOTA,Tyr3-octreotide, 
whereas tumour uptake was higher with 177Lu-DOTA,Tyr3-octreotate [46]. Besides DOTA-NOC, 
the Thr8 counterpart DOTA-NOC-ATE (DOTA0,1-Nal3,Thr8]octreotide) has also been developed, 
as well as DOTA-BOC-ATE ([DOTA0,BzThi3,Thr8]octreotide). Overviews of IC-50 values of these 
peptides, labelled with 68Ga, 90Y, 111In or 177Lu, have been published [93, 116]. Their application 
in imaging and PRRT of neuroendocrine tumours has not yet been established.
Recently pansomatostatin receptor-targeting molecules have been developed that recognise 
all sst subtypes, offering broad application in patients suffering from several cancer types, 
either nonlabelled or radiolabelled [117]. The renal uptake of these radiopeptides is relatively 
high however. 
Almost all somatostatin analogues used in diagnostic and therapeutic settings are agonists. 
These molecules are internalized into the cells after receptor binding, resulting in deposition 
and retention of the radionuclide in the lysosome close to the nucleus. It has recently been 
demonstrated that somatostatin antagonist analogues show much higher binding capacity 
to tumour cells than agonists, leading to convincingly higher tumour to kidney ratios [118]. 
The renal retention of both antagonists and agonists was comparable. Because also the reten-
tion over time of antagonists on tumour cells is longer than that of agonists, antagonizing 
radiopharmaceuticals may be very useful for diagnostic imaging. The therapeutic efficacy of 
non-internalized radiolabelled antagonistic peptides will depend on the range and energy of 
the radionuclide used, because the distance to the cell nucleus to induce fatal DNA damage 
is larger than for internalized agonistic radiopeptides. Depending on the therapeutic dose 
administered, reduction of renal uptake may be applied to prevent a harmful kidney dose 
[117].
Conclusions and future outlook
PRRT using radiolabelled somatostatin analogues is a promising new treatment modality for 
otherwise incurable sst2-positive tumours. The renal uptake of the radiolabelled peptides 
is, however, dose-limiting as indicated by clinically observed renal toxicity and the rapidly 
reached kidney threshold of 23 Gy, adopted from external beam radiation therapy. Histologi-
cal damage in PRRT is not different from that seen in external beam radiation therapy. Various 
factors play a key role in the development of renal injury, amongst which are angiotensine II 
and TGF-β. Much progress has been made in recent years in improving PRRT, i.e. achieving 
the highest tumour radiation dose possible within safe margins for the kidney,. Although the 
maximum safe radiation dose to the kidneys is not completely established, recent work indi-
cates that the LQ model can describe the dose-effect relationship seen in PRRT. The critical 
safe renal dose may be different for the different radionuclides and radiopharmaceuticals used 
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in PRRT. Factors that lower one patient’s individual maximum safe kidney dose are hyperten-
sion, diabetes, age and a history of chemotherapy. 
When searching for methods that lower kidney uptake of radiolabelled peptides, knowledge 
of the uptake mechanism is required. Convincing evidence shows that the proximal tubule 
cell is the site of uptake, with the scavenger molecule megalin being the mediator of uptake. 
Methods that interfere with this receptor-mediated endocytosis process have been exten-
sively studied. Infusion of positively charged amino acids is now routinely used to significantly 
reduce kidney radioactivity uptake, empowering PRRT substantially. To further enhance this 
reduction, combining amino acids with the expander Gelofusine or albumin fragments might 
be considered. 
Other strategies to protect the kidneys during PRRT comprise treatment with radioprotec-
tive drugs (amifostine) and interference with the RAAS-system. Renal function in rats treated 
with amifostine during PRRT has been found to be less affected than in non-protected rats, 
but more studies are needed to address the effects on the tumour. Preliminary results have 
not shown an effect of amifostine on tumour uptake of radiolabelled somatostatin analogues 
[119]. Interference with the RAAS showed some benefits in one animal study [112], but more 
studies are needed to broaden our knowledge on the renoprotective effect of ARB and ACE 
inhibitors in PRRT. 
The combination of reducing initial renal uptake during PRRT (by administration of lysine, 
Gelofusine or albumin fragments) with agents to interfere in the development of nephropa-
thy (such as amifostine or RAAS interfering drugs), offers new opportunities to increase the 
therapeutic dose to tumours without risk of late renal failure, leading to improved survival of 
patients. 
The risk of bone marrow toxicity increases with increasing therapeutic dose. Studies into how 
to increase the therapeutic dose (more cycles, higher dose per cycle, improvement of specific 
activity of the compound) to the tumour in a renoprotective (and bone marrow-protective) 
regimen are needed to further improve PRRT with somatostatin analogues in the future. 
Studies on renal protection during PRRT have mainly focused on radiolabelled somatostatin 
analogues, but should be expanded to other peptide analogues. Radiolabelled gastrin ana-
logues targeting CCK-2 receptors are expected to be valuable in imaging and treatment of pa-
tients with medullary thyroid carcinoma or small-cell lung cancer. However, these analogues 
show a higher renal retention than somatostatin analogues though [90, 120]. The same holds 
true for the peptide analogue exendin which binds to the GLP-1 receptor, and is expressed 
on insulinomas. As the charge of these peptides is different from that of somatostatin deriva-
tives, lysine and arginine co-infusion might not be the first choice to lower renal retention. 
Gelofusine or albumin fragments might be better choices for reduction of renal retention in 
these cases as has been confirmed in several preclinical studies [90, 99]. In future studies when 
patients are imaged for diagnostic purposes with radiolabelled gastrin or exendin peptide 
analogues, dosimetry will reveal the need for methods to reduce kidney uptake. 
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Abstract 
Introduction: During therapy with radiolabelled peptides, the kidney is most often the criti-
cal organ. Newly developed peptides are evaluated preclinically in different animal models 
before their application in humans. In this study, the renal retention of several radiolabelled 
peptides was compared in male and female rats and mice.
Methods: After intravenous injection of radiolabelled peptides [somatostatin, cholecystoki-
nin (CCK), minigastrin, bombesin and neurotensin analogues], renal uptake was determined in 
both male and female Lewis rats and C57Bl mice. In addition, ex vivo autoradiography of renal 
sections was performed to localize accumulated radioactivity.
Results: An equal distribution pattern of renal radioactivity was found for all peptides: high 
accumulation in the cortex, lower accumulation in the outer medulla and no radioactivity in 
the inner medulla of the kidneys. In both male rats and mice, an increasing renal uptake was 
found: 111In-DTPA-CCK8 < 111In-DTPA-Pro1,Tyr4-bombesin >> 111In-DTPA-neurotensin < 111In-
DTPA-octreotide << 111In-DTP-MG0. Renal uptake of 111In-DTPA-octreotide in rats showed no 
gender difference, and renal radioactivity was about constant over time. In mice, however, 
renal uptake in females was significantly higher than that in males and decreased rapidly over 
time in both genders. Moreover, renal radioactivity in female mice injected with 111In-DTPA-
octreotide showed a different localization pattern. 
Conclusions: Regarding the renal uptake of different radiolabelled peptides, both species 
showed the same ranking order. Similar to findings in patients, rats showed comparable and 
constant renal retention of radioactivity in both genders, in contrast to mice. Therefore, rats 
appear to be the more favourable species for the study of the renal retention of radioactivity. 
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Introduction
Various tumours frequently overexpress receptors for regulatory peptides. In nuclear medicine, 
analogues of these regulatory molecules are used as peptide-based radiopharmaceuticals, 
specifically targeting these receptors for diagnostic and therapeutic purposes [1]. Visualization 
of (metastasized) neuroendocrine tumours using 
111
In-DTPA-octreotide (Octreoscan®) target-
ing somatostatin receptors (sst2, 3 and 5) is a successful example of this strategy, which has 
been performed routinely since the early 1990s [2, 3]. Peptide receptor radionuclide therapy 
(PRRT) using 90Y-labelled or 177Lu-labelled somatostatin analogues has been accepted as a clin-
ical application in tumour treatment [1, 4]. The development of novel radiopharmaceuticals 
specifically targeting other overexpressed receptors is an ongoing process [5, 6]. Among oth-
ers, bombesin analogues have been developed for, for example, breast and prostate cancers 
[7-10]. Cholecystokinin (CCK)/gastrin analogues can be applied for the diagnosis (and therapy) 
of medullary thyroid carcinoma and small cell lung cancer [11, 12]. Neuroendocrine tumours 
sometimes overexpress CCK-B (CCK2) receptors and can be diagnosed by these analogues as 
well [13]. Finally, neurotensin analogues are candidates for tumour imaging of patients with 
pancreatic adenocarcinoma [14, 15].
Conjugation of small peptides with an appropriate chelator is needed for the complexation 
of radioactive metal ions to the peptide with a high stability. Whereas non-chelated peptides 
are cleared via the liver and intestines, peptides chelated by diethylene triamine pentaacetate 
(DTPA) or dodecanetetraacetic acid (DOTA) are mainly cleared via the urinary tract. This rela-
tively fast renal clearance route is favourable in patients and results in low abdominal back-
ground [16]. However, due to the renal clearance and partial reabsorption of radiolabelled 
DTPA/DOTA-chelated peptides, the uptake and retention of radioactivity in the kidneys can 
be substantial. Therefore the kidneys are the main dose-limiting organs during peptide-based 
radiotherapy of cancer patients using high doses of therapeutic radionuclides.
Recently, we demonstrated that renal radioactivity after 
111
In-DTPA-octreotide administration 
does not show a uniform distribution. Moreover, different patterns were found in human and 
rodent kidneys [17, 18]. The highest amount of radioactivity was found in the renal cortex, 
located in proximal tubular cells. In mice, megalin, an endocytic receptor in proximal tubules, 
was shown to be essential for the renal retention of 
111
In-DTPA-octreotide [19].
Research on new radioligands includes modifying the design of peptides while preserving 
binding affinity for the target receptor. The receptor specificity of newly developed radioli-
gands has to be characterized in in vitro experiments using tumour cell cultures or tumour 
sections, followed by in vivo biodistribution studies in (tumour-bearing) animals [20]. For bio-
distribution studies, several species of rodents, of which rats and mice are the most common 
ones, are being used. The tumour specificity of peptide analogues is usually tested in athymic 
nude mice or severe combined immuno-deficiency (SCID) mice bearing xenografted tumours. 
However, the choice of animal species and the gender might influence the results of these 
studies. 
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The aim of this study was to investigate renal uptake and retention of different 
111
In-labelled 
analogues such as CCK, gastrin, bombesin, neurotensin and somatostatin in rats and mice. 
Furthermore, a comparison of the renal retention of 
111
In-DTPA-octreotide in male and female 
rats and mice was studied at several time points to investigate gender differences. 
Materials and Methods
Radiopharmaceuticals
111InCl
3
 was obtained from Tyco Health Care (Petten, The Netherlands). Radiolabelling was per-
formed according to previously published procedures [21, 22]. The peptide analogues used 
are listed in table 1.
Biodistribution experiments
Animal studies were conducted in agreement with the Animal Welfare Committee, using gen-
erally accepted guidelines.
Lewis rats and C57Bl6 mice or NMRI nude mice (both from Harlan, The Netherlands) were used. 
For biodistribution studies comparing the renal uptake of several radiolabelled peptides, male 
animals were anesthetized with isoflurane and injected intravenously into the dorsal vein of 
the penis. Rats received 0.5 μg of peptide (bombesin analogues, 0.1 μg) radiolabelled with 3 
MBq of 111In in 500 μl of saline (n=3-6 per group); mice received 0.1 μg of peptide radiolabelled 
with 4-10 MBq of 111In in 200 μl of saline (n=4 per group). In the experiment using both gen-
ders, 111In-DTPA-octreotide was administered intraperitoneally to unanesthetized aminals, 6 
MBq per rat (n=2 per group) and 10 MBq per mouse (n=4 per group). The route of administra-
tion does not influence renal uptake [28].
Peptide Structure Company Ref.
Somatostatin DTPA-D-Phe-octreotide Tyco Health Care, Petten, The Netherlands. [2]
Cholecystokinin DTPA-D-Asp1, Nle3,6-CCK-8 BioSynthema, St Louis Mo, USA [23, 24]
Bombesin DTPA-Pro1,Tyr4-bombesin BioSynthema, St Louis Mo, USA [25]
Bombesin
DTPA-ACMpip5,Tha6,βAla11,
Tha13,Nle14-bombesin5-14 
= MP2653 
BioSynthema, St Louis Mo, USA [26]
Neurotensin
DTPA-G(Pip)6,G(Pam)8,
tBuG12-neurotensin6-13  
BioSynthema, St Louis Mo, USA [15]
Minigastrin 0 
DTPA-D-Glu-(Glu)
5
-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH
2
)
 
kindly provided by Dr. M. Behe, Marburg, 
Germany 
[27]
Table 1: Structure of investigated peptide analogues and their manufacturers.
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After euthanasia at indicated time points post injection (p.i.), organs were isolated and blood 
samples were taken. Organs were weighed, and radioactivity was measured using a gamma 
counter (1480 Wizard 3”, Perkin Elmer/Wallac, Turku, Finland). Uptake of radioactivity was ex-
pressed as the percentage of injected activity per gram of tissue (%IA/g). One kidney of each 
animal was frozen embedded in Tissue Tek (OCT compound; Sakura, Zoeterwoude, The Neth-
erlands) using isopentane cooled in liquid nitrogen for autoradiography and immunohisto-
chemistry.
Ex vivo autoradiography
Frozen kidneys were cut into sections of 10 μm (Cryo-Star HM 560 M; Microm, Walldorf, Ger-
many) and mounted on Superfrost plus slides (Menzel, Braunschweig, Germany) for autoradi-
ography. Adjacent slides were used for immunohistochemistry. 
Autoradiography was performed with renal sections exposed to SR phosphor imaging screens 
(Packard Instruments Co., Meriden, USA) in X-ray cassettes. After 24-72 h, screens were read by 
a Cyclone phosphor imager and analysed with the OptiQuant 03.00 image processing system 
(Packard Instruments Co., Groningen, The Netherlands). Quantification of radioactivity was 
performed in five regions of interest in the cortex and in the outer medulla in five different 
sections of each tested kidney and radioactivity was expressed in digital light units per mil-
limetre square (DLU/mm2). 
Immunohistochemistry
Anti-megalin immunostaining was performed as described previously [18, 19], using the pri-
mary antibody goat-anti-megalin SC-16478 P-20 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), directed against both rat megalin and mouse megalin. 
Results
Renal retention of different radiolabelled peptides was determined in male rats and mice. 
Table 2 shows accumulated radioactivity 4 and 24 h after the intravenous injection of  111In-
labelled peptides in kidneys, ranking from the lowest to the highest values. The renal uptake 
of radioactivity was lowest for the CCK analogue, followed by that for the bombesin analogue 
and that for the neurotensin analogue. In rats, renal retention of the neurotensin analogue was 
comparable with that of the somatostatin analogue octreotide, whereas in mice, the neuro-
tensin analogue showed an evidently lower renal uptake than octreotide. Minigastrin 0 (MG0) 
showed renal retention remarkably higher than those of the other peptides, both in rats and 
mice. The rank order of the renal uptake of all analogues included was the same for rats and 
mice. It is noteworthy that renal radioactivity declined readily over time in mice, whereas this 
was not the case in rat kidneys.
Despite quantitative differences in renal uptake, ex vivo autoradiography showed comparable 
localization patterns of radioactivity in kidneys from both rats and mice after the injection 
of different radiolabelled compounds. Figure 1 shows ex vivo autoradiograms of these com-
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pounds in rat kidneys. We found high radioactivity in the cortex, less radioactivity in the outer 
medulla, and no radioactivity in the inner medulla. 
The influence of the gender on the uptake and retention of 111In-DTPA-octreotide in the kid-
neys was investigated over time (4 h, 24 h, 96 h and 168 h p.i.), both in rats and mice. 
In rats, the decline in the renal radioactivity of 111In-labelled DTPA-octreotide over time was 
low, ranging from 2.2 %IA/g at 4 h p.i. to 1.2 %IA/g at 168 h p.i., as demonstrated in Figure 2A. 
Moreover, the gender of rats did not influence kidney uptake: the ratio of uptake in the kid-
neys of females to uptake in the kidneys of males (F/M ratio) was close to 1 at all time points 
(Table 3). The distribution pattern of radioactivity in the kidneys of male and female rats, de-
termined by ex vivo autoradiography, was comparable at all time points post injection (Figure 
3A), and the ratios of accumulated radioactivity in the cortex to accumulated radioactivity in 
the outer medulla (C/OM ratio) were equal in both genders as well (Table 4). 
Rat Mouse
Peptide
111In-labelled peptide 
analogue 4 h p.i. 24 h p.i. 4 h p.i. 24h p.i.
Cholecystokinin DTPA-D-Asp1, Nle3,6-CCK-8 0.2 ± 0.0 0.2 ± 0.1 1.3 ± 0.3 0.9 ± 0.2
Bombesin DTPA-Pro1,Tyr4-bombesin 1.0 ± 0.1 0.6 ± 0.1 4.7 ± 0.7 1.6 ± 0.8
Neurotensin
DTPA-G(Pip)6,G(Pam)8,
tBuG12-neurotensin6-13
1.0 ± 0.0 1.4 ± 0.2 5.3 ± 2.7 2.1 ± 0.7
Somatostatin DTPA-D-Phe-octreotide 1.6 ± 0.1 1.5 ± 0.2 19.6 ± 1.5 3.9 ± 0.6
Minigastrin 0
DTPA-D-Glu-(Glu)
5
-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH
2
)
 
17.6 ± 1.5 16.3 ± 1.7 105.6 ± 7.0 72.1 ± 16.2
Table 2: Uptake (%IA/g) of several 111In-labelled peptide analogues in the kidneys of male rats and mice 4 and 24 h 
after the administration of 3 MBq/0.5 μg peptide (0.1 μg of bombesin) in rats (n=3-6 per group) or the administration 
of 4 MBq/0.1 μg in mice (n=4 per group).
Cholecystokinin Bombesin Neurotensin Octreotide Minigastrin 0
Range 3-100 Range 3-500 Range 3-750 Range 3-1000 Range 3-7500
Figure 1: Ex vivo autoradiograms of frozen sections of rat kidneys 24 h after the administration of 0.5 μg (0.1 μg of 
bombesin) of radiolabelled DTPA peptides with 3 MBq of 111In.
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A:
B:
In contrast, the same experiment performed in mice clearly showed a marked decrease in 
renal radioactivity over time, from >20% IA/g at 4 h p.i. to <1% IA/g at 168 h p.i. (Figure 2B). 
Furthermore, the retained radioactivity in female kidneys was significantly higher than the 
retained radioactivity in male kidneys. The F/M ratio of renal uptake varied and reached a 
maximum value of 4.7 at 24 h p.i. (Table 3). 
Figure 2: Mean uptake (%IA/g) of 111In-DTPA-octreotide in the kidneys of female and male rats (A) and mice (B) at 
4, 24, 96 and 168 h p.i. Rats (n=2 per group) received 6 MBq/0.5 μg radiolabelled peptide, and mice (n=4 per group) 
received 10 MBq/0.1 μg radiolabelled peptide. The diff erence in renal uptake between female and male mice was 
signifi cant (p<0.001) at all time points.
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Gender difference in the renal retention of radiolabelled peptide analogues in mice was con-
firmed in the biodistribution experiment with the bombesin analogue MP2653 (Figure 4). In 
the female kidneys, 2.4 times more radioactivity was retained compared to that in the male 
kidneys, determined 4 h p.i. The localization of the renal radioactivity of 111In-labelled DTPA-
octreotide in mice showed a clear difference between female and male kidneys. In male kid-
neys, we found the pattern described above, whereas in female kidneys, the highest amount 
of radioactivity was found in the outer medulla and less radioactivity was seen in the cortex 
(Figure 3B). This different pattern was found at all time points in female kidneys and, to a 
lesser extent, at 4 h p.i. in male mouse kidneys. Therefore the C/OM ratios showed marked 
differences between male and female mouse kidneys (Table 4). The C/OM ratio in females 
was always <1, whereas it resulted in a ratio of >1 in males, as was also shown in rats after the 
administration of 
111
In-DTPA-octreotide.
Immunohistochemistry using anti-megalin antibodies showed no difference in megalin ex-
pression between male and female mice (Figure 5).
hours post injection Rat Mouse
4 0.95 1.4
24 0.95 4.7
96 1.01 2.7
168 1.05 2.6
Table 3: Rats (n=2 per group) received 6 MBq/0.5 
μg radiolabelled peptide, and mice (n=4 per 
group) received 10 MBq/0.1 μg radiolabelled 
peptide.
hours post injection Female Male
Rat 4 2.4 2.3
24 3.1 3.1
96 5.4 5.0
168 5.2 5.0
Mouse 4 0.3 0.9
24 0.7 1.2
96 0.6 1.9
168 0.6 2.0
Table 4: C/OM ratio determined in ex vivo 
autoradiography studies, using Optiquant 
software, of the kidneys of female and male 
rats and mice 4, 24, 96 and 168 h after the 
administration of 111In-DTPA-octreotide.
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4 h p.i. 24 h p.i. 96 h p.i. 168 h p.i.
Range 3-1000 Range 3-750 Range 3-300 Range 3-150
A:
Female
Male
Range 3-1000 Range 3-750 Range 3-300 Range 3-150
Female
B:
4 h p.i. 24 h p.i. 96 h p.i. 168 h p.i.
Range 3-10000 Range 3-2000 Range 3-1000 Range 3-150
Range 3-10000 Range 3-750 Range 3-500 Range 3-75
Male
Figure 3: Ex vivo autoradiograms of frozen sections of rat (A) and mouse (B) kidneys from female and male animals 
4, 24, 96 and 168 h after the administration of 6 MBq/0.5 μg 111In-DTPA-octreotide in rats and the administration of 10 
MBq/0.1 μg 111In-DTPA-octreotide in mice.
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Discussion
High receptor affinity is a crucial issue in the development of new radiopeptides, mediating 
the ability to target tumour cells expressing the specific receptor. On the other hand, it is also 
essential that unspecific binding to healthy cells and organs be low. While unspecific uptake 
of radioactivity in, for example, the bowel, liver or perirenal region during scintigraphy can 
cause difficulties in the interpretation of scintigraphic images, it could induce severe side ef-
fects due to high radiation absorbed doses during PRRT. As side effects of radiation absorbed 
Figure 4: Uptake (%IA/g) of 111In-MP2653 in the kidneys of 
female and male mice at 4 h p.i. Mice received 10 MBq/0.1 μg 
radiolabelled peptide (n=4 per group). p=0.0015; F/M ratio=2.4.
Female Male
4 h p.i.
24 h p.i.
Figure 5: Immunohistochemical staining on frozen sections of female and male mouse kidneys 4 and 24 h after 
the administration of 10 MBq/0.1 μg 111In-DTPA-octreotide using anti-megalin antibody, visualized with DAB using 
peroxidise-labelled second-stage antibody. Haematoxylin counterstaining was performed. Original magnifi cation, 
x40.
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doses on the bone marrow (myelodysplastic syndrome) or kidneys (nephrotoxicity) have been 
described after PRRT [4, 29].
Before newly developed radiopharmaceuticals can be introduced in clinics, their pharmacoki-
netics, including specific (e.g., tumour) and non-specific (e.g., kidney, liver) uptakes, has to be 
studied in animal models. Besides mice, rats are also frequently used for biodistribution stud-
ies due to lower costs compared to nude or SCID mice. No study investigating the influence 
of the species and gender of laboratory animals on the in vivo biodistribution of radiolabelled 
peptides has been published so far. 
In this study, we demonstrated that the extent of renal uptake and retention is different for 
various 111In-labelled compounds. The same rank order of increasing renal uptake of radioac-
tivity was found in male rats and mice. Renal uptake increased with the charge of the peptide 
analogue. The CCK8 analogue does not contain charged amino acids, whereas bombesin con-
tains an arginine (Arg) residue, and both neurotensin and somatostatin analogues contain a 
lysine (Lys) residue, with Arg and Lys being positively charged amino acids. With six negatively 
charged glutamic acid (Glu) residues and one aspartic acid (Asp) residue, MG0 had the high-
est renal uptake and retention. Newly designed minigastrin analogues that contained less Glu 
residues showed lower renal uptake, pointing to a direct relation of charged amino acids with 
renal retention [30].
The localization pattern of renal radioactivity was comparable for the different analogues, sug-
gesting a similar pathway of renal uptake and retention. All peptides showed high radioactiv-
ity in the cortex and lower amounts of radioactivity in the outer medulla. We have shown in 
mice that the negatively charged multi-ligand scavenger receptor megalin [31] is essential 
for the renal uptake of 
111
In-DTPA-octreotide [19, 31]. It is present at the apical side of cells in 
proximal tubules, with high expression in the S1 and S2 segments of the tubules located in the 
cortex and with lower expression in the S3 segment located in the outer medulla [32], which 
correlates with the localization of retained renal radioactivity [18]. An essential contribution 
of megalin to the reabsorption of radiolabelled octreotide was also demonstrated by in vitro 
experiments with opossum kidney cells [33]. However, since megalin expression is equal in 
female and male mouse kidneys (Figure 5), the aberrant distribution pattern of radioactivity in 
ex vivo autoradiograms of the female kidney after 
111
In-DTPA-octreotide administration cannot 
be explained by differences in megalin-mediated uptake alone. 
The ratio of retained radioactivity in the renal cortex to retained radioactivity in the outer 
medulla (C/OM ratio) for 
111
In-DTPA-octreotide in male rats 24 h p.i is 3 (Table 3), whereas this 
ratio is 12 for the radioactive MG0 peptide analogue, indicating that the renal localization of 
the latter is mainly found in the cortex. This high ratio could be due to the strong negative 
charge of the MG0 analogue. It is unclear if the negatively charged megalin is the  scaveng-
ing receptor for the MG0 analogue. In renal proximal tubules, several transporter families are 
present. Organic anion transporters (OATs) and organic cation transporters, both at the api-
cal and basolateral sides of tubular cells, are two of them. These transporters are responsible 
for the elimination of many compounds, such as drugs and metabolites, from endogenous 
and exogenous origins [34]. The (high) renal retention of MG0 might be due to binding to an 
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OAT transporter molecule. Reduction of the renal uptake of MG0 has been achieved after the 
co-administration of a chain of at least five consecutive polyglutamic acids [27]. Cationic ami-
no acids Lys and Arg) interfere with the mechanism of the renal uptake of cationic peptides 
(megalin in the case of 111In-DTPA-octreotide), and anionic amino acids may reduce the renal 
uptake of anionic peptides such as MG0 by interfering with another mechanism that might 
be an OAT transporter system. Gotthardt et al. [35] demonstrated that Gelofusine, a gelatine-
based plasma expander, effectively reduced the renal retention of both MG0 and octreotide, in 
agreement with the involvement of reabsorption mechanisms other than megalin in the renal 
retention of radiolabelled peptides. 
We have previously shown in rats that the amount of radioactivity retained in the outer me-
dulla slowly decreased over time between 1 and 24 h p.i., whereas cortical radioactivity re-
mained quite constant, resulting in a rising C/OM ratio over time [18]. In the present study 
we expanded these results until 168 h p.i., demonstrating an increased C/OM ratio until 96 h 
p.i., after which it remained constant until 168 h p.i.. Thus, retention of radioactivity appears 
to be more stable in cortical proximal tubuli (S1 and S2) than in proximal tubuli located in the 
outer medulla (S2 and S3). The reason for these differences in renal retention is the subject of 
further studies.
From patient studies, it has been concluded that the renal retention of radiolabelled soma-
tostatin analogues over time was fairly stable [36]. These authors also showed that after cor-
rection for actual kidney volume based on CT studies, the renal uptake of radioactivity was not 
different between male and female patients [36]. In the present study, rat renal retention of 
radiolabelled somatostatin analogues was found to be fairly constant, without a clear gender 
difference. In contrast, renal uptake of radiolabelled somatostatin analogues in mice was read-
ily declining over time, and a marked gender difference was found. Therefore, rats appear to 
be a better choice than mice for the investigation of renal uptake in a preclinical animal model. 
Consequently, when using xenografted mice to study renal uptake versus tumour uptake, the 
gender of mice and the time point after injection have to be considered.
The observation made - that renal radioactivity after the injection of radiolabelled octreotide 
analogues in mice is higher in females than in males - has been previously described by our 
group [19, 37]. This high kidney uptake of 
111
In-DTPA-octreotide in females was also found by 
Froidevaux et al. [38]. However, a satisfying explanation for this phenomenon is still lacking. 
In biodistribution studies using a bombesin analogue, we also found higher renal uptake in 
females compared to males. Thus, gender difference in the renal retention of radiolabelled 
peptides in mice is not restricted to somatostatin analogues. 
Some notions on the possible mechanism of this sex difference may be a guide for future 
investigations unravelling the role of gender in the renal retention of radiolabelled peptides. 
An explanation of the gender difference in renal retention could be the sex-dependent excre-
tion of proteins in the urine of rats and mice. Both females and males excrete protein but the 
amount is fourfold to six fold higher in males in mice (ranging from 10 to 30 mg/ml) [39]. The 
synthesis is sex dependent under the influence of androgens [40]. In rats, the major urinary 
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protein is α
2
-microglobulin, whereas it is called major urinary protein in mice. These two pro-
teins have a strong homology, especially for specific domains [40]. However, the amino acid 
sequence of the binding pocket is different, leading to differences in ligand profile and affini-
ties. Another major difference is that major urinary proteins are glycosylated in rats, but not 
in mice. The high amount of low-molecular-weight proteins (19 kDa) in the primary urine of 
males may interfere with the clearance/reabsorption of other small proteins and peptides, as 
it is known from positively charged amino acids [41].
Another possible explanation for the difference in renal radioactivity retention between mice 
and rats might be kidney-androgen-regulated protein (KAP). This is a 20 kDa protein that is 
abundantly expressed in mouse kidney proximal tubular cells and that has been described 
by Cebrian et al. [42]. The function of KAP is still unknown. The expression of KAP in the corti-
cal S1 and S2 segments is both androgen receptor mediated and testosterone dependent, 
whereas no androgen is required for the expression in the medullar S3 segment. Thus, in male 
kidneys, KAP is expressed on all proximal tubular cells, whereas KAP expression is only found 
in the medullary proximal tubules in females. KAP expression in the female kidney shows a 
pattern [42] similar to the aberrant localisation of radioactivity found in female mice in the 
present study. This might indicate an involvement of KAP in the renal uptake of radiolabelled 
analogues. In rats mRNA for KAP has been found as well, but exhibits only a 53% homology 
with the mouse counterpart. The low homology of the molecule in rats could be the reason 
for the molecule having a different function in these animals. 
Further investigations are needed to fully understand mouse gender differences in renal re-
tention. 
Conclusions
Both rats and mice can be used to compare the renal retention of different radiolabelled pep-
tides since the same rank order in renal uptake was found. Renal uptake increases with the 
charge of the peptide analogue. 
Similar to findings in patients, rats showed constant retention and equal distribution of re-
nal radioactivity in both genders, whereas a fast decline of renal radioactivity over time and 
marked gender differences with aberrant radioactivity localization pattern were found in mice. 
Thus, compared to mice, the rat appears to be the more favourable animal model for the study 
of the renal retention of radiolabelled analogues. 
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Abstract
Introduction: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are 
used for tumour scintigraphy and radionuclide therapy. The kidney is the most important 
critical organ during such therapy owing to the reabsorption and retention of radiolabelled 
peptides. The aim of this study was to investigate in a rat model both the localization and 
the mechanism of renal uptake after intravenous injection of radiolabelled somatostatin ana-
logues. The multi-ligand megalin/cubilin receptor complex, responsible for reabsorption of 
many peptides and proteins in the kidney, is an interesting candidate for renal endocytosis of 
theses peptide analogues.
Methods: For localization studies, ex vivo autoradiography and micro-autoradiography of rat 
kidneys were performed 1-24 h after injection of radiolabelled somatostatin analogues and 
compared with renal anti-megalin immunohistochemical staining pattern. To confirm a role 
of megalin in the mechanism of renal retention of 111In-DTPA-octreotide, the effects of three 
inhibitory substances were explored in rats.
Results: Renal ex vivo autoradiography showed high cortical radioactivity and lower radio-
activity in the outer medulla. The distribution of cortical radioactivity was inhomogeneous. 
Micro-autoradiography indicated that radioactivity was only retained in the proximal tubules. 
The anti-megalin immunohistochemical staining pattern showed a strong similarity with the 
renal 111In-DTPA-octreotide ex vivo autoradiograms. Biodistribution showed that co-injection 
of positively charged D-lysine reduced renal uptake to 60% of control. Sodium maleate re-
duced renal 111In-DTPA-octreotide uptake to 15% of control. Finally, cisplatin pre-treatment of 
rats reduced kidney uptake to 70% of control. 
Conclusion: Renal retention of 111In-DTPA-octreotide is confined to proximal tubules in the 
rat kidney, in which megalin-mediated endocytosis may play an important part.
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Introduction
Tumours of neuroendocrine origin frequently show an over-expression of receptors with 
high affinity for regulatory peptides, such as somatostatin. Tumour targeting using the ra-
diolabelled somatostatin analogue 111In-DTPA-octreotide (Octreoscan®) [1, 2] is commonly 
performed for diagnostic purposes. For therapeutic applications, somatostatin analogues la-
belled β—-particle-emitting radionuclides, such as 90Y-DOTA,Tyr3-octreotide or 177Lu-DOTA,Tyr3-
octreotate, have shown promising anti-tumour effects [3, 4]. One of the topics in the field of 
peptide receptor radionuclide therapy (PRRT) concerns the radiation dose to tumours versus 
critical organs, such as kidney and bone marrow. 
Although the vast majority of radiolabelled peptides is excreted into the urine after intrave-
nous injection into the patient, a small percentage is retained in the kidneys after glomerular 
filtration and reabsorption from the primary urine. Late irreversible radiation damage in kid-
neys has been described [5, 6] when high activities are administered during PRRT. In many 
PRRT clinical trials, individual dosimetry calculations and renal protection using amino acid 
infusions have been performed to avoid renal radiation doses exceeding 23-27 Gy. External 
beam radiation studies have shown that higher renal radiation doses may lead to nephrotoxic-
ity in 5-50% of the patients after 5 years of follow-up [7]. Dosimetric estimation is usually per-
formed assuming a homogeneous distribution of radioactivity in renal parenchyma. However, 
a recent study [8] in three patients showed that after i.v. 111In-DTPA-octreotide administration, 
radioactivity is confined to certain areas in the kidney. 
The aim of this study was therefore to gain more insight into both the localization and the 
mechanism of uptake and retention of radiolabelled somatostatin analogues in the rat kidney. 
A potential mechanism for renal retention of these somatostatin analogues has not previously 
been revealed. Megalin, a 600 kDa protein and a member of the LDL protein family, might be 
a candidate for receptor-mediated retention of radiolabelled peptides in the kidney. Besides 
expression in lungs, oviducts, thyroid, parathyroid, eyes and ears, the most abundant expres-
sion of megalin is found in the proximal tubules in the kidney [9]. The megalin (gp330)/cubilin 
complex is a scavenger protein receptor which is involved in reabsorption of a large variety of 
ligands such as (binding) proteins, hormones, drugs, toxins and enzymes [10, 11]. It is prob-
ably the most important receptor in the active receptor-mediated endocytosis of proteins in 
the proximal tubule. Megalin is negatively charged, showing preferential affinity for positively 
charged molecules, such as the somatostatin analogues, in primary urine. The expression of 
megalin in rat kidney varies between the segments of the proximal tubules. Expression in-
creases in the first part (S1) of the proximal convoluted tubule (PCT), is strongest in the S2 part 
of the PCT and is weaker in the proximal straight tubule (S3) [12]. S1 and S2 are located in the 
renal cortex, whereas S3 is located in the outer zone of the medulla (Figure 1).
We hypothesised that this megalin/cubilin complex is responsible for renal uptake and reten-
tion of radiolabelled somatostatin analogues after PRS and PRRT. Therefore, we performed 
biodistribution studies in rats to unravel the possible part of megalin in renal uptake of ra-
diolabelled peptides, using whole kidney counts, ex vivo autoradiography and anti-megalin 
immunohistochemistry. 
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Materials and Methods
Radionuclides and peptides
Commercially available kits of DTPA-octreotide and 111InCl
3
 were obtained from Tyco Health 
Care (Petten, The Netherlands). The radiolabelling procedure was performed in accordance 
with standard procedures [13]. 
177LuCl
3
 was from IDB, Baarle Nassau, The Netherlands. DOTA,Tyr3-octreotate was supplied by 
BioSynthema (St Louis Mo, USA). 177Lu-and 111In labelling of DOTA,Tyr3-octreotate was per-
formed as described [14, 15]. Specific activities for 111In-labelled peptides ranged from 6 to 100 
MBq/μg: normally 6 MBq/μg was used; the higher specific activity of 100 MBq/μg was used 
when micro-autoradiography was to be performed. For 177Lu-DOTA,Tyr3-octreotate, specific 
activity was 50 MBq/μg. Labelling efficiency of all analogues exceeded 99%, as confirmed by 
instant thin-layer chromatography.
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Figure 1: Illustration of a nephron in 
the kidney. The localization of S1, S2 and 
S3 segments in the proximal tubules is 
depicted. PCT = proximal convoluted 
tubule, PST = proximal straight tubule.
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Biodistribution experiments
Animal studies were conducted in agreement with the Animal Welfare Committee require-
ments of our institution using generally accepted guidelines. Male Lewis rats (Harlan, The 
Netherlands, 150-180 g) were used in all experiments, except for those studying gender dif-
ferences. For biodistribution studies, rats were ether anesthetized and injected intravenously 
with 0.5 μg peptide, labelled with at least 3 MBq radionuclide, in 500 μl saline into the dorsal 
vein of the penis. In gender studies, radiolabelled peptide was administered in 200 μl into the 
sublingual vein in both male and female rats. 
After euthanasia at the indicated time points post injection (p.i.), several organs and blood 
samples were taken. Organs were weighed and radioactivity was measured using a gamma 
counter (Perkin Elmer, Wallac, 1480 Wizard 3”, Turku, Finland). Uptake of radioactivity was ex-
pressed as percentage of injected activity per gram tissue (%IA/g).
One of the kidneys of each animal was quickly frozen and embedded in Tissue Tek (OCT com-
pound, Sakura, Zoeterwoude, The Netherlands) using liquid nitrogen cooled isopentane for 
autoradiography and immunohistochemistry.
To block renal uptake, D-lysine (400 mg/kg, LD50 not available; LD50 L-lysine: 4.000 mg/kg i.p. 
and 10.000 mg/kg oral), maleate (di-sodium salt) (400 mg/kg, LD50: 700 mg/kg oral) or cis-
platinum (cis-diamineplatinum dichloride) (5 mg/kg, LD50: 7.4 mg/kg i.v.) were used. All these 
compounds were obtained from Sigma, Steinheim, Germany.
D-lysine (400 mg/kg) was co-injected with the radiolabelled somatostatin analogue. Maleate 
(400 mg/kg) was either co-injected or administered 4 h before the radiolabelled somatostatin 
analogue. Cisplatin (5 mg/kg) was given i.p. daily 5 days before the analogue injection. In 
these experiments organs were collected 4 or 24 h post tracer administration.
Ex vivo autoradiography
After isolation and freezing of the radioactive rat kidney, 10 μm frozen sections (Microm Cryo-
Star HM 560 M, Walldorf, Germany) were mounted on Superfrost plus slides (Menzel, Braun-
schweig, Germany). Several slides were used for autoradiography, whereas adjacent slides 
were used for immunohistochemistry. For autoradiography, renal sections were exposed to 
phosphor imaging screens (Packard Instruments Co., Meriden, USA) in X-ray cassettes. After 
24-72 h screens were read by a Cyclone phosphor imager and analysed with an OptiQuant 
03.00 image processing system (Packard Instruments Co., Groningen, The Netherlands). Con-
ventional haematoxylin and eosin (HE) or periodic acid-Schiff staining was performed on the 
same or adjacent sections.
Quantification of radioactivity was performed using OptiQuant in five regions of interest of 
approximately 5 mm2 each drawn over the cortex and the outer medulla, on five different sec-
tions of each tested kidney. Radioactivity was expressed in digital light units (DLU) per square 
millimetre.
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Statistics
Uptake data from biodistribution studies (%IA/g) and quantified radioactivity data from ex 
vivo autoradiograms (DLU/mm2) were expressed as mean ± standard deviation (SD). Statistical 
analysis was performed using Student’s t test or one-way ANOVA.
Immunohistochemistry
Frozen renal sections adjacent to those used in ex vivo autoradiography were fixed with 10% 
formalin and used for indirect immunohistochemical staining for megalin. Primary antibody 
goat-anti-rat megalin SC-16478 P-20 (Santa Cruz Biotechnology, Santa Cruz, USA) was incu-
bated in optimal dilution (1:25) overnight at 4°C. P-20 is an affinity purified polyclonal antibody 
raised against a peptide mapping near the carboxy terminus of megalin. Horseradish perox-
idise-conjugated secondary antibody rabbit-anti-goat-Ig (DAKOcytomation, Glostrup, Den-
mark) was incubated for 1 h at room temperature. Visualisation of the staining was achieved 
with H
2
O
2
 activated diaminobenzidin (DAB) substrate (DAKOcytomation, Glostrup, Denmark). 
Nuclei were counterstained using haematoxylin. 
Micro-autoradiography
Kidneys from rats injected 177Lu-DOTA,Tyr3-octreotate were removed at 24 h p.i., fixed in 10% 
formalin for 3 days, dehydrated and embedded in paraffin. Sections, 4 μm thick, were mount-
ed on Superfrost slides, rehydrated and dried in a 60°C incubator for 30 min. Slides were coat-
ed in dark room conditions with LM-1 Hypercoat emulsion RPN40 (Amersham Biosciences, 
Freiburg, Germany) and dried overnight. Each gram of the photographic emulsion contained 
0.09 g of silver grains with an average crystal diameter of 0.2 μm. After 3 weeks of exposure at 
4°C, slides were developed with Kodak D-19 (Kodak, Rochester, USA) for 5 min and fixed with 
250 mM Na
2
S
2
O
3
.5H
2
O and 25 mM K
2
S
2
O
5
 for 10 min. Counterstaining was performed using 
conventional HE staining.
Results
Localization studies
The amount and distribution of radioactivity in organs of rats after i.v. administration of ra-
diolabelled somatostatin analogues was examined by counting radioactivity in several intact 
organs and by ex vivo autoradiography of frozen renal sections prepared after isolation of the 
radioactive kidney. From the renal autoradiograms, the distribution of various somatostatin 
analogues appeared to be inhomogeneous, showing a clearly localised pattern, as demon-
strated in Figure 2. The strongest signal was found in the cortex, showing a striped pattern, 
whereas a more homogeneous and weaker signal was demonstrated in the outer medulla 
(about 50-60% of cortical activity, expressed as DLU/mm2). No radioactivity was found in the 
inner medulla or the renal pelvis.
No difference in localization of radioactivity was found in ex-vivo autoradiograms of the soma-
tostatin analogues 111In-DTPA-octreotide, 177Lu-DOTA,Tyr3-octreotate or 111In-DOTA,Tyr3-octreo-
tate (Figure 2), whereas absolute uptake ranged from about 1.5 to 2.5 % IA/g kidney.
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No gender variation was detected in renal retention of radiolabelled peptides; renal uptake of 
male and female rats was not significantly different and in both genders a similar localization 
pattern of retained renal radioactivity was found (Figure 3). 
Micro-autoradiography was performed to show the microscopic localization of the renal ra-
dioactivity. Black silver grains, revealing the presence of radioactivity, were mostly localized 
in the proximal tubules of the kidney whereas much less radioactivity was detected in distal 
tubules and glomeruli (Figure 4).
 A B C
Figure 2: Ex vivo autoradiograms of frozen sections of rat kidney. A: 24 h p.i. 111In-DTPA-octreotide. B: 24 h p.i. 177Lu-
DOTA,Tyr3-octreotate. C: 24 h p.i. 111In-DOTA,Tyr3-octreotate. 
C = cortex, OM = outer medulla
Figure 3: A: Uptake (%IA/g) of 177Lu-DOTA,Tyr3-octreotate in kidney of male and female Lewis rats, 24 h p.i. Mean ± 
SD. n = 2. B, C: Ex vivo autoradiograms of frozen sections of rat kidney, 24 h p.i. 177Lu-DOTA,Tyr3-octreotate: B male rat, 
C female rat
 A B C
C
OM C
OM
C
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Figure 4: Micro-autoradiography of a paraffi  n section of rat kidney 24 h p.i. of 177Lu-
DOTA,Tyr3-octreotate counterstained with conventional HE staining. Black silver grains 
indicate high radioactivity concentration. G: glomerulus, PT: proximal tubule, DT: distal 
tubule. Magnifi cation x 1.000.
Figure 5: A: Uptake (%IA/g) of 
177Lu-DOTA,Tyr3-octreotate in 
pancreas and kidney of rats at 1, 
2, 4 and 24 h p.i. B: Radioactivity 
(DLU/mm2) in cortex and outer 
medulla of rat renal sections 
at 1, 2, 4 and 24 h p.i. of 177Lu-
DOTA,Tyr3-octreotate. Mean ± SD; 
n = 25. * p < 0.005 versus t = 1 
h p.i.
A
DT
PT
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In agreement with previous reports [16], we showed renal retention of radioactivity after in-
jection of radiolabelled somatostatin analogues. No changes in total renal uptake of 177Lu-
DOTA,Tyr3-octreotate were observed when measurements were performed at different time 
points (1, 2, 4, and 24 h p.i.) (Figure 5A). Quantification of autoradiogram data in cortex and 
outer medulla revealed that the amount of radioactivity present in the outer medulla de-
creased slightly with time, whereas cortical radioactivity remained at the same level (Figure 
5B).
Mechanism studies
We investigated the mechanism(s) responsible for the renal retention of these radiolabelled 
peptides. Excess, 1.000-fold molar of unlabelled octreotide almost abolished 111In-DTPA-oc-
treotide uptake in somatostatin receptor-positive organs, such as pancreas, but was not ef-
fective in blocking renal uptake (Figure 6), thus suggesting that the latter is not a process 
mediated by somatostatin receptors.
Immunohistochemical localization of megalin in rat kidneys showed a strong similarity to 
renal ex vivo autoradiograms after administration of radiolabelled peptides. Strong cortical 
expression and weaker expression in the outer medulla on the proximal tubules were found 
(Figure 7).
Figure 6: Uptake (%IA/g) 
of 111In-DTPA-octreotide 
in rat pancreas and 
kidney at 24 h p.i. with 
or without co-injection 
of excess (0.5 mg) 
unlabelled octreotide. 
Mean ± SD; n = 3. ** p < 
0.001 versus control.
Figure 7: Immunohistochemical staining on a 
frozen section of rat kidney using anti-megalin 
antibody, visualised with DAB using peroxidase-
labelled second stage antibody. Haematoxylin 
counterstaining was performed. C: cortex, OM: outer 
medulla. Magnifi cation x 20.
C
OM
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In light of these findings, we studied the role of megalin as scavenging receptor for radiola-
belled somatostatin analogues in the kidneys in several biodistribution studies in rats.
Firstly, we investigated the effect of i.v. co-injection of the positively charged D-lysine (400 
mg/kg) with 111In-DTPA-octreotide. A significant reduction of retained radiolabelled peptide 
(60% compared with controls) was found in the intact kidney and in the renal autoradiograms 
for both cortical and outer medullary radioactivity (Figure 8). 
Secondly, rats were inject-
ed with sodium maleate 
(400 mg/kg), a potent in-
hibitor of megalin-mediat-
ed endocytosis. Injection 
of maleate 4 h prior to the 
radiolabelled analogue 
111In-DOTA,Tyr3-octreotate or by co-injection resulted in an impressive reduction of renal up-
take to 15% of control (Figure 9). 
Finally, after cisplatin (5 mg/kg) pre-treatment a significant reduction to 70% of control renal 
uptake was found. Renal autoradiograms of cisplatin-treated rats revealed strongly decreased 
and disturbed localization of radioactivity in the outer medulla with scattering of radioactivity 
throughout the renal medulla, whereas the cortical autoradiogram was not affected (Figure 
10).
A D
B C
Figure 8: Renal radioactivity in rat kidneys 24 h p.i. of 111In-DTPA-octreotide with or without co-injection of D-lysine 
(400 mg/kg). A: Uptake (%IA/g) of 111In-DTPA-octreotide. n = 3. * p < 0.05 versus control. B, C: Ex vivo autoradiograms 
of frozen sections of rat kidney, 24 h p.i.. 111In-DTPA-octreotide: B: control, C: co-injection with D-lysine. D: Radioactivity 
(DLU/mm2) in cortex and outer medulla of renal autoradiograms. Mean ± SD; n = 25. ** p < 0.001 versus control.
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Figure 10: Renal radioactivity in rat 
kidneys 4 h p.i. of 111In-DTPA-octreotide 
with or without cisplatin pretreatment 
(5 mg/kg). A: Uptake (%IA/g) of 111In-
DTPA-octreotide. n = 4. * p < 0.001 versus 
control. B, C: Ex vivo autoradiograms of 
frozen sections of rat kidney, 4 h p.i.. 111In-
DTPA-octreotide: B: control, C: cisplatin 
pre-treated. D: Radioactivity (DLU/mm2) 
in cortex and outer medulla of renal 
autoradiograms. Mean ± SD; n = 25. * p 
< 0.001 versus control. nd: could not be 
determined.
Figure 9: Renal radioactivity in rat kidneys 24 h p.i. of 111In-DOTA,Tyr3-octreotate with or without co- or pre-injection 
of sodium maleate (400 mg/kg). A: Uptake (%IA/g) of 111In-DOTA,Tyr3-octreotate. n = 2. * p < 0.05 versus control. B-D: 
Ex vivo autoradiograms of frozen sections of rat kidney, 24 h p.i.. 111In-DOTA,Tyr3-octreotate: B: control, C: maleate, t=-4 
h, D: co-injection with maleate. E: Radioactivity (DLU/mm2) in cortex and outer medulla of renal autoradiograms. 
Mean ± SD; n = 25. ** p < 0.001 versus control.
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Discussion
After intravenous administration of radiolabelled somatostatin analogues, there is fast ac-
cumulation in receptor-dense organs and/or tumours and rapid clearance from the blood. 
Metabolic studies have shown that the majority of radiolabelled analogues are excreted in the 
urine, mostly as the intact analogue [17]. Due to partial reabsorption of radiolabelled peptides 
after glomerular filtration, the retention of radioactivity in the radiosensitive kidney is, how-
ever, substantial.
The first aim of this study was to reveal the localization of retained radioactivity in the rat 
kidney after intravenous injection of various radiolabelled somatostatin analogues. Most ra-
dioactivity appeared to be retained in the proximal tubules (i.e. the S1 and S2 segments) in the 
renal cortex, while less uptake was found in the outer medulla (the S3 segment of the proximal 
tubules). No radioactivity was found in cortical glomeruli, distal tubules, inner medulla or renal 
pelvis (Figures 2, 4). This inhomogeneous distribution of radioactivity in rat kidney after the 
injection of radiolabelled somatostatin analogues is in agreement with recent reports in hu-
man kidneys [8].
In this study in rats, we observed no gender-determined differences in renal uptake and lo-
calization of 111In-DTPA-octreotide (Figure 3), whereas in a study in Balb/c mice we found sig-
nificantly different renal uptake of 111In-DTPA-octreotide in males and females [18]. It seems 
that this sex-dependent distinct renal handling of the analogue only occurs in mice, since in 
humans, too, no differences have been described. No satisfactory explanation for this observa-
tion can be given at present.
The renal handling of proteins and peptides is a complex process, consisting of glomerular 
filtration followed by tubular reabsorption. As early as 1977 it was assumed that negatively 
charged “receptors” on the proximal tubules play a part in the mechanism of renal clearance 
of proteins and peptides, which was confirmed later for radiolabelled peptides and antibody 
fragments [19, 20]. However, these receptors have not yet been identified. Therefore, the sec-
ond aim of the current study was to gain more insight into the mechanism of renal retention 
of radiolabelled somatostatin analogues.
Co-injection of excess of unlabelled octreotide did not reduce renal uptake of radiolabelled 
somatostatin analogues. Furthermore, in an earlier study in somatostatin receptor subtype 
2 (sst2)
 
knockout mice we found an equal or even higher renal retention of the analogue 
compared with wild type mice after administration of 111In-DTPA-octreotide. Ex vivo autora-
diograms showed the same localization of renal radioactivity in both mouse strains [21]. From 
these observations it can be concluded that the somatostatin receptor is not responsible for 
renal radioactivity retention.
In the kidney, megalin is present on the microvilli and apical membrane of proximal tubules 
and acts as a scavenger receptor for many ligands, predominantly proteins and peptides 
[11]. Therefore, we hypothesised that megalin plays a part in the renal retention of positively 
charged radiolabelled somatostatin analogues, particularly because megalin is a negatively 
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charged molecule. It is known that the molecular charge of the labelled peptide influences 
the renal uptake and retention. In 1983, Christensen et al. [22] reported that cationic pro-
teins showed an enhanced proximal tubular uptake compared with anionic proteins. A higher 
isoelectric point enhanced renal reabsorption. Akizawa et al. concluded that an increase in 
negatively charged amino acids in peptide molecules reduced renal uptake of radiolabelled 
peptides [23].
The comparable localization pattern of renal radioactivity of the various radiolabelled soma-
tostatin analogues used, suggesting a common transporter, is probably due to the nearly 
identical amino acid sequence of the peptide analogues. Most importantly, all somatostatin 
analogues examined contain a positively charged lysine residue at position 5.
The similar immunohistochemical staining pattern in renal sections using anti-megalin anti-
body compared with renal 111In-DTPA-octreotide ex vivo autoradiogram patterns also points to 
a role for megalin in the renal retention of radiolabelled analogues.
It is interesting to study the interference in this putative megalin-mediated mechanism of 
retention in animal models because development of strategies to reduce renal uptake and 
retention of radioactivity is a field of great interest. Nowadays, infusion or injection of cationic 
amino acids, lysine and arginine, is widely used in patients undergoing PRRT [20, 24, 25]. Renal 
uptake of radiolabelled peptides is significantly reduced in patients receiving amino acids 
compared with controls. This allows the administration of higher activities during therapy in 
order to increase the therapeutic effect. The mechanism of this renal protection by amino ac-
ids has not been fully elucidated, although the positively charged amino group in the amino 
acids seems to be essential for achievement of the protective effect in the kidney. 
In our rat biodistribution experiments, co-injection of D-lysine with 111In-DTPA-octreotide re-
sulted in reduction of renal uptake, in both the cortex and the outer medulla, without af-
fecting megalin expression in the kidney. Competition between D-lysine and octreotide mol-
ecules for binding to megalin can explain this phenomenon. Probably because megalin is a 
receptor with a very high capacity, renal uptake of radiolabelled octreotide cannot be blocked 
completely by lysine; 50-60% reduction is the maximum achievable. Another possibility is that 
fluid phase endocytosis partly contributes to renal uptake of the radiolabelled analogues.
Maleate has often been used in rats to induce an experimental model of Fanconi syndrome by 
a generalised renal transport defect in the proximal tubules [26]; increased urinary excretion 
of glucose, amino acids, peptides and proteins is found after maleate administration. Male-
ate inhibits membrane recycling during endocytosis, and decreases energy metabolism by 
reduction of coenzyme A levels, thus inhibiting citric acid cycle and reduction of cellular ATP. 
Megalin has been proposed as a target molecule for the effect of maleate on renal proximal 
tubules [27]. In this study we examined the effect of sodium maleate treatment on the renal 
uptake of 111In-DTPA-octreotide, expanding our previous results [28]. The renal uptake of 111In-
DTPA-octreotide was strikingly affected when maleate was given prior to or co-injected with 
the radiolabelled peptide. The kidney uptake in the maleate groups, both in whole organ 
counts and in ex vivo autoradiograms, was dramatically reduced compared with controls. The 
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observation that the reduction of renal uptake was less impressive when maleate was given 
several hours prior to administration of radiolabelled peptide pointed to a temporary effect 
of maleate on the endocytic processes in the kidney. Immunolabelling in the affected kidneys 
revealed that megalin expression was not affected by maleate, indicating that impairment of 
the energy metabolism in the endocytosis process is most likely the reason for the reduction 
in renal uptake. Recent experiments using colchicine [29, 30], an inhibitor of microtubule func-
tion, confirm the observation that interference in the process of endocytosis reduces renal 
uptake of radiolabelled somatostatin analogues.
The use of the anti-cancer drug cisplatin (cis-diamine-platinum dichloride) is limited because 
of the high risk of nephrotoxicity [31]. In rats, polyuria with increased excretion of proteins, 
including albumin and vitamin D binding protein, is induced [32]. Pathologically, damage in S3 
segment (straight part) of the proximal tubule is found [33]. We examined the effect of cispla-
tin pre-treatment of rats on the uptake and localization of 111In-DTPA-octreotide in the kidney. 
The 30% reduction in renal uptake achieved by cisplatin pre-treatment was low compared 
with the results using D-lysine or maleate. The first parts (S1 and S2) of the proximal tubules 
were not affected by cisplatin, whereas S3 in the outer medulla was clearly affected, as shown 
by both ex vivo autoradiograms and anti-megalin immunohistochemistry. Therefore, the reab-
sorption process of the radiolabelled peptides was impaired only in PST (S3).
These results point to an important role of megalin in the renal retention of radiolabelled 
analogues. This may be crucial for further research into renal uptake-reducing strategies dur-
ing PRRT. Competition for megalin using irrelevant cationic peptides or amino acids or use of 
known megalin inhibitors can be further explored. 
Conclusion
Renal radioactivity after intravenous injection of various radiolabelled somatostatin analogues 
in rats was localised predominantly in the proximal convoluted tubules in the renal cortex 
and to a lesser extent in the proximal straight tubules located in the outer medulla, but not in 
glomeruli or distal tubules. 
Several lines of evidence point to megalin being the receptor responsible for renal uptake 
of radiolabelled somatostatin analogues. In animal models, renal uptake of radiolabelled so-
matostatin analogues could be reduced by competing with megalin or by interfering in the 
endocytosis process or energy metabolism of megalin-mediated reabsorption.
Identification of megalin as the receptor for tubular uptake of radiolabelled somatostatin ana-
logues may be essential for the development of new strategies to further reduce renal uptake 
when using PRRT in patients.
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Abstract
Introduction: Radiolabelled somatostatin analogues have been shown to be important ra-
diopharmaceuticals for tumour diagnosis and radionuclide therapy. The kidney has appeared 
to be the critical organ during radionuclide therapy because of peptide reabsorption and 
retention in the proximal tubules after glomerular filtration. The molecular mechanism of re-
nal reabsorption of these analogues has not been clarified. A possible receptor candidate is 
megalin, a multi-ligand scavenger receptor in the renal proximal tubules. The objective of this 
study was to investigate the role of megalin in tubular reabsorption of radiolabelled soma-
tostatin analogues by using kidney-specific megalin-deficient mice versus mice with normal 
renal megalin expression. 111In-DTPA-octreotide was used as a practical model of peptide. 
Methods: Renal uptake of 111In-DTPA-octreotide was determined by animal SPECT scintigra-
phy at different time points after injection of the tracer and by measurement of radioactivity 
after isolation of the organs. Furthermore, ex vivo autoradiography of renal sections revealed 
the zonal distribution of radioactivity in the megalin-deficient and megalin-expressing kid-
neys. 
Results: SPECT scintigraphy of 111In-DTPA-octreotide at 3 and 24 h after injection clearly 
showed lower renal radioactivity in megalin-deficient kidneys than in megalin-expressing kid-
neys, both in male and female mice, in accordance with counts obtained after isolation of the 
organ (70%-85% reduction of uptake in the megalin-deficient kidneys; p<0.001). Renal uptake 
of 111In-DTPA-octreotide was significantly higher in female than in male kidneys (p<0.001). Ex 
vivo autoradiograms clearly showed that renal radioactivity was not homogeneously distrib-
uted in the megalin-expressing kidneys, but localised in the renal cortex. Quantifi cation of the au-
toradiogram data confi rmed the reduced radioactivity in the renal cortex of megalin-defi cient kidneys. 
Conclusion: This study revealed the molecular mechanism of 111In-DTPA-octreotide uptake 
in renal proximal tubules involving the receptor megalin. Identification of megalin may be 
crucial for further research into strategies to reduce renal uptake.
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Introduction
Radiolabelled receptor-binding peptides have been shown to be important radiopharma-
ceuticals for tumour diagnosis and therapy. Radiolabelled somatostatin analogues are suc-
cessfully applied for visualization of somatostatin receptor-positive tumours, and scintigraphy 
with 111In-DTPA-octreotide (Octreoscan®) has proven to be a sensitive and specific method to 
localize somatostatin receptor-positive tumours and their metastases [1]. Continuing research 
is aimed at developing a therapeutic analogue taking advantage of the specificity of the re-
ceptor binding and the localised radiation dose from the radionuclide linked to the peptide. 
Apart from short-ranged therapeutic Auger electrons, 111In also emits two lonγ-range γ-rays 
and therefore it is not optimal for therapeutic usage. 90Y-DOTA,Tyr3-octreotide, with the high-
energy β—-emitter 90Y (mean energy, 0.93 MeV; half-life, 64 h) stably linked in the DOTA-cage, 
is now clinically being evaluated for peptide receptor radionuclide therapy (PRRT) by various 
groups [2-8]. The promising rate of complete plus partial responses seen in the various 90Y-
DOTA,Tyr3-octreotide studies consistently exceeds those obtained with 111In-DTPA-octreotide 
for radionuclide therapy.
Another β—-emitter used for PRRT is 177Lu (half-life, 6.7 d). It emits β—-particles with a lower 
energy (mean energy, 0.13 MeV) than 90Y and γ-rays of 113 keV at 6% per decay and 208 keV 
at 10% per decay. 177Lu complexed to the somatostatin analogue Tyr3-octreotate via the che-
lator DOTA forms a promising therapeutic compound with considerably enhanced uptake 
in receptor-positive tumours and excellent therapeutic results in animal models and patient 
studies [9-11]. 
During PRRT using somatostatin analogues labelled with the β—-emitters 90Y and 177Lu, the 
kidney is the critical organ because it excretes and partially retains radioactivity, leading to a 
high renal radiation dose. Lowering renal uptake of radioactivity will allow higher activities to 
be administered and higher tumour radiation doses to be obtained. Studies on animals and 
patients have shown that renal uptake of radiolabelled octreotide can be inhibited by admin-
istration of the positively charged amino acids lysine and arginine [4, 12-15]. The effects of 
these positively charged amino acids can be explained by competition for negatively charged 
binding sites at the proximal tubule cell surface. We also found that tubular reabsorption of 
radiolabelled somatostatin analogues requires energy. Injection of 400 mg/kg maleate, which 
inhibits the citric acid cycle, reduced renal uptake of 111In-DTPA-octreotide by about 74% in 
rats [12]. 
The molecular mechanism of uptake of radiolabelled somatostatin analogues in the kidney 
has not been clarified. Previous in vitro studies using opossum kidney cells and in vivo stud-
ies in rats pointed to a role of megalin in reabsorption of radiolabelled octreotide [16, 17]. 
Megalin serves as a scavenger receptor for endocytosis of multiple ligands in the kidneys. It is 
expressed in the proximal tubules, consistent with the localisation of renal radioactivity in rat 
kidneys after injection of radiolabelled somatostatin analogues [18, 19].
The aim of this study was to reveal the radioactivity distribution in mouse kidneys and the role 
of megalin therein by the use of renal megalin-deficient mice [20]. These mice have kidney-
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specific inactivation of the megalin gene. 111In-DTPA-octreotide, a practical model of peptide 
for the somatostatin analogues currently used for scintigraphy and radionuclide therapy, was 
injected in kidney-specific megalin-deficient versus megalin-expressing control mice. Renal 
uptake of radioactivity was determined by animal SPECT scintigraphy at different time points 
after injection and by measurement of radioactivity using a γ-counter after isolation of the 
organs. Furthermore, ex vivo autoradiography revealed the zonal distribution of radioactivity 
in the megalin-deficient and megalin-expressing kidneys.
Materials and methods
Radiolabelling 
Commercially available Octreoscan® kits of DTPA-octreotide (MW 1,500) and 111InCl
3
 were 
obtained from Tyco Health Care (Petten, The Netherlands). The radiolabelling procedure was 
performed in accordance with the standard procedure listed on the package insert. Labelling 
efficiency was >99%, as confirmed by instant thin-layer chromatography.
Tissue distribution of 111In-DTPA-octreotide
Animal experiments were performed in compliance with the regulations of the institutions 
and with generally accepted guidelines governing such work.
Generation of the mouse model used has been described by Leheste et al. [20]. In short, Lox 
P recombination sites were introduced into the murine megalin gene, and mice carrying the 
modified receptor gene through their germ line were generated. Animals homozygous for 
the floxed megalin gene (megalinlox/lox) exhibit normal development and unimpaired viability. 
In parallel, a mouse model was established with renal expression of Cre recombinase (Cre) 
using a fragment of the human apolipoprotein (apo) E promoter to drive the Cre transgene 
(apoECre). Mice doubly transgenic for the floxed megalin gene and the Cre gene (megalinlox/
lox;apoECre) were produced by breeding of the individual lines and used in these experiments. 
Cre-mediated inactivation of the megalin gene in (megalinlox/lox;apoECre) mice resulted in sig-
nificant reduction of renal megalin expression. No decrease in megalin levels was observed in 
other tissues expressing the receptor.
In various experiments, male and female kidney-specific megalin-deficient and megalin-ex-
pressing mice were injected with 111In-DTPA-octreotide (10-100 MBq, 1-2 μg). Injections were 
performed intravenously or intraperitoneally. At indicated time points, SPECT scintigrams 
were made. After euthanasia of the animals at 3 and 24 h after injection, organs were isolated. 
Radioactivity was measured in isolated organs using a γ-counter. Groups consisted of 2-6 ani-
mals. Statistical analysis was performed using the Student t test. 
Animal SPECT
SPECT Device. The animal SPECT (LinoView Systems) is based on four γ-detectors (5.1 x 12.7 
cm [2 x 5 inches]) based on pixelated CsI(Na) scintillators (5-mm thickness, 2.44 x 2.44 mm 
pixel size). The intrinsic detector energy resolution at 140 keV is 35%, and the intrinsic sensi-
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tivity in an energy window of 35% width centred on the photopeak is 42%. Detectors were 
equipped with rake collimator with a tuneable slit aperture, composed of two iridium square 
rods (2 x 2 x 60 mm). 
Acquisition. Mice were scanned 3 or 24 h after injection with a collimator width of 0.2-0.4 mm. 
Two acquisitions of 15 min each were performed, the bed being shifted by 1.22 mm between 
the two acquisitions, resulting in reconstructed transverse slices spaced every 1.22 mm. The 
orbit ranges of the detectors were set in such a way that the four slit apertures would draw 
the narrowest rectangle possible around the object to be imaged. The distance between the 
slit aperture and the phantom or the animal boundary was typically about 3 mm. The acquired 
data were stored in list mode and included the following: detector number, (x, y) event posi-
tion, event time and event energy. This linear orbit acquisition generates linograms forming 
a complete set of tomographic data, that is, sufficient to exactly reconstruct the activity map 
[21].
Reconstruction. Events from the list mode file, with an energy within a 50% window centred 
on the photopeaks, were rebinned to provide linograms. All reconstructions were performed 
using the maximum likelihood expectation maximization algorithm without attenuation, scat-
ter correction or spatial resolution recovery [22, 23].
Autoradiography
One of the kidneys of each animal was frozen quickly after isolation at 3 or 24 h after in-
jection and processed for cryosectioning and autoradiography. Tissue sections (10 mmm) 
were mounted on glass slides. Several slides were used to make autoradiograms, and ad-
jacent sections were haematoxylin-eosin or periodic acid Schiff stained. The sections were 
exposed overnight to phosphor imaging screens (Packard Instruments Co., Meriden, USA) in 
radiographic cassettes. The screens were analysed using a Cyclone phosphor imager and a 
computer-assisted OptiQuant 03.00 image processing system (Packard Instruments Co, Gron-
ingen, The Netherlands).
Immunohistochemistry
Frozen sections were fixed with 10% formalin and used for indirect immunohistochemical 
staining for megalin. Primary goat-anti-rat megalin antibody SC-16478 (Santa Cruz Biotech-
nology, USA) was incubated at optimal dilution overnight at 4°C. Horseradish peroxidase-con-
jugated secondary rabbit-anti-goat-Ig antibody (DakoCytomation, Glostrup, Denmark) was 
incubated for 1 h at room temperature. Staining was achieved with H
2
O
2
 activated diamino-
benzidine substrate. Nuclei were counterstained using haematoxylin.
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Results
Renal uptake in male mice
SPECT scintigraphy at 3 h after injection of 111In-DTPA-octreotide in renal megalin-deficient 
and renal megalin–expressing male mice (Figure 1) showed that radioactivity was not ho-
mogeneously distributed over the kidney but concentrated in the cortical area. Furthermore, 
renal radioactivity was lower in the megalin-deficient kidneys than in control kidneys. This is in 
accordance with biodistribution data obtained after isolation and counting of the kidneys at 3 
and 24 h after injection (Figure 2), indicating that injected 111In-DTPA-octreotide was partially 
reabsorbed after glomerular filtration and retained in megalin-expressing kidneys, whereas 
uptake there in the megalin-deficient kidneys was much lower (p<0.001 at both time points). 
In the other organs, both somatostatin receptor positive and somatostatin receptor negative, 
uptake was not significantly different between mice with megalin-deficient kidneys and mice 
with megalin-expressing kidneys (data not shown). 
Figure 3 shows ex vivo autoradiograms of megalin-deficient and 
megalin-expressing kidneys at 3 h after injection of 111In-DTPA-oc-
treotide in male mice. Radioactivity was not homogeneously distrib-
uted in the megalin-expressing kidneys, as was shown also on the 
scintigrams, but localised in the cortex and outer medulla of the kidney. 
Quantifi cation of the autoradiography data revealed strongly reduced ra-
dioactivity in the megalin-defi cient kidneys, likely reflecting the residual 
renal megalin activity in this tissue-specific deficient line (Figure 4). 
Comparison of renal uptake in male and female mice
SPECT scintigraphy at 24 h after injection of 111In-DTPA-octreotide is shown for female renal 
megalin-deficient and female control mice in Figure 5. Renal radioactivity was lower in mega-
lin-deficient kidneys than in megalin-ex-
pressing kidneys, in accordance with the 
data obtained in the male mice. The scinti-
grams are in agreement with the autoradi-
Figure 2: Renal uptake of 111In-DTPA-octreotide in 
renal megalin-deficient and megalin-expressing 
male mice at 3 and 24 h after intravenous injec-
tion. Uptake is expressed as percentage injected 
activity per gram of kidney (%IA/g) (mean and SD, 
n=2-6 for each group). *: p<0.001 vs. megalin-ex-
pressing kidneys.
Figure 1: Male megalin-expressing (A) and megalin-deficient (B) kidneys. Images 
were obtained in a similar way and with the same acquisition time on an animal 
SPECT device (LinoView Systems) 3 h after injection of 111In-DTPA-octreotide. Col-
limator width was 0.2 mm. Two acquisitions of 15 min each were performed, the 
bed being shifted by 1.22 mm between the two acquisitions. Reconstructions were 
performed using the maximum-likelihood expectation maximization algorithm 
without attenuation correction, scatter correction or spatial resolution recovery.
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ography data (Figure 6) and with biodistribution data obtained after isolation of the organs at 
24 h after injection (Figure 7), indicating significantly lower uptake of 111In-DTPA-octreotide in 
megalin-deficient kidneys than in megalin-expressing kidneys in both male and female mice 
(p<0.001). Renal uptake of 111In-DTPA-octreotide was significantly higher in female than in 
male kidneys, in both megalin-expressing and megalin-deficient kidneys. 
Discussion
After intravenous administration to patients, radiolabelled DTPA- or DOTA-chelated soma-
tostatin analogues accumulate in receptor-positive tumours, and radioactivity clears rapidly 
from the blood via the kidneys. Because part of the radiolabelled analogues is reabsorbed af-
ter glomerular filtration, retention in the kidney is substantial [3, 24, 25]. This renal uptake and 
retention is the major dose-limiting factor in PRRT using these somatostatin analogues, and 
lowering the renal accumulation will allow larger activities to be administered, thereby enlarg-
ing the therapeutic window of PRRT using somatostatin analogues. It has been shown that 
renal uptake of radiolabelled octreotide in rats is reduced by positively charged amino acids 
such as lysine and arginine; about a 50 % reduction is obtained by a single intravenous admin-
istration of 400 mg/kg of body weight L- or D-lysine in rats [12]. Therefore, during PRRT using 
somatostatin analogues, an infusion containing the positively charged amino acids L-lysine 
Figure 3: Autoradiograms of longi-
tudinal renal sections from mega-
lin-expressing (A) and megalin-de-
ficient (B) kidneys from male mice 
3 h after injection of 111In-DTPA-
octreotide. Both sections had same 
(overnight) period of exposure.
A B
Figure 4: Immunohistology (using primary goat-anti-rat megalin antibody SC-16478) showing megalin distribu-
tion in sections from megalin-expressing (A) and megalin-deficient (B) kidneys from male mice. 
A B
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and L-arginine can be given to patients during and after the 
infusion of the radiopharmaceutical to reduce renal uptake. 
Various protocols have been described, resulting in up to a 
55% reduction in renal uptake of radioactivity, thereby allow-
ing a higher administered dose [4, 13-15]. The mechanism 
of this renal protection by amino acids has not been fully 
elucidated. The positively charged amino group in the amino 
acids seems to be essential to achieve the protective effect 
in the kidney. 
With regard to localisation of renal radioactivity in rats, we recently found that most renal ra-
dioactivity after injection of radiolabelled somatostatin analogues appeared to be retained in 
the proximal tubules of the renal cortex, whereas no radioactivity was present in the glomeruli 
or distal tubules [17]. Less radioactivity than in the cortex was present in the outer medulla, 
whereas no radioactivity was found in the inner medulla and pelvis of the kidney. Our conclu-
sion that radioactivity is not homogeneously distributed in rat kidneys is consistent with the 
results of a recent study on human kidneys [26] and with the results from the present study 
on mice. Here, we also encountered a significant difference in renal uptake between male and 
female mice, in accordance with earlier findings [27]. 
The molecular mechanism of the 
uptake of radiolabelled octreo-
tide analogues in renal proximal 
tubules has not been clarified. 
Megalin is a negatively charged 
600-kDa type I transmembrane 
glycoprotein belonging to the 
low-density-lipoprotein recep-
tor family. It is present on the 
microvilli and apical membrane 
of proximal tubules and is a 
scavenger receptor for tubular 
reabsorption of many ligands, 
predominantly proteins and 
peptides [18, 19]. Therefore, we 
hypothesised that megalin is the 
receptor responsible for the renal 
retention of radiolabelled soma-
Figure 5: Animal SPECT images of female megalin-expressing (A) and 
megalin-deficient (B) kidneys 24 h after injection of 111In-DTPA-octreo-
tide. Images were obtained in a similar way and with the same acqui-
sition time. Collimator width was 0.4 mm. Two acquisitions of 15 min 
each were performed, the bed being shifted by 1.22 mm between the 
two acquisitions. Reconstructions were performed using the maximum-
likelihood expectation maximization algorithm without attenuation cor-
rection, scatter correction or spatial resolution recovery.
Figure 6: Autoradiograms of longitudinal renal sections from fe-
male (A and B) and male (C and D) mice having megalin-expressing 
(A and C) or megalin-deficient (B and D) kidneys. Images were ob-
tained 24 h after injection of 111In-DTPA-octreotide. All sections had 
the same (overnight) period of exposure.
A B
C D
2.3
Megalin-mediated octreotide reabsorption 105
tostatin analogues, and previous in vitro studies using opossum kidney cells and in vivo studies 
in rats were consistent in finding a role for megalin in reabsorption of radiolabelled octreotide 
[16, 17].
The present study demonstrated by the use of megalin-deficient mice that the endocytic 
receptor megalin is indeed essential for the renal reabsorption of 111In-DTPA-octreotide, be-
cause megalin-deficient mice showed severely impaired renal tubular uptake of this analogue 
(70%-85% reduction of uptake). The Cre-mediated inactivation of the megalin gene in these 
(megalinlox/lox;apoECre) mice did not result in complete cessation of renal megalin expression 
(Figure 4), possibly accounting for the residual renal uptake of 111In-DTPA-octreotide found in 
the megalin-deficient mice. 
The vast extracellular domains of megalin can accommodate a variety of ligands. Therefore, it 
seems plausible that megalin, together with the multi-ligand receptor cubilin, facilitates up-
take of many proteins and peptides, including radiolabelled somatostatin analogues, from 
the primary filtrate in the kidney. This possibility is supported by the finding of low-molecular-
weight proteinuria in megalin-deficient mice [20].
Conclusion
This study revealed the molecular mechanism of 111In-DTPA-octreotide uptake in the renal 
proximal tubule cells involving the endocytic receptor megalin. Identification of the receptors 
for tubular uptake of 111In-DTPA-octreotide may be essential for development of new strate-
gies to reduce renal uptake of these radiolabelled peptides.
Figure 7: Renal uptake of 111In-
DTPA-octreotide in renal megalin-
deficient and megalin-expressing 
male and female mice 24 h after 
intraperitoneal injection. Uptake is 
expressed as percentage injected 
activity per gram of kidney (%IA/g) 
(mean and SD, n=2-6 for each 
group). *: p<0.001 vs. megalin-ex-
pressing kidneys.
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Abstract
Introduction: Radiolabelled peptides used for peptide receptor radionuclide therapy are 
excreted mainly via the kidneys and are partly reabsorbed and retained in the proximal tubular 
cells. The resulting high renal radiation dose can cause nephrotoxicity, limiting the maximum 
activity dose and the effectiveness of peptide receptor radionuclide therapy. The mechanisms 
of kidney reabsorption of these peptides are incompletely understood, but the scavenger 
receptor megalin has been shown to play a role in the reabsorption of 111In-octreotide. In this 
study the role of megalin in the renal reabsorption of various relevant radiolabelled peptides 
is investigated.
Methods: Groups of kidney-specific megalin-deficient mice and wild-type mice were in-
jected with 111In-labelled somatostatin, exendin, neurotensin or minigastrin analogues. Single 
photon emission computed tomographic (SPECT) images of the kidneys were acquired and 
analysed quantitatively, or animals were euthanized 3 h post injection and the activity con-
centration in the kidneys was measured.
Results: Megalin-deficient mice showed significantly lower uptake of all studied radiola-
belled peptides in the kidneys, ranging from 22% (111In-DTPA-octreotide) to 65% (111In-DTPA-
exendin) of uptake in wild-type kidneys. Quantitative analysis of renal uptake by SPECT and ex 
vivo measurements showed very good correlation.
Conclusions: Megalin is involved in the renal reabsorption of radiolabelled octreotide, oc-
treotate, exendin, neurotensin and minigastrin. This knowledge can help in the design of 
strategies to reduce this reabsorption and the resulting nephrotoxicity in peptide receptor 
radionuclide therapy, enabling more effective therapy. Small animal SPECT is an accurate tool, 
allowing in vivo quantification of renal uptake and serial measurements in individual mice.
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Introduction
In peptide receptor radionuclide therapy (PRRT), radiolabelled peptide analogues are used 
to target tumours expressing particular receptors, such as the somatostatin receptor. Most 
radiolabelled peptides are predominantly cleared from the body via the kidneys. Rapid clear-
ance of the radiolabelled peptides from the blood and low retention in the kidneys minimise 
the radiation dose to normal tissues. However, part of the filtered load of these small proteins 
and peptides is reabsorbed from the ultrafiltrate in the proximal tubules. Evidence suggests 
that, after glomerular filtration, proteins and peptides in the ultrafiltrate bind to endocytic 
receptors at the luminal surface of proximal tubular cells and are internalised. Subsequently, 
the compounds are transferred to the lysosomes, where they are proteolytically degraded 
into amino acids [1]. These are transported back into the bloodstream. However, residualis-
ing radiolabels (e.g. N-terminal amino acid chelate conjugates or lysine chelate conjugates) 
are trapped in the tubular cell lysosomes and can deliver high radiation doses to the kidney 
tubules and glomeruli [2]. Nephrotoxicity is dose limiting in PRRT with somatostatin analogues 
such as 90Y-DOTA,Tyr3-octreotide [3, 4].
The receptors involved in the tubular reabsorption of peptides have not yet been completely 
characterised, but for various non-radiolabelled peptides involvement of megalin has been 
shown [5]. Megalin is a multiligand receptor belonging to the LDL receptor family. The recep-
tor contains four large cysteine rich ligand binding domains and is a high-capacity pathway 
for the reabsorption of different structurally non-related peptides and proteins such as albu-
min, vitamin D binding protein, β
2
-microglobulin and aprotinin [5, 6]. De Jong et al. recently 
described that the renal uptake of 111In-octreotide was significantly lower in kidney-specif-
ic megalin-deficient mice than in their wild-type counterparts, implicating involvement of 
megalin in the renal reabsorption of radiolabelled somatostatin analogues [7]. Many other 
radiolabelled peptides that are being studied for their potential in tumour imaging and PRRT 
display a renal retention several fold higher than octreotide. Examples include exendin and 
minigastrin, targeting glucagon-like peptide-1 and cholecystokinin
2
 receptors, respectively [8, 
9]. It is unknown whether megalin is also involved in the renal uptake of these peptides.
In clinical PRRT with somatostatin analogues, the standard renoprotective regimen nowadays 
consists of co-infusion of basic amino acids, which are thought to interfere with the binding of 
somatostatin analogues to megalin or other endocytic receptors on the proximal tubular cells 
[10, 11]. However, Gotthardt et al. showed that the renal uptake of 111In-minigastrin was not re-
duced significantly by co-infusion of basic amino acids [9], suggesting that the reabsorption of 
this peptide is mediated by other receptors. Knowledge about the molecular mechanisms of 
proximal tubular reabsorption of different radiolabelled peptides is important to devise new 
methods to reduce their renal retention, for example by selecting or designing more efficient 
inhibitors of their renal reabsorption, or by structurally modifying the peptides to reduce their 
binding to renal receptors.
In this study the role of megalin in the renal retention of 111In-DTPA,D-Phe1-octreotide (111In-
octreotide), 111In-DTPA,D-Phe1,Tyr3-octreotate (111In-octreotate), Lys40(111In-DTPA)-exendin-3 
(111In-exendin), 111In-DOTA,Glu1-minigastrin (111In-minigastrin) and 111In-DTPA0-neurotensin[6-13] 
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(111In-neurotensin) was studied in mice. The renal uptake of the peptides was measured by sin-
gle photon emission computed tomography (SPECT) imaging and by ex vivo measurements 
of kidney-specific megalin-deficient mice (megalinlox/lox;apoECre [12]) and wild-type mice. Since 
the level of renal uptake of radiopeptides may differ between female and male mice [13], both 
genders were imaged by SPECT.
Materials and Methods
Animals
The megalin-deficient mice used were megalinlox/lox;apoECre mice [12]. The principles of creat-
ing tissue-specific gene knockout models are described in detail elsewhere [14, 15]. In short, 
in megalinlox/lox;apoECre mice, expression of the enzyme Cre recombinase is controlled by the 
apolipoprotein E (apoE) promotor, and thus produced only in tissues where the apoE gene is 
transcribed. In these tissues, Cre recombinase excises sequences from the genome that are 
flanked by two loxP sequences, in this case the megalin gene [14]. Animals were bred locally 
using males heterozygous in the apoECre gene. Offspring expressing the apoECre gene were 
identified by means of polymerase chain reaction (PCR) analysis as described below. Animals 
not expressing the apoECre gene (megalinlox/lox mice) were used as wild-types in the biodistribu-
tion studies. In the SPECT studies, C57Bl/6 mice were used as wild-types.
PCR analysis
For PCR the primers CCCAAGAAGAGGAAGGTG (forward) and GCTGGCCCAAATGTTGCTG (re-
verse) were used. The reaction mixture consisted of approximately 50 ng mouse DNA in a 
total of 25 μl colourless PCR-buffer (Go Taq Flexi Reaction buffer, Promega) with 5 mM MgCl
2
 
(Promega), 0.5 mM deoxyribonucleotide triphosphate mix (dNTP, Promega), 12.5 pmol forward 
primer, 12.5 pmol reverse primer and 2.5 IU Taq polymerase (Promega). This mixture was heat-
ed for 4 min at 950C, followed by 32 cycles of 30 s at 950C, 30 s at 560C and 30 s at 720C. After 
these cycles, the temperature was maintained at 720C for 10 min and subsequently lowered to 
100C. The formed DNA was analysed by agarose gel electrophoresis.
Radiolabelled compounds
The following peptide derivatives were studied: 111In-DTPA,D-Phe1-octreotide (Covidien) [16], 
111In-DTPA,D-Phe1,Tyr3-octreotate (Biosynthema) [17], DTPA0-neurotensin[6-13] (Biosynthema) 
[18], Lys40-DTPA-exendin-3 (exendin, Peptide Specialty Laboratories) [19], DOTA-Glu1-miniga-
strin (Peptide Specialty Laboratories) [20]. Relevant properties of the peptides are summarized 
in Table 1.
Peptides were labelled with 111InCl
3
 (20 MBq/nmol for SPECT studies, 10-80 MBq/nmol for ex 
vivo biodistribution studies) after addition of 1.25 M sodium acetate, pH 4.0-4.5 and a mixture 
of gentisic acid, ascorbic acid and ethanol. Methionine-containing peptides were labelled in 
the presence of 50 mM L-methionine instead of ethanol. The mixtures were incubated for 20-
30 min at room temperature (DTPA-peptides) or at 950C (DOTA-minigastrin).
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Labelling efficiency and radiochemical purity of the labelled peptides and proteins were de-
termined by silica gel instant thin layer chromatography (SG-ITLC) and reverse phase high 
performance liquid chromatography (RP-HPLC). Radiochemical purity was >95% for all com-
pounds.
SPECT studies
Megalin-deficient and wild-type mice (male and female, n = 4-6 per group) received an in-
travenous (i.v.) injection of 40 MBq (0.2 ml, 2 nmol) 111In-octreotide. The exact injected activ-
ity was determined by measuring the syringe in a dose calibrator before and after injection. 
Three and 24 h after injection, a 24 min SPECT scan of the kidney region was acquired with the 
four-headed helical NanoSPECT/CT system (Bioscan) using Nucline software (v2.01, Mediso). 
Multi-pinhole mouse collimators with 9 pinholes (1.4 mm diameter) per head were used, with 
a matrix of 256x256 and 24 projections (2 min per projection). During the scan the animals 
were isoflurane/O
2
 anaesthetized and body temperature was maintained. This procedure was 
repeated in the same mice with 111In-octreotate, 111In-exendin, 111In-neurotensin and 111In-
minigastrin consecutively, after intervals of at least three weeks. Some of the animals devel-
oped signs of kidney damage at the end of this series of experiments, probably caused by the 
relatively high renal uptake of 111In-exendin, resulting in a high radiation dose to the kidneys 
[21]. Therefore, the 111In-exendin, 111In-neurotensin and 111In-minigastrin data were discarded 
and an extra experiment with these peptides was carried out in a new set of animals. To re-
duce the risk of kidney damage, the injected activity of 111In-minigastrin and 111In-exendin was 
reduced to 10 MBq, while the peptide dose was kept constant at 2 nmol. In this second series, 
SPECT scans were acquired only at 3 h post injection (p.i.).
SPECT scans were reconstructed iteratively, using InVivoScope software (v1.32, Bioscan) with 
medium noise reduction, a voxel size of 0.3 mm3 and standard reconstruction settings. The 
amount of radioactivity in a volume of interest drawn around the kidneys was quantified and 
expressed as % of injected activity per gram tissue (%IA/g). To achieve accurate quantification, 
Characteristics of studied peptide analogs 
Peptide analogue Target receptor
Molecular 
weight (kDa)
Number of AA residues 
(positive / negative)
Charge 
at pH 7
111In-octreotide Somatostatin R
2
1.5 8 (1+ / 0-) +1
111In-octreotate Somatostatin R
2
1.5 8 (1+ / 0-) +1
111In-exendin Glucagon-like peptide 
R-1
4.8 39 (4+ / 6-) -2
111In-minigastrin Cholecystokinin R2 
and Gastrin R
2.1 13 (0+ / 6-) -6
111In-neurotensin Neurotensin R 1.3 8 (1+ / 0-) +1
Table 1: R = receptor, AA = amino acid.
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the camera was calibrated by scanning a 20 ml polypropylene tube mouse phantom filled 
with a known amount of 111In activity. 
After the final SPECT scan, the animals were euthanized and biodistribution of 111In-minigas-
trin and 111In-exendin was studied as described in the next section, to confirm the accuracy of 
the SPECT measurements.
Ex vivo biodistribution studies
Animals (n = 4-6 per group) received an i.v. injection of 0.4 MBq (0.2 ml, 5-40 pmol) 111In-
octreotide, 111In-exendin, 111In-neurotensin or 111In-minigastrin. For 111In-octreotide the experi-
ment was performed with male and female mice, for the other peptides only female mice 
were used. Three hours after injection, the animals were euthanized and organs were dis-
sected. Biodistribution of the 111In-labelled peptides was assessed by weighing the organs and 
measuring radioactivity in a gamma counter. Measured activity was expressed as %IA/g. The 
right kidney of each animal was cut in half. One half was snap-frozen in liquid nitrogen and 
processed for cryosectioning, the other half was processed for paraffin sectioning. Frozen 10-
μm sections were mounted on glass slides to perform autoradiography. A phosphor imaging 
screen was exposed to the sections for two days and scanned using a BAS 1800-II phosphor 
imager (Fujifilm). 
Immunohistochemistry
Frozen 5 μm kidney sections were fixed in 4% formalin for 10 min. After rinsing with 0.05% 
polysorbate 80 in PBS, the sections were incubated with goat anti-rat megalin polyclonal an-
tibody (SC-16478, Santa Cruz) 10 μg/ml in PBS, 5% BSA for 1 h at room temperature, followed 
by incubation with horseradish peroxidase-conjugated donkey anti-goat IgG, F(ab’)
2
 (SC-3851, 
Santa Cruz) 1/100 for 30 min at room temperature. Peroxidase activity was visualized with 
diaminobenzidine (Powervision) and nuclei were counterstained using haematoxylin. Slides 
were dehydrated with ethanol and xylene and embedded in slide mounting fluid (Permount), 
after which they were studied microscopically. Megalin expression was scored visually by an 
independent, blinded observer on an arbitrary scale of 0 (negative) to 4 (all tubules positive).
Statistical analysis 
Data are presented as mean values ± standard deviation. Comparison of renal uptake values 
was performed using Student t test. For the SPECT studies of 111In-minigastrin and 111In-exen-
din after which the mice were sacrificed, the correlation between renal uptake measured on 
the SPECT images and uptake in the same mice measured ex vivo was determined. Spearman’s 
rank correlation coefficient was calculated with SPSS 16.0 (SPSS Inc).
Results
Immunohistochemistry
Immunostaining revealed lower expression of megalin in the kidney cortex of the megalin-
deficient mice as compared to the wild-type mice. The expression of megalin in the megalin-
2.4
Megalin in renal radiopeptide uptake 115
deficient kidneys varied considerably, ranging from almost absent (score 0) to moderate ex-
pression (score 2). Examples are shown in Figure 1. 
SPECT measurement of renal peptide uptake
As shown in Figure 2, the kidneys were visualized very well on the SPECT scans acquired at 3 h 
p.i. The images indicated that the radioactivity mainly accumulated in the renal cortex. 
The measured renal uptake values of the 111In-labelled peptides as derived from the SPECT im-
ages at 3 h p.i. and the ratios of uptake between megalin-deficient mice and wild-type mice 
are presented in Table 2A. The data are summarised together with the ex vivo biodistribution 
data in Figure 3. 
Figure 1: Anti-megalin immunostaining of kidney cortex from a wild-type mouse (A) and two megalin-defi cient 
mice, exhibiting relatively high (B) and relatively low (C) residual expression of megalin
A B C
Figure 2: SPECT images of the kidneys of wild-type (A) and megalin-defi cient (B) mice, 3 h p.i. of 111In-minigastrin. 
Maximum intensity projections on the left, coronal slices on the right.
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111In-exendin expressed the highest renal uptake: 371 ± 35 %IA/g in female wild-type mice. 
The peptide with the lowest renal uptake (15 ± 2.7 %IA/g in female wild-type mice) was 111In-
neurotensin. In the SPECT studies, the renal retention of all 111In-labelled peptides was signifi-
cantly lower in megalin-deficient mice than in wild-type mice, both in males and females. The 
effect was most prominent for 111In-neurotensin, for which the renal uptake in female megalin-
deficient mice was only 23% of the uptake in wild-type mice (p<0.0001). The least effect was 
observed with 111In-exendin, for which the uptake in female megalin-deficient mice was 62% 
of the uptake in wild-type mice (p=0.003).
Renal uptake of radiolabelled peptides on SPECT, 3 h p.i. 
Wild-type
(%IA/g±SD)
Megalin-deficient
(%IA/g±SD)
Ratio megalin-deficient/
wild-type (%)
111In-octreotide female 17 ± 2.4 8.5 ± 2.6 49% (p=0.001)
male 22 ± 5.6 5.7 ± 2.0 26% (p=0.0003)
111In-octreotate female 16 ± 4.6 7.6 ± 2.4 46% (p=0.007)
male 16 ± 2.8 5.9 ± 1.9 36% (p=0.0001)
111In-exendin female 371 ± 35 230 ± 58 62% (p=0.003)
male 328 ± 51 171 ± 34 52% (p=0.001)
111In-minigastrin female 89 ± 10 33 ± 8.9 37% (p<0.0001)
male 104 ± 13 52 ± 14 49% (p=0.0003)
111In-neurotensin female 15 ± 2.7 3.6 ± 1.18 23% (p<0.0001)
male 18 ± 9.0 4.6 ± 1.1 25% (p=0.02)
Table 2A: Renal uptake of radiolabelled peptides in wild-type and megalin-defi cient mice. %IA/g = % injected 
activity per gram kidney; SD = standard deviation.
Renal uptake of radiolabelled peptides on SPECT, 24 h p.i. 
Wild-type
(%IA/g±SD)
Megalin-deficient
(%IA/g±SD)
Ratio megalin-deficient/
wild-type (%)
111In-octreotide female 2.2 ± 0.25 1.4 ± 0.47 64% (p=0.0001)
male not measurable not measurable -
111In-octreotate female 5.3 ± 0.97 2.5 ± 0.71 47% (p=0.001)
male 1.6 ± 0.37 0.44 ± 0.20 28% (p=0.0003)
111In-exendin female 148 ± 11 82 ± 24 55% (p=0.0005)
male 142 ± 10 69 ± 19 49% (p=0.0001)
Table 2B: Renal uptake of radiolabelled peptides in wild-type and megalin-defi cient mice. %IA/g = % injected 
activity per gram kidney; SD = standard deviation.
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The data measured 24 h p.i. are presented in Table 2B. The renal uptake of the studied radio-
labelled peptides remained significantly lower in the megalin-deficient mice, both in females 
and in males. Overall, the uptake of 111In-octreotide and 111In-octreotate was significantly lower 
in male mice than in female mice: the retention of 111In-octreotide in males was too low to de-
lineate the kidneys and the uptake of 111In-octreotate was more than threefold lower in males 
than in females. For 111In-exendin, no difference between the genders was observed.
Ex vivo measurement of renal uptake
The ex vivo measured renal uptake of the 111In-labelled peptides in megalin-deficient and 
wild-type mice is presented in Table 3 and summarized in Figure 3. The renal uptake of 111In-
octreotide, 111In-octreotate, 111In-minigastrin and 111In-neurotensin was significantly lower in 
the megalin-deficient mice than in the wild-type mice. The effect was most prominent for 
111In-octreotide, for which the renal uptake in female megalin-deficient mice was only 22% of 
the uptake in wild-type mice (p=0.0007). For 111In-exendin, no significant difference in renal 
uptake between both groups was observed when a peptide dose of 5 pmol was used. How-
ever, when a higher peptide dose of 2 nmol was administered for SPECT imaging, a significant 
difference was measured, both on SPECT and ex vivo (see Table 3).
Autoradiography of the kidneys revealed a patchy distribution of the 111In-labelled peptides, 
mainly in the renal cortex (Figure 4) and confirmed lower uptake in the kidneys of the mega-
lin-deficient mice.
Biodistribution of 111In-labelled octreotide, octreotate, neurotensin and minigastrin in organs 
other than the kidneys did not differ significantly between the wild-type and megalin-defi-
cient mice (data not shown). For the high dose of 111In-exendin (2 nmol), lung uptake in the 
wild-type animals was significantly higher than in the megalin-deficient mice (1.2 ± 0.18 %IA/g 
vs. 0.23 ± 0.037 %IA/g in females and 0.98 ± 0.039 %IA/g vs. 0.26 ± 0.034 %IA/g in males, both 
p<0.0001). However, in the animals that received the low dose of 5 pmol 111In-exendin, no 
Renal uptake of radiolabelled peptides measured ex vivo, 3 h p.i. 
Wild-type
(%IA/g±SD)
Megalin-deficient
(%IA/g±SD)
Ratio megalin-deficient/
wild-type (%)
111In-octreotide female 38 ± 9.8 8.4 ± 3.5 22% (p=0.0007)
male 25 ± 12 7.9 ± 2.7 32% (p=0.03)
111In-exendin 2 nmol** female 331 ± 33 215 ± 34 65% (p=0.001)
111In-exendin 5 pmol** female 225 ± 35 183 ± 39 81% (ns)
111In-minigastrin female 66 ± 5.9 17 ± 9.1 26% (p<0.0001)
111In-neurotensin female 5.1 ± 0.94 1.7 ± 0.18 34% (p<0.0001)
Table 3: Renal uptake of radiolabelled peptides in wild-type and megalin-defi cient mice. %IA/g = % injected activity 
per gram kidney; SD = standard deviation; ns = not signifi cant.
** 111In-exendin was measured ex vivo in two experiments: after the fi nal SPECT scan using 2 nmol peptide, and in a 
separate biodistribution experiment using 5 pmol peptide.
Chapter 2.4118
Figure 3: Renal uptake of 111In-labelled peptides in wild-type and megalin-defi cient mice, as measured by ex vivo 
biodistribution studies and SPECT 3 h p.i.. Results are presented as mean % ID/g, error bars indicate standard error of the 
mean. * indicates p<0.05
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difference in lung uptake was observed: both in wild-type and in megalin-deficient mice, the 
lung uptake was 11 %IA/g, much higher than in the animals that received 2 nmol of peptide. 
Correlation between biodistribution and SPECT
The correlation between renal uptake values measured with biodistribution and SPECT was 
very good, as depicted in Figure 5. Spearman’s rank correlation coefficient was 0.924 (r2 = 0.85, 
p<0.0005).
Figure 4: Autoradiography of kidneys of wild-
type and megalin-defi cient mice that received 
111In-exendin (A), 111In-minigastrin (B) or 111In-
neurotensin (C).
Figure 5: Correlation between 
renal uptake measured ex vivo 
and uptake measured with 
SPECT. Data from individual 
mice that were studied ex vivo 
after the fi nal SPECT-scan (111In-
minigastrin and 111In-exendin). 
Solid lines: linear fi tted trend 
line with 95% confi dence 
interval.
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Discussion
In PRRT, the renal retention of radiolabelled peptides can lead to long-term nephrotoxici-
ty, which limits the maximum radiation dose that can safely be administered. Recently, the 
multi-ligand receptor megalin was shown to be essential for the renal reabsorption of 111In-
octreotide [7]. In the present study we show that megalin is also involved in the proximal tu-
bular reabsorption of 111In-octreotate, 111In-minigastrin 111In-neurotensin and probably also of 
111In-exendin, and we confirm megalin’s role in the reabsorption of 111In-octreotide: the renal 
uptake of these peptides in megalin-deficient mice was reduced to 23% - 65% of the uptake 
in wild-type mice.
The remaining renal uptake of the radiolabelled peptides in the megalin-deficient mice may 
be due to residual megalin expression. The knock-out of megalin expression in the kidneys 
of these megalinlox/lox;apoECre mice occurs in a mosaic pattern, with a considerable percent-
age of tubular cells expressing normal levels of megalin, presumably caused by insufficient 
expression of Cre recombinase. Leheste et al. initially reported that approximately 10% of the 
proximal tubular cells of these mice express normal levels of megalin [12]. However, Motoyo-
shi reported residual megalin expression in 35%-50% of the proximal tubular cells in the same 
mouse strain [22]. Immunohistochemical staining of kidney sections in the present study con-
firmed incomplete reduction of megalin expression and considerable variation between indi-
vidual mice. In addition to residual expression of megalin, part of the residual uptake may also 
be explained by the involvement of other uptake mechanisms in the reabsorption of these 
peptides, such as fluid phase endocytosis [23] or ligand-specific receptors. Proximal tubular 
expression of receptors for somatostatin, glucagon-like peptide-1 and cholecystokinin
2
 has 
been described [24-26]. Another multiligand receptor, cubilin, is also involved in the proximal 
tubular reabsorption of several substances, including peptides and proteins [5, 27]. Cubilin 
lacks a transmembrane domain and is dependent on other transmembrane proteins such as 
megalin and amnionless for its internalisation [28, 29]. In megalin-deficient mice, the internali-
sation of cubilin may also be reduced. Therefore, involvement of cubilin in the reabsorption of 
the studied radiolabelled peptides cannot be excluded.
The data obtained in the current study with 111In-exendin were paradoxical: significantly re-
duced renal uptake in megalin-deficient mice was measured when the animals received an 
imaging dose of 2 nmol, but no significant difference between the two groups was found at a 
biodistribution dose of 5 pmol 111In-exendin. This paradox is probably caused by the residual 
megalin expression in the megalin-deficient mice, which may still be able to handle the 5 
pmol dose, while it is saturated by the 2 nmol dose. Even though proximal tubular endocyto-
sis is regarded as a low specificity, high capacity pathway, it can be blocked competitively by 
excesses of ligands [30, 31]. The difference between 111In-exendin and the other peptides in 
this respect might be explained by a relatively high affinity of 111In-exendin for megalin and/
or associated receptors such as cubilin. This may also account for the very high baseline renal 
uptake of this peptide (225 – 371 %IA/g) and suggests that megalin is indeed involved in the 
renal reabsorption of 111In-exendin. Since peptide doses used in PRRT are relatively high, the 2 
nmol dose reflects the clinical situation better than the 5 pmol dose. 
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The renal uptake of the radiolabelled peptides at 3 h p.i. was similar in male and female mice. 
However, at 24 h p.i. the uptake of 111In-octreotide and 111In-octreotate was significantly lower 
in male mice, which has been described previously [13]. This suggests that the proximal tubu-
lar processing and retention of 111In-labelled somatostatin analogues differ between male and 
female mice, leading to more rapid wash-out of radioactivity in males. However, the ratios of 
uptake between megalin-deficient and wild-type mice were comparable in both genders at 
both time points, which suggests that the role of megalin in the reabsorption of radiopeptides 
is independent of gender influences.
Reduced proximal tubular reabsorption of radiolabelled peptides is expected to cause in-
creased excretion of the radiolabelled peptides in the urine without affecting plasma clear-
ance, since glomerular filtration is not affected and reabsorbed radiolabelled peptides are 
not returned to the bloodstream. This is confirmed by our observation that the radioactivity 
concentrations of these radiolabelled peptides in the blood and in most organs other than 
the kidneys did not differ between megalin-deficient and wild-type mice. The one exception, 
lower uptake of 111In-exendin in the lungs of megalin-deficient mice, was only observed at the 
high peptide dose of 2 nmol. At the lower dose of 5 pmol, no difference between megalin-
deficient and wild-type animals was observed, and lung uptake was approximately 5-fold to 
20-fold higher than in the 2 nmol groups. The lower uptake at higher peptide dose is most 
likely due to saturation of specific lung uptake, which was also described recently by Brom 
et al. [19]. The lower lung uptake in the megalin-deficient mice in this group may indicate 
involvement of megalin in the pulmonary uptake of this peptide. Megalin is expressed in the 
lungs [32], and this high-capacity receptor may contribute significantly to peptide uptake 
at higher concentrations, when specific glucagon-like peptide-1 receptor mediated uptake 
(high affinity but lower capacity) is saturated. Although the megalinlox/lox;apoECre mice are de-
scribed to be kidney-specific megalin deficient mice [12], apoE is also expressed in the lungs 
[33], which may cause reduced expression of megalin in the lungs of these animals. Possible 
lower expression of megalin in the lungs is unlikely to have affected the renal uptake of the 
studied peptides, as their concentrations in blood and other organs did not differ significantly 
between the megalin-deficient and wild-type mice.
In this study the renal uptake measured ex vivo and on SPECT images correlated very well. This 
confirms the previously reported accuracy of the small animal SPECT system [34]. Small animal 
SPECT is an accurate alternative to biodistribution studies, enabling serial measurements in 
vivo and possibly reuse of animals in multiple experiments. However, SPECT remains much 
less sensitive than ex vivo organ measurement, which means that relatively high radiation 
doses have to be administered and only organs with a considerable uptake can reliably be 
quantified. This can lead to complications: in the present study, mice that received a relatively 
high kidney radiation dose from 111In-exendin developed long-term kidney damage - which is 
described and analysed in detail elsewhere [21]. This necessitated repeating the experiments 
in a new set of mice. In addition, high activity doses require administration of a high peptide 
dose, as the maximum specific activity is limited. Peptide dose can influence a peptide’s phar-
macokinetics and biodistribution [19, 35]. As outlined above, the higher peptide dose needed 
for SPECT better reflects the PRRT dose.
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Our results indicate that megalin plays an important role in the renal reabsorption of these 
diverse 111In-labelled peptides. The variety of radiolabelled peptides and other ligands that 
are taken up via megalin suggests that it might also be involved in the renal reabsorption 
of other radiolabelled peptides. Insight into the role of megalin in the renal uptake of these 
radiolabelled peptides can help to develop new strategies for the reduction of renal peptide 
reabsorption, thus reducing the risk of nephrotoxicity after PRRT. For example, administration 
of an excess of other megalin ligands can reduce the uptake of radiolabelled peptides by 
competitive binding to megalin. Our group recently showed that co-injection of peptides de-
rived from albumin, an important ligand of megalin, reduces the renal uptake of 111In-labelled 
octreotide, exendin and minigastrin in rats [36]. Succinylated gelatin, a peptide-based plasma 
expander, has also been shown to interfere with proximal tubular reabsorption: a transient low 
molecular weight proteinuria was reported after administration of Gelofusine, with urinary loss 
of β
2
-microglobulin, a ligand of megalin [5, 30, 37]. We previously found that co-administration 
of succinylated gelatin also reduced the renal uptake of 111In-labelled octreotide, exendin and 
minigastrin in rats and of 111In-octreotide in humans [38-40]. Other compounds that have been 
studied for the reduction of renal uptake of radiolabelled peptides are less universally appli-
cable than succinylated gelatin and albumin. Lysine, a positively charged amino acid, is used 
clinically to reduce nephrotoxicity of somatostatin analogue PRRT [10]. However, Gotthardt et 
al. showed that lysine did not reduce the renal uptake of negatively charged minigastrin ana-
logues, whereas negatively charged polyglutamic acids did reduce uptake of 111In-minigastrin, 
but not of the positively charged 111In-octreotide [9]. These observations suggest that dif-
ferent mechanisms are involved in the uptake of these radiolabelled peptides and seems to 
contradict our present findings that megalin is involved in the renal uptake of both peptides. 
However, megalin contains four large binding domains [6], and lysine and polyglutamic acid 
may bind selectively to distinct regions of these domains, thereby only interfering with the 
binding of specific radiolabelled peptides. The peptide mixtures in succinylated gelatin and 
albumin fragments are more likely to block several binding regions on the megalin receptor, 
thereby interfering with the binding and uptake of several different radiolabelled peptides.
In conclusion, the multiligand receptor megalin plays an important role in the renal reabsorp-
tion of 111In-labelled octreotide, octreotate, minigastrin, exendin and neurotensin. This knowl-
edge can be used to develop new methods to reduce the renal retention of these peptides, 
thus reducing the risk of nephrotoxicity and improving the possibilities for safe and effective 
PRRT.
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Abstract
Introduction: Peptide receptor radionuclide therapy using β—-emitting radiolabelled so-
matostatin analogues like DOTA,Tyr3-octreotate, shows beneficial results in patients suffering 
from somatostatin receptor overexpressing tumours. However, after high-dose therapy partial 
renal reabsorption of radiopeptides may lead to nephrotoxicity. Co-infusion of lysine/arginine 
lowers renal retention of these radiopeptides without affecting tumour uptake. Recently co-
administration of Gelofusine has been described to have a comparable kidney-protecting ef-
fect in rats. In the present study optimal dosing of Gelofusine co-administration was studied 
in tumour-bearing rats.
Methods: Doses of 40, 80, 120 or 160 mg/kg Gelofusine were co-injected with 15 μg 
DOTA,Tyr3-octreotate, labelled with 3 MBq 111In for biodistribution (24 h post injection, n = 4 
per group) and with 60 MBq 111In for micro-SPECT imaging experiments at 3 h, 24 h and 48 
h post injection. An additional group of rats received 80 mg/kg Gelofusine plus 400 mg/kg 
lysine co-injection. Biodistribution studies were performed both in older (475 g) and younger 
(300 g) rats, the latter bearing CA20948 tumours. 
Results: Co-injection of 40 mg/kg Gelofusine resulted in 40-50% reduction of renal uptake 
and retention of 111In-DOTA,Tyr3-octreotate, whereas higher doses further increased the reduc-
tion to 50-60% in both groups of rats. Combining Gelofusine and lysine caused 70% reduction 
of renal uptake. The uptake of radiolabelled octreotate both in somatostatin receptor-express-
ing normal tissues and tumours was not affected by Gelofusine co-injection. 
Conclusions: In rats co-injection of 80 mg/kg Gelofusine resulted in maximum reduction of 
renal retention of 111In-DOTA,Tyr3-octreotate, which was further improved when combined 
with lysine. Tumour uptake of radiolabelled octreotate was not affected, resulting in an in-
creased tumour to kidney ratio.
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Introduction
The treatment of patients with somatostatin receptor-positive tumours with peptide receptor 
radionuclide therapy (PRRT) has shown convincing beneficial effects [1, 2]. The radiolabelled 
peptides are rapidly cleared via the glomeruli in the kidneys into the urine, but a low per-
centage is reabsorbed and retained in the cortical proximal tubules [3, 4]. After glomerular 
filtration a fraction of the administered peptides is internalized via endocytic receptors, in this 
process megalin has been demonstrated to play an essential role [5, 6]. Transfer of the radio-
peptides to the lysosomes is followed by degradation of the peptide, after which amino acid 
chelate conjugates are trapped in the lysosomes of the tubular cells [7], delivering a high ra-
diation dose to the renal cortex during PRRT. The maximum tolerated dose in PRRT in patients 
is not exactly known. However, from data from external beam radiation therapy a limit of 23 
Gy on the kidney has been adapted as the upper limit of the dose that can be administered 
safely [8]. Because of the differences with external beam irradiation individual dosimetry has 
been introduced recently in PRRT. This is to correct for the characteristic features of the radio-
nuclide and of the patient, like inhomogeneous intra-organ distribution, shorter penetration 
range, dose rates following exponential decay and patient-specific geometry. Calculation of 
the biological equivalent dose (BED), with a correction for CT-assessed kidney volume and 
dose fractionation, has been adapted resulting in more accurate prediction of kidney toxicity. 
Using an upper limit of a BED of 40-45 Gy has been described to be safe to prevent nephro-
toxicity during PRRT [9-11]. Co-infusion of lysine and arginine (Lys/Arg) has become a standard 
procedure in our institution during PRRT with 177Lu- or 90Y-labelled somatostatin analogues, 
reducing the renal retention of the radiopeptides with approximately 35% [12-14]. These posi-
tively charged amino acids probably interfere in the megalin-mediated reabsorption process 
[4]. As a result higher radioactivity doses can be administered without risk of nephrotoxicity. In 
some cases, however, amino acid infusion may lead to nausea and vomiting, sometimes even 
to hyperkalaemia [13]. 
Recently, the reduction of renal retention of radiopeptides by co-infusion of the plasma ex-
pander Gelofusine was described [15, 16]. A transient low molecular weight proteinuria [17, 
18] induced by Gelofusine led to a 40% reduction of renal reabsorption of radiolabelled oc-
treotide, both in animals [15, 19, 20] and in humans [16]. The combination of both Lys and 
Gelofusine appeared to have an additive effect on the reduction of renal uptake of radiola-
belled somatostatin analogues [19, 20]. This pointed to different mechanisms of interfering in 
the reabsorption process in the renal proximal tubules.
Most of these experiments have been performed with a fixed dose of Gelofusine. The aim of 
the current study was to investigate the dose-response effect of Gelofusine on renal retention 
of the 111In-labelled somatostatin analogue DOTA,Tyr3-octreotate. Biodistribution studies were 
performed in rats bearing CA20948 tumours expressing somatostatin receptors. Co-infusion 
of Lys has been described to have no effect on the tumour uptake of radiolabelled somatosta-
tin analogues [21]; the effect of Gelofusine (with or without Lys) on receptor-mediated tumour 
uptake has not been described yet. 
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Materials and methods
Radionuclides, peptide, chemicals
111InCl
3
 was purchased from Covidien (Petten, The Netherlands). DOTA,Tyr3-octreotate was 
obtained from BioSynthema (St Louis, MO, USA). Radiolabelling was performed according to 
previously published procedures [22]. The labelling efficiency exceeded 99%, as confirmed by 
thin-layer chromatography [22]. Specific activity of 111In-DOTA,Tyr3-octreotate was 3 MBq/15 
μg peptide for biodistribution studies and 60 MBq/15 μg peptide for NanoSPECT imaging 
experiments. Gelofusine (40 g/l) was obtained from Braun Medical (Oss, The Netherlands) and 
L-lysine from Sigma (Zwijndrecht, The Netherlands). Shortly before use a 400 mg/ml L-lysine 
solution in saline was prepared.
Biodistribution experiments
Animal studies were conducted in agreement with the Animal Welfare Committee require-
ments of our institution using generally accepted guidelines. For all experiments male Lewis 
rats (Harlan, Horst, The Netherlands) were used (n=4 per group for biodistribution studies). 
A group of young, slim rats was used at 14 weeks of age (mean body weight of 300 g), and 
a group of old, heavier rats at 45 weeks of age (mean body weight of 475 g) at the time of 
biodistribution.
The young rats were subcutaneously inoculated with 500 μl of a CA20948 tumour cell sus-
pension [23], prepared from 5 g crude tumour tissue in 100 ml saline, at both sides in the 
shoulder region. On day 24 after inoculation the biodistribution and imaging experiments 
were performed. 
For biodistribution studies rats were anaesthetized with isoflurane/O2 and injected with Gelo-
fusine (or saline in control animals) intravenously via the tail vein. The volume ranged from 300 
μl to 2.000 μl, depending on the administered dose ranging from 40 mg/kg to 160 mg/kg. In 
the experiment with the young rats one extra group received both 80 mg/kg Gelofusine and 
400 mg/kg L-lysine. The injection of Gelofusine was immediately followed by the administra-
tion of 111In-DOTA,Tyr3-octreotate. A peptide dose of 15 μg was used because this amount 
is required to administer the optimal activity dose of 555 MBq 177Lu-DOTA,Tyr3-octreotate in 
CA20948 tumour-bearing rats [21]. For the biodistribution studies 3 MBq 111In-DOTA,Tyr3-oc-
treotate/15 μg in 250 μl was injected via the dorsal vein of the penis, whereas for imaging 
of the young tumour-bearing rats, one extra rat per group received 60 MBq 111In-DOTA,Tyr3-
octreotate/15 μg in 250 μl.
After euthanasia at 24 h post injection (p.i.), organs and tumours were dissected and blood 
samples were taken. Organs and tumours were weighed and radioactivity was measured in a 
gamma counter (Wallac, 1480 Wizard 3”, Perkin Elmer, Turku, Finland). Uptake of radioactivity 
was expressed as percentage of injected activity per gram tissue (%IA/g). Data were expressed 
as percentage of control. For autoradiography one kidney and the tumours of each animal 
were frozen embedded in OCT compound (Tissue Tek, Sakura, Zoeterwoude, The Netherlands) 
using isopentane cooled in liquid nitrogen.
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MicroSPECT/CT imaging
One additional rat from each group of the CA20948 tumour-bearing rats was imaged with the 
four-headed multi-pinhole NanoSPECT/CT camera (Bioscan Inc., Washington DC, USA) [24]. 
Rats were anaesthetized with isoflurane/O
2
. Nine pinhole apertures with a diameter of 2.5 mm 
were used on each head, with a field of view (FoV) of 24 mm. Settings of  the 111In energy peaks 
were 171 and 245 keV. Based on the CT topogram, a body range of 85 mm ranging from neck 
to bottom was scanned in 24 min with 60 s per projection. A 6 min CT at 45 kV
p 
was acquired. 
Animals were imaged at 3, 24 and 48 h p.i. to measure  the retention of 111In-DOTA,Tyr3-octreo-
tate and allow calculation of the kidney and tumour dose.
Using the InVivoScope software quantification of the amount of radioactivity in the volume of 
interest (VOI) of kidneys and tumours was performed. Each tumour nodule inside a CA20948 
tumour was analysed separately. The amount of radioactivity in the VOI was expressed in MBq/
ml tumour.
To achieve accurate quantification, the camera was calibrated by scanning a phantom, repre-
senting the attenuation of rats, filled with a known amount of 111In activity. 
Ex vivo autoradiography
Frozen kidneys and CA20948 tumours were cut into sections of 10 μm (Microm Cryo-Star HM 
560 M, Walldorf, Germany). Autoradiographs of the sections were made by exposing them to 
SR phosphor imaging screens (Perkin Elmer, Groningen, The Netherlands) in X-ray cassettes. 
After 24-72 h screens were read by a Cyclone phosphor imager and analysed with OptiQuant 
03.00 image processing system (Perkin Elmer, Groningen, The Netherlands). After exposure 
the sections were stained with haematoxylin and eosin (HE). Based on the results of this stain-
ing regions of interest (ROI) were determined. OptiQuant software was used to quantify the 
intensity of radioactivity and expressed in digital light units (DLU)/mm2. Of each tumour five 
sections were analysed and at least five ROI per section. 
Dosimetry
The dosimetry was based on the MIRD schema to calculate the dose by the product of the 
organ residence times and the S values for dose per cumulated activity. Radiation doses to the 
kidneys and CA20948 tumours were determined. The residence time of 111In was determined 
by the kinetics of the radioactivity retention at three time points after administration. The kid-
ney S values were calculated as described earlier [25], adapted to the actual mass of the kid-
neys, and the absorbed dose in mGy/MBq was calculated. This dose was calculated separately 
for the whole kidney and for the cortex, because the majority of the radioactivity was retained 
in the cortex containing glomeruli and proximal tubules. Only the self-absorption dose from 
activity uptake in the kidneys was calculated. Tumour S values also were dependent on the 
actual mass of each tumour. Olinda/EXM software was used for calculation of the absorbed 
dose in mGy/MBq [26].
Statistics
Data were expressed as mean ± standard deviation (SD). Statistical analysis was performed 
using Student t test.
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Results
In rat biodistribution studies the renal uptake of 15 mg 111In-DOTA,Tyr3-octreotate was exam-
ined, without or with co-injection of increasing doses of Gelofusine (ranging from 40 to 160 
mg/kg). The retained amount of radioactivity without Gelofusine co-administration was 4.6 ± 
0.3 or 4.1 ± 0.1 % IA/g in the young and older rats, respectively, at 24 h p.i.. A dose of 40 mg/
kg Gelofusine significantly reduced the renal retention of 111In-DOTA,Tyr3-octre otate. (Figure 
1A, B). This lowest dose of Gelofusine induced a reduction of renal uptake of 40% in young 
Figure 1: Biodistribution at 24 h p.i. of 15 μg 111In-DOTA,Tyr3-
octreotate in rats, without or with co-injection of Gelofusine 
in increasing doses ranging from 40 to 160 mg/kg. In young 
rats Gelofusine 80 mg/kg in combination with Lys 400 mg/
kg was tested as well. Uptake was calculated as % injected 
activity/gram (%IA/g). The %IA/g of the control group was set 
at 100%, values obtained in Gelofusine groups were expressed 
as percentage of control values; n = 4 per group. 
A: Renal retention in 45-week-old rats with a mean body 
weight of 475 g
B: Renal retention in 14-week-old rats with a mean body weight 
of 300 g
C: Kidney sections after ex vivo autoradiography demonstrating 
localization of 111In-DOTA,Tyr3-octreotate 24 h p.i. in a 
representative kidney from the control and Gelofusine 80 mg/
kg group of the 45-week-old rats
D: Uptake in pancreas, adrenals and stomach in 14-week-old 
rats 
E: Uptake in CA20948 tumours in 14-week-old rats
* p <0.05; ** p <0.001; *** p <0.005
A B
C D
E
control 80 mg/kg Gelofusine
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and of 50% in older rats. When a dose of 80 mg/kg was given a further reduction of uptake 
in the kidneys was found of 50% and 60%, respectively, compared to controls. With the 120 
and 160 mg/kg Gelofusine doses no further reduction of the renal retention was measured; 
therefore the 80 mg/kg dose seemed sufficient to induce the maximum achievable reduction 
of renal retention of 111In-DOTA,Tyr3-octreotate. The maximum total volume of Gelofusine and 
radiopeptide that was administered to the heavy rats was more than 2000 μl; no side effects 
were observed. 
Ex vivo autoradiography of kidney sections demonstrated that the localization of the radioac-
tivity was not affected by addition of Gelofusine (Figure 1C); radioactivity mainly localized in 
the cortex and to a lesser extent in the outer medulla. When the 80 mg/kg Gelofusine dose 
was combined with Lys co-administration a significant additive effect on reduction of renal 
uptake of radiolabelled octreotate was measured; 68% reduction compared to control values 
was achieved (Figure 1B). In the biodistribution study in the young rats it was found that the 
administration of large amounts of Gelofusine, with or without Lys, did not affect the uptake of 
111In-DOTA,Tyr3-octreotate in somatostatin receptor-expressing organs (Figure 1D) and subcu-
taneously grown somatostatin receptor-expressing CA20948 pancreatic tumours (Figure 1E). 
Quantification of retained radioactivity in CA20948 tumour sections in ex vivo autoradiograms 
confirmed that Gelofusine co-administration had no significant effect on tumour uptake of 
radiolabelled octreotate (Figure 2A, B). 
Tumour to kidney activity uptake ratios at 24 h p.i. of the control, the Gelofusine 80 mg/kg 
and the combination of Gelofusine and Lys situation were 0.18 ± 0.08, 0.30 ± 0.12, 0.38 ± 0.23 
respectively. This was also nicely visualized in the NanoSPECT/CT images of CA20948 tumour-
bearing rats (Figure 3A) [27]. Quantification of the tumour uptake of 111In-DOTA,Tyr3-octreotate 
24 h p.i. in the images revealed again that increasing doses of Gelofusine did not affect tumour 
uptake of radiolabelled octreotate expressed in MBq/ml tumour (Figure 3B).
Figure 2: Ex vivo autoradiography of CA20948 after 
biodistribution study with 111In-DOTA,Tyr3-octreotate, 
without or with co-injection of increasing doses of 
Gelofusine.
A: Quantifi cation of intensity of retained radioactivity 
in frozen sections of CA20948 tumours after ex vivo 
autoradiography of which the biodistribution results 
are shown in Figure 1E. Amount of radioactivity is 
expressed in DLU/mm2. Only regions containing 
tumour cells were analysed, as demonstrated in the 
HE stained section. No signifi cant diff erences were 
found.
B: Examples of CA20948 tumour sections after ex vivo 
autoradiography.
Control 40 mg/kg 80 mg/kg 120 mg/kg 160 mg/kg 80 mg/kg + Lys
A
B
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Figure 3: NanoSPECT/CT imaging, quantifi cation and dosimetry.
A: NanoSPECT/CT images of CA20948 tumour-bearing rats, 3 h p.i. of 15 μg 111In-DOTA,Tyr3-octreotate, labelled with 
60 MBq of 111In, without or with co-injection of Gelofusine 80 mg/kg (and 400 mg/kg Lys). Earlier published in [27].
B: Quantifi cation of retained radioactivity in CA20948 tumours of imaged rats using InVivoScope software. Amount 
of radioactivity was expressed in MBq/ml tumour. Each tumour nodule inside a CA20948 tumour was analysed 
separately. No signifi cant diff erences were found.
C: Residence time of 111In in kidneys, as determined in NanoSPECT/CT images at 3, 24 and 48 h p.i. of 15 μg 111In-
DOTA,Tyr3-octreotate. Wash-out of 111In was plotted for three rats: control, with Gelofusine 80 mg/kg alone and 
combined with 400 mg/kg Lys. 
D: Dose calculation of 111In-DOTA,Tyr3-octreot ate for whole kidney or renal cortex only, expressed in mGy/MBq 111In. 
Renal radiation dose in a control rat is compared with rats receiving Gelofusine 80 mg/kg alone or combined with 
400 mg/kg Lys as co-administration.
A
B C
D
control 80 mg/kg Gelofusine 80 mg/kg Gelofusine + Lys
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Images of the rats acquired at 3, 24 and 48 h p.i. were analysed to determine the kidney and 
tumour dosimetry. The kinetics of the washout of 111In-DOTA,Tyr3-octreotate from the kidneys 
and CA20948 tumours were similar in the control and the Gelofusine (+ Lys) groups; kidney 
data are shown in Figure 3C. After determination of the correct S values based on the actual 
masses of both kidneys and tumours, the absorbed doses were calculated. The dose on the 
renal cortex in the rats that received Gelofusine 80 mg/kg appeared to be 40% of the dose in 
the rats without renal protection, whereas the dose in the rats that received the combination 
of Gelofusine with Lys was only 30% of the dose in the control group as shown in Figure 3D. 
The total absorbed radiation dose caused by 111In to the renal cortex in the control group was 
1.7 ± 0.1 Gy, whereas the doses to the CA20948 tumours varied between 0.3 and 0.75 Gy and 
was independent of administration of renal protection agents.
Discussion
Reduction of renal retention of radiolabelled somatostatin analogues is an important issue 
in PRRT, since after treatment with therapeutic doses of 90Y-labelled octreotide or octreotate 
nephrotoxicity has been described [28, 29], especially when renal doses exceeding 23 Gy 
were applied [14, 30]. The partial reabsorption of somatostatin analogues can be reduced by 
co-infusion with the cationic amino acids lysine and arginine during the administration of 
therapeutic doses of 90Y- or 177Lu-labelled somatostatin analogues. This is a commonly used 
method nowadays, resulting in about 35% reduction of renal uptake of radioactivity [2, 13]. 
Approximately 30% of the patients suffer from nausea and 15% from vomiting as well during 
the 4 h infusion of 2.5% lysine and 2.5% arginine in 1 l of saline, in spite of administration of the 
antiemitic granisetron [31]. Hyperkalaemia has not been demonstrated with these amounts 
of amino acids, but was only found in patients receiving a total dose of 75 g lysine [13]. There-
fore, increasing the Lys dose is no option to improve the reduction of renal uptake. Research 
to further reduce renal retention of such high-energy radiolabelled peptides is warranted to 
increase the therapeutic window of PRRT. 
The net charge of radiolabelled peptides is an important factor influencing renal retention 
[32]. The Lys residue in octreotide and octreotate seems responsible for the relatively high 
uptake in kidney. In a preclinical study comparing different neurotensine analogues it was 
shown that Lys co-administration also reduced renal retention of other radiolabelled peptides, 
but this only occurred when a Lys residue formed part of the peptide [33]. This points to a 
competitive mechanism which has been revealed to be, at least partly, a megalin-mediated 
process. This negatively charged multi-ligand scavenger receptor which is expressed on renal 
proximal tubules plays a key role in the endocytosis of radiolabelled somatostatin analogues 
[4, 6].
Gelofusine is a succinylated gelatine consisting of polypeptides with an average molecular 
weight of 30 kDa. It is used as a plasma expander in critically ill patients. ten Dam et al. de-
scribed that after Gelofusine infusion an increased amount of α
1
- and β
2
-microglobulin was 
excreted in the urine, pointing to a disturbed protein reabsorption process [17]. Based on this 
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observation Gelofusine was co-administered with radiolabelled somatostatin analogues and 
offered a reduction of renal uptake of radiolabelled octreotide to an extent comparable to that 
of cationic amino acids, as recently described in animals and in healthy volunteers [15, 16]. The 
exact mechanism of the reducing effect of Gelofusine is still unknown. When the renal uptake 
of several non-somatostatin peptide analogues was studied, it appeared that their renal re-
tention could be reduced as well, whereas in the cases of gastrin and exendin analogues Lys 
co-injection had no effect [19, 34]. Gotthardt et al. suggested that Lys and poly-glutamic acid 
only interfere with one of the four clusters of anionic amino acid repeats of megalin respon-
sible for binding of a variety of ligands, while Gelofusine administration acts on all four clusters 
enabling reduced retention of all radiolabelled peptides tested thus far [19, 35]. 
To further reduce uptake and retention of radioactivity in the kidneys the combination of both 
agents was tested, demonstrating an additive effect. This combination of agents is promising, 
because more cycles of therapeutic doses could be safely administered in clinical PRRT using 
this combination without exceeding the mentioned 23 Gy absorbed kidney dose or 45 Gy 
BED limit. Until now in most experiments in rats and mice a fixed dose of Gelofusine was used 
[15, 19]. In the study of Rolleman et al. [20], a limited dose-response effect was suggested in 
the range between 50 and 80 mg/kg. In the current study this observation was confirmed. 40 
mg/kg Gelofusine caused already a reduction of renal retention of 111In-DOTA,Tyr3-octreotate, 
which was further increased with a 80 mg/kg dose. These doses were independent of the 
body weight of the animals, since comparable results were obtained in both groups without 
significant difference. The 80 mg/kg dose appeared to be the dose being sufficient to induce 
maximum reduction of renal retention, since higher doses did not improve the reduction of 
kidney uptake of radiolabelled octreotate. Apparently maximal induction of proteinuria and/
or blocking of receptors responsible for endocytosis already is achieved at this 80 mg/kg Gelo-
fusine dose. 
Comparing literature data with the currently described results, it is clear that the percentage of 
reduction of renal uptake by Gelofusine co-administration in a 80 mg/kg dose is comparable 
for all somatostatin analogues tested (111In-DTPA,Tyr3-octreotide, 177Lu-DOTA,Tyr3-octreotate, 
111In-DOTA,Tyr3-octreotate) and is independent of the administered amount of peptide (0.5 
mg, 15 mg), while the % IA/g kidney of control animals ranged from 1 to 4% IA/g [15, 19, 20].
The potential effect of Gelofusine on tumour uptake of 111In-DOTA,Tyr3-octreotate was inves-
tigated as well. The biodistribution experiment showed no interference of Gelofusine with 
radioactivity uptake in CA20948 tumour, although the tumour uptake varied largely due to 
the irregularly shapes and structures of the tumours, whereas the mean volume of the tu-
mours was similar in all groups, although with a high variability. When radioactivity in separate 
tumour nodules in the frozen sections was quantified using ex vivo autoradiography, vari-
ability of tumour uptake was smaller and mean DLU/mm2 was not reduced when Gelofusine 
was co-administered. Furthermore, the recently developed method to quantify the amount 
of radioactivity which is retained in imaged organs and tumours using microSPECT/CT, also 
confirmed that tumour uptake of 111In-DOTA,Tyr3-octreotate was not influenced by Gelofusine 
with or without Lys [20, 24].
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Quantification of the retained renal radioactivity by imaging the same rat at several time 
points after injection of the radiolabelled octreotate allowed estimation of the radiation dose 
to the kidneys and tumours. The clearance rate of 111In-DOTA,Tyr3-octreotate from the kidneys 
and the tumours was similar in the control and in the renal protection groups. This confirms 
that Gelofusine and Lys had a transient effect on the renal reabsorption mechanism and only 
interfered in the initial retention of radiopeptides in the proximal tubules, but had no effect on 
the wash out of the radiometals. The induced reduction in radiation dose to the whole kidney 
or to cortex alone was comparable to the reduction found in the biodistribution study: up to 
70%, which is very favourable for kidney protection when therapeutic radionuclides like 177Lu 
or 90Y will be applied. 
Taken together our results indicating significant renal protection but unaffected uptake in so-
matostatin receptor-expressing tumours and organs, warrant a randomized cross-over trial to 
test the combination of amino acid infusions with or without Gelofusine in patients receiving 
PRRT with 177Lu-DOTA,Tyr3-octreotate in our centre. 
It is hard to translate our reported optimal dose of 80 mg/kg Gelofusine for renal uptake re-
duction of 111In-DOTA,Tyr3-octreotate in rats, which was administered as a bolus injection, to 
the clinical situation where Gelofusine will be co-infused during several hours. The Gelofusine 
dose that was administered in the healthy volunteers was a bolus of 40 mg/kg per 10 min fol-
lowed by a 3 h infusion of 0.8 mg/kg per min (144 mg/kg), resulting in a total dose of almost 
200 mg/kg over a 3-h period of time [16]. In Bad Berka 450 ml of 4% Gelofusine solution was 
infused in 4 h combined with Lys/Arg, during PRRT, which means a dose of 225 mg/kg per 4 h 
for a patient with a body weight of 80 kg [36].
A drawback of the use of Gelofusine might be the risk of an allergic reaction in less than 
1% of the patients, probably because of its bovine origin [37, 38]. Therefore patients need 
to be strictly monitored. When a significantly reduced renal retention of radioactivity can be 
obtained with extra Gelofusine administration, an adapted regimen to protect kidneys from 
renal toxicity during PRRT may be used in future. This will allow administration of more cycles 
of PRRT without risk of nephrotoxicity, while a higher tumour radiation dose will be achieved. 
Due to crossfire from circulating radioactivity in the blood the bone marrow is the second or-
gan at risk during PRRT. The clearance of radioactivity from the blood was not delayed by the 
administration of Gelofusine and Lys. Therefore, especially when the cumulative dose will be 
increased further, monitoring of blood cell counts is needed to detect haematological toxicity, 
like cytopaenia or myelodysplastic syndrome [2].
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Conclusion
In rats a Gelofusine dose of 80 mg/kg body weight induced maximal reduction of 50-60% of 
renal retention after administration of a therapeutic peptide dose of 15 mg of 111In-DOTA,Tyr3-
octreotate. Combination of this dose of Gelofusine with 400 mg/kg L-lysine resulted in a 70% 
reduced kidney uptake, while the somatostatin receptor-specific uptake in pancreas, stomach, 
adrenals and CA20948 pancreatic tumour was not affected. Application of combined Lys/Arg 
and Gelofusine infusions during PRRT in patients will enlarge the therapeutic window. 
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Abstract
Introduction: Megalin-mediated renal retention of radiolabelled somatostatin analogues 
may result in nephrotoxicity during clinical PRRT; co-infusion of cationic amino acids can re-
duce the renal uptake though. The radical scavenger amifostine is being used as cytoprotector 
in external beam and chemotherapy, whereas protection from long-term nephrotoxicity in 
rats during PRRT with 177Lu-DOTA,Tyr3-octreotate has also been demonstrated. Here we aimed 
to further investigate the renal protection mechanism of amifostine and potential interference 
with anti-tumour effects during PRRT.
Methods: In vitro uptake studies were performed with 111In-DOTA,Tyr3-octreotate using BN-16 
and CA20948 cells, expressing megalin/cubilin- and somatostatin receptors (sst) respectively, 
in combination with amifostine or WR-1065, the active metabolite of amifostine. In CA20948 
tumour-bearing rats biodistribution and therapy studies were performed using 3 MBq 111In-
DOTA,Tyr3-octreotate (0.5 or 15 μg peptide) or 555 MBq 177Lu-DOTA,Tyr3-octreotate (15 μg) 
respectively with or without amifostine co-administration, either s.c. or i.v.. 
Results: Surprisingly, addition of amifostine and WR-1065 reduced uptake of 111In-DOTA,Tyr3-
octreotate in BN-16 cells to 66% and 55% of control, respectively, but not in CA20948 cells. In 
agreement with this, amifostine decreased renal uptake of 15 μg radiolabelled octreotate in 
biodistribution studies to 62% of control level after s.c. and to 39% after i.v. co-administration, 
but tumour uptake was not affected. This was consistent with complete tumour remission 
after PRRT in the presence of amifostine. 
Conclusions: Our results support evidence that amifostine may provide renal protection 
during PRRT, both by reduction of the absorbed kidney radiation dose and by the earlier re-
ported radical scavenging, whereas anti-tumour effects were not attenuated. 
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Introduction
Patients with metastasized somatostatin receptor over-expressing tumours can significantly 
benefit from peptide receptor radionuclide therapy (PRRT) using 177Lu- or 90Y-labelled soma-
tostatin analogues, e.g. Tyr3-octreotate [1, 2]. However, megalin receptor-mediated retention 
of radiopeptides in the renal proximal tubules may lead to a high renal radiation dose and 
therefore to long-term renal damage [3, 4]. Renoprotection by co-infusion of the cationic 
amino acids lysine and arginine (Lys/Arg) is commonly applied during administration of PRRT, 
because a reduced renal uptake of 60% of control levels can be achieved [5, 6] which may 
be further improved when combined with co-infusion of the gelatin-based plasma expander 
Gelofusine [7, 8]. Thus, inhibition of the initial renal uptake of radiopeptides is a successful way 
to reduce the risk of late renal dysfunction. On the other hand kidney protection can also be 
achieved by mitigation of radiation-induced tissue damage by radioprotective drugs such as 
amifostine [9, 10].
The radical scavenger amifostine, or Ethyol or WR-2721, was developed by the Walter Reed 
Army Institute of Research to protect people from radiation effects during a nuclear war. It is 
approved by the FDA to be used during radiotherapy [11, 12] and chemotherapy [13-15] to 
protect healthy tissues such as kidneys, salivary glands and progenitor cells in bone marrow 
[16]. The mechanisms of action of the antioxidant amifostine have been reported to include 
scavenging of oxygen radicals reducing development of inter-strand cross-links, hydrogen 
atom donation and induction of intracellular hypoxia by auto oxidation [17, 18]. The pro-drug 
amifostine is converted into the active compound WR-1065 after dephosphorylation by the 
enzyme alkaline phosphatase (AP) which is present on plasma membranes of e.g. arteriolar 
endothelium of various normal tissues and proximal tubular epithelium in the kidney [19]. The 
molecular structures of amifostine and WR-1065 are shown in Figure 1. 
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Figure 1: Molecular structures of 
amifostine, WR-1065 and lysine.
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In rats administration of amifostine protected kidneys from radiation-induced fibrosis and tu-
bular atrophy beyond 150 days after external beam irradiation [20], confirming the antioxi-
dant effects of amifostine [21]. We previously reported that co-administration of amifostine 
also protected kidneys from long-term toxicity after irradiation by 177Lu-DOTA,Tyr3-octreotate 
during PRRT in non-tumour-bearing rats [9]. Potential protection of the tumour against the 
therapeutic effects of PRRT by amifostine could not be examined in that study though. Sound 
vascularisation and high capillary AP activity in normal tissues compared to neovascularisa-
tion, less AP expression and a relatively low pH value in tumour tissues, support the tissue 
selectivity and preferential conversion of amifostine and uptake of WR-1065 in normal cells 
[22-24]. Hence attenuation of tumour therapy by amifostine is not expected, although pre-
clinical reports are ambiguous on this issue [22, 25, 26]. 
Because the combination of amifostine and somatostatin analogue-based PRRT was not stud-
ied before in tumour-bearing animals, in the current study we aimed to gain more insight 
into the renal protection mechanism of amifostine during PRRT and into potential tumour 
protection, i.e. interference of amifostine with anti-tumour effects. Uptake of 111In-DOTA,Tyr3-
octreotate was studied in vitro using megalin/cubilin receptor-expressing BN-16 cells and sst-
expressing CA20948 tumour cells, with or without amifostine or WR-1065 and also with Lys 
as positive control inhibiting somatostatin analogue uptake in BN-16 cells. In vivo biodistri-
bution studies using 111In-DOTA,Tyr3-octreotate were performed in CA20948 tumour-bearing 
rats, with or without co-administration of amifostine. Furthermore, tumour-bearing rats were 
treated with 177Lu-DOTA,Tyr3-octreotate, with or without amifostine, and were followed be-
yond 150 days post therapy (p.t.) to monitor anti-tumour effects.
Materials and methods
Radionuclides, peptide, chemicals
177LuCl
3
 was obtained from IDB (Baarle Nassau, The Netherlands) and 111InCl
3
 was purchased 
from Covidien (Petten, The Netherlands). DOTA,Tyr3-octreotate and octreotide were supplied 
by BioSynthema (St Louis, MO, USA). Radiolabeling was performed according to previously 
published procedures with a labelling efficiency exceeding 95%, as confirmed by thin-layer 
chromatography [27, 28].
The specific activity of 111In-DOTA,Tyr3-octreotate for the in vitro uptake experiments was 50-80 
MBq/μg peptide. In biodistribution studies 111In-DOTA,Tyr3-octreotate was administered either 
as 3 MBq/15 μg or 3 MBq/ 0.5 μg peptide. A peptide amount of 15 μg was administered 
because this amount is required to label the therapeutic dose of 555 MBq 177Lu to DOTA,Tyr3-
octreotate for PRRT in CA20948 tumour-bearing rats [29]. A peptide amount of 0.5 μg was 
applied as well because in earlier studies we showed that this resulted in the highest uptake 
in sst-expressing tissues and CA20948 tumours [30].
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Human serum albumin (HSA) kits (Vasculocis) were purchased from IBA Molecular Benelux 
(Louvain-la-Neuve, Belgium) and 99mTc-labelled according to the provided procedure. Final 
99mTc-HSA concentration was 10 MBq/2mg/ml.
Amifostine (Ethyol) was purchased from Pinnacle biologics (Almere, The Netherlands) in vi-
als containing 500 mg, to be reconstituted in 9.7 ml saline. WR-1065 was kindly provided by 
the Drug Synthesis and Chemistry Branch, Division of Cancer Treatment, National Institutes 
of Health (Bethesda, MD, USA). L-lysine and bovine serum albumin (BSA) were obtained from 
Sigma (Zwijndrecht, The Netherlands). 
In vitro BN-16 and CA20948 cell assays
Rat yolk sac carcinoma epithelial (BN-16) cells, expressing megalin/cubilin receptors, were 
kindly provided by Prof. P.J. Verroust from the department of Anatomy, University of Aarhus, 
Denmark [31, 32]. BN-16 and CA20948 cells [33] were cultured at 370C in DMEM (Invitrogen, 
Breda, The Netherlands) supplemented with 10% foetal calf serum (FCS). Cells were seeded 
into 12-well plates and cultured until confluence. Before addition of 10-9M radiopeptide (plus 
amifostine, WR-1065 or Lys) cells were rinsed twice with 2 ml warm PBS (pH 7.4) and incu-
bated for 1h at 370C with 1 ml serum-free DMEM and rinsed twice again with 2 ml warm PBS 
(pH 7.4). Amifostine, WR-1065 or Lys were prepared as 2.10-2M stock solution in Ringer’s solu-
tion (B. Braun Medical, Oss, The Netherlands) with 10mM HEPES (pH 7.4). Dilutions of 2.10-3M 
and 2.10-4M were prepared. Per well 500 μl of the three concentrations of amifostine, WR-
1065 or Lys were added in triplicate or 500 μl Ringer’s solution was added as negative control 
[34]. To each well 500 μl of 2.10-9M 111In-DOTA,Tyr3-octreotate was added and the well-plates 
were incubated for 1h at 37°C. Cells were rinsed twice with Ringer’s solution after which 1 ml 
of 1 M NaOH was added to lyse the cells. The lysates were counted in a gamma counter (Perkin 
Elmer, Wallac, 1480 Wizard 3”, Turku, Finland). This protocol was also followed to measure the 
uptake of 3.10-3M 99mTc-HSA, to check BN-16 megalin receptor expression, because albumin 
is one of the main megalin ligands. Octreotide (10-5M) or BSA (10 mg/well) were added as 
positive controls for specific inhibition of 111In-DOTA,Tyr3-octreotate or 99mTc-HSA uptake, re-
spectively.
Counts were expressed as percentage of added radioactivity (%A) per mg protein of cell lysate, 
the latter determined using a commercially available colorimetric assay (BioRad, Veenendaal, 
The Netherlands). Effects of co-incubation with the different agents were expressed as per-
centage of 111In-DOTA,Tyr3-octreotate uptake in control wells.
Animal experiments
Animal studies were conducted in accordance with the guidelines of the Animal Welfare Com-
mittee. Male Lewis rats with a mean body weight (BW) of ~250 gram were purchased from 
Harlan (Horst, The Netherlands). 
1. Biodistribution 
CA20948 tumour cells were cultured in DMEM supplemented with 10% FCS and ~106 cells in 
500 μl Hank’s balanced salt solution (Invitrogen, Breda, The Netherlands) were inoculated s.c. 
in both flanks of the rats. Two weeks after inoculation the biodistribution experiments were 
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performed, n=4 rats per group. Rats were anaesthetized with isoflurane/O
2
 and injected with 
1 ml of amifostine solution (50 mg amifostine, or ~200 mg/kg) or saline (control animals) via 
the tail vein. The injection of amifostine was followed either immediately or after 30 min by the 
administration of 111In-DOTA,Tyr3-octreotate via the penis vein. One group received amifostine 
s.c. immediately before radiolabelled octreotate. This biodistribution assay was performed us-
ing either 0.5 μg or 15 μg 111In-DOTA,Tyr3-octreotate peptide.
After euthanasia at 24 h post injection (p.i.) tumours, kidneys and other organs were dissected 
and blood samples were taken. Tissues were weighed and radioactivity was measured in the 
gamma counter. Uptake of radioactivity was expressed as percentage of injected activity per 
gram tissue (%IA/g). Data obtained in amifostine-treated rats were expressed as percentage of 
data obtained in control rats. 
2. Peptide receptor radionuclide therapy (PRRT) 
One to two weeks after inoculation of CA20948 cells into one flank, when the tumour reached 
a size of 4-10 cm2, rats received 555 MBq/15 μg 177Lu-DOTA,Tyr3-octreotate or saline as con-
trol, injected via the penis vein (250 μl). Thirty min before administration of 177Lu-DOTA,Tyr3-
octreotate, two groups of rats were injected with 1 ml amifostine (50 mg, or 200 mg/kg), 
either s.c. (AMI sc) or i.v. followed by s.c. doses of 10 mg for 5 days (AMI iv-sc). Rats in the 177Lu-
DOTA,Tyr3-octreotate only group received saline instead of amifostine. BW and tumour size 
were determined twice a week up to 150 days post therapy (p.t.). The 2 largest perpendicular 
tumour diameters were measured using a calliper and the tumour volume was calculated by 
multiplication and expressed in cm2. Loss of more than 10% of original BW and tumour size 
beyond 15 cm2 were indications to euthanize the animal.
Statistics
Data were expressed as mean ± standard deviation (SD). Statistical analyses were performed 
using Student t test. Concerning the differences in BW (Figure 4A) analysis was performed 
using ANOVA. Six time points (0, 2, 10, 15, 20 and 22 weeks p.t.) and the four treatments were 
included as independent variables and absolute BW as dependent variable. 
Results
BN-16 cells are known to express megalin/cubilin receptors [31], whereas sst are not present 
on these cells. On the other hand, CA20948 cells express sst on their cell membranes [30]. 
Since albumin is one of the main ligands of megalin receptors their expression was checked 
using 99mTc-HSA, resulting in an uptake level in BN-16 cells of more than 20 %A/mg cellular 
protein after 1 h of incubation at 370C, which could be nearly completely blocked by an ex-
cess of 10 mg BSA (data not shown). The uptake level of 111In-DOTA,Tyr3-octreotate in BN-16 
cells was 0.7 %A/mg protein and 13.5 ± 0.8 %A/mg protein in CA20948 cells; these levels 
were set at 100% for the two cell lines. Addition of excess BSA or octreotide inhibited uptake 
of 111In-DOTA,Tyr3-octreotate in BN-16 cells; BSA to 49.2 ± 6.4 % and octreotide to 73.6 ± 5.6 
% of control. In CA20948 cells octreotide completely blocked the uptake of radiolabelled oc-
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treotate whereas no competitive effect of BSA was found, confirming that these cells only 
express somatostatin- and no megalin/cubilin-receptors (Figure 2). In BN-16 cells amifostine 
or WR-1065 co-incubation showed significant inhibition of 111In-DOTA,Tyr3-octreotate uptake 
in a dose dependent way, WR-1065 to 55.0 ± 7.8 % and amifostine to 65.9 ± 6.3% of control 
at 10-2 M. Co-incubation with 10-2M Lys reduced uptake of 111In-labelled octreotate to 47.4 ± 
6.1% of control, comparable with WR-1065 and BSA. In CA20948 cells no significant competi-
tive effects of these three agents on 111In-DOTA,Tyr3-octreotate uptake were found (Figure 2).
In vivo biodistribution studies in tumour-bearing rats were performed with 0.5 or 15 μg of 111In-
DOTA,Tyr3-octreotate, to simulate the effect of amifostine co-administration with both diag-
nostic and PRRT peptide amounts. The uptake of 111In-DOTA,Tyr3-octreotate 24 h p.i. in kidneys 
and especially in CA20948 tumours and sst-expressing tissues such as pancreas, stomach and 
adrenals, was dependent on the peptide amount (Table 1). Radioactivity levels in the kidneys 
Figure 2: In vitro uptake of 111In-DOTA,Tyr3-
octreotate in BN-16 and CA20948 cells without or 
with addition of amifostine (AMI), WR-1065 or Lys.
After extensive rinsing, cells were incubated for 1 h at 
370C with 10-9M 111In-DOTA,Tyr3-octreotate, without 
or with addition of 10-4M, 10-3M or 10-2M AMI, WR-
1065 or Lys in 12-well plates confl uent with megalin 
receptor-expressing BN-16 cells or sst-expressing 
CA20948 cells. In the latter only 10-2M of each agent 
was tested. 10 mg/well BSA or 10-5M octreotide were 
added as positive controls to BN-16 and CA20948 
cells, respectively. Uptake was calculated as % of 
added activity/mg cellular protein (%A/mg) and 
the value obtained in control wells was set at 100%. 
Uptake values obtained after co-incubation with the 
diff erent agents were expressed as percentage of 
control values ± SD. At least two experiments were 
performed in triplicate.* = p <0.05, *** = p <0.0001 
vs. control, ns = not signifi cant.
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Figure 3: Biodistribution data 24 h p.i. of 15 μg (A) or 0.5 μg (B) 111In-DOTA,Tyr3-octreotate (3 MBq) in CA20948 
tumour-bearing rats without or with co-administration of 50 mg amifostine (AMI) via diff erent routes of injection.
AMI iv co = intravenously (i.v.) co-injection of AMI with 111In-DOTA,Tyr3-octreotate, AMI iv pre = i.v. injection of AMI 
30 min before 111In-DOTA,Tyr3-octreotate, AMI sc = subcutaneous (s.c.) injection of AMI immediately before 111In-
DOTA,Tyr3-octreotate. Uptake was calculated as % IA/g and the value of the saline group was set at 100%. Uptake 
values obtained in AMI groups were expressed as percentage of control values ± SD. n = 4-6 rats per group. *** = p 
<0.0001 vs. saline group. Diff erences between renal uptake using 15 μg 111In-DOTA,Tyr3-octreotate in AMI sc group vs. 
AMI iv co and AMI iv pre were signifi cantly diff erent as well (p <0.0001 and p=0.0002 respectively), ns = not signifi cant.
 %IA/g ± SD 0.5 μg 15 μg
Kidney 6.85 ± 0.45 8.54 ± 1.46
CA20948 7.62 ± 1.48 1.65 ± 0.33
Pancreas 8.27 ± 0.87 0.99 ± 0.06
Adrenals 9.00 ± 1.91 1.15 ± 0.09
Stomach 1.29 ± 0.20 0.14 ± 0.01
Table 1: Biodistribution data 24 h p.i. of 0.5 or 15 
μg 111In-DOTA,Tyr3-octreotate in rats without co-
administration of amifostine. 
Uptake in kidneys, sst-expressing CA20948 tumours 
and organs (pancreas, adrenals and stomach) was 
calculated as % injected activity/gram (%IA/g) 
± standard deviation (SD). n = 4 rats per group. 
Diff erence in renal uptake between the two groups 
was not signifi cantly diff erent (p=0.07), whereas 
the uptake in sst-expressing tissues was highly 
signifi cantly diff erent (p<0.0001).
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Figure 4: PRRT using 555 MBq 177Lu-DOTA,Tyr3-octreotate (15 μg) in CA20948 tumour-bearing rats without or with 
co-administration of amifostine (AMI) via diff erent routes of injection. 
Saline = group without PRRT and AMI (n=13), PRRT = group i.v. 177Lu-DOTA-Tyr3-octreotate without AMI (n=5), AMI 
sc = group s.c. injection of 50 mg AMI immediately before 177Lu-DOTA-Tyr3-octreotate (n=6), AMI iv-sc =  group i.v. 
injection of 50 mg AMI 30 min before 177Lu-DOTA,Tyr3-octreotate, followed by 5 daily s.c. doses of 10 mg AMI (n=12). 
A: Body weight (BW) over time p.t., monitored twice a week up to day 150 p.t., expressed as percentage of initial BW. 
At 22 weeks p.t. the BW of the PRRT AMI iv-sc group was signifi cantly higher than the BW of the PRRT AMI sc group 
(ANOVA, p<0.05, Scheff é’s correction for multiple comparisons).
B: Tumour sizes over time p.t., measured twice a week up to day 150 p.t. Rats in the saline group had to be euthanized 
when tumour size > 15 cm2. Tumour response in PRRT and PRRT AMI sc group was 100%, in PRRT AMI iv-sc group 83%.
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of both amounts of 111In-DOTA,Tyr3-octreotate were not significantly different. Sst-mediated 
uptake levels in tumours and organs, however, were significantly less when the high 15 μg 
peptide dose was administered compared to tissues from rats that were injected with the 0.5 
μg octreotate amount [30].
Three ways of co-administration of amifostine were tested in biodistribution experiments with 
the 15 μg peptide amount (Figure 3). The s.c. route led to 39% reduction of the renal reten-
tion, but i.v. administered amifostine even caused a 61-62% reduction of renal radioactivity. 
On the other hand, a reduction of renal retention of 27% was found when amifostine was 
co-injected i.v. with 0.5 μg 111In-DOTA,Tyr3-octreotate. Concerning sst-mediated uptake, ami-
fostine co-administration with the 15 μg amount of radiolabelled octreotate caused no signifi-
cant effect on CA20948 tumour uptake, but a nearly twofold increased level of radioactivity in 
sst-expressing tissues (pancreas, adrenals and stomach) was detected. This phenomenon of 
increased uptake levels in sst-expressing organs was also encountered when the low, 0.5 μg 
peptide amount was administered, but in this case a significant 48% reduction of the tumour 
uptake was encountered. 
Monitoring body weight (BW) after PRRT is being used as a marker of the state of health of 
treated rats. Non-tumour bearing, non-treated control rats gain BW steadily over time [9]. In 
the current experiment the non-treated tumour-bearing animals had to be euthanized be-
cause of too large tumours at day 20 after start of the experiment, so they were lost for follow-
up (Figure 4). Administration of amifostine via both routes induced a transient BW loss in 
tumour-bearing rats during the first week after PRRT with 555 MBq 177Lu-DOTA,Tyr3-octreotate 
(Figure 4A). From day 25 on, BW was similar to that of the rats that received PRRT without 
amifostine. All PRRT-treated rats afterwards gained weight until day 35 post therapy (p.t.) and 
stabilized until day 90 after which loss of BW was observed. Rats from the iv-sc AMI group lost 
less BW than the other two groups. Significant BW differences at the six tested time points 
between PRRT+AMI iv-sc vs PRRT+AMI sc and PRRT only treatments were found (p<0.001). 
In this study, the very effective therapeutic effects of 555 MBq 177Lu-DOTA,Tyr3-octreotate on 
CA20948 tumours were clearly illustrated again. At day 25 p.t. all tumours were not palpable 
anymore (100% complete response). However, in 2 out of the 12 rats in the AMI iv-sc PRRT 
group tumours escaped at 22 and 60 days p.t., resulting in a 83% final tumour eradication vs. 
the 100% score in the other PRRT groups. 
Discussion
Amifostine (Ethyol, WR-2721) is currently being applied as a cytoprotective agent for nor-
mal tissues against harmful effects of both ionizing irradiation or chemotherapeutic agents. 
Clinical applications include prevention of external beam irradiation-induced xerostomia in 
patients suffering from head and neck carcinoma and reduction of renal toxicity in patients 
treated with cisplatin because of advanced ovarian cancer [12, 16]. 
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In several studies the pharmacokinetics of amifostine has been reported in the literature. Ami-
fostine, either administered intraperitoneally (i.p), i.v. or s.c, is very rapidly cleared from the 
blood; within 6-30 min. p.i. only 6-10% of the parent drug is left, while 5-10 min p.i. the maxi-
mum tissue concentrations of the active metabolite WR-1065 are reached in liver and kidneys 
[25, 35-37]. A comparative study in cynomolgus monkeys using both i.v. and s.c. routes of 
amifostine administration demonstrated that the WR-1065 peak level after s.c administration 
was reached later, declined more slowly and remained at a higher level than after i.v. adminis-
tration [37]. In the initial clinical studies in which amifostine was co-administered, the i.v. route 
was recommended. Because amifostine should be infused within half an hour before irradia-
tion logistical issues complicated incorporation into clinical practice. Furthermore, common 
adverse effects were associated with this i.v. route of administration. Transient hypotension 
occurred in ~50% of cases and interruption of amifostine infusion was indicated when a fall of 
20% in systolic blood pressure was observed [15, 18]. Besides hypotension, dose dependent 
side effects such as nausea, vomiting and local skin reactions occurred [18]. In a clinical study 
s.c. administered amifostine appeared to be well tolerated by 85% of patients, showing less 
adverse events such as hypotension [38], whereas the radioprotection efficacy was similar to 
studies applying i.v. amifostine administration [11]. Moreover the s.c. route is simpler and saves 
time in clinical practice.
Radioprotective effects of amifostine were described in several preclinical studies. In rats ami-
fostine offered long-term kidney protection when administered i.p. in a 200 mg/kg BW dose 
30 min before 6 Gy external kidney irradiation [20]. The same amifostine dose, administered 
either i.v. or s.c., was described to protect rats efficiently from mucositis after a 15 Gy dose 
of external beam irradiation, whereas lower doses accomplished less beneficial effects. No 
significant differences in cytoprotective effects were found using either route of administra-
tion, however a prolonged beneficial effect after s.c. administration was found [39]. Earlier we 
described renal protective effects of amifostine after a 35-70 Gy absorbed kidney radiation 
dose induced by 278 or 555 MBq 177Lu-DOTA,Tyr3-octreotate PRRT [9]. In this study a dose of 
i.v. 200 mg/kg BW was administered as well, followed by 7 daily s.c. doses of 25 mg/kg. These 
daily maintenance doses were thought to be essential to sustain a protective WR-1065 level 
during the first week post therapy (p.t.), because of the short half-life of WR-1065. Scavenging 
of oxygen radicals delivered after 177Lu-radiation in the kidneys by WR-1065 seemed to have 
protected the renal function because of maintained BW and 99mTc-DMSA uptake, less urinary 
protein excretion and relatively low serum creatinine and urea levels after PRRT plus amifos-
tine compared to the group that received PRRT without amifostine. Therefore, we chose this 
administration route of amifostine again for one of the groups in the current PRRT study and 
compared it with a group that received a single s.c. amifostine dose of 200 mg/kg shortly 
before PRRT. The BW of the AMI iv-sc group of rats stabilized beyond 90 days p.t. vs. a decline 
in BW in the PRRT only and AMI sc groups (Figure 4A) confirming a higher level of well-being 
[9]. This supported the hypothesis that continuous presence of WR-1065 during the first days 
after administration of PRRT is essential for long-term kidney protection.
The potential risk of undesired tumour protection by amifostine is an issue being discussed 
since co-treatment was started. In some early preclinical radiotherapy studies using high ra-
diation doses and high amounts of amifostine, undesired tumour protection seemed to occur 
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[25]. Recent reviews and meta-analyses concluded that anti-tumour efficacy of chemo- and 
radiotherapy was not compromised by amifostine though [12, 18, 26, 40, 41]. In the current 
rat study tumour protection by amifostine from anti-tumour effects was also not found. All tu-
mours showed a complete response after injection of 555 MBq  177Lu-DOTA,Tyr3-octreotate (15 
μg), although over time in the AMI iv-sc group two out of 12 rats encountered a relapse of tu-
mour growth. This unaltered beneficial therapeutic effect is in agreement with the unaffected 
in vitro uptake of radiolabelled octreotate in CA20928 cells in the presence of amifostine and 
WR-1065 and also with the in vivo results of the CA20948 biodistribution study using 15 μg 
111In-DOTA,Tyr3-octreotate, in which at 24 h p.i. similar uptake levels were reached in rats with 
or without amifostine co-administration. 
The fact that renal radioactivity was reduced after amifostine co-administration in the 111In-
DOTA,Tyr3-octreotate biodistribution experiments was unexpected. AP content is abundant 
in kidney and liver, as well as in other types of normal tissues, in epithelium, connective tissue 
and vasculature [35]. So the conversion from amifostine into WR-1065 will take place locally in 
the kidneys, and WR-1065 will remain present because only a limited amount appeared to be 
excreted into the urine [36]. Therefore this positively charged amifostine metabolite may act 
as a competitor in the megalin-mediated renal reabsorption of radiolabelled octreotate. This 
hypothesis is based on the fact that the positively charged amino acids lysine (and arginine) 
interfere with the reabsorption process of radiolabelled somatostatin analogues, which has 
been demonstrated by in vitro assays using the megalin receptor-expressing BN-16 cells [5, 34, 
42]. In this in vitro assay addition of WR-1065 and, to a lesser extent, the parent drug amifostine 
also reduced the in vitro uptake of 111In-DOTA,Tyr3-octreotate to a similar level as was reached 
with BSA and Lys (Figure 2). This is a clear indication that these positively charged agents inter-
fered in the megalin-mediated uptake of the radiolabelled peptide and might therefore rep-
resent a mechanism responsible for reduction of renal retention of 111In-DOTA,Tyr3-octreotate 
in vivo. 
Administration of amifostine 30 min prior to PRRT was adapted from radioprotection protocols 
to enable metabolization of WR-1065 before generation of harmful oxygen species by irradia-
tion. Since the WR-1065 blood level already peaks at 5-10 min after amifostine administra-
tion, this 30 min time interval is not needed to obtain less renal radioactivity after injection 
of the radiopeptides, in line with the fact that no significant differences in renal uptake were 
detected between pre- or co-injection of amifostine (Figure 3A). However, the WR-1065 peak 
level after s.c. amifostine administration occurs later and is lower, explaining the decrease of 
reduction of renal radioactivity in this group (Figure 3A). So, although the s.c. route of admin-
istration of amifostine seemed to be more favourable in studies concerning cytoprotection 
after ionizing radiation because of less side-effects [38, 39] in the present study concerning 
kidney protection by amifostine during PRRT, i.v. co-administration proved to be more effec-
tive in reducing the initial renal retention of radiolabelled octreotate than the s.c. route. 
The percentage of reduction of renal radioactivity by i.v. amifostine co-injection was less if 
0.5 μg 111In-DOTA,Tyr3-octreotate was injected compared to 15 μg, i.e. 27 vs 61% reduction, 
respectively (Figure 3B). Since we did not register blood pressure in the rats, we only can 
speculate that a transient drop in systolic blood pressure induced by the bolus injection of 
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amifostine reduced the renal clearance rate of the radiopeptides. This was most obvious with 
the high amount of peptide [15]. Due to a longer circulation time of a higher concentra-
tion of 111In-DOTA,Tyr3-octreotate the uptake in the sst-expressing organs could have reached 
the higher levels as compared to tissues from rats without amifostine co-administration. This 
is in contrast however with the decreased uptake in CA20948 tumours when 0.5 μg 111In-
DOTA,Tyr3-octreotate was used. In rats the pharmacokinetics of the binding of radiolabelled 
somatostatin analogues to sst-expressing normal tissues or to tumours appeared to be dif-
ferent [30, 43]. Rat CA20948 tumour uptake of 111In-DOTA,Tyr3-octreotide was optimal using 
a peptide mass of 0.5 μg, while pancreas showed an increasing uptake until 5 μg per rat. We 
postulate that hypotension may have hampered the blood flow into the tumour, vascular-
ised by newly formed blood vessels, and affected the optimal, high tumour uptake realized 
with 0.5 μg radiolabelled octreotate. Amifostine will not be used during diagnostic application 
of somatostatin analogue based scintigraphy when low peptide amounts are administered; 
therefore this reduced tumour uptake will not be an issue in clinical practice.
The earlier described protective effects on late kidney function and histology when amifostine 
was given together with 278 MBq 177Lu-DOTA,Tyr3-octreotate were attributed to the radical 
scavenger properties of the amifostine derivative WR-1065 because of interference in the cas-
cade of events leading to the development of fibrosis in the kidney [9]. In the current study 
we discovered that also the initial renal uptake and retention of 111In-DOTA,Tyr3-octreotate was 
reduced when amifostine was co-administered. Therefore two mechanisms may have contrib-
uted to the kidney protective effect of amifostine: a combination of a lower absorbed kidney 
radiation dose because of reduced renal uptake and an attenuation of the process leading to 
long-term renal fibrosis elicited by free oxygen species. To discriminate between the effects 
mediated by these two mechanisms, in future experiments long-term kidney protection will 
be monitored after administration of amifostine prior to PRRT and compared to the protection 
after amifostine administration post PRRT. 
Conclusions:
Co-administration of the cytoprotector amifostine with radiolabelled octreotate reduced the 
initial renal uptake and retention of this peptide. There is strong evidence that this effect is 
based on partial inhibition of the megalin-mediated renal reabsorption of radiopeptides by 
amifostine and/or WR-1065. Therefore amifostine may provide kidney protection when ap-
plied during PRRT both by reduction of the absorbed kidney radiation dose and by radical 
scavenging reducing late development of radiation induced renal fibrosis as reported earlier. 
Furthermore, we were able to demonstrate that amifostine did not affect tumour response 
after 177Lu-DOTA,Tyr3-octreotate PRRT in rats. Thus, the application of amifostine during clinical 
PRRT might be a promising strategy to reduce the risk of radiation induced nephrotoxicity. 
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Abstract
Introduction: In peptide receptor radionuclide therapy (PRRT), the dose-limiting organ is 
most often the kidney. However, the precise mechanism and the exact localization of kidney 
damage during PRRT have not been fully elucidated. We studied renal damage in rats, after 
therapy with different amounts of 1 77Lu-DOTA,Tyr3-octreotate and investigated 99mTc-DMSA as 
a tool to quantify renal damage after PRRT.
Methods: Twenty-nine rats were divided over three groups and injected with either 0, 278 
or 555 MBq 177Lu-DOTA,Tyr3-octreotate, leading to about 0, 46 and 92 Gy to the renal cortex. 
More than 100 days after therapy, kidney damage was investigated using 99mTc-DMSA (Dimer-
captosuccinic acid) SPECT (single photon emission computed tomography), autoradiography, 
histology, and blood analyses. 
Results: In vivo SPECT with 99mTc-DMSA resulted in high resolution (<1.6mm) images. The 
99mTc-DMSA uptake in the rat kidneys was related inversely with the earlier injected activ-
ity of 177Lu-DOTA,Tyr3-octreotate and correlated inversely with serum creatinine values. Renal 
ex vivo autoradiograms showed a dose dependent distribution pattern of 99mTc-DMSA. 99mTc-
DMSA SPECT could distinguish between the rats that were injected with 278 or 555 MBq 
177Lu-DOTA,Tyr3-octreotate, whereas histological damage grading of the kidneys was nearly 
identical for these two groups. Histological analyses indicated that lower amounts of injected 
radioactivity caused damage mainly in the proximal tubules, while as well the distal tubules 
were damaged after high dose radioactivity. 
Conclusion: Renal damage in rats after PRRT appeared to start in a dose dependent way in 
the proximal tubules and continued to the more distal tubules with increasing amounts of in-
jected activity. In vivo SPECT measurement of 99mTc-DMSA uptake was highly accurate to grade 
renal tubular damage after PRRT. 
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Introduction
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogs has be-
come an important tool in the management of neuroendocrine tumors. Convincing results 
were found for both objective tumor response and quality of life [1-4]. During PRRT using 
somatostatin analogs labelled with ß-emitters like 90Y and 177Lu, usually the kidney is the dose-
limiting organ [5, 6].
Although the major part of the radiopharmaceutical is excreted into the urine, the partial 
reabsorption in the tubular cells leads to a considerable radiation dose to the radiosensitive 
kidneys [7, 8]. It was shown recently that the localization of the radiopeptide in the kidney 
is not homogeneous, but predominately in the cortex where it forms a striped pattern, with 
most of the radioactivity centered in the inner cortical zone [9]. In the only study that included 
biopsies of human kidneys after PRRT, mainly thrombotic microangiopathy was found despite 
minor tubular atrophy and interstitial fibrosis [10]. In addition it is known that PRRT can lead to 
radiation nephritis [11, 12]. The precise mechanism of renal damage however is not fully eluci-
dated; especially the localization of the most pronounced damage has not been identified yet. 
The potential coherence of the inhomogeneous distribution of radioactivity in the kidney and 
the localization of damage is highly relevant since a number of radionuclides potentially suit-
able for therapy are available. The β—-emitters 90Y, 177Lu and 131I are widely used for therapies 
with a number of vectors [13, 14]. Several therapy studies were performed with the Auger 
emitter 111In and several new radionuclides, including α-emitters, are under investigation [15, 
16]. The different physical characteristics of these radionuclides result in a different tissue pen-
etration range of the therapeutic particles and will therefore lead to a different distribution 
pattern of absorbed radiation dose in the kidney [17].
The aim of this study was to investigate rat kidneys more than 100 days after injection of 
different amounts of 177Lu-DOTA,Tyr3-octreotate. The highest activity injected was intended 
to induce severe kidney damage. The kidneys were investigated with a number of methods: 
ex vivo autoradiography, histological analysis with different staining methods and measure-
ment of serum creatinine to get a complete overview of function and morphology. As it is 
known that radiopeptides are absorbed partially in the tubular epithelial cells, in vivo SPECT 
(single photon emission computed tomography) with 99mTc-DMSA (dimercaptosuccinic acid), 
as a marker for renal tubular damage [18, 19], were acquired with a dedicated animal SPECT 
camera (NanoSPECT), that allows absolute in vivo quantification of renal 99mTc-DMSA-uptake 
[20]. The 99mTc-DMSA scintigrams were performed to evaluate the value of this tracer in the 
follow up of renal function after PRRT in rats in order to develop a sensitive method to follow 
renal function over time. 
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Materials and Methods 
Radiopharmaceuticals
177Lu-DOTA,Tyr3-octreotate was synthesized and labelled as described previously [21]. The 
99mTc-DMSA (Dimercaptosuccinic acid) kit was purchased from GE Healthcare (Buckingham-
shire, United Kingdom) and labelled according to the indicated procedure.
Animal studies 
Animal experiments were performed in compliance with the regulations of the institution and 
with generally accepted guidelines governing such work. Twenty nine young, male Lewis-
rats (Harlan, Horst, The Netherlands) with a body weight of 250 - 300 grams were divided 
over 3 groups. The control group consisted of 9 rats. Ten rats were i.v. injected with 278 MBq 
177Lu-DOTA,Tyr3-octreotate and 10 rats with 555 MBq 177Lu-DOTA,Tyr3-octreotate. In 20 rats (5 
controls, 7 of the 278 MBq group and 8 of the 555 MBq group) SPECT scans with 99mTc-DMSA 
were acquired. Since renal damage is late toxicity, the scans were acquired between 109 - 146 
days after the injection of 177Lu-DOTA,Tyr3-octreotate. The 99mTc-DMSA uptake in the kidneys 
was quantified. Thereafter, an autoradiogram of the 99mTc-DMSA uptake was performed in 6 
rats (two from each group). Kidneys from all animals were analysed histologically.
Animal SPECT (NanoSPECT) and software 
SPECT imaging was performed with a four-headed multiplexing multi-pinhole NanoSPECT 
(Bioscan Inc., Washington D.C., USA). Each head is outfitted with an application-specific tung-
sten collimator with 9 pinholes. For this study we imaged with rat apertures that are com-
prised of a total of 36, 2 mm diameter pinholes imaging a cylindrical field of view that is 60 
mm in diameter by 24 mm in length. These rat apertures provided a reconstructed resolution 
below 1.6 mm at 140 keV with an average sensitivity of 1100 cps/MBq across the field of view 
(FOV). The images are acquired in a step-and-shoot helical scan-mode which allows to image 
a defined range from 24 to 270 mm according to the region to be imaged. The energy-peak 
for the camera was set at 140 keV. The window width was ± 10%. The rats were scanned 4-6 
hours after the injection of 50 MBq 99mTc-DMSA. An acquisition time of 30 seconds per projec-
tion was chosen resulting in total acquisition times ranging from 6-9 minutes per animal. The 
data were reconstructed iteratively with the HiSPECT© software (Bioscan), a dedicated ordered 
subsets-expectation maximisation (OSEM) software package for multiplexing multi-pinhole 
reconstruction. The NanoSPECT was calibrated with a phantom, approximately of the size of 
the animals, filled with a known activity of 99mTc such that voxel values in the reconstruction 
provide a proper estimate of the activity level without further calculation. 
A volume of interest (VOI) was drawn manually around both kidneys; the 3D activity distribu-
tion within the VOI was then summed to determine the uptake. Because of the favourable 
biodistribution of 99mTc-DMSA, limited to the kidneys, the VOI could be drawn generously to 
prevent partial-volume effects at the edges. All measured activities were corrected for decay 
and expressed as % injected activity [%IA]. The injected activity was determined by measuring 
the syringe in a dose-calibrator before and after injection of the animal. The difference was de-
fined as the injected activity. The quantification of the VOI was performed with the INTERVIEW 
XP© software (Mediso Ltd., Budapest, Hungary). After imaging the rats were sacrificed. 
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Autoradiography
In six animals (2 from each group) after euthanasia one kidney was removed, quickly frozen 
on liquid nitrogen cooled isopentane and processed further for autoradiography. The tissue 
was embedded in TissueTek (Sakura, Zoeterwoude, The Netherlands) and processed for cryo-
sectioning as described previously [22]. Briefly, tissue sections (10 μm) were mounted on glass 
slides. The sections were exposed to SR phosphor imaging screens (Packard Instruments Co., 
Canberra CT, USA) for 1 d in radiographic cassettes. The screens were analysed using a Cyclone 
phosphor imager and a computer-assisted OptiQuant 03.00 image processing system (Pack-
ard). 
Histology 
Immediately after removing from the animal, kidneys were fixed in 10% neutral buffered for-
malin, trimmed and processed by standard techniques for embedding in paraffin. Four-micron 
sections were cut and stained with haematoxylin-eosin (HE) or periodic acid-Schiff reagent 
(PAS). The microscopic renal damage score (RDS) was graded blinded to the treatment proto-
col ranging from 0 (no damage) to 4 (severe damage). The criteria for these grades are listed 
in Table 1. 
The PAS stained sections were used for better differentiation between proximal and distal 
tubules. 
Grade Overview Glomeruli Tubules
1
More or less normal 
aspect
High cell count glom-
eruli
Apoptotic cells in the 
endothelium
Inflammatory infiltrate
Apoptotic cells 
Rough protein staining
Little dilated  
Normal BM 
No protein cylinders  
2
Dilation of tubules
Damaged tubule cells 
Like grade 1
More apoptotic cells
More pronounced dilation
BM thickened
Little protein cylinders in tubules
Regenerating cells (mitotic activity)
3
Stronger dilated 
tubules
Cell rich infiltrate
Regenerating tubules
PAS: thickened BM 
PAS: protein cylinders
Vascular lumina small-
er, few erythrocytes
Sometimes shrinkage
Flat epithelium, partly total loss of 
epithelium
Strong dilation
Inflammatory infiltrate
Regeneration present
Protein cylinders
More pronounced BM thickening
4
Heavily dilated tubules
Heavily thickened BM 
Protein cylinders
Like grade 3
More optical empty 
space due to shrink-
age glomeruli
Like grade 3, but more protein 
cylinders
Periferal fibrosis
Table 1: Criteria for the histological kidney damage score.
Abbreviation: BM = basal membrane
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Blood analyses
Blood chemistry and haematological parameters were determined by standard hospital analy-
sis procedures. 
Statistics 
To correlate the results, Pearson’s correlation coefficient was calculated. The Student t test was 
used to test significance of differences. A p-value <0.05 was considered significant. 
Results
The administration of 177Lu-DOTA,Tyr3-octreotate to the rats was straightforward. No acute dis-
comfort was observed in the rats treated. After inclusion, the body weight of the rats from all 
groups dropped slightly by not more than 5%. After this initial decline, the body weight of 
the control rats increased continuously as expected. In contrast, the body weight of the rats 
treated with 278 MBq initially increased slightly and then remained stable, while the body 
weight of the rats treated with 555 MBq initially increased and dropped beyond approximately 
70 days after PRRT. (Figure 1A-C). 
By SPECT with 99mTc-DMSA in all rats both kidneys could be visualized although kidneys in 
the group injected with 555 MBq where visible only faintly. The spatial resolution of the im-
ages was high with a spatial resolution below 1.6 mm. Differentiation between functional 
parenchyma characterized by tracer accumulation and the cold regions indicative of the renal 
Figure 1: Body weight (g) (mean ± SD) of the rats 
treated with 0 MBq 177Lu-DOTA,Tyr3-octreotate (A), 
with 278 MBq 177Lu-DOTA,Tyr3-octreotate (B) and with 
555 MBq 177Lu-DOTA,Tyr3-octreotate (C). 
A B
C
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pelvis was easily possible (Figure 2A-C). The renal uptake of 99mTc-DMSA was significantly dif-
ferent between the three groups (all p < 0.01). The mean values ± SD were 23.2 ± 1.2 %IA for 
the control group, 9.9 ± 6.3 %IA for the group injected with 278 MBq and 1.4 ± 0.5 %IA for the 
group injected with 555 MBq.
Figure 3A-C show examples of the autoradiograms with 99mTc-DMSA from rat kidneys after 
treatment with 0, 278 and 555 MBq 177Lu-DOTA,Tyr3-octreotate. Figure 3A shows a normal 
distribution of 99mTc-DMSA in a control rat with a high accumulation in the renal cortex. In 
Figure 2: Coronal SPECT slices of rat kidneys acquired 4 – 6 h after the injection of 50 MBq 99mTc-DMSA. The slices 
correspond to the kidneys in Figure 3 and 4. (A) is from a control animal, (B) from an animal 115 days after therapy with 
278 MBq 177Lu-DOTA,Tyr3-octreotate and (C) from an animal 109 days after therapy with 555 MBq 177Lu-DOTA,Tyr3-
octreotate.
Figure 3: Renal autoradiograms after an in vivo injection of 50 MBq 99mTc-DMSA. The rats were sacrifi ced 6 h after 
injection. Figure 3A shows the autoradiogram of a control animal with a normal radioactivity distribution. Figure 3B 
shows the autoradiogram of an animal 115 days after therapy with 278 MBq 177Lu-DOTA,Tyr3-octreotate. Figure 3C 
shows the autoradiogram of an animal 109 days after therapy with 555 MBq 177Lu-DOTA,Tyr3-octreotate. The images 
correspond to the kidneys in Figure 2 and 4.
A B C
A B C
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contrast, in figure 3C showing an autoradiogram of a rat treated with 555 MBq 177Lu-DOTA,Tyr3-
octreotate, hardly any 99mTc-DMSA uptake can be seen, indicating severely damaged tubular 
function. Figure 3B shows an autoradiogram of a rat treated with 278 MBq 177Lu-DOTA,Tyr3-
octreotate. Here, intermediate renal 99mTc-DMSA uptake was found. The distribution pattern of 
the radioactivity was obviously different compared to that of the control rat. We found a “shift” 
of the radioactivity from the cortex to the outer medulla. The corresponding SPECT scans are 
displayed in Figure 3A-C. A very good match between SPECT and autoradiograms was found, 
underlining the high accuracy of the SPECT images. 
In the third row (Figure 5A-C) the corresponding histological HE stained overview images of 
adjacent sections of those providing the autoradiograms are shown. A dose dependent loss of 
eosinophile cytoplasm can be seen already in the low power (3x) overview.  
The detailed histology showed, as expected, no significant abnormalities in the control rats. 
One kidney was scored with a damage score of 2, all other kidneys did not show any damage 
and were scored 0. An example of a histological, PAS stained slice of a control rat is shown in 
Figure 5A. 
In the rats treated with 555 MBq, detailed histology revealed intense changes in the proximal 
and distal tubules 177Lu-DOTA,Tyr3-octreotate. A mixed picture with inhomogeneous nuclei, 
apoptotic and necrotic cells was found (Figure 5C). In all kidneys of this group we found exten-
sive protein leakage into the tubules and collecting tubes. Furthermore interstitial nephritis 
with inflammation cells was found. The glomeruli however showed none or only very mild 
changes. Based on the criteria given in Table 1 all kidneys of the rats treated with 555 MBq 
were histologically scored as grade 4 damage.
The rats treated with 278 MBq showed severe histological damage as well. Especially the proxi-
mal tubules were heavily damaged with atrophy, dilatation, apoptotic nuclei and necrosis. 
However, in contrast to the kidneys of the rats that were treated with 555 MBq there was a 
Figure 4: (A-C) Low power overviews (3x) of coronal histological slices of rat kidneys, stained with HE. The slices 
correspond to Figures 2 and 3. 
A B C
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notable number of tubules that did not show histological damage. The PAS staining revealed 
that these were mainly distal tubules, located in the outer medulla. In addition to the tubular 
damage, signs of interstitial nephritis with inflammation cells were found as well (Figure 5B). 
The tubular damage was accentuated in the cortex which reflects the uptake of 99mTc-DMSA 
very well. The histological scoring resulted in one grade 2 score, one grade 3 and 8 grade 
4 scores. Thus, regarding only the histological score, no significant difference to the group 
treated with 555 MBq was found (p=0.18). 
At the day of sacrifice a blood sample was drawn by cardiac puncture to measure the se-
rum creatinine values. The results (mean ± 
SD) were 36.5 ± 17.5 μmol/l in the control 
group, 129.7 ± 79.9 μmol/l in the group 
injected with 278 MBq, and 425.3 ± 219.2 
μmol/l in the group injected with 555 
MBq. All differences between all groups 
were significant (p<0.05) (Figure 6). Fur-
thermore a significant (p<0.01) correlation 
was found between the creatinine values 
and and the %IA determined by SPECT.  
Figure 5: Histological sections of the cortex 
and outer medulla of rat kidneys, PAS stained, 
magnifi cation 20x. (A) shows a normal histology from 
a control animal. (B) is from an animal 115 days after 
therapy with 278 MBq 177Lu-DOTA,Tyr3-octreotate, 
showing a decrementation of tubular cells with 
necrotic epithelial cells, infl ammatory infi ltration, 
and intact distal tubules. (C) is from an animal 109 
days after therapy with 555 MBq 177Lu-DOTA,Tyr3-
octreotate. Infl ammatory infi ltration, nearly complete 
decrementation of morphologically normal tubular 
cells, and protein leakage to the tubular volume can 
be seen. 
Figure 6: Serum creatinine values (μmol/l, mean ± SD) of 
the three groups at the day of sacrifi ce. 
A B
C
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Discussion 
High dose PRRT could cause severe renal damage in rats as well as in humans because of the 
radiation absorbed dose to the kidney during therapy [5, 8, 10, 12]. Recently a number of new 
drugs were introduced with potential to reduce renal toxicity during PRRT, but the effective-
ness of these drugs during PRRT remains to be proven in patients [23-26]. Worthwhile to be 
highlighted are the studies with amifostine because this is the first drug investigated for PRRT 
that does not aim at reducing the renal uptake but which acts as a radical scavenger to reduce 
systemically the toxic effects of the radiation. Because amifostine is acting by a completely 
different mechanism, a combination with drugs that reduce the renal uptake appears most 
promising [23].
To improve kidney protection during PRRT it is important to understand the mechanism of 
renal damage. One step towards a better understanding could be close monitoring of kidney 
function after PRRT in vivo and over time. The newly available dedicated small animal gamma 
cameras offer the possibility to investigate physiological processes in the same animal over 
time. However a tracer, easily available for daily routine, needs to be defined. The relation that 
was found between 99mTc-DMSA uptake and serum creatinine values as well as the relation 
between 99mTc-DMSA uptake and the injected activity of 177Lu-DOTA,Tyr3-octreotate indicate 
that 99mTc-DMSA is an accurate marker for renal function after PRRT in these animals. 
The only work containing histological data from human kidneys after PRRT reports, despite 
minor fibrosis and tubular atrophy, mainly thrombotic microangiopathy (involving glomeruli, 
arterioles, and small arteries). These pathological changes were comparable to the changes 
found after external beam radiation when the kidney is within the field of radiation. The data 
for this study were generated investigating kidney biopsies of patients after treatment with 
DOTA,Tyr3-octreotide labelled with 90Y, a high energy β—-emitter [10].
Recently published data showed that the highest concentration of radiolabelled peptides in 
rat kidneys and in human kidneys as well was found in the proximal tubular cells [9, 22]. The 
multiligand scavenger receptor megalin appeared to play a crucial role for the reabsorption 
of radiopeptides into the tubular cells [27]. Using the high energy β—-emitter 90Y, emitting β 
particles with a maximum energy of 2.27 MeV, will result in a fairly homogenous energy distri-
bution over the whole kidney including a high radiation absorbed dose to the glomeruli [28]. 
For this study 177Lu was used, emitting β particles with a maximum energy of 0.50 MeV which 
results in a significant lower tissue penetration range of these particles and a different energy 
distribution over the kidney. Taking into account the space between tubules and glomeruli as 
well as microdosimetric aspects, a lower radiation absorbed dose to the glomeruli when using 
177Lu compared to 90Y can be expected. It was calculated recently that other radiolanthanides 
with even lower energy β—-particles could improve the energy distribution further [16]. Re-
cently several articles were published using α emitters for internal radiation therapy [28-30]. 
After the administration of 213Bi labelled DOTA,Tyr3-octreotide to Lewis-rats, no histological 
changes were observed in kidney glomeruli and tubules. As a consequence of the treatment 
with 22.2 MBq of 213Bi-DOTA,Tyr3-octreotide merely mild interstitial nephritis was observed. 
It is very likely that the physical characteristics of the radionuclide used might have a strong 
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influence on kidney damage and might be one of the reasons why no histological changes in 
the glomeruli were found in this study using 177Lu. 
The estimated radiation absorbed dose to the kidney is high after single dose administration 
of 278 or 555 MBq 177Lu-DOTA,Tyr3-octreotate in rats. Dosimetric calculations showed that in-
jecting these activities into rats resulted in doses to the cortex of approximately 46 and 92 Gy 
respectively and approximately 35 and 70 Gy respectively to the whole kidney [17]. For the 
treatment of patients a maximum tolerated dose to the kidneys of 23 Gy is generally accepted 
although this value is derived from external beam radiation, dealing with different properties 
especially concerning the dose rate and energy distribution within the kidney [6]. Taking into 
account the potential dose reduction by the co-infusion of amino acids, 278 MBq of 177Lu-
DOTA,Tyr3-octreotate would result in approximately 23 Gy. 
The results of this rat study strongly suggest that late renal damage after high dose 177Lu-
DOTA,Tyr3-octreotate therapy is mainly tubular. This is supported by the results of the 99mTc-
DMSA studies, being a marker for the renal tubular function. The dose dependent reduction 
of 99mTc-DMSA uptake in the rat tubules suggests that 177Lu-DOTA,Tyr3-octreotate provokes a 
dose dependent tubular damage. 
In conclusion 99mTc-DMSA appears to be a good marker to quantify the extent of damage after 
PRRT. Using 99mTc-DMSA in combination with a dedicated small animal gamma camera will al-
low the following of renal function after PRRT in animals over time. 
Localization and extent of damage respectively after PRRT was found to be dose dependent. 
While in rats treated with 278 MBq 177Lu-DOTA,Tyr3-octreotate kidney damage was found to be 
mainly in the proximal tubule, higher injected radioactivities resulted in a decline of morpho-
logically undamaged tubules.
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Abstract 
Introduction: High kidney radiation doses during clinical peptide receptor radionuclide 
therapy (PRRT) with β—-particle emitting radiolabelled somatostatin analogues will lead to 
renal failure several months after treatment, urging co-infusion of cationic amino acids lysine 
(Lys) and arginine to reduce the renal radiation dose. In rat PRRT studies renal protection by 
co-administration of Lys was confirmed, based on histological examination of kidney speci-
mens indicating nephrotoxicity. In the current study we investigated dedicated small animal 
SPECT/CT renal imaging in rats to monitor renal function in vivo during follow-up of PRRT, with 
and without Lys. 
Methods: Three groups of rats were imaged using the multi-pinhole NanoSPECT/CT camera: 
(1) controls and (2) rats >90 days post therapy (p.t.) with 460 MBq/15 μg 177Lu-DOTA, Tyr3-
octreotate without or with (3) 400 mg/kg Lys co-injection as kidney protection (n=6 per 
group). At 90 and 140 days p.t. static kidney scintigraphy was acquired 2 h post injection of 25 
MBq 99mTc-DMSA. In addition, dynamic dual isotope renography was performed using 50 MBq 
111In-DTPA and 50 MBq 99mTc-MAG3 at d100-120 p.t. 
Results: 111In-DTPA and 99mTc-MAG3 studies revealed a time-activity pattern comparable to 
those in patients with a peak at 2-6 min followed by decline of renal radioactivity. Reduced 
111In-DTPA, 99mTc-MAG3 and 99mTc-DMSA uptake indicated renal damage in the PRRT group (2), 
whereas the PRRT + Lys group (3) only showed a decrease of 99mTc-MAG3 peak activity. These 
results indicating nephrotoxicity in group (2) and renal protection in group (3) correlated with 
levels of urinary protein and serum creatinine and urea, and were confirmed by renal histol-
ogy.
Conclusion: Quantitative dynamic dual isotope imaging using both 111In-DTPA and 99mTc-
MAG3 and static 99mTc-DMSA imaging in rats is feasible using small animal SPECT, enabling 
longitudinal monitoring of renal function. Especially 99mTc-MAG3 renography appears to be 
a more sensitive marker of tubular function after PRRT than serum chemistry or 99mTc-DMSA 
scintigraphy. 
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Introduction
Recent technical improvements of the resolution and sensitivity of dedicated small animal 
SPECT cameras opened new possibilities in preclinical research. Multi-pinhole collimated 
cameras achieve submillimeter spatial resolution and accurate quantification of the amount 
of radioactivity in tissues is feasible [1, 2]. Therefore the non-invasive technique of in vivo func-
tional imaging can be used to 
follow-up longitudinal induc-
tion and progression of disease 
[3].
Peptide receptor radionuclide 
therapy (PRRT) in patients suffer-
ing from somatostatin receptor-
overexpressing neuroendocrine 
tumours using radiolabelled 
somatostatin analogues like 
octreotate, shows beneficial 
results. Significant tumour re-
sponse, survival benefit and 
improvement of quality of life 
is obtained [4]. However, partial 
reabsorption of the radiopep-
tides in the kidneys may lead to 
long-term nephrotoxic effects, 
especially when 90Y-labelled an-
alogues are administered [5, 6]. 
Recent developments to further 
improve tumour response rates 
include salvage therapy and 
combined therapy with both 
90Y- and 177Lu-labelled radiopep-
tides, supporting the need for 
kidney protection [7-9]. Nowa-
days co-infusion of lysine/argi-
nine during PRRT is a protective 
measure in the clinic resulting 
in a 35-40% reduction of the 
kidney radiation dose [10-12] 
also found in preclinical animal 
models [13]. Therapy with 555 
or 278 MBq 177Lu-DOTA,Tyr3-
octreotate resulted in complete 
remission (CR) [14] or 80% CR 
and 20% partial remission [15] 
Figure 1: Blood enters the functional units of the kidneys, the nephrons, 
via an aff erent arteriole (AA) of the renal artery. In the capillary network 
in the glomerulus (G), waste and useful molecules are fi ltered from the 
blood and transported into the proximal tubules (PT). Waste molecules 
are excreted in the primary urine via the loop of Henle (LH) and the distal 
tubules (DT) into the collecting duct (CD) leading to the renal pelvis 
and the bladder. In the fi rst convoluted part of the PT megalin(/cubilin)-
receptors are expressed playing a signifi cant role in reabsorption of 
useful molecules. Extraction from blood in the eff erent arteriole (EA)
[27] directly into the PT is another route of excretion of molecules into 
the urine, which is the most prominent way of 99mTc-MAG3 clearance. 
111In-DTPA is only cleared via glomerular fi ltration and directly excreted 
into the urine, whereas 99mTc-DMSA is partly fi ltrated in the glomeruli 
followed by partial reabsorption in the PT. 99mTc-DMSA is also partially 
peritubularly extracted from the blood, primarily in the last straight part 
of the PT which may extent into the outer medulla of the kidney. RV = 
renal vein.
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of somatostatin receptor expressing tumours in rats, respectively. PRRT with 555 MBq how-
ever, delivers a 60 Gy radiation dose to the kidneys inducing renal toxicity beyond 90 days 
after therapy [16, 17]. 
In patients renal function can be monitored by renography, in addition to measurements of 
serum creatinine and creatinine clearance as markers of glomerular filtration rate (GFR) [14, 
18]. The uptake of 99mTc-radiolabelled dimercaptosuccinic acid (99mTc-DMSA) by the kidneys is 
directly related to tubular function. Although 99mTc-DMSA scintigraphy is clinically widely used 
to provide information on renal cortical morphology [19], the exact mechanism of renal han-
dling is unknown. Peritubular extraction or absorption of  plasma protein bound 99mTc-DMSA 
directly from the blood into the proximal tubular cells or glomerular filtration followed by 
tubular reabsorption are the two postulated mechanisms of 99mTc-DMSA uptake. Discussions 
on the relative contribution of each of these two pathways are ongoing [20-26]. Dynamic im-
aging of the clearance of radiolabelled diethylenetriaminepentaacetic acid (DTPA) monitors 
glomerular filtration, because this small molecule is only cleared via this route. 99mTc-labelled 
mercaptoacetyltriglycine (MAG3) is primarily rapidly extracted from the blood, besides a 10-
15% fraction that is cleared via glomerular filtration. Extraction of 99mTc-MAG3 by basolateral 
uptake into cells lining proximal tubules is mediated by an active organic anion transport 
(OAT1) system, especially in the first convoluted part (S1 and S2) of the proximal tubules [27]. 
In the current study dynamic dual isotope imaging of 111In-DTPA and 99mTc-MAG3 and static 
99mTc-DMSA imaging (Figure 1) were performed to study glomerular filtration, tubular secre-
tion and peritubular absorption in rats beyond 90 days post therapy (p.t.) with 177Lu-DOTA,Tyr3-
octreotate PRRT, with or without kidney protection by lysine (Lys) co-administration and com-
pared with untreated controls. For this purpose the multi-pinhole collimated small animal 
NanoSPECT/CT camera was used [24]. Data were correlated with urine and serum chemistry 
and kidney histology.
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Materials and Methods
Animals
Animal studies were conducted in accordance with the guidelines of the Animal Welfare Com-
mittee of our medical centre. For all experiments male Lewis rats (Harlan, Horst, The Nether-
lands) were used (n=6-9 per group). Body weight (BW) was determined twice a week up to 
140 days p.t. Urine samples were collected every three weeks p.t. in metabolic cages for 24 h.
Radionuclides, peptide, radiopharmaca and chemicals
177LuCl
3
 was obtained from IDB Holland (Baarle Nassau, the Netherlands) and DOTA,Tyr3-oc-
treotate was obtained from BioSynthema (St Louis, MO, USA). Radiolabelling was performed 
according to previously published procedures [29]. A PRRT dose of 460 MBq 177Lu-DOTA,Tyr3-
octreotate/15 μg was used. A fresh 400 mg/ml L-lysine (Sigma, Zwijndrecht, The Netherlands) 
solution was prepared and co-injected with 177Lu-DOTA,Tyr3-octreotate in a 400 mg/kg BW 
dose [13].
111InCl
3
 as well as DMSA and MAG3 kits were purchased from Covidien (Petten, The Nether-
lands), the latter two being 99mTc-labelled according to the provided procedure. For 99mTc-DM-
SA the concentration was 100 MBq/ml for 99mTc-MAG3 250 MBq/ml. 111In-DTPA was prepared 
by addition of 100 μl 4 mM DTPA to 400 MBq 111InCl
3
 (pH 3.5-4) and adjusted with saline to a 
concentration of 250 MBq/ml. 
Molecular imaging
Rats were imaged using a four-headed multi-pinhole SPECT/CT camera (NanoSPECT/CT, Bio-
scan Inc., Washington D.C., USA). Settings of the energy peaks (window width ± 10%) for 177Lu 
were 55, 113 and 208 keV, for 111In 171 and 245 keV and for 99mTc 140 keV. During 111In and 99mTc 
dual isotope imaging no visible cross talk from the γ-rays emitted by 111In into the 140 keV 
window was observed.
Nine pinhole apertures with a diameter of 2.5 mm were used on each camera head, with a 
transaxial field of view (FOV) of 60 mm. Based on the CT topogram, the axial scan length was 
55 mm covering the renal region, which was used for all mentioned imaging procedures. 
Animals were imaged while anesthetized with isoflurane/O
2
 and body temperature was main-
tained using a heated bed.
Four days p.t. rats were scanned to quantify the renal 177Lu activity dose. 99mTc-DMSA scans 
were performed at day 90 and 140 p.t. Scans were acquired at 2 h post injection (p.i.) of 25 MBq 
99mTc-DMSA, administered in 250 μl via the dorsal penis vein. 177Lu-DOTA,Tyr3-octreotate and 
99mTc-DMSA images were acquired for 12 min using 24 projections of 60 s/projection per head. 
Between 100-120 days p.t. dual-isotope dynamic scans were obtained. Before scans were start-
ed, rats were anesthetized and a 27G infusion set with a tubing length of 30 cm (Venisystems, 
Hospira, Sligo, Ireland) filled with saline supplemented with heparin (50 IE/ml), was inserted 
into a tail vein. Immediately after the start of the scan 200 μl (50 MBq) 99mTc-MAG3 followed 
by 200 μl (50 MBq) 111In-DTPA was administered and flushed with 700 μl saline (dead volume 
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of catheter was 400 μl). 20 scans of 2 min each (16 projections per head, 9 s/projection) were 
acquired, resulting in a total acquisition time of 40 min. To study the influence of extra hydra-
tion on the efflux of 99mTc-MAG3 and 111In-DTPA from the kidneys an extra group of control rats 
was imaged starting 45 min after intraperitoneal injection of 5 ml saline. 
Quantification of the amount of radioactivity in a volume of interest (VOI) over the kidneys was 
performed using InVivoScope software (Bioscan). Detected counts in the VOI were converted 
into MBq using a correction factor obtained by scanning a water phantom with the same 
volume as a rat body to correct for attenuation, filled with a known amount of radioactiv-
ity. Radioactivity in VOI over the whole kidneys, or over a cortical part in 99mTc-MAG3 images, 
was quantified and expressed as percentage injected activity per kidney or cm3 renal cortex 
in each of the 20 scans during renography to create a time-activity curve. Peak activity of 
99mTc-MAG3 or 111In-DTPA was defined as the mean activity 2-6 min p.i. and 2-4 min p.i. respec-
tively.
Analytical procedures
Urinary protein content and serum urea and creatinine levels were measured as previously 
published [16]. At day 90 p.t blood was drawn from a tail vein before injection of 99mTc-DMSA 
and at euthanasia at day 140 p.t. blood was collected to store serum.
Ex vivo autoradiography and histology
As previously described the localization of 99mTc-DMSA in kidneys was visualized by ex vivo 
autoradiography [17] and the grade of renal damage was evaluated microscopically according 
to a scale from grade 0 (no damage), grade 1 (little tubular dilation), grade 2 (basal membrane 
thickening), grade 3 (shrinkage of glomeruli, flat tubule epithelium) to grade 4 (severe tubular 
and glomerular damage) as described earlier in detail [16].
Statistics
Data were expressed as mean ± standard deviation (SD). Statistical analyses were performed 
using Student t test.
Results
Quantification of 177Lu in the kidneys four days p.t. with 460 MBq 177Lu-DOTA,Tyr3-octreotate 
showed that 3.8 ± 0.3 MBq was retained per kidney of the unprotected animals, whereas 2.0 ± 
0.1 MBq 177Lu localized in kidneys of Lys protected rats (Table 1); a significant reduction of renal 
retention of ~45%. Irradiation of the renal tubular cells by the β—-particles emitted by 177Lu ob-
viously led to renal problems starting from 50 days p.t in PRRT rats without Lys kidney protec-
tion. Instead of the normal BW increase over time, stabilization of the BW along with urinary 
protein loss was observed when compared to controls. Further increase of protein loss in urine 
and rise of urea and creatinine serum levels determined at day 90 p.t. confirmed development 
of renal damage (Table 1). Histological grading of renal damage at day 140 p.t. correlated with 
these observations. Both massive tubular and glomerular damage was observed in kidneys of 
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unprotected rats, whereas after Lys co-injection only minor abnormalities in tubular morpho-
logy were observed (Table 1). 
days 
p.t.
Control
(p Control vs 
PRRT)
PRRT
(p PRRT vs 
PRRT + Lys)
PRRT + Lys
(p Control vs 
PRRT + Lys)
177Lu uptake (MBq/kidney) 4 - 3.8 ± 0.3 (***) 2.0 ± 0.1
Body weight, % vs. day 0 90 134 ± 3 (***) 111 ± 6 (**) 127 ± 5 (*)
Body weight, % vs. day 0 140 143 ± 4 (***) 113 ± 11(**) 138 ± 6 ns
Protein in urine (mg/24h) 100 11 ± 2 (***) 62 ± 9 (***) 22 ± 8 (***)
Urea in serum (mmol/l) 90 5.8 ± 0.2 (***) 10.5 ± 2.2 (*) 7.2 ± 1.0 (**)
Urea in serum (mmol/l) 140 5.3 ± 0.5 (***) 32.6 ± 9.4 (***) 7.3 ± 0.6 (***)
Creatinine in serum (mmol/l) 90 21 ± 2 (***) 60 ± 5 (***) 37 ± 3 (***)
Creatinine in serum (mmol/l) 140 24 ± 1 (***) 108 ± 20 (***) 35 ± 4 (***)
Grading histological renal 
damage
140 0.4 ± 0.6 (***) 4 ± 0 (***) 1.3 ± 0.5 (*)
99mTc-DMSA (%IA/kidney) 90 13.7 ± 1.4 (***) 6.4 ± 2.4 (***) 12.5 ± 1.2 ns
99mTc-DMSA (%IA/kidney) 140 18.1 ± 1.9 (***) 5.6 ± 3.2 (***) 14.3 ± 1.1 (**)
99mTc-MAG3 (%IA/kidney, 2-6 min) 100-120 13.1 ± 2.6 (***) 4.3 ± 1.5 (***) 8.5 ± 1.6 (***)
99mTc-MAG3 (%IA/cm3 cortex, 2-6 
min)
100-120 6.9 ± 1.9 (***) 2.6 ± 1.3 (*) 3.8 ± 1.0 (***)
111In-DTPA (%IA/kidney, 2-4 min) 100-120 4.7 ± 1.0 (**) 2.1 ± 1.4 ns 4.4 ± 0.6 ns
Table 1: Overview of results in control, PRRT and PRRT + Lys rats. Quantifi cation of retained renal radioactivity: total 
MBq/kidney of 177Lu, %IA/kidney for 99mTc-DMSA, peak activity expressed in %IA/kidney for 111In-DTPA and 99mTc-MAG3 
or peak activity expressed in %IA/cm3 cortex for 99mTc-MAG3. Body weight of rats expressed as % of body weight at 
day 0. Urine and blood chemistry: protein loss in urine expressed in mg/24 h urine, serum urea and creatinine content 
expressed in mmol/l or μmol/l. Histological grading of renal damage expressed on a scale of 0-4. (*) = p<0.05, (**) = 
p<0.001, (***) = p<0.0001.
Chapter 4.2186
Tubular damage beyond day 90 p.t. was confirmed by 99mTc-DMSA static imaging (Table 1, 
Figure 2). Renal 99mTc-DMSA uptake in non-treated animals ranged from 14-19% IA per kidney, 
which was significantly decreased to 2-8% IA in PRRT treated rats (p<0.0001) and slightly de-
creased to 11-15 % IA in kidneys of rats co-injected with Lys (p<0.001). Ex vivo autoradiography 
confirmed these data.
Dual isotope dynamic studies with 111In-DTPA and 99mTc-MAG3 revealed a similar pattern in the 
time-activity curves as in humans with a peak of renal uptake for 111In-DTPA at 2-4 min and of 
99mTc-MAG3 at 2-6 min after administration, followed by a decline of renal radioactivity until 
most radioactivity was excreted at 20 min p.i. and stabilized until 40 min p.i. (Table 1, Figure 
3). Quantification of total renal 99mTc-MAG3 radioactivity showed a mean peak activity in non-
treated rats of 13.1% IA, while in PRRT rats only 4.3% IA was detected. Lys co-administration 
protected 99mTc-MAG3 extraction capacity of tubular cells after PRRT, because a significantly 
Control PRRT PRRT + Lys
MIP
Coronal slices
Ex vivo auto-
radiograms
Figure 2: Typical examples of maximum intensity projections (MIP) (upper row) and coronal slices (middle row) of 
kidney images after 99mTc-DMSA scintigraphy performed at day 140 p.t. in non-treated Control rats (column left), PRRT-
treated (column middle) or PRRT+Lys-treated rats (column right). Ex vivo autoradiograms of frozen kidney sections, 
prepared immediately after imaging, are shown in the lower row.
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higher uptake (p<0.0001) of 8.5% IA renal radioactivity was quantified in the PRRT+Lys group. 
Mean peak activity quantified only in cortical regions of the kidneys of these groups were 6.9, 
2.6 and 3.8% IA/cm3 cortex, respectively. 111In-DTPA imaging revealed a small, but not-signif-
icant difference in peak activity between the control and PRRT+Lys groups (4.7 vs. 4.4% IA 
respectively), however. 111In-DTPA uptake in the PRRT only group, was significantly less though 
(2.1% IA, p=0.0003), indicating that glomerular filtration was impaired after PRRT without kid-
ney protection.
In clinical renography studies patients are hydrated, i.e. drinking 500 ml water 1 h before imag-
ing, but are imaged with an empty bladder to stimulate efflux of radioactivity from the renal 
pelvis. Therefore, an extra group of control rats was imaged after extra hydration before the 
scan. The mean peak activities of 99mTc-MAG3 and 111In-DTPA remained unaltered, while the ex-
cretion of 111In-DTPA was unchanged and the efflux of 99mTc-MAG3 was moderately enhanced 
during the last phase between 20 and 40 min p.i. (data not shown).
Figure 3: A and B: Renography after injection of 
50 MBq 99mTc-MAG3, expressed as %IA/kidney 
(A) and %IA/cm3 cortex (B).C: Renography after 
injection of 50 MBq 111In-DTPA, expressed as 
%IA/kidney D: Typical example of a MIP dual 
isotope image in control rats, 6 min p.i. Single 
99mTc-MAG3 on the left, single 111In-DTPA in the 
middle and the merged image on the right.
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Discussion
In this small animal SPECT study in rats non-invasive renal imaging using 99mTc-DMSA, 99mTc-
MAG3 and 111In-DTPA gave insight into both tubular and glomerular functions after high ab-
sorbed kidney radiation doses to monitor renal function as follow-up after PRRT. Simultane-
ous renography using dual isotope dynamic imaging with 99mTc-MAG3 and 111In-DTPA was 
advantageous to restrict animal discomfort. Accurate quantification of renal radioactivity was 
obtained in short scans when 50 MBq of both 99mTc-MAG3 and 111In-DTPA were administered 
leading to activity levels of 0.6-6 MBq per kidney for 99mTc, and 0.4-2.5 MBq for 111In. Compared 
to clinical renography using frames of 15 s during a 20 min scan, the 2 min frames in the rats 
were relatively long, but had to be chosen because of the rotation time of the camera heads 
between projections. Recently Bioscan developed high sensitivity apertures with enlarged 
pinhole diameter offering improved time resolution. In the Linoview study [26] continuous 
dynamic SPECT imaging was performed using 15 s frames for 30 min p.i. of 99mTc-MAG3 and 
the newly developed U-SPECT dedicated small animal SPECT camera (Milabs, Utrecht, The 
Netherlands) also enables acquisition of shorter frames than used in this study [30]. 
Renographic 99mTc-MAG3 studies demonstrated more efficient elimination of the radioactivity 
from the kidneys in conscious mice than in anesthetized ones, indicating that the metabolic 
state of the animals is a confounding factor during dynamic renal imaging [26]. Although the 
clearance rate of 99mTc-MAG3 and 111In-DTPA in our current study in anesthetized rats might 
not reflect the true physiological state, the three groups of rats to be compared were imaged 
under equal, controlled conditions. Furthermore, the efflux of the radiopharmaceuticals from 
the kidneys to the bladder could be hampered by a filled bladder. To stimulate emptying of 
the bladder by extra hydration of the rats 45 min before imaging, the efflux of 99mTc-MAG3 
during the last phase of clearance was only slightly improved, while the peak uptake of 99mTc-
MAG3 and 111In-DTPA remained unchanged. Since this was the readout in this study, hydration 
of the rats was not considered essential.
Previous experiments demonstrated that approximately 3% of the radiopeptides is reabsorbed 
per kidney [16, 17]; a process being mediated by the multi-ligand scavenger receptor megalin, 
which is expressed in the first part of the cortical proximal tubules [31, 32]. Competition for the 
megalin receptor by Lys and radiolabelled octreotate, containing one Lys residue, might ex-
plain the reduction of renal retention found after co-administration with cationic amino acids 
[10, 13, 32]. In the current study PRRT was performed using 460 MBq of 177Lu-DOTA,Tyr3-octre-
otate, but long-term nephrotoxic effects were similar to those after 555 MBq PRRT, although 
the reduction of 99mTc-DMSA uptake was less severe [17]. The aberrant localization pattern in 
PRRT kidney 99mTc-DMSA autoradiograms (Figure 2) demonstrated that 99mTc-DMSA only was 
retained in the non-megalin receptor expressing S3 part of the proximal tubules, located in 
the outer medulla, in contrast to the localization in control kidneys. Since 111In-DTPA renogra-
phy demonstrated a very poor glomerular filtration in PRRT rats, 99mTc-DMSA will not or hardly 
be filtered and therefore not be reabsorbed in the proximal tubules. Therefore, peritubular 
extraction was the only route of 99mTc-DMSA retention in this part of the proximal tubules, as il-
lustrated by the radioactivity localized in the outer medulla. The reduced level of retained 177Lu 
in kidneys of PRRT+Lys rats protected from affected glomerular filtration and megalin-medi-
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ated damage in the first convoluted part of the cortical proximal tubules, as demonstrated by 
the unimpaired 99mTc-DMSA localization pattern. A role of megalin in the tubular reabsorption 
of 99mTc-DMSA after glomerular filtration is confirmed by our observation that only 35-55% of 
99mTc-DMSA renal uptake was found when we imaged kidney-specific megalin-deficient mice 
[28] compared to wild-type mice (data not shown). Also in Clcn5 knockout mice, a model of 
Dent’s disease showing defective megalin and cubilin-mediated endocytosis, heavily reduced 
99mTc-DMSA uptake was observed, which matched with results described in studies in patients 
suffering from Dent’s disease or Fanconi syndrome [25, 26, 33]. Therefore the conclusion from 
Müller-Suur et al. that only peritubular extraction is responsible for renal 99mTc-DMSA uptake 
has been contradicted by these observations [22]
99mTc-MAG3 imaging showed no peak of tubular extraction in PRRT rats, both after total renal 
and cortex-only 99mTc-quantification; the latter method avoiding confounding radioactivity al-
ready excreted into the renal pelvis (Figure 3B). The clearance of 99mTc-MAG3 is not megalin- or 
cubilin receptor dependent as described in Clcn5 knockout mice [26], which we confirmed 
in megalin-deficient mice (data not shown), but is OAT1-mediated. This transport system is 
expressed in cells at the basolateral side of the convoluted proximal tubules and appeared 
to be inactive beyond 100 days after PRRT. Although Lys co-administration during PRRT sig-
nificantly protects kidney function, yet 99mTc-MAG3 tubular extraction was clearly impaired 
when compared to control rats. It has been proposed earlier that 99mTc-DMSA was the optimal 
tracer to monitor and predict renal function [3, 34]. However, the current data suggest that 
99mTc-MAG3 renography is a more sensitive method to quantify loss of function of cortical 
proximal tubules than 99mTc-DMSA scintigraphy after PRRT. Unaffected 99mTc-MAG3 renography 
is one of the inclusion criteria before 90Y- or 177Lu-based PRRT and is also used during follow-
up in one centre [12, 35] next to GFR markers used in other medical centres [8, 14]. Although 
further clinical validation is warranted, introduction of routine 99mTc-MAG3 renography might 
be considered in more PRRT centres, especially in patients with compromised renal function. 
Also, patients receiving extra cycles of PRRT [7, 8], are appropriate candidates for 99mTc-MAG3 
follow-up when the accepted safe limit of 23-27 Gy absorbed kidney radiation dose adapted 
from external beam radiation or the 37-45 Gy limit of the biologically equivalent dose (BED) 
on the kidney, taking into account the kidney mass and the non-uniform localization of renal 
radioactivity [36, 37] is being exceeded. The application of renal imaging using 99mTc-DMSA 
or 99mTc-MAG3 can be extended to follow-up renal proximal tubule function in other diseases 
when the kidney is the organ at risk [26, 38].
Conclusion
We demonstrated that quantitative renal imaging in rats is feasible using the NanoSPECT/CT 
small animal camera, enabling monitoring of renal function over time in a non-invasive way. 
Both static 99mTc-DMSA scintigraphy and dynamic dual isotope 111In-DTPA and 99mTc-MAG3 re-
nography demonstrated that tubular and glomerular functions were affected beyond 90 days 
after PRRT with 460 MBq 177Lu-DOTA-Tyr3-octreotate. Lys co-administration preserved kidney 
function as monitored by 111In-DTPA and 99mTc-DMSA. These results were consistent with the 
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findings of kidney histology. Moreover, 99mTc-MAG3 renography seems to be a more sensitive 
marker of tubular function after PRRT than 99mTc-DMSA imaging, serum urea urinary protein 
content or histology. Therefore 99mTc-MAG3 scintigraphy might gain a more prominent role in 
clinical PRRT. 
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Abstract
Introduction: We determined the renal radiation dose of a series of 111In-labelled peptides 
using animal SPECT. Because the animals’ health deteriorated, renal toxicity was assessed. 
Methods: Wild-type and megalin-deficient mice were imaged repeatedly at 3- to 6-week 
intervals to quantify renal retention after injection of 40-50 MBq 111In-DTPA-labelled peptides 
(octreotide, exendin, octreotate, neurotensin, and minigastrin analogues), and the absorbed 
kidney radiation doses were estimated. Body weight, renal function parameters, and renal 
histology were determined 16-20 weeks after the first scan and compared with those in naive 
animals.
Results: Because of high renal retention, 111In-DTPA-exendin-4 scans resulted in a 70 Gy kid-
ney radiation dose in wild-type mice. Megalin-deficient kidneys received 20-40 Gy. The other 
peptides resulted in much lower renal doses. Kidney function monitoring indicated renal 
damage in imaged animals. 
Conclusions: Micro-SPECT enables longitudinal studies in one animal. However, long-term 
nephrotoxic effects may be induced after high renal radiation doses, even with 111In-labelled 
radiotracers.
4.3
Nephrotoxicity after 111In-SPECT 197
Introduction
Malignant cells often express a high density of membrane receptors for regulatory peptides 
such as somatostatin, gastrin and exendin [1]. Radiolabelled peptide analogues specifically 
targeting these receptors are used as either diagnostic or therapeutic tools in tumour imaging 
and radionuclide therapy. Peptide receptor radionuclide therapy (PRRT) using 90Y- or 177Lu-
labelled somatostatin analogues (Tyr3-octreotide or Tyr3-octreotate) have led to significant 
therapeutic results in terms of tumour response, survival, and quality of life [2]. 90Y and 177Lu 
both are β—-particle-emitting radionuclides, whereas 111In emits mainly γ-rays and addition-
ally Auger and conversion electrons (CEs). The mean range in tissue is 3900 mm (β—) and 200 
mm (β—) for 90Y and 177Lu, respectively, and 0.02-10 mm (Auger) and 200-500 mm (CE) for 111In. 
When 111In-labelled analogues were applied during PRRT, less therapeutic benefit was gener-
ated [3, 4], probably because of the short range of the high linear energy transfer of Auger 
electrons, without cross-fire effect. In line with these observations, 111In-octreotate was more 
efficacious for the treatment of smaller, than larger, tumours in CA20948 tumour-bearing rats 
[5]. 
A potential side effect of PRRT with somatostatin analogues is late renal damage due to partial 
renal retention of radioactivity in the proximal tubules. Nephrotoxic effects in patients have 
been described after administration of 90Y-PRRT [6], but rarely after 177Lu-PRRT [7], and not after 
111In-PRRT [3]. 
The scavenging receptor megalin, facilitating the renal reabsorption of many proteins and 
peptides in the proximal tubules, has proven to be essential for renal reabsorption of radiola-
belled octreotide in mice. The uptake of 111In-octreotide was significantly less in kidney-spe-
cific megalin-deficient mice than in wild-type (WT) mice in biodistribution studies [8], similar 
to the reducing effect of the co-administration of lysine in WT animals [9]. In this study, we ex-
amined the role of megalin in the renal retention of 111In-labelled somatostatin analogues and 
other peptides by imaging WT and megalin-deficient mice using a dedicated animal micro-
SPECT/CT camera. In consecutive experiments, five different 111In-labelled peptide analogues 
were administered to the same animals at intervals of at least three weeks [10]. Relatively high-
activity doses of 111In (40-50 MBq per mouse) were injected, permitting the accurate quantifi-
cation of renal radioactivity. The renal uptake of all tested peptides in megalin-deficient mice 
was only 23%-62% of the uptake in WT mice [10].
The purpose of the current study was to assess the effects of high-dose SPECT imaging us-
ing 111In-labelled peptide analogues with regard to risk of nephrotoxicity. The total absorbed 
radiation dose to the kidneys of WT and megalin-deficient mice was calculated. These results 
were correlated with renal histology and kidney function parameters, which were determined 
approximately 20 weeks after the start of the experiment. 
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Materials and Methods
Animals
Animal studies were conducted in accordance with the guidelines of the Animal Welfare Com-
mittee of both medical centres. Kidney-specific megalin-deficient mice (Megalinlox/lox;apoECre), 
generated as described previously [11], were kindly provided by Thomas E. Willnow (Berlin, 
Germany). Animals were bred locally, and animals expressing the apoECre gene were identi-
fied by polymerase chain reaction analysis. Megalin-deficient animals were compared with 
WT C57Bl/6 mice (Harlan); five animals of each strain and sex were imaged. Urine, serum, and 
kidneys from naive animals were tested for reference values.
Radionuclides and peptides
111InCl
3
 was purchased from Covidien (Petten, the Netherlands). Diethylenetriamine-pentaace-
tic acid (DTPA) peptides, as listed in Table 1, were radiolabelled as described previously [12, 13]. 
Specific activity was 20 MBq/nmol of peptide, with a radiochemical yield exceeding 95%, as 
confirmed by thin-layer chromatography [12]. 
Molecular imaging
Mice were imaged using a four-headed multi-pinhole SPECT/CT camera (NanoSPECT/CT, 
Bioscan Inc., Washington D.C., USA). Scans were obtained at 3 and 24 h after the injection of 
40-50 MBq 111In-DTPA-peptide (2 nmol) while the animals were anesthetized with isoflurane/
O
2
 and body temperature was maintained using a heated bed. The imaging procedure was 
repeated in these animals after at least three weeks of decay of 111In. The order and intervals 
of the experiments are listed in Table 2. After the final scan, the animals were euthanized; rel-
evant tissues were dissected and weighed, and their activity was determined in a γ-counter.
Nine-pinhole apertures with a diameter of 1.4 mm were used on each head of the camera, the 
field of view was 16 mm. On the basis of the CT topogram, a body range of 30 mm covering 
the renal region was scanned in 24 min, with 120 s per projection. Settings of the 111In energy 
peaks were 171 and 245 keV. The amount of radioactivity in a volume of interest of the kidneys 
was quantified using InVivoScope software (Bioscan, Inc.). Detected counts were converted to 
Peptide Structure MW Company
Octreotide DTPA-octreotide 1000 Covidien, Petten, The Netherlands
Octreotate DTPA,Tyr3-octreotate 1000 Mallinckrodt, St Louis, MO, USA
Exendin DTPA-Lys40-exendin-4 4200
Peptide Specialty Laboratories 
GmbH Heidelberg, Germany
Neurotensin
DTPA-G(Pip)6,G(Pam)8,tBuG12-
neurotensin6-13  
815 BioSynthema, St Louis Mo, USA
Minigastrin 0 
DTPA-D-Glu-(Glu)
5
-Ala-Tyr-Gly-
Trp-Met-Asp-Phe-NH
2
)
 
1832
kindly provided by Dr. M. Behe, Mar-
burg, Germany 
Table 1: Structure of investigated peptide analogues, their molecular weight, and manufacturers
4.3
Nephrotoxicity after 111In-SPECT 199
MBq using a correction factor obtained by scanning a phantom, filled with a known amount 
of 111In activity, with the same volume as the mouse body to correct for attenuation. 
Dosimetry
The mathematic dosimetry model for mice as developed by Hindorf et al. [14] was used. The 
residence time of 111In was assumed to follow a single exponential clearance pattern. Fur-
thermore, only the kidney self-radiation dose was assumed. The renal uptake of 111In-labelled 
octreotide in male mice and 111In-labelled neurotensin in both sexes was too low to quantify 
at 24 h after injection; therefore, the clearance rate was assumed to be similar to that of 111In-
labelled octreotide in female mice.
Analytical procedures
Urinary protein was measured using a commercially available colorimetric assay purchased 
from BioRad (Veenendaal, The Netherlands). Urine was collected for 24 h in metabolic cages, 
12 weeks (male mice) or 16 weeks (female mice) after 111In-DTPA-exendin-4 imaging. At eu-
thanasia, four or three weeks later, respectively, serum was collected to determine urea and 
creatinine levels using standard clinical chemistry procedures. 
Histology
One of the dissected kidneys was fixed in 10% buffered formalin and embedded in paraffin. 
Sections (4 μm) were cut, stained with haematoxylin-eosin or periodic acid-Schiff reagent, and 
evaluated microscopically to score renal damage according to a scale from grade 0 (no dam-
age) to grade 4 (severe damage) as described previously [15]. 
Results
The absolute amount of retained radioactivity in WT female controls 3 h after injection ranged 
from 5% (neurotensin) to 10-15% (somatostatin analogues), 65% (minigastrin), and 225% 
(exendin) injected activity per gram of kidney. All peptides tested showed less renal uptake 
in megalin-deficient mice than in WT controls (reduction ranging from ~40% [exendin] to 
~55% [minigastrin], ~60% [somatostatin], and ~75% [neurotensin]) [10]. The uptake values 
combined with the S value [14], related to kidney mass as determined after euthanasia, were 
used to calculate the absorbed kidney dose after each scan. As an example, this calculation is 
shown in Table 3 for 111In-DTPA-exendin-4, resulting in absorbed kidney radiation doses rang-
ing from 20-40 Gy in megalin-deficient to more than 70 Gy in WT mice (Table 2). 
Surveillance of the animals revealed that female WT mice showed some subdued but still 
responsive behaviour approximately 16 weeks after this dose. Body weight loss was observed 
as well (data not shown). The relationship with increased urinary protein levels was not sig-
nificant, but a trend of elevated levels in imaged animals was found (Figure 1). Some weeks 
later, serum urea and creatinine levels were found to be elevated in scanned animals - creati-
nine both in WT and megalin-deficient mice, urea only in WT animals (Figure 1). Grading of 
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histological renal damage revealed that the most pronounced effects were found in scanned 
female WT mice, showing thickening and necrosis of tubular basal lamina and glomeruloscle-
rosis. In megalin-deficient mice, similar histological damage was detected but less frequently 
(Figure 2). 
absorbed 
kidney dose (Gy) Female mice Male mice
Time 
(wk) WT
Megalin-
defi cient
Time 
(wk) WT
Megalin-
defi cient
octreotide 0 wk 2.1 ± 0.5 1.0 ± 0.2 0 wk 1.9 ± 0.5* 0.4 ± 0.2 *
exendin 4 wk 73 ± 9 38 ± 11 4 wk 72 ± 6 21 ± 4
octreotate 13 wk 3.3 ± 1.0 1.1 ± 0.3 9 wk 2.9 ± 0.6 0.5 ± 0.1
neurotensin 20 wk 0.8 ± 0.2 * 0.16 ± 0.04 * 13 wk 0.7 ± 0.2 * 0.16 ± 0.04 *
minigastrin 23 wk 28 ± 4 5 ± 3 20 wk 30 ± 2 7 ± 1
Table 2: Absorbed kidney radiation doses (mean ± SD) after subsequent injection of 111In-labelled peptides 
Clearance assumed to be equivalent to octreotide in females.
Data are mean ± SD.
Figure 1: Urine and serum chemistry of both sexes 
of WT and kidney-specifi c megalin-defi cient mice, 
either non-scanned (no RA) or scanned (111In). 
A: Urinary protein (mg/24 h) measured 12-16 weeks 
after 111In-DTPA-exendin-4 imaging. 
B and C: Urea in serum (mmol/l (B) and creatinine in 
serum (μmol/l) (C), both determined at 16-19 weeks 
after 111In-DTPA-exendin-4 imaging. 
n = 2-8 per group. Values are presented as mean ± 
SD. Meg def = megalin-defi cient 
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Discussion
Recent improvements in resolution and sensitivity of 
small-animal SPECT cameras opened new possibilities in 
preclinical research, including serial imaging of the same 
animal, leading to reduction of animal numbers [16]. In 
this study in mice, we quantified renal uptake of several 
111In-labelled peptides, enabling dosimetric calculations. 
Although the sensitivity of multi-pinhole micro-SPECT 
cameras is relatively high, we aimed for 1 MBq in the 
targeted organ to allow accurate quantification. In this 
comparative study, we administered 40-50 MBq of each 
111In-labelled peptide to achieve reliable quantification of 
renal retention, even in megalin-deficient mice with an 
expected renal uptake lower than that in WT mice. How-
ever, renal damage developed at approximately 16 weeks 
after an unexpectedly high (38-70 Gy) kidney radiation 
dose. On the basis of these results, we had to repeat im-
aging of some peptides in naive animals to exclude the 
possibility that results were affected by impaired renal 
function.
Patients treated with 111In-DTPA-octreotide PRRT did not 
encounter long-term nephrotoxic effects after a cumula-
tive kidney dose of 45 Gy [3], whereas a safe kidney dose 
limit of 23 Gy was adapted from external-beam radiation 
[17]. These patients acquired the total 111In-dose, fraction-
ated in a minimum of eight cycles with at least two week 
intervals, whereas the mice in the current study received 
the 40- to 70-Gy kidney dose after a single administra-
tion. Kidney protection by dose fractionation also was 
observed after 177Lu-octreotate PRRT in rats [15].
Dose calculations were based on published S values for 
111In in mouse kidneys [14]; however,  other authors de-
scribed different, but comparable, S values [18, 19]. All 
are voxel-based models using either geometrical shapes 
representing organs [14] or more realistic shapes [18, 19], 
assuming homogenous distribution of the radioactivity. 
This may lead to underestimation of the effective dose, 
because renal radioactivity is primarily localized in the 
cortex, resulting in higher radiation doses to the tubules 
(and glomeruli) [20]. Another reason for dose underes-
timation might be the assumption of exponential clear-
ance based on only two time points. Acquiring images at 
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more, especially later, time points will provide better insight into the clearance and residence 
time of radiolabelled peptides and lead to more accurate dosimetry. In addition, biodistribu-
tion studies should be performed when relatively low renal uptake has to be quantified [12]. 
In humans, the total kidney dose delivered by 111In is partially due to γ-irradiation; this dose is 
less important in mice because of much smaller kidneys. Taken together, these issues hamper 
comparison between mice and humans concerning effects of absorbed kidney doses.
Body weight loss was the first indication of nephrotoxicity in these mice. Renal dysfunction 
was confirmed by elevated urinary protein content and by elevated urea and creatinine se-
rum levels, both to a moderate extent. Microscopic evaluation of kidney sections revealed 
histological damage in both tubuli and glomeruli. So, after megalin-mediated reabsorption of 
111In-labelled peptides into proximal tubular cells, the glomeruli were also affected. The maxi-
mal range of Auger electrons (0.02-10 mm), and especially the longer range of CEs (200-500 
mm), is sufficient to reach adjacent glomeruli. In the future – in addition to the chemical and 
histological studies that have been performed [16] - we will perform renographic studies us-
ing 99mTc-DMSA (dimercaptosuccinic acid), 99mTc-MAG3 (mercapto acetyl tri glycine), and 111In-
DTPA to gain insight into both tubular and glomerular function after high absorbed kidney 
doses. 
In retrospect 111In-DTPA-exendin-4 imaging should have been performed as the last peptide in 
the series, and the injected activity dose could have been less - 10 MBq instead of 40-50 MBq.
Figure 2: A: Renal damage score of both sexes of WT 
and kidney-specifi c megalin-defi cient mice, either 
non-scanned (no RA) or scanned (111In). Kidneys of 
scanned mice were removed at 16-19 weeks after 
111In-DTPA-exendin-4 imaging. Scores are based on 
histological examination of periodic acid-Schiff -
stained sections according to grading scale from 0 to 
4 [15]. Values are presented as mean ± SD.
B: Examples of periodic acid-Schiff -stained, 4 μm 
paraffi  n-embedded kidney sections (x 250, bar = 50 
μm). Arrow points to glomerulosclerosis. n = 2-5 per 
group. * = tubular basal lamina thickening and/or 
necrosis of tubular epithelial cells.
A
B
 WT WT (111In) Meg def (111In)
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Conclusion
An absorbed kidney dose of more than 40 Gy due to renal accumulation of 111In-labelled pep-
tides resulted in long-term nephrotoxicity in mice. The small-range, low-energy Auger elec-
trons and CEs emitted by 111In caused both tubular and glomerular damage. Micro-SPECT 
offers the opportunity to perform follow-up studies in one animal by consecutive scanning. 
However, the risk of side effects due to high radiation doses must be considered.
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Summary
Specific tumour targeting using radiolabelled peptide analogues is an attractive modality to 
visualize primary tumours and tumour metastases. In addition it can be applied to treat tu-
mour patients. Tumours originating from neuroendocrine cells often overexpress hormone 
receptors; e.g somatostatin-, gastrin- or glucacon-like peptide-1 (GLP-1)- receptors [1]. These 
receptors can be targeted using radiolabelled somatostatin, minigastrin/CCK or exendin pep-
tide derivatives, respectively. 
In 1994 the somatostatin analogue 111In-DTPA-octreotide (Octreoscan®) was approved by the 
FDA for clinical γ-camera imaging, i.e. peptide receptor scintigraphy (PRS) for diagnostic pur-
poses to monitor the disease in patients with NET. Octreoscan® is characterized by high affin-
ity for somatostatin receptor (sst) subtypes 2, 3 and 5 [2], whereas most neuroendocrine tu-
mours overexpress sst2 [3]. Since 111In is emitting therapeutic Auger- and conversion electrons 
next to γ-radiation, 111In-DTPA-octreotide was tested for peptide receptor radionuclide therapy 
(PRRT), but objective tumour responses were rare [4]. 
Tyr3-octreotate, with a very high affinity to sst2, was developed [5, 6] and DOTA-chelation 
enabled stable radiolabelling with the therapeutic β—-emitters 90Y and 177Lu. Nowadays PRRT 
with 90Y-DOTA,Tyr3-octreotide or 177Lu-DOTA,Tyr3-octreotate has been implemented in several 
centres [7-9], with favourable therapeutic results compared to historical controls [10-12]. Ac-
cor ding to SWOG criteria 177Lu-DOTA,Tyr3-octreotate PRRT resulted in ~55% of the patients in 
an objective response, while in ~30% stable disease was found and in ~15% of the patients 
progression of disease was still encountered [7].
Besides specific binding of radiolabelled somatostatin peptide analogues to tumour cells, 
uptake is also found in the spleen, liver and kidneys. The first publications on clinical 90Y-
DOTA,Tyr3-octreotide PRRT reported that late nephrotoxicity occurred in about 10% of pa-
tients leading to end stage renal disease [13, 14]. Since these alarming reports the cumulative 
absorbed kidney doses during PRRT were limited to 23-27 Gy, based on experiences with EBRT 
[15], or to 37-45 Gy applying the principle of the biological equivalent dose (BED), correcting 
a.o. for the effect of dose fractionation, regional distribution of the radioactivity and kidney 
size [16-18]. Furthermore, co-infusion of cationic amino acids during the administration of 
PRRT reduced the renal retention of radiolabelled somatostatin analogues with approximately 
40% offering kidney protection [13, 19, 20]. Recent reviews evaluating the incidence of long-
term renal toxicity after PRRT describe very few cases of renal damage when 177Lu-DOTA,Tyr3-
octreotate with amino acids was applied [11, 16]. However, in 30% of patients receiving 90Y-
DOTA,Tyr3-octreotide PRRT low grade renal toxicity was observed with rising creatinine levels 
and loss of creatinine clearance [16, 21] illustrating the need of kidney protection during PRRT. 
In Chapter 1.1 the aim of the current research to identify the mechanism of renal uptake of 
radiolabelled peptides in order to design ways to protect the kidneys from harmful side effects 
of PRRT was introduced.
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A broad overview of the current status of kidney protection during PRRT using radiolabelled 
somatostatin analogues is been given in Chapter 1.2, which focussed mainly on the basic 
amino acids lysine and arginine and their interference with the renal reabsorption of radio-
labelled somatostatin analogues. This method is successfully used in the clinical setting dur-
ing PRRT nowadays. Recently, also Gelofusine and albumin fragments were defined as agents 
achieving similar reductions of renal retention of different radiopeptides upon co-administra-
tion. 
For research into prevention of renal damage elicited by irradiation during PRRT the uptake 
mechanism responsible for renal uptake and retention of radiolabelled peptide analogues 
was investigated The conclusion that megalin plays an important role in the renal uptake of 
radiopeptides appeared to be helpful to develop new strategies for kidney protection as is 
described in Chapter 2.
The level of renal uptake of radiolabelled somatostatin, bombesin, neurotensin, minigastrin 
and CCK analogues covered a range from very low (CCK) to very high (minigastrin) uptake in 
the kidneys of rats and mice, as is reported In Chapter 2.1. The rank order of CCK < bombesin 
= neurotensin < octreotide << minigastrin was similar in both species, with a faster washout 
from mouse kidneys. Moreover, we found no gender difference in the renal uptake in rats, 
whereas in mice up to four times higher levels of retained renal radioactivity was found for 
octreotide and bombesin analogues in females vs. males. In clinical studies no gender dif-
ferences in renal uptake of radiopeptides are described [17], therefore we concluded that 
the rat is a favourable model over the mouse to study the renal uptake of newly developed 
radiopeptides. 
The localization of the radioactivity in the kidney as determined by ex vivo autoradiography 
was similar for all tested radiopeptides: most radioactivity was localized in the renal cortex, 
less in the outer medulla and no radioactivity was detected in the renal pelvis. This pattern 
correlated with the results of immunohistochemical staining of kidney sections using antibod-
ies recognizing megalin, which is predominantly expressed in the first convoluted parts of the 
proximal tubules (PCT), located in the renal cortex, whereas less expression in the proximal 
straight tubules (PST) located in the outer medulla is found. 
The suggestion that the net negatively charged multi-ligand scavenging receptor megalin 
plays a role in the renal uptake of radiopeptides was confirmed in the studies described in 
Chapter 2.2. First, using micro-autoradiography, it was demonstrated that the localization of 
radioactivity was restricted to the proximal tubules in the renal cortex. Radioactivity was not 
observed in the glomeruli or distal tubules. Next, three agents; lysine, sodium maleate and 
cisplatin, were co-administered in rats with radiolabelled somatostatin analogues because of 
their potential interference with the active endocytic processes mediated by megalin in the 
proximal tubules in the reabsorption of many small proteins and peptides. All tested agents re-
sulted in renal uptake reduction of radioactivity to 60%, 15% and 70%, respectively. An excess 
of the positively charged amino acid lysine co-administered with radiolabelled octreotide, 
containing one lysine residue, probably interfered with the reabsorption of this compound 
resulting in decreased renal radioactivity. The agent sodium maleate induces reduction of the 
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energy metabolism of cells and inhibition of the membrane reconfiguration during endocy-
tosis. This might explain the huge reduction of radioactivity levels in the kidneys after pre- or 
co-treatment with maleate. The chemotherapeutic drug cisplatin often induces nephrotoxic 
side effects, but only in PST, explaining the relatively low reduction of renal uptake of 111In-
DTPA-octreotide. Because of serious side effects after both maleate and cisplatin, these agents 
are not suited for clinical implementation in kidney protection regimes during PRRT. 
Kidney-specific megalin-deficient mice offered the opportunity to investigate the renal uptake 
and retention of 111In-DTPA-octreotide in these animals versus wild-type mice with normal 
renal megalin expression. The first results are described in Chapter 2.3. Molecular imaging 
at 4 and 24 h after injection of 111In-DTPA-octreotide was performed using a dedicated small 
animal SPECT camera. After the last scan the amount of radioactivity per kidney was quanti-
fied. In both sexes a striking 70%-85% reduction of uptake in the megalin-deficient kidneys 
was found, which was confirmed by ex vivo autoradiography of frozen sections of the kidneys. 
In the next study using these megalin-deficient animals, described in Chapter 2.4, the renal 
uptake of 111In-labelled neurotensin, exendin, and minigastrin analogues was determined and 
compared to that of octreotide and octreotate. Quantification of the uptake and retention in 
the kidneys of megalin-deficient and wild-type mice was based on micro-SPECT. Consecutive 
imaging experiments in the same mice were performed with 3-9 week intervals. Separately 
biodistribution studies were performed. Less uptake of all tested radiopeptides was observed 
in the kidneys of the megalin-deficient mice compared to wild-type controls. Thus, the renal 
reabsorption of radiopeptides from various peptide families, with different sizes and with vari-
able net charges appeared to be at least partly megalin-mediated.
Based on the conclusion that megalin plays an important role in renal reabsorption after ad-
ministration of radiopeptides, Gelofusine was tested for reduction of renal uptake of radio-
peptides. This plasma expander consists of negatively charged succinylated gelatin, with a 
mean molecular weight of 30 kDa. Gelofusine is used in the clinic to treat hypovolemia in 
states of shock in critical care patients. A transient loss of proteins and peptides is detected in 
the patients’ urine after infusion, pointing to a temporal drop in efficiency of renal reabsorp-
tion [22]. Indeed, in a study in healthy volunteers, Gelofusine co-infusion with Octreoscan® 
offered a similar reduction of the renal retention as co-infusion with cationic amino acids [23]. 
In Chapter 3.1 we determined the optimal Gelofusine dose to be co-administered in rats to 
obtain the highest reduction of renal uptake of 111In-DOTA,Tyr3- octreotate. A dose of 80 mg/
kg body weight was sufficient to accomplish 50%-60% reduction of renal retention, this was 
even improved to 70% reduction when Gelofusine was combined with lysine. Furthermore we 
demonstrated that the tumour uptake of 111In-DOTA,Tyr3-octreotate was not affected by co-
administration of Gelofusine and lysine, offering a threefold increase of the tumour to kidney 
ratio versus control.
Another agent, the radical scavenger or anti-oxidant amifostine is applied as cytoprotector 
during clinical radiotherapy to attenuate side effects in healthy tissues induced by reactive 
oxygen radicals resulting from irradiation. Previous investigations in rats proved that co-ad-
ministration of amifostine during 177Lu-DOTA,Tyr3-octreotate PRRT reduced long-term neph-
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rotoxic effects [24]. In the study as described in Chapter 3.2 we aimed to elaborate on the 
mechanism underlying the kidney protection by amifostine and to rule out possible tumour 
protection. The effects of co-administration of amifostine with radiolabelled octreotate was 
tested in tumour-bearing rats, both in biodistribution studies 24 h after injection of 111In-
DOTA,Tyr3-octreotate and in a PRRT study using 177Lu-DOTA,Tyr3-octreotate with a follow-up of 
>120 days post therapy (p.t.). No interference of amifostine with tumour uptake or therapeutic 
effects was demonstrated. However, the initial renal uptake was decreased to 40% of control 
level when amifostine was co-injected. This unexpected phenomenon was confirmed in an in 
vitro assay using the megalin-receptor expressing BN-16 cell line. Co-incubation of amifostine 
or its active metabolite WR-1065 reduced binding of 111In-DOTA,Tyr3-octreotate to these cells 
to 66% and 55% of control level, respectively. These data suggest that amifostine/WR1065 
reduced initial renal radioactivity levels in a megalin-mediated way, comparable to the reduc-
tion obtained with lysine co-administration. Therefore, besides scavenging of harmful oxygen 
species interfering in the cascade of events leading to renal fibrosis, a lower level of retained 
β—-emitting 177Lu in the kidneys could have led to kidney protection during PRRT when ami-
fostine is co-administered [24].
The development of nephropathology after irradiation is a long-term process taking several 
months in rats. Monitoring of kidney function over time can be performed by measurements 
of serum creatinine, urea or urinary protein levels. Another non-invasive way to detect the 
onset of renal failure is imaging of the uptake or clearance of radiotracers specific for visualiza-
tion of kidney function using a γ-camera. 99mTc-DMSA, a tracer retained in the cortical tubules, 
has been tested to monitor the kidney function in rats during the follow-up of PRRT using a 
dedicated small animal SPECT/CT camera. The results of these studies are described in Chap-
ter 4.1. The dose dependent level of renal damage >100 days after 278 or 555 MBq 177Lu-
DOTA,Tyr3-octreotate PRRT inversely correlated with 99mTc-DMSA uptake per kidney based on 
static imaging. The higher the absorbed renal radioactivity dose, the lower the 99mTc-DMSA 
uptake when measured 100-150 days after PRRT. Moreover the pattern of retained renal 99mTc-
DMSA demonstrated specific loss of function of cortical tubules; only in the PCT after the 
low PRRT dose and in the PST as well after the high PRRT dose. In Chapter 4.2 monitoring 
of rat kidney function after 460 MBq 177Lu-DOTA,Tyr3-octreotate PRRT with or without lysine 
co-injection is described, using the tracers 111In-DTPA, 99mTc-MAG3, and 99mTc-DMSA. 111In-DTPA 
and 99mTc-MAG3 were used to image the dynamic processes of glomerular filtration (111In-
DTPA) and tubular secretion (99mTc-MAG3). In control rats 111In-DTPA and 99mTc-MAG3 showed 
time-activity curves with a peak a few minutes after injection, followed by rapid secretion into 
the tubules and excretion into the urine. When renal damage was developed >90 days after 
PRRT, hardly any peak activity of both agents could be detected. In rats that received PRRT plus 
lysine co-administration to protect the kidneys, 111In-DTPA clearance and 99mTc-DMSA uptake 
remained unaffected. In contrast, 99mTc-MAG3 clearance still showed an aberrant pattern. We 
concluded that 99mTc-MAG3 is a more sensitive marker of early renal damage induced after 
PRRT than 99mTc-DMSA uptake or serum chemistry measuring creatinine and urea levels. 
In Chapter 4.3 we describe that nephrotoxic effects were detected in mice after consecu-
tive imaging experiments using 111In-labelled radiopeptides. This was unexpected, because 
in early clinical 111In-DTPA-octreotide PRRT studies no renal damage was encountered, even 
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after a renal absorbed dose of 45 Gy, thus clearly exceeding the accepted safety limit of 23 
Gy. However, it appeared that the very high renal uptake and retention of 111In-exendin (225% 
IA/g kidney) delivered a 70 and 40 Gy dose in kidneys of wild-type and megalin-deficient mice, 
respectively, leading to renal failure in both mouse strains >90 days after the 111In-exendin 
injection. Thus, a high renal radiation dose by γ-radiation and Auger- and conversion elec-
trons emitted by 111In, may also cause long-term nephrotoxicity. Small animal SPECT enables 
monitoring of disease or treatment in one animal over time, but the risk of an accumulated 
radiation dose to the kidneys exceeding the safety limit has to be considered, as shown in this 
chapter.
Additional studies
Given the fact that megalin plays a pivotal role in the renal reabsorption of various radiola-
belled peptides, potential inhibition of this process by co-administration of albumin deriva-
tives, was a logical step for further investigation because albumin is one of the main ligands 
of megalin. Intact albumin (68 kDa) is only marginally filtered in the glomeruli, therefore en-
zymatically cleaved fractions of albumin (FRALB) were co-administered with 111In-DTPA-oc-
treotide in rats, resulting in less renal uptake than in control rats [25]. This confirmed the hy-
pothesis that co-administration of albumin fractions decreases the level of megalin-mediated 
reabsorption of somatostatin analogues. In a follow-up study well-defined synthetic peptides 
derived from albumin, with varying charges also were tested as specific inhibitors of renal 
uptake. Co-administration of a 36 amino acid peptide (3.8 kDa) derived from the C-terminal 
end of albumin (ALBPEP), offered a broad reduction of renal uptake of various radiopeptides, 
ranging from 26% (exendin) and 33% (octreotide) to 88% (gastrin) inhibition [26].
Figure 1: Biodistribution data 24 h after injection of 15 μg 111In-DOTA,Tyr3-octreotate (111In-DOTA-tate) in rats with or 
without co-administration of albumin derived peptide (ALBPEP (4 mg/rat)) and/or Gelofusine (GF (80 mg/kg)).
Uptake in kidneys and sst-expressing CA20948 tumours was calculated as % injected activity/gram (%IA/g) ± SD 
and the value of the saline group was set at 100%. n = 4 rats per group. Diff erence in renal uptake vs. saline group of 
single ALBPEP and GF groups (** = p<0.01) and the ALBPEP+GF (*** = p<0.001) group were signifi cant, whereas the 
diff erence between ALBPEP+GF and single ALBPEP or GF also was signifi cantly diff erent (** vs. ALBPEP, *** vs GF). No 
signifi cant diff erences were found for CA20948 tumour uptake.
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To assess possible interference of albumin 
derived peptide with tumour uptake, 111In-
DOTA,Tyr3-octreotate biodistribution stud-
ies in CA20948 tumour-bearing rats were 
performed (Figure 1). The combination of 
co-administration of both albumin derived 
peptide and Gelofusine was tested as well, 
resulting in a significant additive reduction 
of the renal retention of 111In-DOTA,Tyr3-
octreotate. No effects on tumour uptake 
were noticed. 
An overview of all obtained results on re-
duction of renal uptake of radiolabelled 
octreotate in rats after co-administration 
of lysine (Lys), Gelofusine (GF), ALBPEP and 
amifostine (AMI) (and combinations), are 
summarized for both renal and tumour 
uptake in Figure 2. 
None of the administered agents affected 
the somatostatin receptor-mediated tu-
mour uptake of 111In-DOTA,Tyr3-octreotate 
significantly, in contrast to the overall re-
duced renal uptake and retention. Some 
combinations of agents showed signifi-
cant additive reduction of renal retention, 
whereas others did not. The observation 
that Lys+GF+ALBPEP did not result in 
further reduction compared to Lys+GF 
and GF+ALBPEP suggests that either the 
lowest achievable level of renal uptake of 
radiolabelled octreotate was reached, or 
that reabsorption via the same regions of 
megalin domains was inhibited. Lys+AMI/
WR1065 also did not show a cumulative 
reduction of radioactivity in the kidneys, 
which could be explained by a similar 
mechanism of action. 
The remaining level of renal uptake after 
maximum kidney uptake inhibition by sev-
eral agents and in kidney-specifi c megalin-
defi cient mice may be due to fl uid phase 
endocytosis. Besides active renal reabsorp-
Figure 2: Biodistribution data 24 h after injection of 15 μg 
111In-DOTA,Tyr3-octreotate (111In-DOTA-tate) in rats with or 
without co-administration of Lys (400 mg/kg), GF (80 mg/
kg), ALBPEP (4 mg/rat) and/or AMI (50 mg/rat).
Uptake in kidneys and sst-expressing CA20948 tumours 
was calculated as % injected activity/gram (%IA/g) ± SD. 
n = 2-4 rats per group. The value of the saline group was 
set at 100%. Diff erence in renal uptake vs. saline group 
of all single agent groups was signifi cant (p<0.001). 
Combination of Lys+GF and GF+ALBPEP showed 
signifi cant additive reduction vs. single use (p<0.01 = 
*1), whereas Lys+GF+ALBPEP was not signifi cantly (ns2) 
diff erent vs. Lys+GF or GF+ALBPEP. The combination of 
AMI+Lys did not result in signifi cantly less renal uptake 
vs. single Lys or AMI (ns2). No signifi cant diff erences were 
found for CA20948 tumour uptakes in all groups.
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tion this is another process by which compounds are captured from the blood and primary 
urine in the kidney; this process cannot be inhibited by amino acids [27]. Furthermore, in mice 
and men, but not in rats, sst-expression is demonstrated in the kidney, responsible for some 
receptor-specifi c retention of somatostatin analogues in the kidneys that will not be infl uenced 
by agents interfering in the megalin-mediated uptake [28, 29]. In patients this sst-expression 
maximally accounts for 20% of renal radioactivity. Besides proximal tubular expression of soma-
tostatin receptors, GLP-1R and CCK2-R has been described as well [30-32].
The successful results on kidney protection from radiolabelled octreotate obtained with ly-
sine, Gelofusine and album in derived peptide prompted us to investigate potential additive 
reducing effects on renal uptake of radiolabelled minigastrin analogues showing very high 
renal uptake values in tumour-bearing rats. A prominent reduction of more than 80% of the 
renal uptake of 111In-DOTA-minigastrin 0 was found after single co-administration of albumin 
derived peptide or Gelofusine. Co-injection of their combination resulted in a significant extra 
reduction to 90% of the renal uptake found in rats that received saline as control (Figure 3). 
CA20948 tumour uptake remained unaffected in all cases. The reduced radioactivity levels in 
the kidneys after ALBPEP+GF without interference with tumour uptake accomplished a 2.5 
and 10-fold increase of the tumour to kidney ratios after 111In-DOTA,Tyr3-octreotate and 111In-
DOTA-minigastrin 0 injection, respectively. 
In Table 1 the results of several renal protection studies in rats from the literature have been 
summarized along with our recently obtained results, concerning biodistribution studies with 
radiolabelled somatostatin, exendin and minigastrin 0 analogues. The percentages of reduc-
tion of renal retention obtained are compared with those in non-protected animals.
Figure 3: Biodistribution data 24 h after injection of 0.1 μg 111In-DOTA-minigastrin 0 (111In-DOTA-MG0) in rats with or 
without co-administration of ALBPEP (4 mg/rat) and/or Gelofusine (GF (80 mg/kg)).
Uptake in kidneys and sst-expressing CA20948 tumours was calculated as % injected activity/gram (%IA/g) ± SD 
and the value of the saline group was set at 100%. n = 4 rats per group. Diff erence in renal uptake of all groups vs. 
saline group was signifi cant (p<0.001), diff erences between single ALBPEP and GF vs. GF+ALBPEP as well = ***1. No 
signifi cant diff erences were found for CA20948 tumour uptake in all groups.
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Since minigastrin contains 6 anionic glutamic acid (Glu) residues, no effect on renal uptake 
was expected from co-administration with lysine (Lys). Indeed only marginal effects were de-
tected [33]. When polyglutamic acids (PGA) of at least five Glu residues were used, however, a 
80%-90% inhibition of renal radioactivity was achieved [34]. Co-administration of Lys or PGA 
with 111In-exendin showed less convincing results, indicating the choice of the inhibitory ami-
no acids should be specifically adapted to the composition of the administered radiolabelled 
peptide analogue. Charge seems to play an important role in this respect. 
Application of Gelofusine and albumin derivatives offered reduction of renal uptake of all 
tested radiopeptides, although the extent of reduction varied largely. Simultaneous co-ad-
ministration of these two agents with radiolabelled octreotate effectuated even enhanced 
inhibitory effects on renal uptake, which was even more prominent when co-administered 
with radiolabelled minigastrin.
Reduction of the risk of nephrotoxicity after 
PRRT can be achieved by lowering the initial 
uptake and retention of radiolabelled pep-
tides in the kidneys, but also by mitigation 
of long-term PRRT induced renal damage, 
often fibrotic lesions. Based on radiation 
protection of the kidneys during EBRT by 
scavenging of active oxygen radicals using 
anti-oxidants or angiotensin II inhibition, 
we recently investigated rat kidney protec-
tion after PRRT using taurine as anti-oxidant; 
L158.809, an angiotensin II receptor blocker 
(ARB); or captopril, an angiotensin convert-
ing enzyme inhibitor (ACEI), reducing ACE 
dependent conversion of angiotensin I into 
angiotensin II [36, 37]. When the data on kid-
ney function of these rats were compared 
with those of rats after PRRT without ad-
ditives in the drinking water, we were not 
able to prove significant beneficial effects of 
Lys GF GF + 
Lys
PGA GF + 
PGA
FRALB ALBPEP ALBPEP + 
GF
Octreotide/
octreotate
40-50 40-50 50-65 0-15 nd 30-35 30-45 65
Exendin 0-15 20-25 nd 25-35 35-45 50-55 25 nd
Minigastrin 0 0 45-80 nd 80-90 80-90 90-95 80-85 90
Table 1: Summary of renal protection studies in rats, adapted from [25, 26, 33-35] and recently obtained results. Gross 
percentage reduction of renal retention is given. Lys=lysine, GF=Gelofusine, PGA=polyglumatic acid, FRALB=albumin 
fractions, ALBPEP=albumin derived peptide, nd =  not determined
Figure 4: Extent of histological renal damage at day 146 
(460 MBq 177Lu-PRRT) or day 180 (370 MBq 177Lu-PRRT) 
after therapy with or without co-treatment with taurine 
(10 g/l), captopril (0.5 g/l) and L158.809 (20 mg/l) added 
to drinking water.  n = 6-8 per group.
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these agents on kidney function after PRRT. The data on histological damage are shown in Fig-
ure 4. We concluded that taurine, L158.809 and captopril are not suited as mitigating agents 
of nephrotoxic effects induced by 177Lu-DOTA,Tyr3-octreotate-based PRRT. 
Future directions
Our current clinical protocol of 177Lu-DOTA,Tyr3-octreotate PRRT, consisting of four cycles with 
a total cumulative dose of 29.6 GBq and co-infusion of cationic amino acids, seems to be 
safe with respect to kidney function [38]. However, after 90Y-DOTA,Tyr3-octreotide PRRT, in a 
cumulative dose of 15.2 GBq as used in several clinical studies, kidney safety is an issue [21]. 
The therapeutic outcome of PRRT is favourable compared to conventional NET treatment mo-
dalities, with an objective tumour response in ~55% of the patients and occasional complete 
tumour regression. However, further increase of cure rates is highly warranted [7]. Therefore, 
there is a need of safe administration of higher cumulative therapeutic doses to obtain im-
proved tumour responses, in which kidney protection will play a major role [39]. 
Options to accomplish increased tumour response include:
• Application of more cycles of 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotate [40]
• Combination of 90Y-DOTA,Tyr3-octreotide and 177Lu-DOTA,Tyr3-octreotate, either within each 
cycle or start with 90Y-based cycles followed by 177Lu-cycles or alternating 90Y-and 177Lu-cycles 
[8, 41-43]
• Combination of 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotate with radiosensitizing 
agents, such as capecitabine or other chemotherapeutics [11]
• Intra-arterial (locoregional) administration of 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-oc-
treotate instead of the commonly used systemic intravenous route [44, 45]
• Combination of anti-angiogenic agents, e.g. anti-vascular endothelial growth factor anti-
bodies or α
v
β
3
-integrin targeting agents such as thalidomide or RGD constructs, with 90Y-
DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotate [46, 47]. Nowadays these agents are com-
bined with radioimmunotherapy.
• Research into induction of increased tumour somatostatin receptor-levels to enhance inter-
nalization of 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotate analogues [48] 
• Introduction of new peptide analogues with higher affinity and/or pansomatostatin receptor 
specificity [49]
• Combination of different peptide analogues targeting different receptors co-expressed on 
tumours, such as sst2 and GLP-1R in gastrinomas [50]
The absorbed kidney radiation dose will increase when more cycles of 177Lu- or 90Y-labelled 
PRRT will be administered per patient, therefore optimal kidney protection will be essential. 
Moreover, the bone marrow will be the next organ at risk, because of an increased absorbed 
radiation dose mediated by circulating radioactivity in the blood [38].
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As described in Chapter 3.1 and by others, the combination of Gelofusine with Lys/Arg 
co-infusion will offer further reduction of the renal uptake of somatostatin analogues [23]. 
Although this combination of renal protection agents is already clinically applied with prom-
ising results, comparative data on levels of retained renal radioactivity are not available yet 
[8, 39]. Therefore a pilot study will be started in our institution in the near future to perform 
kidney and tumour dosimetry during 177Lu-DOTA,Tyr3-octreotate PRRT in which single Lys/
Arg co-infusion during one cycle will be compared with combined Gelofusine and Lys/Arg 
co-infusion in the next cycle or vice versa. A small percentage of 0.04% of severe anaphylactic 
reactions and of 1.4% of mild to moderate allergic side effects after Gelofusine administration 
have been described, therefore vital functions such as heart rate and blood pressure will be 
registered [39, 51]. 
Compounds mitigating renal damage after irradiation may be combined with agents reduc-
ing the initial renal uptake and retention of radiopeptides, enabling safe implementation of 
higher therapeutic PRRT doses. In this respect the application of the anti-oxidant amifostine 
as kidney protector during PRRT needs more research. Previously, favourable effects on long-
term kidney function and histology were described [24], which could partly be attributed to 
reduction of the absorbed kidney radiation dose as described in Chapter 3.2. New experi-
ments in which amifostine will be co-administered either prior or post PRRT will discriminate 
between its short- or long term effects. Even though patients may encounter hypotension, 
nausea, vomiting and skin rash as side effects after amifostine administration, further research 
into this drug with respect to PRRT is intriguing. Especially because protection of bone mar-
row progenitors from harmful radiation effects has been described as well [52-54]. 
Besides kidney toxicity, bone marrow suppression resulting in a drop of platelets, red and 
white blood cells may also be encountered during PRRT [38, 55]. Haematologic toxicity is 
generally mild and reversible and the risk of developing myelodysplastic syndrome (MDS) 
or leukaemia after PRRT is low when a dose limit of 2 Gy to the bone marrow is maintained. 
Nevertheless several cases of bone marrow toxicity after PRRT have been described [11]. Ap-
plication of higher cumulative doses of PRRT, accompanied by an optimal kidney protection 
regimen, will increase the risk of bone marrow toxicity and the bone marrow will become the 
dose-limiting organ. The absorbed radiation dose to the bone marrow is caused by cross fire 
from the blood circulating in the vicinity of bone marrow cells [56]. Specific uptake of radiola-
belled somatostatin analogues by somatostatin receptor-expressing progenitor bone marrow 
cells might play a (minor) role as well [56, 57]. Therefore bone marrow protective strategies 
similar to kidney protection to reduce the initial uptake will not be effective, except for mitiga-
tion of radiation induced damage by amifostine e.g. Autologous bone marrow transplanta-
tion may be considered to provide bone marrow support when patients encounter severe 
haematological toxicity after PRRT. This procedure is already successfully being applied during 
radioimmunotherapy [58].
The blood clearance of radiopeptides in patients takes much longer than in rats or mice, be-
cause of the smaller total blood volume and the higher heart rate in the latter species [59]. 
This will result in a higher absorbed radiation dose of human bone marrow cells compared to 
the dose in animals. Moreover, sst-expression is not found on rat bone marrow cells in contrast 
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to human progenitor cells [57, 60]. Differential bone marrow cell count of terminally ill rats 
because of nephrotoxicity >100 days after 177Lu-DOTA,Tyr3-octreotate PRRT with >50 Gy on the 
kidneys, did not reveal aberrations in the bone marrow. Also the blood cell counts of these 
rats were comparable to those in control rats, indicating that haematological toxicity was 
not encountered in these rats. Therefore, preclinical investigations in small animals into bone 
marrow protection during PRRT by amifostine, other agents, or by autologous bone marrow 
support will not be feasible.
In summary, we demonstrated in preclinical studies that besides cationic amino acids, Gelo-
fusine, albumin derivatives, amifostine, or combinations thereof are promising agents to re-
duce the renal retention of various tumour-targeting radiopeptides in patients. This is espe-
cially important when increased PRRT doses will be administered to obtain improved cure 
rates. First, safety issues concerning allergic reactions to Gelofusine and putative toxicity of 
albumin derived peptides should be studied thoroughly. Moreover, albumin derived peptides 
should be prepared according to good manufacturing practice regulations before they can 
be tested in clinical trials. Such an agent offers promising prospectives for broad application 
concerning kidney protection. 
Our experience with reduction of radioactivity levels in the kidney may be extended to other 
newly developed radiolabelled biomolecules, such as neurotensin or bombesin analogues 
containing one or more Lys residues [61], folate derivatives, Affibody molecules or nanobodies 
suffering from high levels of retained radioactivity in the kidneys [62-64]. 
As described in this thesis, kidney radiation by radionuclides, and by X-rays as well, can cause 
late nephropathy. However, several agents also are known to cause nephrotoxicity as side ef-
fect after application in some cases. Renal tubular damage is reported after administration of 
aminoglycoside based antibiotics such as gentamicin [65], the antifungal drug amphotericin 
[66], the anti-folate agent methotrexate [67], used as anti-cancer drug, and Cyclosporine A [68] 
used to prevent rejection of transplanted organs. The latter two drugs also suppress the ef-
fects of auto-immune diseases. Co-administration of Gelofusine or albumin derived peptides 
might interfere in the renal handling of these substances to reduce the risk of renal damage, 
similar to what we described during the application of radiopeptides.
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 Samenvatting
De toepassing van radioactief gelabelde peptide analogen is een aantrekkelijke manier om 
primaire tumoren en uitzaaiingen ervan op een doelgerichte, specifieke manier in beeld te 
brengen. Daarnaast kunnen deze peptiden therapeutisch worden toegepast om tumorpati-
enten te behandelen. Tumoren die zijn ontstaan uit cellen van het neuro-endocriene systeem 
brengen vaak hormoonreceptoren in hoge mate tot expressie; bijv. somatostatine-, gastrine- 
of glucagon-like peptide-1 (GLP-1)- receptoren [1]. Deze receptoren kunnen doelgericht wor-
den aangetoond m.b.v. respectievelijk radioactief gelabelde somatostatine, minigastrine/CCK 
of exendin peptidederivaten. 
In 1994 werd het somatostatine analoog 111In-DTPA-octreotide (Octreoscan®) goedgekeurd 
door de FDA voor klinische toepassing voor beeldvorming m.b.v. een γ-camera, de zgn. pepti-
de receptor scintigrafie (PRS) voor diagnostische toepassingen om het ziekteproces in patiën-
ten met neuro-endocriene tumoren (NET) te vervolgen. Octreoscan® wordt gekarakteriseerd 
door een hoge affiniteit voor de somatostatine receptoren (sst) van subtypes 2, 3 en 5 [2], 
terwijl de meeste NET sst2 tot over-expressie brengen [3]. Omdat 111In behalve γ-straling ook 
therapeutische Auger- and conversie elektronen uitzendt werd 111In-DTPA-octreotide getest in 
peptide receptor radionuclide therapie (PRRT), maar objectieve tumor respons was zeldzaam 
[4]. 
Tyr3-octreotaat, met een hele hoge affiniteit voor sst2, werd ontwikkeld [5, 6] en door het 
gebruik van de DOTA-chelator was het mogelijk om een stabiele radiolabeling te verkrijgen 
met de therapeutische radionucliden 90Y en 177Lu die β—-straling uitzenden. Sinds enkele jaren 
wordt PRRT met 90Y-DOTA,Tyr3-octreotide of 177Lu -DOTA,Tyr3-octreotaat in verschillende me-
dische centra toegepast [7-9], waarbij gunstige therapeutische resultaten werden verkregen 
in vergelijking tot historische controles [10-12]. Beoordee ld volgens SWOG criteria, resulteert 
177Lu-DOTA,Tyr3-octreotaat PRRT bij ~55% van de patiënten in een objectieve respons, terwijl 
bij ~30% stabiele ziekte wordt bewerkstelligd. Bij ~15% van de behandelde patiënten blijft de 
ziekte helaas progressief [7]. 
Behalve specifieke binding van de radioactief gelabelde somatostatine peptide analogen aan 
tumorcellen, wordt ook opname gevonden in de milt, lever en nieren. De eerste publicaties 
over klinische 90Y-DOTA,Tyr3-octreotide PRRT rapporteerden dat bij ongeveer 10% van de pa-
tiënten late nierschade (nefrotoxiciteit) optrad, leidend tot het eindstadium van nierfalen [13, 
14]. Na deze alarmerende publicaties werden de cumulatieve geabsorbeerde stralingsdoses 
op de nieren tijdens PRRT gelimiteerd tot 23-27 Gy, gebaseerd op ervaringen uit de radiothera-
pie [15]. Ook wordt een bovengrens van 37-45 Gy toegepast op basis van het principe van de 
biologische equivalente dosis (BED), die corrigeert voor o.a. het effect van dosisfractionering, 
de nierafmeting en de niet-homogene verdeling van de radioactiviteit in de nieren [16-18]. 
Daarnaast worden positief geladen (kation) aminozuren gelijktijdig toegediend (co-infusie) 
met de radioactief gelabelde somatostatine analogen voor PRRT, waardoor de nierretentie van 
deze peptiden met ongeveer 40% werd verminderd met bescherming van de nieren als resul-
taat [13, 19, 20]. Recente overzichtsartikelen die de incidentie van late nierschade veroorzaakt 
door PRRT evalueren, beschrijven slechts enkele gevallen van nierschade als 177Lu-DOTA,Tyr3-
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octreotaat met co-infusie van aminozuren wordt toegepast [11, 16]. Echter bij 30% van de pa-
tiënten waarbij 90Y-DOTA,Tyr3-octreotide PRRT met aminozuren wordt toegediend, wordt wel 
enige nierschade aangetroffen met stijgende serumwaardes van kreatinine en vermindering 
van de kreatinine klaring [16, 21]. Hiermee wordt de noodzaak van nierbescherming tijdens 
PRRT met 90Y-DOTA,Tyr3-octreotide aangetoond. 
In Hoofdstuk 1.1 worden de achtergrond en het doel van het huidige onderzoek beschre-
ven. Na identificatie van het mechanisme van de nieropname van radioactieve peptiden, werd 
het mogelijk om verschillende manieren te ontwikkelen die leiden tot bescherming van de 
nieren tegen de schadelijke neveneffecten van PRRT.
Een uitgebreid overzicht van de huidige stand van zaken op het gebied van nierbescher-
ming gedurende PRRT met radioactief gelabelde somatostatine analogen is beschreven in 
Hoofdstuk 1.2, dat zich voornamelijk richt op de toepassing van co-infusie met de basische 
aminozuren lysine en arginine en de hierdoor veroorzaakte verstoring van de terugresorptie 
van radioactief gelabelde somatostatine analogen in de nieren. Deze methode is succesvol 
ingevoerd in de huidige praktijk van klinische PRRT. Recent zijn ook Gelofusine en albumine 
fragmenten gedefinieerd als middelen die bij co-administratie met verschillende radiopepti-
den vergelijkbare reductie van nierretentie bewerkstelligen. 
Voor verder onderzoek naar de preventie van nierschade veroorzaakt door bestraling gedu-
rende PRRT werd het opnamemechanisme verantwoordelijk voor de nieropname en nierre-
tentie van radioactieve peptide analogen onderzocht. De conclusie dat megalin een belang-
rijke rol speelt in dit proces bleek de basis om nieuwe strategieën te ontwikkelen ten behoeve 
van nierbescherming zoals is beschreven in Hoofdstuk 2.
Zoals gerapporteerd in Hoofdstuk 2.1 bleek een grote verscheidenheid te bestaan in de 
mate van nieropname van radioactief gelabelde somatostatine-, bombesine-, neurotensine-, 
minigastrine- en CCK-analogen, variërend van een erg lage (CCK) tot een heel hoge (mini-
gastrine) opname in de nieren van ratten en muizen. De volgorde was: CCK < bombesin = 
neurotensin < octreotide << minigastrine, en was vergelijkbaar in beide diersoorten, maar de 
uitscheiding uit muizennieren was sneller dan bij ratten. Verder vonden we geen geslachts-
verschillen in de nierretentie bij ratten, terwijl bij muizen de hoeveelheid radioactiviteit in de 
nieren vier keer hoger was in vrouwtjes t.o.v. mannetjes voor zowel gelabeld octreotide als ge-
labeld bombesine. Uit klinische studies zijn geen geslachtsverschillen bekend wat betreft nier-
retentie van radiopeptiden [17], daarom concluderen we dat de rat een beter proefdiermodel 
is dan de muis om de nieropname van nieuw ontwikkelde radiopeptiden te bestuderen. 
De lokalisatie van de radioactiviteit in de nier, zoals bepaald m.b.v. ex vivo autoradiografie, was 
vergelijkbaar voor alle geteste radiopeptiden: de meeste radioactiviteit werd gevonden in de 
nierschors (cortex), minder in de buitenste laag van het merg (outer medulla), terwijl geen ra-
dioactiviteit werd gevonden in het nierbekken. Dit patroon kwam overeen met de resultaten 
van een immunohistochemische kleuring van niercoupes m.b.v. antilichamen gericht tegen 
megalin, dat voornamelijk tot expressie komt in het gekronkelde deel van de eerste buisjes 
na de glomeruli (proximale tubuli (PCT)) in de niercortex. Minder expressie wordt gevonden 
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in het rechte deel van de proximale tubuli (PST) gelegen in de outer medulla. Megalin is een 
groot eiwit van 600 kDa; het is een netto negatief geladen zgn. multi-ligand scavenging recep-
tor en belangrijk voor de terugresorptie van veel eiwitten en peptiden uit primaire urine zodat 
deze niet verloren gaan door uitscheiding via de urine. 
De suggestie dat megalin een rol speelt bij de nierretentie van radiopeptiden werd bevestigd 
in de studies beschreven in Hoofdstuk 2.2. Ten eerste werd m.b.v. micro-autoradiografie 
aangetoond dat de lokalisatie van radioactiviteit gelimiteerd is tot de proximale tubuli in de 
niercortex. Radioactiviteit werd niet gevonden in de glomeruli of distale tubuli. Vervolgens 
zijn drie middelen, nl. lysine, natriummaleaat en cisplatin, gelijktijdig met radioactief gelabel-
de somatostatine analogen toegediend aan ratten om mogelijke interventie aan te tonen in 
het actieve endocytose proces van terugresorptie, gemedieerd door megalin. De drie geteste 
middelen resulteerden in een reductie van nierretentie van radioactiviteit tot respectievelijk 
60%, 15% en 70%. Door het gelijktijdig toedienen van een overmaat van het positief geladen 
aminozuur lysine met radioactief octreotide, dat één lysine residu bevat, wordt het terugre-
sorptieproces van deze verbinding verstoord, resulterend in een verlaging van de hoeveelheid 
radioactiviteit in de nieren. Natriummaleaat remt het energie-metabolisme van cellen en de 
reconfiguratie van de celmembraan gedurende endocytose. De grote reductie van radioac-
tiviteit in de nieren na voor- of gelijktijdige behandeling met maleaat kan hierdoor worden 
verklaard. Het chemotherapeuticum cisplatin vaak nefrotoxische neveneffecten, beperkt tot 
het rechte deel van de proximale tubuli (PST). Daarom is de reductie van de nieropname van 
111In-DTPA-octreotide door cisplatin relatief laag. Vanwege de ernstige bijverschijnselen zijn 
zowel maleaat als cisplatin niet geschikt voor implementatie in de kliniek ter bescherming van 
de nieren tijdens PRRT. 
Nier-specifieke megalin-deficiënte muizen boden de mogelijkheid om de nieropname en -re-
tentie van 111In-DTPA-octreotide in deze dieren te vergelijken met die in wild-type muizen met 
een normale nierexpressie van megalin. De eerste resultaten zijn beschreven in Hoofdstuk 
2.3. Moleculaire beeldvorming (imaging) 4 en 24 uur na injectie van 111In-DTPA-octreotide 
werd uitgevoerd m.b.v. een SPECT camera speciaal geschikt voor kleine dieren. Na de laatste 
scan werd de hoeveelheid radioactiviteit per nier gekwantificeerd. In beide geslachten werd 
een opvallende 70%-85% reductie van opname in de megalin-deficiënte nieren gevonden, 
die werd bevestigd door ex vivo autoradiografie van vriescoupes van de nieren. 
In de volgende studie waarin gebruik werd gemaakt van deze nier-specifieke megalin-defici-
ënte dieren, beschreven in Hoofdstuk 2.4, werd de nieropname van 111In-gelabelde neuro-
tensine, exendin, en minigastrine analogen bepaald en vergeleken met die van octreotide en 
octreotaat. Kwantificering van de nierretentie in megalin-deficiënte en wild-type muizen was 
gebaseerd op micro-SPECT analyses. Dezelfde muizen werden in opeenvolgende imaging 
experimenten getest met intervallen variërend van 3 tot 9 weken. Afzonderlijk werden ook 
biodistributiestudies uitgevoerd. Alle geteste radiopeptiden vertoonden minder nieropname 
in megalin-deficiënte muizen dan in wild-type controles. Daarom is de terugresorptie van ra-
diopeptiden uit meerdere peptide families, van verschillende grootte en met variabele netto 
lading, tenminste deels megalin gemedieerd.
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Gebaseerd op de conclusie dat megalin een belangrijke rol speelt in de terugresorptie van ra-
diopeptiden in de nier, werd getest of toedienen van Gelofusine een reducerend effect heeft 
op de nieropname van radiopeptiden. Deze plasmavervanger bestaat uit negatief geladen 
gesuccinyleerd gelatine, met een gemiddeld molgewicht van 30 kDa. Gelofusine wordt toege-
diend in de kliniek om hypovolemie (onvoldoende bloedvolume) te behandelen bij patiënten 
die in shock of kritiek zijn vanwege veel bloedverlies. Bij deze patiënten wordt verlies van 
eiwitten en peptiden in de urine gedetecteerd, maar dit is van voorbijgaande aard, wijzend op 
een tijdelijke verstoring van het efficiënte terugresorptie-proces in de nieren [22]. Inderdaad 
werd in een studie bij gezonde vrijwilligers aangetoond dat co-infusie van Gelofusine met Oc-
treoscan® resulteerde in een vergelijkbare reductie van nierretentie als co-infusie met positief 
geladen aminozuren [23]. In Hoofdstuk 3.1 hebben we in ratten de optimale dosis Gelofu-
sine bepaald die gelijktijdig met 111In-DOTA,Tyr3-octreotaat moet worden toegediend om de 
hoogst haalbare reductie van nieropname te verkrijgen. Een dosis van 80 mg/kg lichaamsge-
wicht was voldoende om 50%-60% reductie van nieropname te realiseren, wat zelfs verbeterd 
kon worden tot 70% reductie als Gelofusine werd gecombineerd met lysine. Daarnaast heb-
ben we aangetoond dat de tumoropname van 111In-DOTA,Tyr3-octreotaat niet werd beïnvloed 
door het gelijktijdig toedienen van Gelofusine en lysine, waardoor een verdrievoudiging van 
de tumor/nier ratio werd bereikt.
Amifostine, een scavenger (‘wegvanger’) van vrije radicalen en een antioxidant, wordt toege-
past als beschermend medicijn tijdens klinische radiotherapie. De neveneffecten van bestra-
ling, geïnduceerd door vrijkomende reactieve zuurstofradicalen, worden m.b.v. amifostine in 
gezonde weefsels verminderd. Eerder onderzoek in ratten heeft aangetoond dat gelijktijdige 
toediening van amifostine tijdens 177Lu-DOTA,Tyr3-octreotaat PRRT het ontstaan van nierscha-
de op de lange termijn verminderde [24]. In de studie beschreven in Hoofdstuk 3.2 was 
het doel om het mechanisme dat ten grondslag ligt aan deze manier van nierbescherming 
m.b.v. amifostine verder te onderzoeken en om mogelijke tumorbescherming voor de thera-
pie uit te sluiten. De effecten van co-administratie van amifostine met radioactief gelabeld 
octreotaat werd getest in tumordragende ratten, zowel in biodistributie studies 24 uur na 
injectie van 111In-DOTA,Tyr3-octreotaat als in een PRRT studie met 177Lu-DOTA,Tyr3-octreotaat. 
De dieren werden meer dan 120 dagen na therapie vervolgd. Interferentie van amifostine 
met tumoropname of met het therapeutisch effect van 177Lu-DOTA,Tyr3-octreotaat werd niet 
gevonden. De initiële nieropname werd echter gereduceerd tot 40% van het controle niveau 
na co-injectie met amifostine. Dit was een onverwacht fenomeen dat werd bevestigd in een 
in vitro test waarbij gebruik gemaakt werd van BN-16 cellen die megalin tot expressie bren-
gen. Co-incubatie met amifostine of de actieve metaboliet ervan, WR-1065, reduceerde de 
binding van 111In-DOTA,Tyr3-octreotaat aan BN-16 cellen tot respectievelijk 66% en 55% t.o.v. 
controlewaardes. Deze data suggereren dat de reductie van de initiële nieropname van 111In-
DOTA,Tyr3-octreotaat door amifostine/WR-1065 verloopt via megalin, vergelijkbaar met de 
reductie zoals verkregen met lysine co-administratie. Daarom kan de nierbescherming gevon-
den na co-administratie van amifostine tijdens PRRT [24] veroorzaakt zijn door twee proces-
sen. Enerzijds door het wegvangen van schadelijke zuurstofradicalen, waardoor de cascade 
van processen leidend tot nierfibrose doorbroken wordt, anderzijds door vermindering van 
β—-straling uitzendende 177Lu-retentie in de nieren.
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De ontwikkeling van nierziekte of nefropathologie na bestraling is een langdurig proces dat in 
ratten enkele maanden duurt. Het vervolgen van de nierfunctie in de tijd kan worden gedaan 
door het bepalen van kreatinine- en ureumgehaltes in serum of het eiwitgehalte in urine. 
Een andere, niet-invasieve, manier om nierfalen vroegtijdig te detecteren is door m.b.v. een 
γ-camera de opname en uitscheiding van radioactieve tracers, specifiek voor het onderzoeken 
van de nierfunctie, in beeld te brengen en te kwantificeren. 99mTc-DMSA, een tracer met re-
tentie in de corticale tubuli, is getest om de nierfunctie in ratten gedurende de follow-up van 
PRRT te vervolgen m.b.v. een SPECT/CT camera geschikt voor kleine dieren. De resultaten van 
deze studies zijn beschreven in Hoofdstuk 4.1. Het dosisafhankelijke niveau van nierschade, 
gedetecteerd meer dan 100 dagen na 278 of 555 MBq 177Lu-DOTA,Tyr3-octreotaat PRRT, is om-
gekeerd evenredig met de 99mTc-DMSA opname per nier gebaseerd op statische imaging. Hoe 
hoger de geabsorbeerde dosis radioactiviteit in de nieren, hoe lager de 99mTc-DMSA-opname 
gemeten 100-150 dagen na PRRT. Bovendien liet het lokalisatiepatroon van de opgenomen 
99mTc-DMSA in de nier zien dat er specifiek verlies van functie optreedt in de corticale tubuli; 
alleen in het gekronkelde deel (PCT) na een lage PRRT dosis, maar ook in het rechte deel (PST) 
na een hoge PRRT dosis. 
In Hoofdstuk 4.2 wordt het vervolgen van de rattennierfunctie beschreven na 460 MBq 177Lu-
DOTA,Tyr3-octreotate PRRT met of zonder lysine co-injectie, m.b.v. de radiotracers 111In-DTPA, 
99mTc-MAG3 en 99mTc-DMSA. 111In-DTPA en 99mTc-MAG3 werden toegepast om het dynamische 
proces van glomerulaire filtratie (111In-DTPA) en tubulaire secretie (99mTc-MAG3) in beeld te 
brengen. In controle ratten lieten zowel 111In-DTPA als 99mTc-MAG3 tijd-activiteit curves zien 
met een piek een paar minuten na injectie, gevolgd door een snelle klaring via de tubuli ge-
volgd door uitscheiding via de urine. Als nierschade was ontstaan, na meer dan 90 dagen na 
PRRT, kon bij beide tracers slechts een lage piekactiviteit worden gedetecteerd. In ratten die 
PRRT plus lysine co-administratie hadden gekregen als nierbescherming, bleef de 111In-DTPA 
klaring en 99mTc-DMSA-opname onaangetast, in tegenstelling tot de 99mTc-MAG3 klaring die 
wel een afwijkend patroon liet zien. We concludeerden dat 99mTc-MAG3 een gevoeliger manier 
is om vroege nierschade, geïnduceerd door PRRT, te detecteren dan 99mTc-DMSA-opname of 
serumchemie waarbij de kreatinine- en ureumgehaltes worden bepaald. 
In Hoofdstuk 4.3 beschrijven we dat nefrotoxische effecten werden gevonden in muizen 
na opeenvolgende scans waarbij 111In-gelabelde radiopeptiden werden toegediend. Dit was 
onverwacht omdat in vroege klinische 111In-DTPA-octreotide PRRT studies geen nierschade 
werd gevonden, zelfs niet na een geabsorbeerde stralingsdosis in de nieren van 45 Gy, een 
duidelijke overschrijding van de geaccepteerde veilige dosislimiet van 23 Gy. Echter, het bleek 
dat de hele hoge nieropname en –retentie van 111In-exendin (225% IA/g nier) in wild-type 
en megalin-deficiënte muizen respectievelijk een nierdosis van 70 en 40 Gy opleverde, die 
leidde tot nierfalen in beide muizenstammen na meer dan 90 dagen na de toediening van 
111In-exendin. Een hoge stralingsdosis op de nieren veroorzaakt door γ-straling en Auger- en 
conversie elektronen uitgezonden door 111In, kan dus ook lange-termijn nefrotoxiciteit ver-
oorzaken. SPECT van kleine dieren maakt het mogelijk om ziekte- en behandelingsprocessen 
te vervolgen in de tijd in één dier, maar het risico van een geaccumuleerde stralingsdosis op 
de nieren die de veiligheidslimiet overschrijdt moet in overweging worden genomen, zoals is 
aangetoond in dit hoofdstuk.
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Aanvullende studies
Gebaseerd op het feit dat megalin een cruciale rol speelt in de terugresorptie in de nier van 
meerdere radiopeptiden, is het bestuderen van potentiële remming van dit proces door co-ad-
ministratie van albuminederivaten een logische stap voor verder onderzoek omdat albumine 
één van de belangrijkste moleculen is die bindt aan megalin. Intact albumine (68 kDa) wordt 
vanwege de grootte slechts marginaal gefilterd in de glomeruli. Co-administratie van kleinere 
fragmenten van albumine (FRALB), verkregen door enzymatische afbraak, met 111In-DTPA-oc-
treotide resulteerde in lagere nieropname dan in controle ratten [25]. Deze waarneming be-
vestigde de hypothese dat co-administratie van albuminederivaten de megalin-gemedieerde 
terugresorptie van somatostatine-analogen reduceert. In een vervolgstudie zijn verschillende 
goed gedefinieerde synthetische peptiden, afgeleid van albumine, met variërende ladingen 
getest als specifieke remmers van nieropname. Co-administratie van een peptide bestaande 
uit 36 aminozuren (3.8 kDa), afgeleid van het C-terminale einde van albumine (ALBPEP), be-
werkstelligde een reductie van nieropname van meerdere radiopeptiden, variërend van 26% 
(exendin) en 33% (octreotide) tot 88% (gastrine) remming [26].
Om mogelijke interferentie vast te stellen van ALBPEP met tumoropname van 111In-DOTA,Tyr3-
octreotaat zijn biodistributiestudies uitgevoerd in CA20948 tumordragende ratten (Figuur 1). 
De combinatie van zowel ALBPEP als Gelofusine als co-administratie werd ook getest, resulte-
rend in een significante additieve reductie van de nierretentie van 111In-DOTA,Tyr3-octreotaat, 
terwijl de tumoropname niet werd aangetast. 
Figuur 1: Biodistributie gegevens 24 uur na injectie van 15 μg 111In-DOTA,Tyr3-octreotaat (111In-DOTA-taat) in ratten 
met of zonder co-administratie van peptide, afgeleid van albumine (ALBPEP (4 mg/rat)) en/of Gelofusine (GF (80 mg/
kg)).
Opname in nieren en CA20948 tumoren die sst tot expressie brengen werd berekend als % van de geïnjecteerde 
activiteit/gram (%IA/g) ± SD en de waarde van de fysiologisch zout controle groep werd op 100% gezet. n = 4 ratten 
per groep. Het verschil in nieropname t.o.v. de controle groep van groepen die alleen ALBPEP en GF kregen (** = 
p<0.01) en de ALBPEP+GF (*** = p<0.001) groep was signifi cant, terwijl het verschil tussen ALBPEP+GF en ALBPEP 
of GF alleen ook signifi cant verschillend was (**t.o.v. ALBPEP, *** t.o.v. GF). Geen signifi cante verschillen werden 
gevonden voor CA20948 tumoropname.
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Een overzicht van alle verkregen resultaten 
betreffende reductie van nier- en tumor-
opname van radioactief gelabeld octreo-
taat in ratten na gelijktijdig toedienen van 
lysine (Lys), Gelofusine (GF), ALBPEP en 
amifostine (AMI) (en combinaties ervan) is 
samengevat in Figuur 2. 
Geen van de toegediende middelen re-
sulteerde in significante vermindering van 
de somatostatine receptor-gemedieerde 
tumoropname van 111In-DOTA,Tyr3-oc-
treotaat, in tegenstelling tot de algemene 
reductie van nierretentie. Enkele combi-
naties van middelen vertoonden een signi-
ficante additieve reductie van nieropname, 
terwijl andere combinaties dat niet bewerkstelligden. De waarneming dat Lys+GF+ALBPEP 
niet resulteerde in verdere reductie in vergelijking tot Lys+GF en GF+ALBPEP suggereert dat òf 
het laagst haalbare niveau van nieropname van radioactief gelabeld octreotaat was bereikt, òf 
dat terugresorptie via dezelfde regio’s van megalin domeinen was geremd. Lys+AMI/WR1065 
liet eveneens geen cumulatieve reductie van radioactiviteit in de nieren zien, hetgeen kan 
worden verklaard door een vergelijkbaar werkingsmechanisme. 
Het resterende niveau van nieropname na maximale remming van nieropname met verschil-
lende middelen en in nier-specifieke megalin-deficiënte muizen kan worden veroorzaakt door 
zgn. vloeibare fase endocytose. Naast actieve terugresorptie in de nier is dit een ander pro-
ces waarbij (afval)stoffen worden weggevangen vanuit het bloed en de primaire urine in de 
Figuur 2: Biodistributie gegevens 24 uur na injectie 
van 15 μg 111In-DOTA,Tyr3-octreotaat (111In-DOTA-taat) 
in ratten met of zonder co-administratie van Lys (400 
mg/kg), GF (80 mg/kg), ALBPEP (4 mg/rat) en/of AMI 
(50 mg/rat).
Opname in nieren en CA20948 tumoren die sst 
tot expressie brengen werd berekend als % van de 
geïnjecteerde activiteit/gram (%IA/g) ± SD en de 
waarde van de fysiologisch zout controle groep 
werd op 100% gezet. n = 2-4 rats per groep. Het 
verschil in nieropname t.o.v. de controle groep 
van alle middelen die alleen werden getest was 
signifi cant (***=p<0.001). Combinatie v an Lys+GF 
en GF+ALBPEP liet signifi cante additieve reductie 
t.o.v. alleen Lys, GF of ALBPEP (p<0.01 = *1), terwijl 
Lys+GF+ALBPEP niet signifi cant verschillend (ns2) 
was t.o.v. Lys+GF of GF+ALBPEP. De combinatie van 
AMI+Lys resulteerde niet in signifi cant verminderde 
nieropname t.o.v. alleen Lys of AMI (ns2). Geen 
signifi cante verschillen werden gevonden voor 
CA20948 tumoropname in alle groepen.
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nieren; dit proces kan niet worden geremd m.b.v. aminozuren [27]. Daarnaast is bij de muis 
en de mens, maar niet bij de rat, sst-expressie in de nier aangetoond, dat verantwoordelijk is 
voor enige receptor-specifieke nierretentie van somatostatine analogen dat niet beïnvloed 
kan worden door middelen die interfereren in de megalin-gemedieerde opname [28, 29]. In 
patiënten bedraagt de bijdrage van deze sst-expressie maximaal 20% van de totale radioacti-
viteit in de nieren. Behalve expressie van somatostatine receptoren op proximale tubuli, is ook 
GLP-1R en CCK2-R expressie beschreven [30-32].
De succesvolle resultaten betreffende nierbescherming voor radioactief gelabeld octreotaat, 
verkregen met lysine, Gelofusine en ALBPE P, stimuleerden ons om potentiële additief redu-
cerende effecten op nieropname van radioactief gelabelde minigastrine analogen (met heel 
hoge nieropname) te onderzoeken in tumordragende ratten. Een hoge reductie van meer dan 
80% van de nieropname van 111In-DOTA-minigastrine 0 werd gevonden na co-administratie 
van alleen ALBPEP of Gelofusine. Co-injectie van de combinatie van deze twee middelen re-
sulteerde in een significante extra reductie tot 90% van de nieropname t.o.v. ratten die fysiolo-
gisch zout als controle kregen (Figuur 3). CA20948 tumoropname bleef in alle gevallen gelijk. 
Omdat de mate van radioactiviteit in de nieren na ALBPEP+GF werd gereduceerd zonder aan-
tasting van de tumoropname, werd een 2,5- en 10-voudige verhoging van de tumor/nier ratio 
bereikt na respectievelijk 111In-DOTA,Tyr3-octreotaat en 111In-DOTA-minigastrine 0 toediening. 
In Tabel 1 zijn de resultaten van biodistributiestudies met radioactief gelabelde somatostatine, 
exendin and minigastrine 0 analogen samengevat van meerdere nierbeschermingsstudies in 
ratten zoals beschreven in de literatuur, aangevuld met onze recent verkregen resultaten. De 
waargenomen reductie van nierretentie is weergegeven als percentage t.o.v. de nierretentie 
in onbeschermde dieren.
Figuur 3: Biodistributie gegevens 24 uur na injectie van 0.1 μg 111In-DOTA-minigastrine 0 (111In-DOTA-MG0) in ratten 
met of zonder co-administratie van ALBPEP (4 mg/rat) en/of Gelofusine (GF (80 mg/kg)).
Opname in nieren en CA20948 tumoren die sst tot expressie brengen werd berekend als % van de geïnjecteerde 
activiteit/gram (%IA/g) ± SD en de waarde van de fysiologisch zout controle groep werd op 100% gezet. n = 4 ratten 
per groep. Het verschil in nieropname t.o.v. de controle groep was signifi cant (***=p<0.001), en ook de verschillen 
tussen alleen ALBPEP en GF t.o.v. GF+ALBPEP = ***1. Geen signifi cante verschillen werden gevonden voor CA20948 
tumoropname in alle groepen.
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Omdat minigastrine 0 zes anionische glutaminezuur (Glu) residuen bevat, werd geen effect 
op de nieropname verwacht van gelijktijdige lysine (Lys) toediening. Inderdaad werden al-
leen marginale effecten gevonden [33]. Maar, bij toepassing van polyglutaminezuur (PGA) 
met tenminste vijf Glu residuen, werd een 80%-90% vermindering van radioactiviteit in de 
nieren verkregen [34]. Co-administratie van Lys of PGA met 111In-exendin vertoonde minder 
overtuigende resultaten, wat er op wijst dat de keuze van de toegepaste remmende amino-
zuren specifiek aangepast moet zijn aan de samenstelling van het toegediende radiopeptide, 
waarbij lading een belangrijke rol lijkt te spelen. 
Het gebruik van Gelofusine en albuminederivaten bood reductie van nieropname van alle 
geteste radiopeptiden, hoewel de mate van reductie erg varieerde. Gelijktijdige toediening 
van deze twee middelen met radioactief gelabeld octreotaat bewerkstelligde zelfs een toe-
genomen additief remmend effect op de nieropname, wat nog duidelijker was wanneer deze 
combinatie werd toegediend met radioactief gelabeld minigastrine.
Vermindering van het risico op nierschade na PRRT kan dus worden verkregen door verlaging 
van de initiële nierretentie van radioactief gelabelde peptiden, maar ook door het tempe-
ren (mitigeren) van de door PRRT veroorzaakte lange-termijn nierschade. Gebaseerd op de 
beschreven stralingsbescherming van nieren 
gedurende externe bestraling door het weg-
vangen van actieve zuurstofradicalen of het 
remmen van angiotensine II, hebben we recent 
in ratten het nierbeschermend effect na PRRT 
onderzocht van taurine als antioxidant; van 
L158.809, een angiotensine II receptor blokker 
(ARB); en van captopril, een ACE-remmer (angio-
tensine converting enzyme), dat de omzetting 
van angiotensine I naar angiotensine II remt [36, 
Tabel 1: Samenvatting van nierbeschermingsstudies in ratten, overgenomen uit [25, 26, 33-35] en aangevuld met 
recent verkregen resultaten. Het gemiddelde percentage van reductie van nierretentie is weergegeven. Lys=lysine, 
GF=Gelofusine, PGA=polyglumatinezuur, FRALB=albumine fracties, ALBPEP= van albumine afgeleid peptide, nu = 
niet uitgevoerd.
Lys GF GF + Lys PGA
GF + 
PGA FRALB
ALB-
PEP
ALBPEP 
+ GF
Octreotide/
octreotaat
40-50 40-50 50-65 0-15 nu 30-35 30-45 65
Exendin 0-15 20-25 nu 25-35 35-45 50-55 25 nu
Minigastrine 0 0-15 45-80 nu 80-90 80-90 90-95 80-85 90
Figuur 4: De mate van histologische schade op dag 146 
(460 MBq 177Lu-PRRT) of dag 180 (370 MBq 177Lu-PRRT) na 
therapie met of zonder behandeling met taurine (10 g/l), 
captopril (0.5 g/l) and L158.809 (20 mg/l) toegevoegd aan 
het drinkwater, n = 6-8 per groep. 
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37]. Wanneer de gegevens over de nierfunctie van deze ratten werden vergeleken met die 
van ratten na PRRT zonder toevoegingen aan het drinkwater, konden we geen significante 
verbetering van nierfunctie aantonen. De resultaten van histologische nierschade zijn weer-
gegeven in Figuur 4. We concludeerden dat taurine, L158.809 en captopril niet geschikt zijn 
om vermindering van nefrotoxische effecten veroorzaakt door PRRT m.b.v. 177Lu-DOTA,Tyr3-
octreotaat te bewerkstelligen. 
Richtlijnen voor de toekomst 
Het huidige protocol van 177Lu-DOTA,Tyr3-octreotaat PRRT in de kliniek, bestaande uit vier cy-
cli met een totale cumulatieve dosis van 29.6 GBq met co-infusie van de kation aminozuren 
lysine en arginine, lijkt veilig te zijn wat betreft de nierfunctie [38]. Echter, na 90Y-DOTA,Tyr3-
octreotide PRRT, in een cumulatieve dosis van 15.2 GBq zoals toegepast in verschillende kli-
nische centra, kan de veiligheid van de nieren wel in het geding zijn [21]. De therapeutische 
resultaten van PRRT zijn gunstig vergeleken met de conventionele behandelingsmodaliteiten 
bij NET, met een objectieve tumorrespons bij ~55% van de patiënten met soms ook complete 
tumorregressie. Maar een verdere verbetering van het genezingspercentage is nadrukkelijk 
gewenst [7]. Daarom is veilige toediening van een hogere cumulatieve dosis om verbetering 
van tumorrespons te verkrijgen hoogst noodzakelijk, waarbij nierbescherming een cruciale 
rol speelt [39]. 
Opties om verhoogde tumorrespons te verkrijgen zijn:
• Toediening van meer cycli 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotaat [40]
• Combinatie van 90Y-DOTA,Tyr3-octreotide en 177Lu-DOTA,Tyr3-octreotaat, ofwel binnen een 
cyclus òf starten met op 90Y-gebaseerde cycli gevolgd door 177Lu-cycli òf alternerende 90Y-en 
177Lu-cycli [8, 41-43]
• Combinatie van 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotaat met radiosensitiserende 
middelen, zoals capecitabine of andere chemotherapeutica [11]
• Intra-arteriële (locoregionale) toediening van 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-oc-
treotaat in plaats van de algemeen toegepaste systemische intraveneuze manier van toedie-
nen [44, 45]
• Combinatie van anti-angiogene middelen (remmen de nieuwvorming van bloedvaten), 
bijv. anti-VEGF (vasculair endotheel groeifactor) antilichamen of stoffen gericht tegen 
α
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-integrine zoals thalidomide of RGD-constructen, met 90Y-DOTA,Tyr3-octreotide/177Lu-
DOTA,Tyr3-octreotaat [46, 47]. Recent worden deze middelen toegepast in combinatie met 
radioimmunotherapie.
• Onderzoek naar de inductie van verhoogde somatostatine receptor-expressie op tumoren, 
om de internalisatie van 90Y-DOTA,Tyr3-octreotide/177Lu-DOTA,Tyr3-octreotaat te verhogen [48] 
• Introductie van nieuwe peptide analogen met hogere affiniteit en/of pansomatostatine re-
ceptor specificiteit [49]
• Combinatie van verschillende peptide analogen gericht tegen verschillende receptoren die 
tot co-expressie komen op tumoren, zoals sst2 en GLP-1R op gastrinoma’s [50]
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De geabsorbeerde stralingsdosis op de nieren zal toenemen als meer cycli van 177Lu- of 90Y-gela-
belde PRRT zullen worden toegediend per patiënt, waardoor optimale nierbescherming essentieel 
is. Het beenmerg zal het volgende orgaan zijn met risico op stralingsschade, veroorzaakt vanwege 
een verhoogde geabsorbeerde stralingsdosis omdat meer radioactiviteit in het bloed circuleert [38].
Zoals beschreven in Hoofdstuk 3.1 en door anderen, zal door gecombineerde co-infusie van 
Gelofusine en Lys/Arg verdere reductie van nieropname van somatostatine analogen kunnen 
worden verkregen [23]. Hoewel deze combinatie van nierbeschermende middelen al klinisch 
wordt toegepast met veelbelovende resultaten, zijn vergelijkende studies betreffende nier-
retentie van radioactiviteit nog niet beschikbaar [8, 39]. Daarom zal in de nabije toekomst in 
ons centrum een pilotstudie worden gestart om de nier- en tumordosimetrie te vergelijken 
gedurende 177Lu-DOTA,Tyr3-octreotaat PRRT waarbij òf alleen Lys/Arg co-infusie tijdens één cy-
clus wordt gegeven òf gecombineerde Gelofusine en Lys/Arg co-infusie in de volgende cyclus 
of vice versa. Bij een klein percentage van de patiënten komen na Gelofusine toedieningen 
allergische neveneffecten voor; 0.04% met ernstige anafylactische reacties en 1.4% met milde 
tot matige. Daarom zullen vitale functies, zoals hartfrequentie en bloeddruk moeten worden 
geregistreerd [39, 51]. 
Middelen die stralingsschade op de nieren temperen (mitigeren) kunnen worden gecombi-
neerd met stoffen die de initiële nierretentie van radiopeptiden verlagen, zodat op een veilige 
manier het toedienen van hogere therapeutische PRRT doses kan worden geïmplementeerd. 
In dit opzicht is er meer onderzoek nodig naar de toepassing van het antioxidant amifostine 
als nierbeschermend middel tijdens PRRT. Eerder zijn in de rat gunstige effecten op nierhisto-
logie en nierfunctie op de lange-termijn beschreven [24], die gedeeltelijk toegeschreven kun-
nen worden aan de reductie van de geabsorbeerde stralingsdosis op de nier zoals beschreven 
in Hoofdstuk 3.2. Nieuwe experimenten waarbij amifostine toegediend zal worden ofwel 
vóór of ná PRRT moet onderscheid maken tussen de korte- en lange-termijn effecten. Hoewel 
patiënten na toediening van amifostine een verlaagde bloeddruk, misselijkheid, overgeven 
en/of huiduitslag als neveneffecten kunnen ervaren, is verder onderzoek naar de toepassing 
van dit medicijn m.b.t. PRRT intrigerend. Zeker omdat ook bescherming van voorloper been-
mergcellen voor schadelijke bestralingseffecten is beschreven [52-54]. 
Naast niertoxiciteit wordt ook suppressie van beenmerg gevonden gedurende PRRT, resulte-
rend in vermindering van bloedplaatjes en rode- en witte bloedcellen in het bloed [38, 55]. 
Hematologische toxiciteit is meestal mild en omkeerbaar en het risico op het ontwikkelen van 
myelodysplastisch syndroom (MDS) of leukemie na PRRT is laag als een dosis limiet van 2 Gy 
op het beenmerg wordt aangehouden. Toch zijn verschillende gevallen van beenmergtoxici-
teit na PRRT beschreven [11]. De toepassing van hogere cumulatieve doses van PRRT, in een 
optimaal nierbeschermingsprotocol, kan het risico op beenmergtoxiciteit verhogen en daar-
door zal het beenmerg het dosislimiterende orgaan worden. De geabsorbeerde stralingsdosis 
op het beenmerg wordt veroorzaakt door ‘cross fire’ vanuit het radioactieve bloed dat circu-
leert in de nabijheid van beenmergcellen [56]. Specifieke opname door voorloper beenmerg-
cellen die de somatostatine receptor tot expressie brengen zou bovendien een (kleine) rol 
kunnen spelen [56, 57]. Daarom zullen beenmerg-beschermende strategieën zoals toegepast 
voor nierbescherming met reductie van de initiële nierretentie niet effectief zijn, uitgezonderd 
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eventuele vermindering van stralingsschade door bijv. amifostine. Autologe beenmergtrans-
plantatie kan worden overwogen om ondersteuning van de beenmergfunctie te geven als 
patiënten worden geconfronteerd met ernstige hematologische toxiciteit na PRRT. Deze pro-
cedure wordt al succesvol toegepast tijdens radioimmunotherapie [58].
De bloedklaring van radiopeptiden in patiënten duurt veel langer dan in ratten en muizen, 
omdat deze dieren een kleiner totaal bloedvolume en een hogere hartslagfrequentie heb-
ben dan mensen [59]. Dit resulteert in een hogere geabsorbeerde stralingsdosis in humaan 
beenmerg in vergelijking tot de dosis in proefdieren. Bovendien wordt geen expressie van 
somatostatine-receptoren gevonden op rattenbeenmergcellen in tegenstelling tot humane 
voorlopercellen [57, 60]. Differentiële celtellingen van beenmerg van terminaal zieke ratten 
vanwege nefrotoxiciteit langer dan 100 dagen na 177Lu-DOTA,Tyr3-octreotaat PRRT met >50 Gy 
op de nieren, liet geen afwijkingen zien in het beenmerg. Bovendien waren de aantallen van 
meerdere typen bloedcellen van deze ratten vergelijkbaar met die van controle ratten, wat 
erop wijst dat hematologische toxiciteit niet voorkwam bij deze dieren. Daarom is preklinisch 
onderzoek in kleine proefdieren naar bescherming van beenmerg tijdens PRRT door amifos-
tine, andere middelen of door ondersteuning m.b.v. autoloog beenmerg niet mogelijk.
Samenvattend hebben we aangetoond in preklinische studies dat naast kation aminozuren, 
Gelofusine, albumine derivaten, amifostine, of combinaties hiervan veelbelovende midde-
len zijn om de nierretentie te verminderen van verscheidene tumorspecifieke radiopeptiden 
in patiënten. Dit is vooral belangrijk als verhoogde PRRT doses zullen worden toegediend 
om verbeterde genezingspercentages te behalen. Ten eerste zullen de veiligheidsaspecten 
betreffende allergische reacties op Gelofusine en mogelijke toxiciteit van peptiden afgeleid 
van albumine grondig worden bestudeerd. Daarnaast zal de productie van peptiden afgeleid 
van albumine opgezet moeten worden volgens de richtlijnen van GMP (good manufacturing 
practice) voordat deze getest kunnen worden in klinisch onderzoek. Deze peptiden bieden 
veelbelovende vooruitzichten voor brede toepassing als nierbeschermend middel. 
Onze ervaring met het terugbrengen van nierretentie van radiopeptiden kan worden uitgebreid 
naar andere, nieuw ontwikkelde, radioactief gelabelde biomoleculen zoals neurotensine of bom-
besine analogen die één of meer Lys residuen bevatten [61], folaat derivaten, Affi  body moleculen 
of nanobodies die een hoge mate van retentie van radioactiviteit in de nieren laten zien [62-64]. 
Zoals beschreven in dit proefschrift kan bestraling van de nier door radionucliden, maar ook 
door röntgenstraling, late nierschade veroorzaken. Van verscheidene andere geneesmiddelen 
is ook bekend dat deze na toediening nefrotoxiciteit kunnen veroorzaken. Tubulaire schade in 
de nieren is gerapporteerd na toediening van antibiotica gebaseerd op aminoglycoside zoals 
gentamicine [65], het antischimmel middel amphotericine [66], het anti-folaat methotrexaat 
[67], gebruikt als medicijn bij kankerpatiënten, en Cyclosporine A [68], toegepast ter voorko-
ming van afstoting van getransplanteerde organen. De laatste twee medicijnen onderdrukken 
ook de effecten van auto-immuun ziektes. Co-administratie van Gelofusine of peptiden afge-
leid van albumine kunnen mogelijk interfereren met de interactie van deze medicijnen met de 
nier waardoor het risico op nierschade wordt verminderd, vergelijkbaar met wat we hebben 
beschreven voor de toepassing met radiopeptiden.
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 List of abbreviations
AA afferent arteriole
ACE(I) angiotensin converting enzyme (inhibitor)
AMI amifostine
ANOVA analysis of variance
ARB angiotensin II receptor blocker
Arg arginine
BSA bovine serum albumin
BED biological equivalent dose
BW body weight
C cortex
CCK cholecystokinine
CE conversion electrons
CD collecting duct
CT computed tomography  
d day(s)
DAB diaminobenzidine
DMEM Dulbecco’s modified Eagle’s medium
99mTc-DMSA 99mTc-radiolabelled dimercaptosuccinic acid 
DNA desoxyribonuclic acid
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
DT distal tubule
DTPA diethylenetriaminepentaacetic acid
EA efferent arteriole
EBRT external beam radiation therapy
ENETS European Neuroendocrine Tumour Society
18F 18Fluoride
FCS foetal calf serum
FDA Food and Drug Administration
g gram
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G glomerulus
68Ga 68Gallium
GBq Gigabequerel (109 Bq)
GF Gelofusine
GFR glomerular filtration rate
GLP-1 glucagon like peptide-1
GMP good manufacturing practice
GRP gastrin releasing peptide
Gy Gray
h hour(s)
HE-staining haematoxylin-eosin staining
HER2 human epidermal growth factor receptor 2
HPLC high-performance liquid chromatography
HRP horseradish peroxidase
%IA/g or %ID/g percentage of injected activity/dose per gram tissue
IC50 concentration needed to achieve 50% inhibition of binding
IgA/IgM immunoglobulin A/M
IL-8 interleukin-8
111In 111Indium
i.p. intraperitoneal
ITLC instant thin layer chromatography
i.v. intravenous
kBq Kilobequerel (103 Bq)
kDa kilo Dalton
keV kilo electron volt
LD50 median lethal dose for 50% of subjects
LDL low-density-lipoprotein 
LH lis of Henle
177Lu 177Lutetium
Lys lysine
Lys/Arg lysine/arginine 
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mAb monoclonal antibody
99mTc-MAG3 99mTc–labelled mercaptoacetyltriglycine 
MBq Megabequerel (106 Bq)
MDS myelodysplastic syndrome
Meg def kidney-specific megalin-deficient mice
MeV mega electron volt
μg microgram
MG0 minigastrin 0
min minute(s)
μl microlitre (10-6 litre)
ml millilitre (10-3 litre)
MRI magnetic resonance imaging
MTC medullary thyroid cancer  
MW molecular weight
NET neuroendocrine tumour
OM outer medulla
PAS staining periodic acid Schiff staining
PCT proximal convoluted tubules
PET positron emission tomography
Phe phenylalanine
p.i. post injection
PRS peptide receptor scintigraphy
PRRT peptide receptor radionuclide therapy
PST proximal straight tubules
p.t. post therapy
PT proximal tubule
R receptor
RAAS renin-angiotensin-aldosterone system
ROI region of interest
ROS reactive oxygen species
RV renal vein
s second
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SCLC small cell lung carcinoma
SD standard deviation
SPECT single photon emission computed tomography
sst2, 3 or 5 somatostatin receptor subtype 2, 3 or 5
SUVmax maximum standard uptake value 
SWOG South West Oncology 
T
1/2 
half life
99mTc 99mTechnetium
TGF-β transforming growth factor-β
Tyr tyrosine
VIP vasoactive intestinal peptide
VOI volume of interest
WHO World Health Organization
WT wild-type mice
90Y 90Yttrium
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 Dankwoord
Het als laatst geschreven deel van mijn proefschrift, maar misschien wel het meest gelezen… 
Het is overduidelijk dat ik de inhoud van dit boekje nooit in mijn eentje tot stand kan heb-
ben gebracht, hoewel alleen mijn naam op de omslag staat genoemd. Meer dan terecht dus 
dat dit dankwoord vol staat met namen van collega’s en ex-collega’s, andere medewerkers 
en natuurlijk familie en vrienden, die allemaal op hun manier hebben bijgedragen aan het 
verwerkelijken van dit proefschrift.
Toch wil ik niet alleen namen noemen, maar ook allerlei situaties, ontmoetingen en ‘toevallig-
heden’. Dat is omdat ik er van overtuigd ben dat iedereen zijn of haar levensweg gaat met een 
doel in gedachten als richtingwijzer, maar dat meestal door onverwachte omstandigheden 
wordt bepaald hoe de weg feitelijk gaat. Zoals de pelgrim weet dat het gaat om onderweg 
zijn en dat de weg zelf het doel is; daarom kan hij/zij de vertrouwde omgeving verlaten en zich 
overgeven aan dat wat op zijn/haar weg komt. 
“Ik ga een weg en word geleid op die weg”
Etty Hillesum
Mijn wieg heeft gestaan in een boerderij op de Walcherse kleigrond, middenin de stille, vrije 
natuur. Mijn ouders hebben mij, en Helma en André, opgevoed in een sfeer van niet zeuren, 
aanpakken en ‘je best doen’ om iets te bereiken. Een houding die niet altijd makkelijk is, om-
dat perfectionisme op de loer ligt, maar het was de basis waarop ik o.a. dit proefschrift heb 
kunnen afronden. Dus dank daarvoor. Helaas kan mama mijn promotie niet meer meemaken, 
maar ik weet hoe trots ze zou zijn geweest. Pa, je hebt net gehoord dat je ernstig ziek bent; ik 
hoop dat je er de 16e toch bij kan zijn.
De beslissing een vak te kiezen ‘om andere mensen te helpen’ was er al heel vroeg, maar wat? 
Geen verzorgend beroep, maar wel in de gezondheidszorg. Na wat wikken en wegen werd het 
geen studie geneeskunde maar de opleiding tot analist; de medische richting op de laborato-
riumschool. Daar, waar Raymond en ik een stel zijn geworden, heb ik een supergezellige tijd 
gehad. We kregen o.a. les in Immunologie, een nieuw vak destijds wat me direct aansprak. Het 
bleek dat de afstudeeropdracht die ik kreeg tijdens mijn, in velerlei opzichten, leerzame stage 
verband hield met antilichamen; een schot in de roos. Meneer Steenhuis en Felix de Rooij, en 
collega docenten en laboratoriummedewerkers, bedankt dat jullie me op een positieve ma-
nier op weg hebben geholpen het vak van analist op te pakken.
Toen ik solliciteerde naar een baan bij de Klinische Genetica van de Erasmus Universiteit (er-
felijkheid was mijn favoriete onderdeel van de biologielessen) kreeg ik als antwoord dat die 
vacature helaas vervuld was, maar dat ik werd uitgenodigd mee te solliciteren bij drie verschil-
lende groepen van Celbiologie & Genetica. Een daarvan was bij Willem van Ewijk. Tijdens het 
gesprek met hem over inhoud van het beoogde project, kwam ter sprake dat er met proefdie-
ren gewerkt zou moeten worden. Achteraf hoorde ik dat mijn vraag of ik die mocht zien, ertoe 
heeft geleid dat ik de baan kreeg omdat het blijk gaf van een ‘gezonde nieuwsgierigheid’. 
Met Els van Vliet, en ook Peter van Soest, zijn we enthousiast begonnen aan het project wat 
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succesvol kon worden afgesloten; met ER-TR9 als ‘mijn kindje’. Het leverde me werkervaring 
op met o.a. celkweek, ELISA, immunohistochemie en FACS in een stimulerende internationaal 
georiënteerde wetenschappelijke omgeving, waardoor ik o.a. in Washington en later in Mar-
seille heb mogen werken. Na het thymuswerk, o.a. met Pieter Brekelmans, ben ik overgestapt 
naar de monocyt/macrofaag ontwikkeling met Pieter Leenen en Walentina Slieker. Zij hebben 
me geleerd dat je veel data in korte tijd kan genereren (‘postzegels verzamelen’), maar dat het 
uitwerken en publiceren ervan een vak apart is. Zoals ik recent heb geschreven voor het boek 
ter gelegenheid van het 25-jarig jubileum van de afdeling Immunologie, heb ik met zowel 
Willem als Pieter met plezier gewerkt. De kneepjes van het researchwerk zijn me prima bij-
gebracht. Sleutelwoorden waren behalve nieuwsgierigheid, nauwkeurigheid, verbanden leg-
gen, en vooral vragen stellen; een vraag is nooit dom. Leuke resultaten ging samen met een 
goede sfeer met heel veel collega’s die ik niet allemaal bij name kan noemen. De cabarets en 
optredens die werden verzorgd tijdens promotiefeesten waren een hoogtepunt, zoals ook de 
bijdrage aan ons huwelijksfeest. Iedereen, waarbij ik Jane, Huub en Tar toch even wil noemen, 
hartelijk dank voor deze periode. Willem, ik vind het een eer en heel bijzonder dat je nu in mijn 
commissie zit. 
Omdat het interessante, maar drukke researchwerk gecombineerd met de zorg voor een 
dochter zwaar werd, heb ik gekozen om ‘lekker in het dorp’ op de Willem te beginnen als TOA. 
Het verdiepen in de algemene biologie, omgaan met leerlingen, opzetten van nieuwe proef-
jes, levend model van een zwangere vrouw zijn en inzicht krijgen in het reilen en zeilen van 
een grote middelbare school waren heel interessant, maar gaf toch niet genoeg voldoening. 
Collega’s van toen: bedankt voor de prettige samenwerking en misschien tot ziens, op school 
als docent van mijn zoon, in de kerk of op ‘t dorp. 
Toen ik aan twijfelen was over mijn TOA-baan, belde Pieter Leenen me; hij had een baan voor 
20 uur per week in de aanbieding. Alsof hij het aanvoelde. Met beide handen heb ik de kans 
aangegrepen en mocht, begeleid door Maarten en Pieter, zelfstandig aan de slag binnen his-
tiocytose-projecten. Het was goed om weer aan de bench te staan en celkweek verleer je niet. 
In een nieuw, gezellig team (o.a. Janneke, Katarina, Femke, Annabrita, Tanja en Peter-Paul, Paul, 
Michel) was het lekker werken; dank daarvoor! Er was de mogelijkheid de resultaten zelf op te 
schrijven, maar daar kon ik naast werk en gezin geen tijd voor vinden. Gelukkig zijn de data re-
cent gepubliceerd door Pieter en Anjali; een toegift voor mij. Pieter, ontzettend bedankt voor 
je vertrouwen, stimulans en vriendschap. En de wiebel zit prima hè? Het was inspirerend met 
je te brainstormen over stelling 6 waarin onze werkvelden bij elkaar komen.   
Eigenlijk geen reden om te verkassen, maar vanbinnen kriebelde het; in plaats van fundamen-
teel wetenschappelijk onderzoek wilde ik graag klinisch toepasbaar onderzoek doen. Ik ben 
gaan solliciteren, o.a. bij de Nucleaire Geneeskunde naar een MNAA baan omdat ik niveau 5B 
had gehaald vanwege 3H en 35S werk. Het gesprek met Willem Bakker was heel prettig, maar 
een begintijd van 7:00 ’s morgens vroeg was niet te combineren met de zorg voor drie kinde-
ren als (deels) alleenstaande moeder. Na een korte periode bij de Immunologie frontservice, 
ben ik bij Cardialysis gaan werken. Ook als analist, maar achter een beeldscherm i.p.v. aan de 
labtafel, heb ik o.a. ECG’s leren analyseren: een nuttige ervaring rijker. Het was boeiend om 
kennis te maken met het bedrijfsleven; de strikte werktijden, hardere mentaliteit en sterke 
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hiërarchie waren een contrast met wat ik gewend was. Heather en Hilde, bedankt voor jullie 
lessen. Nol, Ellie, Annemarie (2x), Lali, Petra en Paula o.a., bedankt voor jullie collegialiteit. Daar 
kwam abrupt een einde aan toen de geldpot voor mijn aanstelling leeg was. 
Inmiddels was er weer een vacature bij de Nucleaire. Willem herkende mijn naam en cv en 
belde me met de vraag of ik i.p.v. in de genoemde MNAA-vacature interesse had in een baan 
bij de preklinische groep omdat ik ook bevoegdheid had om met proefdieren te werken. Voor 
die opmerkzaamheid ben ik je super-erkentelijk, Willem. Na mijn sollicitatiegesprek met Ma-
rion en Bert zag ik tijdens de rondleiding over het lab een kweekkast en een cryostaat staan; 
toen kon het niet meer stuk. Arthur, je koos voor een switch van prekliniek naar de MNAA-
groep. Dat gaf mij de kans om preklinisch onderzoek te gaan doen; precies wat ik zocht toen 
ik de Immunologie verliet. 
Toen ik startte in 2003 bestond de preklinische groep uit Marion de Jong, Bert Bernard, Magda 
Bijster, Ria van den Berg, Astrid Capello, Suzanne Verwijnen en Monique de Visser en voor 
de radiochemie Wout Breeman en Erik de Blois. Marion, bedankt dat je bent ingegaan op 
de suggestie van Willem en me de kans hebt gegeven te werken in je groep. Voor mij ben 
je een inspirerende en stimulerende leidinggevende, die ruimte geeft om met eigen ideeën 
te komen. Arthur heeft me nog ingewijd in de kunst van autoradiografie voor zijn definitieve 
overstap. Bert speelde een belangrijke rol bij het inwerken op het gebied van celkweek van 
hechtende tumorcellijnen, het werken met radioactiviteit in veel grotere hoeveelheden dan 
ik gewend was, en met ratten die veel groter zijn dan muizen (met langere tanden) en die 
opgepakt worden om de romp i.p.v. aan de staart. Even wennen… Magda, je ruime ervaring 
met ratten en histologie zijn van grote waarde geweest. De gradering van nierschade op basis 
van histologie was essentieel. Ria, van jou heb ik de internalisatie methode tot in de puntjes 
geleerd. Op de werkvloer en tijdens werkbesprekingen volgde ik de promotie-onderzoeken 
van Astrid, Suzanne en Monique en spong bij met praktische hulp waar nodig. 
Daarnaast kreeg ik de gelegenheid om zelfstandig experimenten te doen, vooral m.b.v. auto-
radiografie en ook micro-autoradiografie, het afstudeeronderwerp van stagiaire Katy van de 
Wansem. Het abstract dat over dit werk werd ingestuurd naar de EANM werd genomineerd 
voor de ‘Marie Curie award’, wat inhield dat er een artikel over geschreven moest worden. 
Ziedaar mijn eerste schreden op het pad van eigen publicaties schrijven, waarbij mijn vroe-
gere buurvrouw Bea Rowlinson de correctie Engelse taal voor haar rekening nam. Het tweede 
artikel wat ik mocht schrijven (niet opgenomen in dit proefschrift) was n.a.v. een poster die 
verrassend werd gekozen als een van de beste tijdens een IRIST meeting. Uit een experiment 
van Astrid en Magda, bleek er sprake te zijn van verhoogde receptordichtheid op progressieve 
tumoren na relapse zoals gekwantificeerd m.b.v. autoradiografie. 
Ondertussen kwamen er nieuwe collega’s: Edgar Rolleman, arts en oude bekende van de af-
deling, om zijn promotie-onderzoek over nierbescherming tijdens PRRT af te ronden. Via de 
zijlijn was ik af en toe betrokken bij dit onderwerp; ik wist toen nog niet dat zijn roze-paarse 
proefschrift niet meer van mijn bureau weg te denken zou zijn. Edgar, ik ben je veel dank ver-
schuldigd voor alle uitleg die je me in de loop van de tijd hebt gegeven. Eerst op het lab en 
later vooral via de mail bij gedeelde auteurschappen, zoals je review dat ik mocht gebruiken 
als deel van de inleiding (Hoofdstuk 1.2). 
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Verder hadden we ongeveer 1,5 jaar lang Cristina Müller uit Zürich en Flavio Forrer uit Basel 
te gast. Besides practising English, it was inspirational to collaborate with two experienced 
Swiss scientists, either with medical or chemical background. I appreciated the discussions on 
methods concerning cell culture and in vitro assays, animal imaging with several radiophar-
maca, tumour and kidney autoradiography e.g., resulting (among others) in the paper which 
is included with permission in this thesis as Chapter 4.1. Flavio, it’s a great pleasure for me that 
you will be a member of the Committee during my thesis defense. Cristina, your dedication 
and organization of your research were an example for me. I’m looking forward to our colla-
boration in the near future. 
Toen in 2007 geen geschikte kandidaat kon worden gevonden voor de AIO-vacature binnen 
het KWF-project, toegekend als vervolg op het onderzoek van Edgar, vroeg Marion of ik die 
functie wilde invullen, met Monique als analist. Vooral tijdens de laatste fase van Monique’s 
promotie-onderzoek betreffende bombesine analoga, heb ik meegewerkt aan haar experi-
menten en nu binnen het nieuwe nierbeschermingsproject waren de rollen omgekeerd. Om-
dat we allebei waren ingewerkt konden we een vliegende start maken. De samenwerking 
was prima; we maakten gebruik van elkaars sterke kanten. Er zou een tijdschrift moeten be-
staan waarin resultaten die een hypothese niet kunnen bevestigen, toch gepubliceerd kun-
nen worden. Ondanks het vele werk, leverde het testen van een eventuele rol voor taurine, 
L158.809 en Captopril ter nierbescherming tijdens PRRT, helaas geen publicabele conclusie 
op! Je besluit het lab achter je te laten en je volledig te wijden aan je gezin en grootste pas-
sie, het dansen, kon ik alleen maar respecteren. Toen je afscheid nam, heb ik je gevraagd of je 
t.z.t. mijn paranimf wilde zijn. Gelukkig was je direct positief, zodat we straks drie-vrouw sterk 
voor de commissie staan. Ontzettend bedankt voor je nauwgezette en handvaardige inzet bij 
experimenten en dataverwerking en je persoonlijke betrokkenheid.
Een aparte alinea voor de vier stagiaires die ik mocht begeleiden tijdens hun afstudeerperi-
ode binnen de prekliniek. Na het halen van stralingshygiëne niveau 5B en aanleren van de 
meest gangbare technieken kregen jullie een eigen stage-opdracht. Lennert heeft optimale 
omstandigheden voor autoradiografie met verschillende peptiden getest. Satish werkte aan 
de karakterisering van een folaat analoog met Cristina. Walter heeft heel wat ratten gewogen 
en coupes gesneden, maar ook autoradiografie uitgevoerd met 68Ga-gelabeld octreotaat. Ook 
Wilmer was betrokken bij de follow-up van ratten na een therapeutische dosis en bepalingen 
van eiwit in urine, aangevuld met kwaliteitscontrole van de autoradiografieschermen. Ik ben 
jullie erkentelijk voor jullie bijdrage aan genoemde onderzoeksprojecten en voor mij was de 
studentenbegeleiding een leerzame ervaring.  
De samenstelling van de groep bleef veranderen. Stefan Pool, Rogier Schroeder, Ingrid Thuis 
en Marleen van de Poel startten met hun AIO onderzoek. En Jan de Swart stapte over van de 
klinische gamma-camera’s naar de prekliniek als specialist voor de microSPECT- en microPET-
camera’s, met Corine als ‘collega voor een dag per week’. Ingrid en mijn naamgenote twee 
stopten vrij snel, en ook Sandra Dieleman, die Ingrid opvolgde, bleef niet lang. Toch was het 
fijn elkaar te leren kennen en een Sinterklaasfeest met deels Vlaamse invloeden was heel ge-
zellig. Door de pensionering van Bert (regelneef wat betreft bestellingen, EDC, SBE, o.a.), Ria 
(fijne kamergenote als we op congres gingen) en Magda (goed vrouw-tot-vrouw contact, 
vooral rondom het overlijden van mijn moeder) en de keus voor een ander beroep van Su-
zanne (bedankt voor je energieke enthousiasme en persoonlijke aandacht) en Monique kwam 
er ruimte voor een nieuwe generatie. Met eerst Saskia, later Stuart (bedankt voor je prachtige 
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illustratie bij het nierscan artikel) en Linda, als analisten, Sander als AIO, Harald als post-doc en 
Mark Konijnenberg als fysicus is de groep totaal vernieuwd. En door nauwere samenwerking 
met de preklinische groep o.l.v. Monique Bernsen van de Radiologie ook sterk vergroot. Saskia, 
Stuart en Linda: jullie vakkundige bijdrage aan biodistributies, scans (vooral de dual isotope 
dynamische) en in vitro experimenten beschreven in de recentste hoofdstukken uit dit proef-
schrift heb ik zeer gewaardeerd.
Voor de inbreng van hun expertise in verschillende artikelen uit dit proefschrift wil ik mijn ka-
mergenoten van het laatste jaar, Jan en Mark, hartelijk dankzeggen. Ook voor de betrekkelijke 
stilte als we ‘zij aan zij’ of ‘rug aan rug’ gekluisterd waren aan het beeldscherm. En natuurlijk 
voor de vele kopjes heet water waar nog een theezakje door gezwengeld moest worden.
En: last but not least, in fact most important: Het is onmogelijk om onderzoek te doen bij de 
Nucleaire zonder radioactief gelabelde analoga! Wout en Erik, vanaf het begin kon ik bij jullie 
aankloppen met de vraag peptiden te labelen in allerlei specifieke activiteiten voor verschil-
lende in vivo en in vitro doeleinden. Ook Ho-Sze draagt haar steentje bij; nu aangesteld als 
AIO in de groep. Met jullie is het goed discussiëren, dat houdt een mens scherp. Ontzettend 
bedankt voor de vele gevulde loodpotten die ik mocht ophalen.
Aansluitend aan de prekliniek wil ik iedereen van de Nucleaire Geneeskunde bedanken voor 
de collegialiteit en belangstelling! Tijdens afdelingsdagen, lunchmeetings, wetenschapsmid-
dagen, kerstborrels bijv. treffen we elkaar, en tijdens congresbezoek in kleinere groepen ont-
staat vaak intensiever contact. Voor mij is het belangrijk contact te hebben met alle geledingen 
van de afdeling. Via Tracey zijn we sowieso met elkaar verbonden. Van de artsen wil ik Roelf 
met name noemen, omdat hij betrokken was bij de projectaanvraag en heeft meegewerkt 
aan veel van mijn artikelen. Hartelijk dank voor je uitleg en inbreng van klinische aspecten van 
het werk en je aanmoediging en discussie bij het publiceren. Dik, bedankt voor je inbreng wat 
betreft de statistiek in het amifostine stuk. En Lideke voor de contacten betreffende CCK/gas-
trine onderzoek; ik hoop dat we dat kunnen uitbreiden in de toekomst. Ook de MNAA groep 
verdient apart te worden genoemd. Als ik met een bestelbriefje kwam voor 177Lu-octreotaat, 
99mTc-DMSA of 99mTc-MAG3 met een ‘vreemde’ specificatie omdat het aan ratten of muizen 
toegediend zou worden, waren jullie bereid te berekenen hoe eraan kon worden voldaan. Erg 
bedankt voor jullie medewerking! 
Omdat we veel met proefdieren hebben gewerkt, wil ik de (meeste) dierverzorgers van het 
EDC bij name noemen. Hun rol in dit werk is heel belangrijk. Ed en Albert, maar ook Ron, Es-
ther, Dennis, Agnes en andere Dennis; hartelijk dank voor jullie bijdrage. Ook wil ik de verschil-
lende art. 14 functionarissen en hun medewerkers bedanken voor hun inzet bij het voorspoe-
dig afhandelen van vele DEC-aanvragen. Dank aan Frans, Martje, Marcel, Mathieu, Dominique, 
Marleen en Suzanne. Verder Lien voor het bestellen van dieren. Amélie voor haar hulp bij het 
invullen van werkprotocollen en kwaliteitszaken zoals screening van de muizen die uit Nijme-
gen werden ingevoerd. Henk, bedankt voor je hulp bij het regelen van het transport van deze 
dieren, waarmee de resultaten beschreven in Hoofdstuk 2.4 en 4.3 zijn behaald. En Edo als 
lokaal stralingsdeskundige voor de overkoepelende zaken.
Binnen het Erasmus MC wil ik de samenwerking met de afd. Pathologie noemen. Marcel Ver-
meij, ontzettend bedankt voor de beoordeling van muizennierschade zoals beschreven in 
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Hoofdstuk 4.3. En Frank van de Panne voor het bewerken van het histologiefiguur uit datzelfde 
artikel. Ook Wytske van Weerden van de afd. Urologie wil ik bedanken voor haar gedreven 
inbreng in samenwerkingsprojecten; zonder daarbij Suzanne, Corrina en Sigrun te vergeten.
Furthermore, I really appreciated the motivational international contacts and collaborati-
ons with scientists within the field of Nuclear Medicine, either via European COST-actions 
or during conferences. Among others I want to mention (the groups of ) Thea Maina, Steve 
Mather, Helmut Mäcke, Martin Béhé, Jean-Claude Reubi, Richard Baum, Renata Mikolajczak, 
Vladimir Tolmachev, Stanislas Pauwels and Peter Bernhardt.
Gezegend met drie promotoren mocht ik aan de afrondende fase van een promotietraject, het 
schrijven van het proefschrift, beginnen. 
Prof. Eric Krenning, hartelijk dank voor de mogelijkheid om te werken op uw afdeling. Het is 
een luxe omringd te zijn door goede apparatuur en voldoende materiaal, de mogelijkheid te 
krijgen om congressen in het buitenland te bezoeken en deel te nemen aan goed verzorgde 
afdelingsdagen, lunchmeetings en wetenschapsmiddagen. Als hoofd van de afdeling volgde 
u mijn vorderingen met publiceren met interesse; met af en toe een kritische noot; positief, 
met humor en prikkelend geformuleerd. 
Prof. Otto Boerman, letterlijk op afstand, maar nauw betrokken bij het onderzoek. Grote waar-
dering wil ik uitspreken voor de enthousiaste, supersnelle en opbouwende reacties die ik 
kreeg op vragen en n.a.v. manuscripten die correctie behoefden. Ook andere leden van de 
Nijmeegse groep wil ik bedanken; altijd gezellig om elkaar te spreken. O.a. Erik Vegt voor de 
prettige samenwerking resulterend in een aantal gezamenlijke artikelen. Annemarie Eek voor 
je inzet bij de fok en experimenten met megalin deficiënte muizen. En Maarten Brom, veel heb 
ik van je geleerd over werken met muizen. 
Prof. Marion de Jong, beste Marion, heel erg bedankt dat je me de mogelijkheid hebt geboden 
aan een eigen project te werken, alsmede voor de coaching tijdens de praktische fase van 
het onderzoek. Verder heb ik heel veel van je geleerd op het gebied van resultaatverwerking, 
schrijven en presenteren. Want leuke resultaten moeten worden vertaald naar een overzich-
telijk, leesbaar artikel. Zeer erkentelijk ben ik je voor de vele, vele suggesties en correcties van 
manuscripten, waardoor je de inhoud van dit proefschrift waarschijnlijk wel kunt dromen. De 
kunst van het weglaten, essentieel voor een duidelijke presentatie en níet mijn sterkste kant, 
heb je me bijgebracht. Bedankt ook voor je luisterend oor als het tegenzat. Een bekende uit-
spraak van je is dat problemen gezien kunnen worden als uitdagingen. Dat leef je voor, en is 
voor mij een stimulans om op dezelfde manier met tegenslagen om te gaan. 
De leden van de leescommissie, Prof. Theo Visser, Prof. Ronald de Krijger en Prof. Freek Beek-
man; enorm bedankt voor het plaatsnemen in de commissie en voor het doornemen van het 
manuscript. De positieve reacties leidden tot een soepele afhandeling van de procedures. Ik 
kijk met gezonde spanning uit naar de gedachtewisselingen tijdens de verdediging.
Een proefschrift wordt geen mooi boekje zonder goede lay-out. Ton, dankzij de kersverse sa-
menwerking met de Radiologie mocht jij m’n teksten vormgeven. En daar ben ik superblij 
mee, want het was mij nooit gelukt om zo snel dit prachtige resultaat af te leveren. Gelukkig 
had je er ook zichtbaar lol in om er ‘jouw boek, Marleen’ van te maken inclusief spelen met 
lettertypes, kleuren en het samenstellen van de omslag. 
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De diverse bedrijven die me financieel hebben ondersteund om het drukken van dit proef-
schrift mogelijk te maken, ben ik zéér erkentelijk.
Al met al moge het duidelijk zijn dat ik niet het gangbare traject heb gevolgd, dat leidt tot het 
schrijven van een proefschrift, maar het kwam op mijn pad. 
“Waar ik gelopen heb, is van nu af aan een weg”
Paul de Munnik (Vandaag ben ik gaan lopen)
Omdat ik heel goed besef dat werk (exact: linkerhersenhelft) alleen niet gelukkig maakt, be-
oefen ik ernaast graag activiteiten die eerder creativiteit, gevoel en spiritualiteit aanspreken 
(rechterhersenhelft) om tot een evenwichtige balans te komen. Hierdoor ben ik in contact 
gekomen met heel veel prachtige mensen, waarvan ik er een aantal bij naam wil noemen om 
mijn waardering te uiten.
Het contact met vele zwangere en net bevallen moeders in de tien jaar dat ik contactpersoon 
was voor de vereniging Borstvoeding Natuurlijk, was heel waardevol en heeft me veel geleerd 
zoals omgaan met groepen, luisteren en informatie overbrengen. Collega’s Hanny, Jenny, An-
drea, Liesbeth: bedankt voor de intensieve gesprekken. 
Koorzang is al lang een grote hobby van me, omdat zingen energie geeft als je je gevoel erin 
kan leggen en bovendien is het gezellig. Leden van Mixed Voices (o.a. Henny, Suze, Wilna, An-
net), de cantorij van (nu) de ‘Open Hof ’ (o.a. Leo, Ida, Riet, Lies, Ed, Conny en nog veel meer) 
en Kioso Kyuwenda (teveel om op te noemen): dank jullie wel voor alle kippenvelmomenten! 
Lieve collega-Kioso-koorleden, ik wil jullie uitnodigen om te laten zien en horen dat stelling 
10 waar is!
Begeleid door Sandrina zijn de cursussen ‘Lichtdrager’ en Lichtwerker’ van grote betekenis 
voor me geweest. De ontstane vriendschappen eveneens (o.a. Marian, Lenie, Aad). Datzelfde 
geldt voor de Tarotcursus, o.l.v. Dini, het Talentenspel, o.l.v. Arnold en actief mediteren o.l.v. 
Hans en Connie.
Wandelen, met de verbinding naar pelgrimeren, heb ik mogen meemaken en begeleiden via 
‘de Wandelmaat’, opgericht door pelgrim Henricus. Het ontmoeten van kloosterlingen, reisge-
noten èn mezelf was bezielend en verrijkend, o.a. tijdens de mantra-weekenden met Truus. En 
dat geldt eveneens voor de contacten tijdens pelgrimages, de leeskring, de Vrouwenkring en 
andere bijeenkomsten vanuit de ‘Open Hof ’ en NPB. Speciaal in deze context wil ik ‘Creatief 
bezinnen’ noemen o.l.v. Anna. Het schilderij op de omslag is ontstaan tijdens één van de ses-
sies bij haar.  
Andere waardevolle vriendschappen die ik hier wil noemen zijn die met José (mijn hele leven) 
en Johan, Connie en Hans (21 jaar, net zolang als onze dochters oud zijn), Marian en Charles 
(collega ‘Lichtdrager’ en pelgrim/klusmaat) en René en Marijke (‘nieuwe’ praatvrienden).
De basis van een veilig nest van familie om me heen, is van grote waarde; pa, Helma en Jan, 
André en Marian, bedankt. Verder wil ik mijn schoonfamilie(s) hier noemen. Pa en ma Rom-
bout, jullie hebben me als een dochter opgenomen en tonen altijd belangstelling, samen met 
Maurice en Léon. Monique, bedankt voor alles wat je in de loop van de jaren voor me hebt 
gedaan. Ook de warme interesse die ik ondervind bij de familie van Driel stel ik erg op prijs; o.a. 
de gastvrijheid die ik in Canada heb mogen ervaren was hartverwarmend. 
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De mannen in mijn leven verdienen vanzelfsprekend een belangrijke plaats in dit dankwoord. 
Raymond, met jou heb ik het grootste deel van mijn leven gedeeld. Met hetzelfde diploma 
op zak sloegen we elk een ander vakgebied in, jij de klinische chemie en ik de research. Maar 
we begrepen elkaar wel en tot op de dag van vandaag toon je belangstelling voor mijn werk. 
We hebben samen drie prachtige kinderen op de wereld mogen zetten. Ook nu we uit elkaar 
zijn, kunnen we de zorg voor ze in harmonie delen en is het geen probleem als ik weer eens 
op congres ben. Heel erg bedankt daarvoor, waarbij ik ook Connie van harte wil betrekken. 
Beste Maarten, jij steunde me tijdens één van de moeilijkste periodes in mijn leven, zowel 
praktisch als emotioneel. Ik kijk er met grote dankbaarheid op terug. 
Lieve Anton, rots in de branding van de laatste twee jaar. We hebben elkaar écht ontmoet 
in een periode dat ik al druk was met werk, maar het werd nog drukker omdat ik mezelf het 
ultimatum had gesteld in 2010 te promoveren. Ontzettend bedankt dat je me de ruimte hebt 
gegeven om dat doel, mijn ‘feessie’, te halen, waardoor er minder tijd overbleef om samen te 
zijn. Je rust en luisterend oor, èn je onvoorwaardelijke liefde waren essentieel in deze drukke 
fase. De verbinding die er tussen ons is heeft er niet onder geleden en kan zich in de toekomst 
alleen nog maar verdiepen.
Lieve Nina, Onno en Wibe. Jullie zijn echt de allerbelangrijkste mensen op de hele wereld voor 
me. “The reason to live for.” Ik geniet van jullie en jullie vrienden, want ook Hans en Jessica zijn 
opgenomen in de kring. Het is goed jullie te zien ontwikkelen tot zelfstandige wereldburgers, 
met belangstelling voor waar ik mee bezig ben. Het viel niet mee om aan klasgenoten uit te 
leggen welke baan jullie moeder heeft. Iets met laboratorium, ratten, kanker en radioactiviteit, 
tja… En als blijkt dat oma, en nu ook opa, kanker heeft, dan kan er ik er niets aan doen! Door 
dit soort gesprekken belandde ik wel weer met beide voeten op de grond. Wibe, jij gaat voor-
lopig volop voor de korfbal, maar school gaat ook goed, met toch een voorliefde voor bio… 
Jouw humor, imitatietalent en 538 (!) doorbreken de stilte in mijn huis; een welkome afleiding! 
Onno, met jou heb ik van jongs af aan kunnen oefenen met discussies voeren. Je bent kritisch, 
maar eerlijk en objectief, en nu een goede gesprekspartner over bedrijfskundige aspecten van 
het werk. Nina, ik ben er trots op dat je één van mijn paranimfen bent. Toen je hoorde dat het 
leek op ceremoniemeester zijn, zei je direct ‘ja’ toen ik het vroeg. Organiseren ligt je wel zoals 
blijkt uit je voortgang op de hotelschool. Toen ikzelf paranimf was bij Pieters promotie zat je 
overduidelijk in mijn buik. Nu, 21 jaar later, kan je mij als volwassene bijstaan bij de verdedi-
ging van mijn proefschrift. Een hele leuke bijkomstigheid van promoveren op je 50e!
En nu verder op weg. Het doel lijkt bereikt, maar het is een stap in het onderweg zijn. 
“Dat je de weg mag gaan die je goed doet,
dat je opstaat wanneer je valt,
dat je mens mag worden in Gods ogen en die van anderen.
Weet dat de aarde je draagt,
dat je gaat in het licht en de wind je omgeeft.
Dat je de vruchten van je leven proeft en gaat in vrede.”
19 oktober 2010
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De schrijfster van dit proefschrift, Marleen Melis, werd geboren op 31 juli 1960 te Gapinge. In 1978 
behaalde ze het diploma Atheneum-b aan de Christelijke Scholengemeenschap Walcheren (CSW) 
te Middelburg. Van 1978 tot 1981 volgde ze aan het van ‘t Hoff -instituut te Rotterdam de HBO-b 
laboratoriumopleiding in de medisch-chemische richting. Haar stageperiode vervulde ze bij de 
afdeling Interne Geneeskunde II van AZR Dijkzigt o.l.v. dr. Felix de Rooij. Tijdens haar afstudeerop-
dracht vergeleek ze verschillende methodes om het IgM gehalte in serum te kwantifi ceren. 
Vanaf juli 1981 werd ze aangesteld als analist bij de afdeling Celbiologie II van de Erasmus Uni-
versiteit Rotterdam. Onder leiding van dr. Willem van Ewijk werkte ze samen met Els van Vliet aan 
de productie van monoclonale antilichamen gericht tegen stromale thymus cellen. Deze promo-
veerde op dit onderzoek beschreven in het proefschrift: “Stromal cells in the mouse thymus”. Vanaf 
1986 tot 1991 werkte Marleen in dezelfde groep, die inmiddels onderdeel was van de afdeling 
Immunologie met als afdelingshoofd prof.dr. Rob Benner. Dit keer samen met Pieter Leenen aan 
de totstandkoming van zijn proefschrift getiteld: “Phenotypical analysis of murine macrophage dif-
ferentiation”.
In de jaren 1991 tot 1994 was ze technisch onderwijs assistent (TOA) biologie aan de Christelijke 
Scholengemeenschap (CSG) ‘Willem van Oranje’ in haar woonplaats Oud-Beijerland.
Van 1994 tot 2001 heeft ze weer als research-analist gewerkt op de afdeling Immunologie van 
het Erasmus MC Rotterdam, onder begeleiding van dr. Pieter Leenen en dr. Maarten Egeler, aan 
twee histiocytose-projecten: “A mouse model for malignant histiocytosis: identifi cation of aff ected 
cells and liposome-based therapy” en “A mouse model for Langerhans cell histiocytosis: role of 
E-cadherin”.
Vanaf eind 2001 tot voorjaar 2003 werkte ze op het CoreLab van Cardialysis te Rotterdam als analist 
elektrocardiografi eën (ECG’s) en hart-echo’s. 
In 2003 keerde ze terug naar het Erasmus MC. Ze werd aangesteld als research-analist op de af-
deling Nucleaire Geneeskunde met als afdelingshoofd prof.dr. Eric Krenning. In de preklinische 
groep, geleid door dr.ir. Marion de Jong, werkte ze mee aan verschillende projecten betreff ende de 
ontwikkeling en toepassing van radioactief gelabelde peptide-analogen, gericht op visualisatie en 
behandeling van tumoren. 
Vanaf eind 2007 tot heden werkte Marleen aan het project: “Peptides for targeted tumour therapy 
and the kidney” dat werd gesubsidieerd door KWF Kankerbestrijding, in nauwe samenwerking met 
de afdeling Nucleaire Geneeskunde van UMC St. Radboud in Nijmegen en begeleid door prof.dr.ir. 
Marion de Jong, prof.dr. Otto C. Boerman en dr. Roelf Valkema. De resultaten van het onderzoek zijn 
beschreven in dit proefschrift. 
Als post-doc zal ze verbonden blijven aan de preklinische groep van de afdeling Nucleaire Genees-
kunde van het Erasmus MC.
Marleen is moeder van drie kinderen: Nina (1990), Onno (1992) en Wibe (1995).
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Curriculum vitae
The author of this thesis, Marleen Melis, was born on July 31st, 1960 in Gapinge. She graduated 
from the high school Christelijke Scholengemeenschap Walcheren (CSW) in Middelburg (Athene-
um-b) in 1978. From 1978 to 1981 she joined the Laboratory School ‘van ‘t Hoff -instituut’ in Rot-
terdam to follow the HBO-b course in the medical-chemical direction. During her practical training 
period she was employed at the Department of Internal Medicine II of AZR Dijkzigt, supervised by 
Dr. Felix de Rooij. The subject of her graduation thesis was the comparison of diff erent methods to 
quantify IgM content in serum. 
From July 1981 she worked as a technician at the Department of Cellbiology II at the Erasmus 
University Rotterdam. Supervised by Dr. Willem van Ewijk she was involved in the production of 
monoclonal antibodies directed against thymic stromal cells. This work was performed with Els van 
Vliet who obtained her PhD on the thesis entitled: “Stromal cells in the mouse thymus”. Marleen 
continued her work in the same group, part of the Department of Immunology headed by Prof.dr. 
Rob Benner. Between 1986 and 1991 she participated in the research of Pieter Leenen, described 
in his PhD thesis: “Phenotypical analysis of murine macrophage diff erentiation”.
Between 1991 and 1994 she organized and supervised) during the practical training in biology at 
the high school Christelijke Scholengemeenschap (CSG) ‘Willem van Oranje’ in her residence Oud-
Beijerland.
From 1994 until 2001 she again joined the Department of Immunology of the Erasmus MC Rotter-
dam as research-technician to participate in two projects on histiocytosis under supervision of Dr. 
Pieter Leenen and Dr. Maarten Egeler: “A mouse model for malignant histiocytosis: identifi cation of 
aff ected cells and liposome-based therapy” and “A mouse model for Langerhans cell histiocytosis: 
role of E-cadherin”.
From the end of 2001 until spring 2003 she analysed electrocardiography registrations (ECG) and 
cardiac ultrasound images at the CoreLab of Cardialysis in Rotterdam. 
In 2003 she again got a position at the Erasmus MC as research-technician at the Department of 
Nuclear Medicine headed by Prof.dr. Eric Krenning. In the Preclinical Group, supervised by Dr.ir. Mar-
ion de Jong, she cooperated in several projects concerning the development of various tumour-
targeting radiolabelled peptide analogues for diagnostic or therapeutic applications. 
Since December 2007 she is involved as researcher in a project granted by the Dutch Cancer So-
ciety entitled: “Peptides for targeted tumour therapy and the kidney” in close cooperation with de 
Department of Nuclear Medicine of UMCN St. Radboud in Nijmegen. Marleen has been super-
vised by Prof.dr.ir. Marion de Jong, Prof.dr. Otto C. Boerman and Dr. Roelf Valkema. The results are 
described in this thesis. 
As a post-doc she will continue her work in the Preclinical Group of the Department of Nuclear 
Medicine at the Erasmus MC.
Marleen is the mother of three children: Nina (1990), Onno (1992) and Wibe (1995).
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Name PhD student: Marleen Melis (M.L.)
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PhD period: 1-12-2007 – 1-1-2011
Promotor(s): Prof. M. de Jong, Prof. E.P. 
Krenning and Prof. O.C. Boerman
Supervisor: Prof. M. de Jong
1. PhD training
Year
Workload
(Hours/
ECTS)
General courses 
- Biomedical English Writing and Communication
- Laboratory animal science
- Rapporteren in het Engels
2009
2007
2007
4
4
1
Specific courses (e.g. Research school, Medical Training)
- Course Biomedical Research Techniques
- Introductie tot de Klinische en Fundamentele Oncologie
2007
2008
1
1
Seminars and workshops
- 2nd Small animal imaging workshop Tübingen 2007 1
Presentations
- COST B12 Final conference Warsaw, 1 oral and 1 poster
- IRIST London, 2 posters
- EANM Copenhagen, 1 oral
- COST/IRIST Krakow, 2 orals
- EANM München, 1 oral
- MolMed day, 2 posters
- SNM Toronto, 1 oral and 1 poster
- EANM Barcelona, 2 orals and 1 poster
- MolMed day, 2 posters
- WFNMB Cape town, 2 orals
- EANM Vienna, 1 oral
2005
2006
2007
2008
2008
2009
2009
2009
2010
2010
2010
1
1
1
1
1
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(Inter)national conferences
- COST B12 Final conference
- 18th IRIST meeting London
- 20th meeting of EANM Copenhagen
- Work group meeting of COST BM0607 action, Krakow
- 19th IRIST meeting Krakow
- 21th meeting of EANM München
- SNM Toronto
- 22th meeting of EANM Barcelona
- WFNMB Cape Town
- 23th meeting of EANM Vienna
2005
2006
2007
2008
2008
2008
2009
2009
2010
2010
1
1
1
1
1
Other
2. Teaching
Year
Workload 
(Hours/
ECTS)
Lecturing
- ‘Animal models’ during European 
  Radiopharmacy Course block 2
- ‘Refereeravond’ dept. of Nuclear Medicine
- Lunchmeeting dept. of Nuclear Medicine
- Journal club dept. of Nuclear Medicine
2009
2008
2008
2010
1
} 1
Supervising practicals and excursions, Tutoring
- Practicals AMIE course
- Junior science students and ‘keuzeonderwijs tweedejaars’
2007/2008/
2009
2009, 2010
1
1
Supervising Master’s theses
Students HLO:
- Lennert Aarts
- Satish Boedhoe
- Walter Spreeuwenberg
- Wilmer Wamsteeker
2007
2007
2008
2009
2
2
2
2
Other
Bij de omslag:
“Energie die straalt”
Tijdens het verval van radionucliden wordt vanuit de kern straling uitgezonden. Bijvoorbeeld 
γ-straling; zonder massa met een groot bereik of β-straling, bestaande uit deeltjes met een 
kort bereik. In de nucleaire geneeskunde wordt van de hoge energie van deze straling gebruik 
gemaakt tijdens diagnostiek (γ) of therapie (β). Tumortherapie beoogt het beschadigen van 
tumorcellen, maar straling op gezond weefsel wordt zo goed mogelijk geblokkeerd.
Leven vanuit je kern geeft energie, die uitgestraald wil worden. Dichtbij als bron van liefde 
voor jezelf of verder weg als liefde en licht voor anderen. Blokkeren van energieverlies is echter 
noodzakelijk om te overleven.  
De stralende zonnebloem staat symbool voor het zoeken naar de zon (le tournesol); een bron 
van licht en warmte, net als vuur. 
“Als alles duister is, ontsteek dan een lichtend vuur dat nooit meer dooft”.
Taizé
